<SEC-DOCUMENT>0001125345-21-000099.txt : 20210729
<SEC-HEADER>0001125345-21-000099.hdr.sgml : 20210729
<ACCEPTANCE-DATETIME>20210729160310
ACCESSION NUMBER:		0001125345-21-000099
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210729
DATE AS OF CHANGE:		20210729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		211127346

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39,d:557d5d473e994fd0b54aa1f596b2fd9c--><html xmlns:mgnx="http://macrogenics.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV8yLTEtMS0xLTA_b90c1014-f070-4114-aef9-ec8120f810d6">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV80LTEtMS0xLTA_bb7546ee-24c9-4d85-a832-7f73abf49484">2021</ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV81LTEtMS0xLTA_8b917687-9806-49be-b233-941e471c561d">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGV4dHJlZ2lvbjphOTRhMzQzN2UzYTg0ZGU2YmU1YmMwZGMyN2E3N2QyMF8xMzA_fca966ea-99e4-4272-be96-668d81936d71">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGV4dHJlZ2lvbjphOTRhMzQzN2UzYTg0ZGU2YmU1YmMwZGMyN2E3N2QyMF8xMzI_f6b305f4-31d2-41b3-82f8-f400d1d53585">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i659b6753df8146d889434af7dfe25a17_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99237d698c8c4afdbcef6350116b30ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia19bd22873f74ac0a9a206605b8cae68_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f40f3786724fa1ad473ad09803006a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ff57e352254b318162eb9cc8c0797b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e9beb576154228ae3170843841bbf5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76efd339d1ef4e28bcc5cdc42f49e9c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i853dd351791c4152a984c61563c37d8f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e75e38251ca4a8caee14deab3bdd4f4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7bb08c48834c529595375229b7976a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e184d60537c4ef9839e6bb7da1ac27c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c15e8ab11cd498393b7b69806d30fdf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92cbfaf654bd427b8436cccb669008fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib201915352974536beb53d888f523fcf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c79f10044b14566889926dcb759d15b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917763bbee93419ba52b562b02f1fc9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42019741bffb4bdebf0d0fc10733e31b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dff43be20849fbbfa77443c32bea18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb93b0844574006b7a2e1722733077a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2275ddaf7445d095b40fcc07d6df36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6590518bff442f3b740132dadc9e104_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161452ab42544aa7affbd585c14a6058_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73079c43b74e40a19f380f476c7c8be4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7609a910c2984ce3b597382be696e095_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e70b8e9e28148aba70905165a33b688_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed833c461084728bd70aaae36add592_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b668fed7b4433eb92e9256b8769b2c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacf8ef72a04e4570ae9b32da2e3d487f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8177b0cd284c57877080228c9c1f65_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24f781a3ab9414a96ce5ecf52017885_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22b7b809f714fb1b47a02dbddde5636_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d06b08b99bb4bd48b3d044997ecee6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe0486181da473b833e2f3577c97501_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452ce6d02a3f4d0f8e59b4e1791096e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47458184ab624f7d9b70f6018c42192e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3319bcc35e44daaa195857f42cdf9e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9328ec3a1cbb404aae355d158e8503d4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c305587a633404589fa54ed876d5095_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97169e2cb62e4625b4cc2b1e15526583_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df5ab9d1dac462495733adf3296e40f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5477f3f6684f41afb7accd08c9b72160_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic127167e37e4421ca46cfaf5d2d8ed2b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ca468ec7594cdda6eb47e595f7e56f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f8ccea1a3b42fa835d31417ecc4765_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3d02417b124f71a20bb4eb62366e59_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i707cfef686b74380a90156b94f5ed6cb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9349f9216d947e6995521fe00f225b1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d373902fd2d4b8b9a7bd6404765e98e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70478a7071c64ed8bc2a95031316c799_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6997c210694fe3a545294cd574e330_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb28ceedb1540108416cb8bca024ee4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51ff6fe1df945d6b5eadae49de900c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b573ab28a7443fb6e2a68919628472_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d06e9e2b764360be3789ec5ab6a466_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2e9df501b44b06a59a0ece2160ed78_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d2f52795c84d73812fd8848443f816_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73dcce00de9e4cd2b1e37144f3a6efb4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id543c07e6c994f5e81a39df1116c9a43_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb0c9e3480346519ecf6c1f0c46c8d4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44450b3df944c238f4634852f259160_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8321253ab6944229be7fba40e19eaef4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic17fd2407aa14c1885237d1cc1a99fee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9774f5bea6ae4560a38cc67f40b9694a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b77778502a64bc1ad848b961aa391bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b11553fdaa4460bac14c9901e981643_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3589e18fbb24f8fb2e18deeb6b2ff7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59efcafb8dc24c15928c3bf8b28d0df2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5f4c9915d34ba697c4c5e8998d9344_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1db23c95b04160ac16470c83f6bda2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12e9d4d981b4c19ba9b2c60dd287996_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e33921e4885474fb00cc964f9793e92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife1b38058b7d418fb1b1f00846e9a5a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3868bf3d920462993a7d358e34b30d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc01255ced4f4b16a80a1fce94c5ffe7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0e04aa3d8740cb98428d2ac4def939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd632afb09594801ad294cc7d9a4a993_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8e49b4de5f49a99c026fef5d247a0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52b46015190047069180f72c9a65f3be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4534615a7743539c120849d9bac73f_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63752c4319324224891b621130d37dd7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb5607c3098402584a482d05ebd33a4_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a811db172dc46c389a4e8977a0b88f8_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f80fe9e7bec4828b5adff9615c79488_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6d4183f898a0423387191ba8e659530d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc63dbbc38b240d1af689f955b93c987_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="if8dec3cac0d747668fbb6d511275eb4c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed1c4f887fe4a6ab8129e8f4d557b41_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c024e23c894d508ae4b2d764a1da84_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9def7feacecb40599d50a6c2b00e945b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc58eaa1973040f49a6096c0ae8ec4e8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2554e54b31431db356c26b68680c0d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94ec4f166294424905e9b5dfce87d38_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44ea624c784446d2945c9719b9e70291_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9ef71b5922414e9101d383252c8b6c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497d64ec91f141f692c999a205a6507b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a034427f78f478893b443a6a23c1cd9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd946ed05704d57ad5030149625825b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858f318333da414da051fa53d0aed818_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbaab8beada4a8e8fd4d70b878b36f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f6d5d295fa4f4ab2ad7678c47b90a0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e465ebe0e74740a272ba2347ea429d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0836069df741f4b40628f7e6d2e4cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c80046e2754387bbfb3a68414afafb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718f9275d3084eed957a877fcabb3eed_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624b7721e711450790fb78703bdfac0e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74f1cf826ca407fb2869bea2077efc9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fa68fb09ce643209722e4c7061f1dc6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174499c398454c42876e617baa38de83_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77288252481a45bb8d2a69bd1cc3b2df_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c57174988914ce89f16563fb7997562_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8b966b3515458980b5cd1380246198_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c54b835f12476ebcd59fb59d9aee2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4736835e9e45ac8018479c040ee6e8_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc33644441d49b491f669f6cee3cf52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ee5d7224384f51ae4351da2491f793_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1829ff483154e78a6241246422a7a16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08846d12a1824787806650566090f18b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a3cd8312cf4cf6b4d17e604f6ff948_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a108cdbe85846dcb5a3e8fb692e07e0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8bc10e870f423c915193a8d2f50a02_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ac94940d774c9cb563d01ff4332791_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600a2baf71cc48788b482d5d843710e7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e521811ec142cbab4561d2d0e7f510_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e56a7a7446f43fe9e4dab1edaa5b3f0_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf108d05a1a844ecbaf4f2cf4c8dd881_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85050d9a6f47489bab0765376deae7a9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909de857ac8e40dc9bbdd2e2b24cd20d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878570654cf7443295140f93cce32043_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc441b45390e4e3fbbfbe489832ffed0_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3e59b96ba24ec9bcac6649b8b2df22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa6f92aaf8b145f0b3bd386357f824af_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0031895b9ddb486c9acfd64f0d661e1e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda53c5d5b224a6bad5e09031f6b7b9b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7422fa11414ef6a298de5f4f194412_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e4b9564f0e4552a41d250e30a98c66_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3aad52d4204392803f61f058015d65_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbd69658d2544488a8943aea2078bc1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if53482425e144ebf87797a8800447626_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8751554712487b9de2c28ecbbfccf0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd60f01b1334bea880a5f387322b593_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801e96d91e944a44bdd5ee5ed3764993_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia217df68ded645e8b6c9001175c243cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1541411d98604ec694fc7cf490e3c299_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY184Mg_90beba8c-d575-4cde-a2a2-e472fd866f78">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NWMxNDdmZWE2Y2Q2NGMwMWIzYjM2YzE1ODMzMTE2NGYvdGFibGVyYW5nZTo1YzE0N2ZlYTZjZDY0YzAxYjNiMzZjMTU4MzMxMTY0Zl8wLTAtMS0xLTA_fad9a915-4ceb-4bd9-9104-f5f3b70c420a">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xMTg_42d86a73-cb8b-43d9-83bc-d1ca481d8fb6">June 30, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6MTE4ZGNjMWJmMjc4NGM0YmJkMjlhNGZkMmQ5Njc0ZjEvdGFibGVyYW5nZToxMThkY2MxYmYyNzg0YzRiYmQyOWE0ZmQyZDk2NzRmMV8wLTAtMS0xLTA_20d4dbf9-6703-4f64-bde4-4afcf112c23c">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yMTA_c7f6a98d-5574-4d48-a18c-78f4c52381a7">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yMTM_85cb9c39-2f93-406a-8d18-6c88af1d193f">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8wLTAtMS0xLTA_27416d61-d41a-4b1e-9fee-d88c5ea5aec0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8wLTEtMS0xLTA_e0b037f4-0898-44fa-9391-92c5eda0c647">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl81_92328cdb-2a77-4607-b953-82cdd587b94a">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl84_5d9ade07-75e4-41d0-9af6-15e111ac598a">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl8xMg_e575a9cd-9997-428e-b41f-d272843e1a58">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTEtMS0xLTA_801f725d-957d-4356-ae82-9201f49c593a">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yNzM_2186cd3f-142d-4842-969b-78a2405056f2">301</ix:nonNumeric>-<ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yNzY_85a52d6f-d5c0-4148-ba74-cb063e6a7511">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTAtMS0xLTA_ab27f35e-c279-46c9-92ca-95f4252f8f17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTEtMS0xLTA_28238626-2d69-49a9-a7ea-b1aca67690a6">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTItMS0xLTA_d6509f8a-4ffe-4e59-8eab-c41a8453364d">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIy_ccf81983-b433-4e08-b059-fe25e4ed3953">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIw_c518c64b-716c-4eb3-8d95-2455d2d9f9c1">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV8wLTAtMS0xLTA_5755db92-e896-4c4f-ac7f-006181fc53b4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV8yLTMtMS0xLTA_fbb697f8-4f91-4299-9bb0-6afedc51d6cc">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV80LTEtMS0xLTA_29b00073-3e21-420f-9fff-662905a6457d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIx_b7900040-3492-4e19-9210-455d6c8358ac">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;26, 2021, <ix:nonFraction unitRef="shares" contextRef="i659b6753df8146d889434af7dfe25a17_I20210726" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xODMz_d5ea189e-5bc1-47b1-9378-348199dab0b3">61,107,288</ix:nonFraction> shares of the registrant's common stock, par value $0.01 per share, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_19">Consolidated Balance Sheets at</a> June&#160;30, 2021 (unaudited) and December&#160;31, 2020</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_22">Consolidated Statements of Operations and Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_22">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_22">months ended</a> June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_22"> and </a>June&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_22"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_25">Consolidated Statements of Stockholders' Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_25">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_25">months ended </a>June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_25"> and </a>June&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_25"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28">si</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28">x</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28"> months ended </a>June&#160;30, 2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28"> and </a>June&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_28"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_61">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_82">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_85">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_88">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_91">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_94">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_490">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_97">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i557d5d473e994fd0b54aa1f596b2fd9c_100">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2020), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize MARGENZA and our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for MARGENZA and our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNC0xLTEtMS0w_efb8371b-330c-4b61-946f-36cf13ae46f6">188,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNC0zLTEtMS0w_37e2a447-8335-4867-902d-fe512be91c02">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNS0xLTEtMS0w_990835f0-f945-4770-a8ef-2c19fdbe329c">108,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNS0zLTEtMS0w_f9dd2bf9-8841-4cfc-9720-f9924845f156">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNi0xLTEtMS0w_9afcfd85-6808-41f8-91f8-3a630a3d9252">45,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNi0zLTEtMS0w_49cff3cc-06f3-42f4-b96e-f21aaf0fe67b">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNy0xLTEtMS0w_682193d3-9e26-4929-99af-efd79abaddd7">6,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNy0zLTEtMS0w_8ef901b4-cbc3-49e2-ae30-306df8a6c551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfOC0xLTEtMS0w_b2efe85c-f253-415c-8722-3f5de87bd062">17,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfOC0zLTEtMS0w_9d1dfa89-62e6-48f7-835d-6a96009d5743">16,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTAtMS0xLTEtMA_26eb8ea8-c8a7-4f7e-9ff6-1cfc86fcb3ee">366,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTAtMy0xLTEtMA_4653feb0-b12d-42c3-ba8b-028bcf69d00c">312,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTEtMS0xLTEtMA_93f2f5c6-2416-4e6d-8151-de0375dec203">39,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTEtMy0xLTEtMA_21d7207b-f689-4049-9b7d-d58cb6818f39">42,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTMtMS0xLTEtMA_d002e928-a7d7-4132-a477-24d3397b096b">19,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTMtMy0xLTEtMA_72293abd-537d-4d78-9d59-164fa20b6cb6">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTQtMS0xLTEtMA_b769e9f4-16df-4f07-8244-41b7ecef8689">425,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTQtMy0xLTEtMA_a0d56f80-8d2c-49c2-ae8d-ad198040eef2">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTgtMS0xLTEtMA_9be817e4-5cd1-4cd0-b517-810a6771c53d">9,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTgtMy0xLTEtMA_d8e8e8b9-ec5f-4b25-8de3-c66f6dab3a3a">8,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTktMS0xLTEtMA_b8fbbd42-2937-43dd-9a79-acb7381c42ff">39,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTktMy0xLTEtMA_605f6c48-24bc-4994-83f0-10c3f7a0760b">34,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjAtMS0xLTEtMA_cd765ef9-98df-435a-a161-36bbda564bfb">16,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjAtMy0xLTEtMA_9905a982-6009-43e5-917d-eef29ea31c3d">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjEtMS0xLTEtMA_2c7f26e7-357a-4890-96fa-7b8546fdd08b">4,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjEtMy0xLTEtMA_54c0f662-367a-4a79-9d5b-1f3bfec88c88">3,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjMtMS0xLTEtMA_f6ebbcd7-122c-4c3c-94a7-82959841ce62">69,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjMtMy0xLTEtMA_12c7df5e-6f63-41e6-8afa-3c108499f9b7">50,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjQtMS0xLTEtMA_46087f49-3aaa-4334-9775-c79317ec0b71">13,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjQtMy0xLTEtMA_7b28d27a-371a-4434-8814-d314da2f999a">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjUtMS0xLTEtMA_cc37e24e-3224-4536-a27c-77638ea8320b">23,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjUtMy0xLTEtMA_0dcbe22a-4051-46a2-b89b-c9a2fb84cf8d">25,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjYtMS0xLTEtMA_2e52204d-bcd3-4f7d-baed-5401e728052b">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjYtMy0xLTEtMA_9bd25927-f102-474e-b0ac-f5caa0da0d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjctMS0xLTEtMA_7665df7d-efaf-4f4e-813a-4af75e338f62">106,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjctMy0xLTEtMA_10938a96-5482-4efb-9d86-1519906091f0">82,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzE4_27c69d79-27bf-400d-a38c-6294064a03fc"><ix:nonFraction unitRef="usdPerShare" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzE4_35cd2d32-e30a-4d5d-9ade-b89cadb2ef09">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzM0_464e1198-75df-4ec7-973c-785e77788cc0"><ix:nonFraction unitRef="shares" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzM0_9b19166a-ccdf-4cb2-a5c8-edd10c9ab295">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzU2_d5108268-ca23-4fdb-8583-13f8b482d82f">60,133,447</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzYz_3df84c34-8a3d-4eb0-ba46-b5c295e7b8b1">56,244,771</ix:nonFraction> shares outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMS0xLTEtMA_83494fe9-4141-479c-86fb-aa0444860cef">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMy0xLTEtMA_f991961a-0b71-4c1f-a333-5b0b4725b235">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzAtMS0xLTEtMA_b99b0100-9e1f-442b-83c3-d98ccce6bd3c">1,181,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzAtMy0xLTEtMA_056b8372-dbb9-4fb8-893f-6feae7605e84">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzEtMS0xLTEtMA_f0c7a06f-c4f7-40df-8b2d-815d726e0344">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzEtMy0xLTEtMA_c6db48e6-6540-43bd-8cc9-105fa1233025">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzItMS0xLTEtMA_86ba6082-b6e4-492b-9e19-c13141e9e8e8">863,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzItMy0xLTEtMA_fa18d8d6-83d5-4a7e-856a-77d8d5f17664">771,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzMtMS0xLTEtMA_4a17a2d3-c15d-444d-8004-af12cd1e7c9a">319,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzMtMy0xLTEtMA_2584ddc2-eaab-4a46-b18d-67ed3da02987">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzQtMS0xLTEtMA_fc4a47f9-4d35-400e-bd4c-03237d59e99a">425,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzQtMy0xLTEtMA_d42a2e4d-0f35-484b-88dd-900bd2443ba8">378,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19bd22873f74ac0a9a206605b8cae68_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy0xLTEtMS0w_fed02b53-081c-49c0-9859-2747002d3efc">27,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f40f3786724fa1ad473ad09803006a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy0zLTEtMS0w_f2dcaea8-4a1f-4f5d-b430-1f703ae585c7">15,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff57e352254b318162eb9cc8c0797b_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy01LTEtMS0w_a0a95179-912b-4c0e-b070-b7cff99d9939">42,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e9beb576154228ae3170843841bbf5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy03LTEtMS0w_98074dc5-f19e-4fb2-8d2c-36f502d0aeb5">28,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76efd339d1ef4e28bcc5cdc42f49e9c8_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC0xLTEtMS0w_8fa827df-6ad4-4de7-99d4-6881d112c9bb">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853dd351791c4152a984c61563c37d8f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC0zLTEtMS0w_1fa01183-b338-4ee9-bf04-01fcc7ea3daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e75e38251ca4a8caee14deab3bdd4f4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC01LTEtMS0w_6c0a272a-44b6-46aa-adda-ed64e7bf3183">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7bb08c48834c529595375229b7976a_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC03LTEtMS0w_7b70d452-38cd-4477-9568-e3483ab87aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e184d60537c4ef9839e6bb7da1ac27c_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS0xLTEtMS0w_21e61f97-9319-4d5a-a08d-88094d8a011c">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c15e8ab11cd498393b7b69806d30fdf_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS0zLTEtMS0w_d0dd7c73-e95a-493a-a4e5-399d9cccd610">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92cbfaf654bd427b8436cccb669008fc_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS01LTEtMS0w_fe8ff75d-d7d5-42c9-a044-864ec1d51367">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib201915352974536beb53d888f523fcf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS03LTEtMS0w_0f62f37a-a059-495d-9d4f-02685da8f571">5,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi0xLTEtMS0w_e00b144d-8430-4de9-8a8a-eadc68070edb">30,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi0zLTEtMS0w_ef7436d1-009a-42f5-9d12-86134f6a0ae1">20,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi01LTEtMS0w_2fb695ba-7310-47f5-8b0f-39fb7757037a">47,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi03LTEtMS0w_62a2577c-dc08-4698-9e9f-ababe61f6000">33,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC0xLTEtMS0w_e13859aa-747e-4ffa-9bf6-ed4cef21a1e6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC0zLTEtMS0w_7aa3a343-179b-44f9-8086-d1417c9e71f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC01LTEtMS0w_4c8e1254-1fed-43c4-94a5-26601285e1cc">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC03LTEtMS0w_84b7a245-f89c-42ef-b6e9-277ac7bc7fd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS0xLTEtMS0w_ac17b913-1401-4e4e-b8fb-ed48e081bae3">55,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS0zLTEtMS0w_a2ab7eac-1f77-4c78-98cd-06a8b3c397fd">57,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS01LTEtMS0w_8a45bb4e-a8e7-4982-bbac-713f1f28cfd4">108,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS03LTEtMS0w_8257e7c4-50c5-407b-91bf-e32143d97d54">106,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtMS0xLTEtMA_23dd7115-4c29-4fc9-aece-b1182dd8f11a">15,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtMy0xLTEtMA_94aac6ed-b952-48bd-aafd-1336c7507f89">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtNS0xLTEtMA_983c9f19-3117-4814-9115-73c54209f11e">30,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtNy0xLTEtMA_5d560c04-6a6f-4af5-8472-f4fca5ce73a0">20,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtMS0xLTEtMA_ffb9f854-0d39-42b0-88c6-ecbb53856f32">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtMy0xLTEtMA_6de89dd3-9cda-4258-b4f5-b036171bb22b">67,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtNS0xLTEtMA_867d9e9b-9cb0-41d2-88d5-b5fada71821c">139,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtNy0xLTEtMA_37715cf8-d2fd-417d-8440-6f284071f3c0">126,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItMS0xLTEtMA_e3a2bacb-41bd-4075-85a3-a7720fea4586">40,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItMy0xLTEtMA_8dc508ee-c6af-4cb4-9268-9cbed092f6ce">47,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItNS0xLTEtMA_61a81b82-7857-4c80-abce-7a5e678c644e">91,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItNy0xLTEtMA_0b5dc9c2-1d2e-4c22-98c5-0534fdfa6da8">92,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtMS0xLTEtMA_53bced5e-8967-4a71-9d14-d68e92d1368a">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtMy0xLTEtMA_2ddee466-9320-4ff2-9194-2f4449cb4e4e">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtNS0xLTEtMA_0aeb3709-6d71-4a08-9d36-65f27ecc07ae">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtNy0xLTEtMA_966b4c56-d375-4a2f-baf6-2b172e40925d">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtMS0xLTEtMA_c187e9c3-7e16-4028-9e2e-8c0c48e4ca5b">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtMy0xLTEtMA_dde62575-bb05-41da-b854-0f5ee277eb0d">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtNS0xLTEtMA_3bc508a1-52d8-404c-acf8-24d306ea5847">91,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtNy0xLTEtMA_5cdb5007-30a8-4986-b31b-b39e684c52a4">91,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtMS0xLTEtMA_ca875108-e2da-49a1-b178-eb142f8a2520">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtMy0xLTEtMA_e0983e7c-0137-43a5-a2c6-3c33226bd9ff">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtNS0xLTEtMA_dd258d7f-85aa-486a-9be0-1876ada7c9a7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtNy0xLTEtMA_3555df93-0d63-4036-a4c4-a1f484effb0c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctMS0xLTEtMA_c3d68706-fd6a-4a2d-9b9f-f012770bf77d">39,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctMy0xLTEtMA_a8bb6282-eba1-4aec-be83-ff2753c44c13">46,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctNS0xLTEtMA_3b542390-19b2-4282-994f-a4298a796370">91,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctNy0xLTEtMA_6fa16779-b6fe-4e7b-9d11-643cf9a07e54">91,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMS0xLTEtMA_66564df2-229a-4788-aacb-fe0c8985ca8d"><ix:nonFraction unitRef="usdPerShare" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMS0xLTEtMA_91f69e45-ab60-46ce-8f3a-21903db76f56">0.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMy0xLTEtMA_88453eef-7532-4608-adc4-94ad2d67e68f"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMy0xLTEtMA_aa4a09c3-3ecc-4a6f-9e13-a9e69dd6b92d">0.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNS0xLTEtMA_2397a2f5-361c-4899-b2b4-b8278f316234"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNS0xLTEtMA_a9326181-8dfd-4ba0-bd33-c1fdb1c3d933">1.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNy0xLTEtMA_13cab94b-1510-43cf-b8d8-a40ce84e9e52"><ix:nonFraction unitRef="usdPerShare" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNy0xLTEtMA_2a8ba2fc-d86c-4156-8bb2-156e9a496ce8">1.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMS0xLTEtMA_259c99d7-d503-4d79-b0e9-613abe2f8189"><ix:nonFraction unitRef="shares" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMS0xLTEtMA_bf6cb0bc-80b3-4e96-b08b-f80fccfe5ea1">60,068,315</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMy0xLTEtMA_9c75ceb0-dc5f-44eb-a3e2-aaf184168fba"><ix:nonFraction unitRef="shares" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMy0xLTEtMA_eb246f10-725b-4914-90b0-3978d47722fe">50,018,462</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNS0xLTEtMA_6e60d352-8e8c-40fe-a663-f519abb259e0"><ix:nonFraction unitRef="shares" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNS0xLTEtMA_d7aba41a-d8f4-4581-ab09-94ca42ba853e">58,643,496</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNy0xLTEtMA_1869a4ce-f0c3-4218-8cd4-d8ef42436612"><ix:nonFraction unitRef="shares" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNy0xLTEtMA_83dc6cfa-cc9f-4788-bf91-f8d3e03a4a66">49,515,562</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:25.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.614%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.134%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xLTEtMS0w_67df5104-82d2-4f58-8e51-1476714e140c">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0zLTEtMS0w_98220733-7539-408f-83ab-d7d57ba226a4">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c79f10044b14566889926dcb759d15b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi05LTEtMS0w_06391073-3610-468a-95a4-9d98a6c594fc">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917763bbee93419ba52b562b02f1fc9f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xMS0xLTEtMA_9929ed16-11d6-4c76-ac9f-f23463a7e605">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42019741bffb4bdebf0d0fc10733e31b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xMy0xLTEtMA_bf95cff3-fd19-4f16-8553-00f0dadafb0c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xNS0xLTEtMA_44156634-100e-4181-9292-59ea355a1b77">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMy05LTEtMS0w_6ea46499-c507-481f-a731-1f3a1fed934c">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMy0xNS0xLTEtMA_350a0a79-c45e-4e4c-9775-b891412b98c2">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0xLTEtMS0w_862dd877-9856-4cf9-9dbb-eb350f3661da">3,622,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0zLTEtMS0w_4e435e10-27a8-4c1c-a7b9-989c4fb21a6f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC05LTEtMS0w_75618388-d520-4e20-b0e5-a81e11e04cf3">98,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0xNS0xLTEtMA_abf8074e-370f-4996-a906-d91c28278f41">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0xLTEtMS0w_8b2fbf14-18e5-4067-b96c-b9f8d6bea353">144,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0zLTEtMS0w_40a488cc-e969-4e69-b85d-9c0d327ef94b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS05LTEtMS0w_5ef843be-9913-4f5c-9226-6e0c51f93acf">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0xNS0xLTEtMA_b09f2b50-34ce-4480-97e6-b48f2a24272f">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1dff43be20849fbbfa77443c32bea18_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNi0xMy0xLTEtMA_2f8ded12-73e8-4c94-923b-023c2b59caf6">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNi0xNS0xLTEtMA_6c6b44e3-4f6b-4457-9682-f0ba1fe1b98c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb93b0844574006b7a2e1722733077a_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNy0xMS0xLTEtMA_760bb2f3-73fc-4ccd-ab15-458fff51a994">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNy0xNS0xLTEtMA_6f22f9e6-550e-482c-93c6-9d74fb4f8ae0">51,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec2275ddaf7445d095b40fcc07d6df36_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xLTEtMS0w_d987f761-3ed2-4058-ab02-51315b0e6eca">60,011,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2275ddaf7445d095b40fcc07d6df36_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0zLTEtMS0w_9fa8c1c7-56f9-4e36-8c09-af60f43c3470">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6590518bff442f3b740132dadc9e104_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC05LTEtMS0w_60881dc2-be1b-4165-a83b-f388add96393">1,173,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161452ab42544aa7affbd585c14a6058_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xMS0xLTEtMA_296198a4-3b0d-404d-858d-446a792d2fe7">823,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73079c43b74e40a19f380f476c7c8be4_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xMy0xLTEtMA_a29841ac-bc0c-4f67-be67-aec0443df2eb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7609a910c2984ce3b597382be696e095_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xNS0xLTEtMA_245d9e38-d875-48b0-8c56-0b0468d91c06">350,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOS05LTEtMS0w_bfa55f1c-29f1-4469-ba06-b69f6cf2202e">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOS0xNS0xLTEtMA_289b5957-ea8a-4b85-9f20-01fd10016dcb">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMS0xLTEtMA_2e11ba37-6e54-4684-8447-b5f59fcfb92c">122,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMy0xLTEtMA_841ff142-67a8-4ba4-8e30-3b0fbd9c75b3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtOS0xLTEtMA_977bb1a7-e96d-4abe-bf4c-3d8400a8b49f">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMTUtMS0xLTA_4fecf0c3-e36f-4830-a1e9-f69e41246aef">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e70b8e9e28148aba70905165a33b688_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTEtMTMtMS0xLTA_e7750fe1-dd7f-4a2d-bdcb-6cc93b080180">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTEtMTUtMS0xLTA_36d26c7b-313e-4801-9fb1-9f2f7a9b16c5">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ed833c461084728bd70aaae36add592_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTItMTEtMS0xLTA_e6060651-3875-46af-b769-959458be2d10">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTItMTUtMS0xLTA_43cc7100-d4be-4256-86ca-8d5b2396fd8d">39,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93b668fed7b4433eb92e9256b8769b2c_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMS0xLTEtMA_de5326ee-1ba3-4fad-a76d-be4779a62ead">60,133,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b668fed7b4433eb92e9256b8769b2c_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMy0xLTEtMA_59c3851a-0ae0-42af-8cce-eec1fb575ff6">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf8ef72a04e4570ae9b32da2e3d487f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtOS0xLTEtMA_d76480ce-83be-426f-b73c-d2a54fb3589d">1,181,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c8177b0cd284c57877080228c9c1f65_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTEtMS0xLTA_799fedeb-0c98-4e95-b3d9-f7b035a93742">863,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24f781a3ab9414a96ce5ecf52017885_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTMtMS0xLTA_7ec21b91-a6df-4e5e-b147-c59c440e7cd6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTUtMS0xLTA_8e31e612-6050-421b-ad71-caff8f4e1a0f">319,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"></td><td style="width:25.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.170%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id22b7b809f714fb1b47a02dbddde5636_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xLTEtMS0w_e3a0a257-0c2d-4c6a-8b41-c7b4e617397e">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22b7b809f714fb1b47a02dbddde5636_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0zLTEtMS0w_6358329a-c3ed-4010-b3a5-f5748569a77a">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06b08b99bb4bd48b3d044997ecee6f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi05LTEtMS0w_af15d3a7-321c-4a58-bbf1-62c92990c014">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe0486181da473b833e2f3577c97501_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xMS0xLTEtMA_50a0cb9d-ff10-495d-b98d-486f04a08889">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452ce6d02a3f4d0f8e59b4e1791096e0_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xMy0xLTEtMA_699df73c-5c0f-4332-bea9-9a0c4c136b38">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47458184ab624f7d9b70f6018c42192e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xNS0xLTEtMA_e614ca3c-29e0-4be2-bc76-a940ca24afc0">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMy05LTEtMS0w_1b86d583-1c58-4bfb-89c5-a29e946ccea5">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMy0xNS0xLTEtMA_8b9f5403-461d-4b22-85bf-8b63fd6d31d8">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0xLTEtMS0w_91bd0964-5dcb-465a-a3f2-8a1be73cf38a">172,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0zLTEtMS0w_3427871f-f3b8-4bc0-9cb0-c0b59fe8209a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC05LTEtMS0w_5580fde8-8bd6-469e-9ecb-35a7a755af5f">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0xNS0xLTEtMA_b3f385e4-2c2f-4b82-8425-34931a0d5def">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3319bcc35e44daaa195857f42cdf9e_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNS0xMy0xLTEtMA_d008737b-cc89-4468-8924-b5e03f1ec11d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNS0xNS0xLTEtMA_42853536-8cd2-471b-8f38-47acf19a6ad4">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9328ec3a1cbb404aae355d158e8503d4_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNi0xMS0xLTEtMA_75c0b998-2f70-4a11-a1f7-84176fd2c011">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNi0xNS0xLTEtMA_731a241b-561c-4dd6-8d53-369137839aa3">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c305587a633404589fa54ed876d5095_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xLTEtMS0w_08055792-57ff-4efe-a272-30a3081e1723">49,131,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c305587a633404589fa54ed876d5095_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0zLTEtMS0w_da4a8fd4-330f-4688-8522-50ff3ac99f52">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97169e2cb62e4625b4cc2b1e15526583_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy05LTEtMS0w_9060daa9-aed8-4e50-ab1d-a174e732de46">876,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df5ab9d1dac462495733adf3296e40f_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xMS0xLTEtMA_b5e6b658-7576-444b-ac2b-7460717aa122">686,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5477f3f6684f41afb7accd08c9b72160_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xMy0xLTEtMA_f7b3ced4-ef7e-45e2-8c79-20b21add0ea2">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic127167e37e4421ca46cfaf5d2d8ed2b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xNS0xLTEtMA_25bb634c-70a9-4fec-89bc-f726acccc4af">190,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOC05LTEtMS0w_bec649ca-f70c-4e57-953b-38b2efe9c0f6">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOC0xNS0xLTEtMA_3c6df5d3-2846-46c1-a11d-0bd1b5d3b110">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0xLTEtMS0w_15c5fce1-8d63-42ce-ade6-ae8cec97824e">4,060,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0zLTEtMS0w_b96b16c1-810c-4aea-af0e-286f6507788c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS05LTEtMS0w_d812136b-f5f0-4e29-a006-229cccbcb030">96,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0xNS0xLTEtMA_f51cc2a6-2408-412d-92a9-ca9df7494b67">96,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMS0xLTEtMA_1cee33ca-9fbd-4966-9973-3ca2043f61f8">173,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ca468ec7594cdda6eb47e595f7e56f_D20200101-20200630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMy0xLTEtMA_cf182718-4dfe-43e9-83f3-dd918f5f8d61">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtOS0xLTEtMA_5a313de3-dca2-4fa1-bed1-7876e81f6cbc">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMTUtMS0xLTA_0c19c43c-df91-4258-8aab-9a5e7e51d219">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f8ccea1a3b42fa835d31417ecc4765_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTEtMTMtMS0xLTA_51707647-a6b7-418b-8aa1-df7609fbc08c">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTEtMTUtMS0xLTA_bc7a6fc6-c31a-45c6-bac5-f6d2165a5902">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3d02417b124f71a20bb4eb62366e59_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTItMTEtMS0xLTA_cffccf4c-d7c0-47b3-9eec-4f9f01eaebab">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTItMTUtMS0xLTA_c3cd3865-f580-4730-827d-481a787e184f">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707cfef686b74380a90156b94f5ed6cb_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMS0xLTEtMA_899431d7-d71c-4164-85b8-2a63375cc0dc">53,365,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707cfef686b74380a90156b94f5ed6cb_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMy0xLTEtMA_f788e8e9-8858-4eb1-b666-15d2f8dcdbbf">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9349f9216d947e6995521fe00f225b1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtOS0xLTEtMA_df86e0ca-0a98-42dc-bdb8-b5cfed56baca">980,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d373902fd2d4b8b9a7bd6404765e98e_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTEtMS0xLTA_cc84a419-872a-423f-a793-7a32a6c45868">733,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70478a7071c64ed8bc2a95031316c799_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTMtMS0xLTA_e29316cc-1938-43a8-8cdd-2d96cee8ac5a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6997c210694fe3a545294cd574e330_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTUtMS0xLTA_de2bd85b-0040-4294-8441-52541fc7dd68">247,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:68.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMy0xLTEtMS0w_7aba6030-3d39-4744-bce5-6aa52ee16d38">91,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMy0zLTEtMS0w_c543969c-ef16-4e52-9a34-4c5c0f810cc6">91,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNS0xLTEtMS0w_3ca625b3-cbd0-443a-b2f0-277f2de24eb9">5,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNS0zLTEtMS0w_e5208785-9316-40b5-b8a9-3086cbdf35ef">6,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNi0xLTEtMS0w_d1144b2c-ca8e-4a70-af8f-d2a46a9cbe52">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNi0zLTEtMS0w_0770b1b3-ec21-4cf7-8428-dd60716bde8b">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNy0xLTEtMS0w_4df84b59-2fa2-4d0f-a229-f92f9a3b9a00">11,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNy0zLTEtMS0w_27ac0fa7-5a85-4c61-9c72-f5ead6f8ec3b">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfOS0xLTEtMS0w_14d7752b-e9ed-4604-839a-61cffd849243">22,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfOS0zLTEtMS0w_8230e9a4-6750-496c-a043-b28b84b0cd08">6,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTAtMS0xLTEtMA_9adf7b0f-6b90-4f25-8af0-d4d370efab5e">6,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTAtMy0xLTEtMA_24befbf6-2fa1-4f98-a45a-fe74ad30b42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTEtMS0xLTEtMA_c124f038-2db2-48ab-89bd-954c7a5a5225">974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTEtMy0xLTEtMA_24ade18c-34e9-4f48-8609-17a1e62838b8">3,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTItMS0xLTEtMA_5bc1457c-0323-49c0-8612-bf54937e72c8">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTItMy0xLTEtMA_a98db3cd-7dce-4f6f-b471-b37be9c588b9">995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTMtMS0xLTEtMA_a203e4ee-e448-40bc-8e1b-fa7e2aabfe6d">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTMtMy0xLTEtMA_460dfaee-56fd-46ec-a4f4-088ec821217a">1,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTQtMS0xLTEtMA_c6e46e19-0f57-43c9-80a6-dad1d9f19824">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTQtMy0xLTEtMA_4d8e8c37-8ca3-48e3-ad23-ae9b7f7fd1ff">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTUtMS0xLTEtMA_37ba8c04-f39b-49da-824f-d0002ae779f1">1,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTUtMy0xLTEtMA_bc2e614c-bb09-4dee-b054-6731a13638c2">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTYtMS0xLTEtMA_8fa0c78e-f036-42b4-a59f-97ce4360048b">18,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTYtMy0xLTEtMA_9516fb3f-c274-4971-8ab2-e911bcebe257">3,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTctMS0xLTEtMA_4ea7c9a7-3d27-4360-89ca-efecb6908a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTctMy0xLTEtMA_c4974030-58da-4fcf-b8f5-511af58905fe">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTgtMS0xLTEtMA_5ebf9b88-ba1d-4f9e-aa1c-a3f91109bece">74,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTgtMy0xLTEtMA_49e033cf-3ab3-4b0a-9509-3b43cf3befbd">80,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjAtMS0xLTEtMA_02ce8442-45dd-40bb-ad1b-3040ce4e9946">117,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjAtMy0xLTEtMA_e6783658-1170-4a38-85a1-bf6af483ed10">72,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjEtMS0xLTEtMA_ccaac107-17e2-4806-920c-8e4d11e96018">99,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjEtMy0xLTEtMA_1eb8bf9b-6e4e-4b80-b4a3-7f65c00ec6e0">125,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjItMS0xLTEtMA_fdc36279-c8bf-405f-ae0c-096bc14e2bf0">2,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjItMy0xLTEtMA_ec0f895c-9c56-4e07-b81e-fd25c55d08fa">1,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjMtMS0xLTEtMA_4f914723-a0e2-4d0a-97ce-f29376e10c03">20,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjMtMy0xLTEtMA_b97f4f9a-7f1c-4c42-962d-9aba8892a753">51,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjUtMS0xLTEtMA_7d706e2c-2c92-4ad0-9b5f-ecff078cb114">98,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjUtMy0xLTEtMA_a2c24b40-ee64-4f2f-8803-9ac1fe696aea">96,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjYtMS0xLTEtMA_b5b145f5-65e9-4126-8be1-9e11f737cf3c">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjYtMy0xLTEtMA_cec004be-63bd-476f-a32c-bc1a2244a49d">2,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="mgnx:RetirementOfTreasuryStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMS0xLTEtMTg4NA_24bc5a94-eefd-403e-9a55-c5123a1f5de0">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="mgnx:RetirementOfTreasuryStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMy0xLTEtMTg4OA_e7594163-3acb-4a50-af07-5b3f63a07ac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMS0xLTEtMA_7a1343b1-ebb9-467d-ae67-511199bf8428">103,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMy0xLTEtMA_3b6d5017-2ee5-4253-b3db-94cc84c90426">99,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjgtMS0xLTEtMA_6403467e-3f25-46cf-8656-b3b285f70ce9">7,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjgtMy0xLTEtMA_afb1b3e9-eb76-4a43-a5a6-ad367582b795">70,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjktMS0xLTEtMA_c5cdf419-0805-459d-93a3-eb4cd03a9a57">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47458184ab624f7d9b70f6018c42192e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjktMy0xLTEtMA_d15509e8-5a13-4439-b119-a7badefa9c7e">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzAtMS0xLTEtMA_739fb4df-9b7d-4935-8db7-cb56f1c6d026">188,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6997c210694fe3a545294cd574e330_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzAtMy0xLTEtMA_802065ac-4bf0-45f8-acc3-cee0b2960fed">196,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software included in accounts payable or accruals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzMtMS0xLTEtMA_93af195a-26f0-4ca5-8064-4be308441d2f">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzMtMy0xLTEtMA_bcd6f06b-6c09-40d9-8e3f-a934e441a770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNC9mcmFnOjA4YjBiYTc1ODMwYzQxZTk4NmM0ZDQ5YjlkNzgwYTFmL3RleHRyZWdpb246MDhiMGJhNzU4MzBjNDFlOTg2YzRkNDliOWQ3ODBhMWZfNTEzOQ_22a32144-b2fc-4438-85bd-30db0bca9579" continuedAt="ifd747ce067b04850921236d1914cfe8e" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="ifd747ce067b04850921236d1914cfe8e"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with our commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNC9mcmFnOjA4YjBiYTc1ODMwYzQxZTk4NmM0ZDQ5YjlkNzgwYTFmL3RleHRyZWdpb246MDhiMGJhNzU4MzBjNDFlOTg2YzRkNDliOWQ3ODBhMWZfNTE0Mw_29278ea7-40c7-4361-9be2-04fb73b91b69" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg5MA_68106058-c963-4851-9357-9dbaa2073c72" continuedAt="ia88e4d03b58546ea9afc30a96ac7d720" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia88e4d03b58546ea9afc30a96ac7d720" continuedAt="i654eff97c3d6493897900198b7b18f62"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4Nw_8227fa1a-9257-4401-823d-b361c92e7a5d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources the manufacturing of MARGENZA.  Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, the Company began capitalizing MARGENZA inventory costs.  The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfMzg0ODI5MDcwNjQzNw_42d86a73-cb8b-43d9-83bc-d1ca481d8fb6">June 30, 2021</ix:nonNumeric>, the Company&#8217;s inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4OA_4d9c1dc6-da9c-455d-b6bb-78f97663d7a1" continuedAt="ibf87f4d68a034d21bb232da45c237ca2" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i654eff97c3d6493897900198b7b18f62"><ix:continuation id="ibf87f4d68a034d21bb232da45c237ca2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg5MQ_c3e2d3de-4188-4528-bd80-99c78a05fa44" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4OQ_abd1dafb-3f59-40bd-97f8-5cfff470fb1a" continuedAt="ic12595233e73469ab97a7cceff7a8873" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic12595233e73469ab97a7cceff7a8873">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</ix:continuation>.</span></div></ix:continuation><div id="i557d5d473e994fd0b54aa1f596b2fd9c_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2Nw_9223c22c-a6d8-459f-a891-8d9a2f94739b" continuedAt="i04230c3cc29e4cbd937111de4d61e6cd" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:36pt"><ix:continuation id="i04230c3cc29e4cbd937111de4d61e6cd" continuedAt="i1d3097feb5124bf4a111fc694fe464fe"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2OA_3b545e55-e242-4d91-889d-8d7a7828f11d" continuedAt="i60a6c77757ca4486ba8f7a5c5b64e8ab" escape="true"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i1d3097feb5124bf4a111fc694fe464fe"><ix:continuation id="i60a6c77757ca4486ba8f7a5c5b64e8ab" continuedAt="i966de6a61b1f4f8aa678239803324701"><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:continuation><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i966de6a61b1f4f8aa678239803324701">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</ix:continuation> </span></div><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2NQ_8b2d5752-c505-4724-8d45-1be53291568d" escape="true"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb28ceedb1540108416cb8bca024ee4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC0xLTEtMS0w_a291c283-adea-4716-80c8-03f17ec50db0">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib51ff6fe1df945d6b5eadae49de900c2_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC0zLTEtMS0w_a65cc32f-b47a-4936-a13d-bd3cc4f3a0ac">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b573ab28a7443fb6e2a68919628472_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC01LTEtMS0w_20f071af-4c67-4ed0-9e6e-b1d39101d71a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d06e9e2b764360be3789ec5ab6a466_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS0xLTEtMS0w_90966ee7-616d-4fe3-b264-c5b1a6791cbe">79,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2e9df501b44b06a59a0ece2160ed78_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS0zLTEtMS0w_974f18be-b09e-4e77-862f-8f3d23992aa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d2f52795c84d73812fd8848443f816_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS01LTEtMS0w_ae758fe3-eace-4133-b2b0-50818556b025">79,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73dcce00de9e4cd2b1e37144f3a6efb4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi0xLTEtMS0w_fc4e1a19-a313-4bce-a9cc-6a516635741f">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id543c07e6c994f5e81a39df1116c9a43_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi0zLTEtMS0w_5e27e12e-b2a3-49b3-8124-ea90bafdaa32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb0c9e3480346519ecf6c1f0c46c8d4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi01LTEtMS0w_65bd8721-016d-47cd-8b01-dd30e81eb389">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44450b3df944c238f4634852f259160_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy0xLTEtMS0w_2295c68e-026c-4bb7-bfd9-71da48efe8b4">42,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8321253ab6944229be7fba40e19eaef4_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy0zLTEtMS0w_eadfa205-0ba1-4f07-9bef-2f6083a71ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic17fd2407aa14c1885237d1cc1a99fee_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy01LTEtMS0w_4abb2e1a-d854-4c20-a09c-99d3998aa210">42,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9774f5bea6ae4560a38cc67f40b9694a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS0xLTEtMS0w_05c12200-057b-427e-b6a0-670b862db797">143,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b77778502a64bc1ad848b961aa391bc_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS0zLTEtMS0w_7800f812-cd11-41e8-80a0-d61a41b01f56">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b11553fdaa4460bac14c9901e981643_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS01LTEtMS0w_0a8a7472-1c36-4b8a-9af0-87dc8c700948">126,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3589e18fbb24f8fb2e18deeb6b2ff7b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC0xLTEtMS0w_0c8cacfa-5f88-40ce-89a7-e4a8c9910362">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59efcafb8dc24c15928c3bf8b28d0df2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC0zLTEtMS0w_c859ce7f-02a2-445f-808c-9ca1df46ac1a">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5f4c9915d34ba697c4c5e8998d9344_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC01LTEtMS0w_eb9a6e1e-e978-43f5-82b0-edc0c7028dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1db23c95b04160ac16470c83f6bda2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS0xLTEtMS0w_61eaa00d-7aab-4aba-8207-aa941b9480d6">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12e9d4d981b4c19ba9b2c60dd287996_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS0zLTEtMS0w_734a2b36-43d1-4cbe-be52-c912f90e2372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e33921e4885474fb00cc964f9793e92_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS01LTEtMS0w_613223ce-b0e9-43a9-9f97-1b28c231783d">60,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1b38058b7d418fb1b1f00846e9a5a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy0xLTEtMS0w_e4c98579-cc01-4800-88de-734963f25ec2">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3868bf3d920462993a7d358e34b30d1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy0zLTEtMS0w_47656041-b521-4c5d-bd59-ab7188830fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc01255ced4f4b16a80a1fce94c5ffe7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy01LTEtMS0w_169386cf-2cec-45d4-9e71-6da4909e56d1">33,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0e04aa3d8740cb98428d2ac4def939_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS0xLTEtMS0w_4fa6e61f-798d-4cc6-bcba-a77239c2e990">143,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd632afb09594801ad294cc7d9a4a993_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS0zLTEtMS0w_0b935186-3be9-4871-a479-23f6cae79777">49,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8e49b4de5f49a99c026fef5d247a0d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS01LTEtMS0w_ea8ff338-4326-4916-8e11-e6bffc529d17">94,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i9774f5bea6ae4560a38cc67f40b9694a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMjUwNQ_ce7ad6e5-f9ea-4481-bd9b-d5889bf8731b">34.9</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="iba0e04aa3d8740cb98428d2ac4def939_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMjY1MA_637188b2-bf89-4f40-9388-831b60a2a653">52.0</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfMTAxMA_568ba40f-0ece-419b-b5fc-453d2b4bb3fa" continuedAt="i212e7a46923e49b6a4f9b98606191c4e" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i212e7a46923e49b6a4f9b98606191c4e" continuedAt="i50fc91677d714c6a9465bb1e94c4ae2b"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfMTAxMQ_88083000-8e1a-4ce4-bffe-0c2988a4f492" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi0xLTEtMS0w_9c55ad73-3c81-4939-91b4-cdffcb634c65">79,244</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi0zLTEtMS0w_94e592bc-41cf-4830-a580-be0f1af2de81">5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi01LTEtMS0w_bb3e8a58-28de-492f-b116-6659c2a4142e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi03LTEtMS0w_0f1116fd-fea2-49ef-b9a1-ddb71213c77d">79,249</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy0xLTEtMS0w_969a6207-d4c8-4e6e-aa86-00c5769f6832">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy0zLTEtMS0w_52b47157-fb06-46a7-aa80-0cebbef0329b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy01LTEtMS0w_f5ea98e7-15d5-4929-83bb-274c93eedbec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy03LTEtMS0w_d5873bfd-12a6-4b18-9050-a3c6b3194088">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b46015190047069180f72c9a65f3be_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC0xLTEtMS0w_d597174c-20bb-47ea-9e45-3f06b814bbb7">24,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b46015190047069180f72c9a65f3be_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC0zLTEtMS0w_b1c65b39-2841-4ef9-9d9c-8c9018153336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b46015190047069180f72c9a65f3be_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC01LTEtMS0w_ba1d11ef-9704-4e5a-b23b-4c5abf25b273">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b46015190047069180f72c9a65f3be_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC03LTEtMS0w_73f5fef4-34ee-482f-ab0f-00fda6309aad">24,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS0xLTEtMS0w_884ed37c-04a8-44e8-991e-173cd812fc95">108,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS0zLTEtMS0w_915bb142-08d6-4192-8c41-68baf5339d1a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS01LTEtMS0w_765bea8b-b97d-4140-b539-b83d4799c6bc">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS03LTEtMS0w_8f884f17-ddb2-4ec1-8452-8a14592237f8">108,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi0xLTEtMS0w_85d21c87-6811-4433-bbac-5163af4811a4">60,630</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi0zLTEtMS0w_9eba1c56-6f77-468d-ad81-96a8fbc5ef7c">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi01LTEtMS0w_1f9ef834-22f0-40bf-9ecb-09c86b0adda3">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi03LTEtMS0w_3a518eb1-c495-4a73-9af8-91dde70e360b">60,624</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC0xLTEtMS0w_5571383c-cd42-4186-9699-ac28e851eb0e">30,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC0zLTEtMS0w_7823c6da-a0fb-48c1-b4f9-ce0899dfe9e3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC01LTEtMS0w_5a2e8a4c-a085-4552-8617-d17bbc1a1611">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC03LTEtMS0w_8ae81d9b-3226-49ae-a4a2-e49f40fbecbe">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS0xLTEtMS0w_e2425498-d648-4e77-93f4-0df5a86029c7">91,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS0zLTEtMS0w_47a88a97-d344-4987-a35c-5cad74670756">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS01LTEtMS0w_64d565c5-a923-47b1-8bb8-abccdba1da57">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS03LTEtMS0w_0c017eac-8d43-4d23-bf4c-75490d1fd1c2">91,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i50fc91677d714c6a9465bb1e94c4ae2b">All available-for-sale marketable debt securities held as of June&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfNjc4_9497e606-0069-4a1f-8248-adeb2b9307de"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfNjc4_e417056e-bbb4-41ec-87c3-b39ba19a098f">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RleHRyZWdpb246Nzg4YWM0YjNjMmUzNDAwYWFmMDFmMDcyZDc0NjA1ZDVfNDc2_ca76aeef-df0a-4a93-ba46-f9ffba6338d5" continuedAt="i575883775c724a84bab5c1061c023402" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i575883775c724a84bab5c1061c023402" continuedAt="i31ac14c0820345c490099a60a3eb91a2"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RleHRyZWdpb246Nzg4YWM0YjNjMmUzNDAwYWFmMDFmMDcyZDc0NjA1ZDVfNDc3_e7e04cbf-4ab0-4d18-8650-a31e4249c88f" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMC0xLTEtMS0w_058aadba-8241-4ddf-b575-16259b76f01b">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMS0xLTEtMS0w_7b9bf8f0-1852-4a00-88c5-449999693acf">5,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessAndRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMi0xLTEtMS0w_46391407-7746-4a00-8f44-98c327e6d9df">6,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31ac14c0820345c490099a60a3eb91a2">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA.</ix:continuation>  </span></div><div style="margin-top:3pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_49"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNzY5_2a57a12c-3d3b-4f5c-9c14-f026a1d099f9" continuedAt="i318a5ab6c47d4a609fa61eead17695a5" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i318a5ab6c47d4a609fa61eead17695a5" continuedAt="i9a2a08ffbc80495f8965a116d59ac958">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="iec4534615a7743539c120849d9bac73f_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMjAw_90a9efa1-53fc-4b6e-984c-1617c0206b7b">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNTc2_692a974f-8402-4303-9b51-27add28e538b">3,622,186</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i63752c4319324224891b621130d37dd7_I20210331" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNjQz_c68d1a9c-4e72-4d28-9391-ed14b173a3d3">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNjkw_4178fc80-028f-4336-b04e-d8191a95a968">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a2a08ffbc80495f8965a116d59ac958">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="iec4534615a7743539c120849d9bac73f_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMTA5OTUxMTYyOTI0Mg_46f76411-bbad-4d6e-97f1-7a7974bac04a">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i1fb5607c3098402584a482d05ebd33a4_D20210401-20210430" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMTA5OTUxMTYyOTIyNg_7a067889-c412-4e80-aaab-0613d81d9c55">300.0</ix:nonFraction>&#160;million.  During the three months ended June 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.</ix:continuation>  </span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI3MjI_0e5d6249-b3c5-4ac7-8856-4cbaad7cb79f" continuedAt="i0f43bbab25d64e458f0859e3714e4f46" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="i0f43bbab25d64e458f0859e3714e4f46" continuedAt="ia2045f90b63840cba3f7b84332f1354c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9a811db172dc46c389a4e8977a0b88f8_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjg5_514ddb46-a1b0-4ab6-ad9a-a134568c552a">150.0</ix:nonFraction> million in 2017.  In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. The PDUFA target action date for retifanlimab was July 25, 2021. On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its BLA for retifanlimab.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI1MA_145f8df4-5664-4b3f-9deb-1318ae206280">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTMwNA_08462610-aa3e-4c5f-bb67-ba9f8b45d297">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQyMw_8f04a492-3502-4c68-ba6b-7d72eb9ceda3">70.0</ix:nonFraction> million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i6d4183f898a0423387191ba8e659530d_D20170101-20171231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTU5OA_7e31e45f-cff9-4f9b-a096-6884de2a2b4d">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="idc63dbbc38b240d1af689f955b93c987_D20170101-20171231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTYwNA_18754aea-a40f-4314-b499-e38d8fd67413">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated the Incyte License Agreement under ASC 606 and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjE0Ng_50f9fac0-5288-4ce8-a210-07cd85be2c8d">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjkzMw_957634a0-c1ae-4be3-a241-b7b77355ef82">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, it became probable that a significant reversal of cumulative revenue would not occur for deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lopment milestones totaling $<ix:nonFraction unitRef="usd" contextRef="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDUxMg_8f04a492-3502-4c68-ba6b-7d72eb9ceda3">70.0</ix:nonFraction> million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Therefore the associated consideration was added to the estimated transaction price.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="if8dec3cac0d747668fbb6d511275eb4c_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDc4OA_4199fd66-4e30-4dfb-949a-b7c0b2b8a24b">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $<ix:nonFraction unitRef="usd" contextRef="i7ed1c4f887fe4a6ab8129e8f4d557b41_D20170101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDkxMw_5cc5ab08-bfc0-483b-8ad5-8b939f3336e1">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the three and six months ended June 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it became </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia2045f90b63840cba3f7b84332f1354c" continuedAt="i000295cc635e4b40a14855976b6ea1ba"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">probable that a significant reversal of cumulative revenue would not occur for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $<ix:nonFraction unitRef="usd" contextRef="i18c024e23c894d508ae4b2d764a1da84_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyOTk1MA_0771bb88-3117-4a75-ad98-73ebd6fa46f4">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9def7feacecb40599d50a6c2b00e945b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNTcyMg_fe3b6d5c-ade8-4a64-8197-c455d59b2782">15.0</ix:nonFraction> million in milestones related to development progress of retifanlimab, respectively, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. <ix:nonFraction unitRef="usd" contextRef="icc58eaa1973040f49a6096c0ae8ec4e8_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNTM0OA_df10cece-2790-41fb-8a21-32e506b30f23"><ix:nonFraction unitRef="usd" contextRef="iec2554e54b31431db356c26b68680c0d_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNTM0OA_f9c25227-de23-4493-ac80-9128c34ace18">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2020.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id94ec4f166294424905e9b5dfce87d38_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjQ3NA_10c958a5-ab2c-47d8-bea0-a2949790fc61">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i44ea624c784446d2945c9719b9e70291_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjQ4MQ_3c48e161-145a-40ef-b450-1be8e72e098c">1.5</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i0b9ef71b5922414e9101d383252c8b6c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI4Mg_bccb9cb0-91cd-4bbe-b4dd-05c2d441af27">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i497d64ec91f141f692c999a205a6507b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI4Ng_a4bbc62e-0d35-42c4-b352-61e6573459fc">7.4</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  six months ended June 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8a034427f78f478893b443a6a23c1cd9_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzM1NQ_73f16751-63f6-4e21-96c5-7649bb74dc17">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7dd946ed05704d57ad5030149625825b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI5Mw_7084dec6-b01d-44ea-a6d0-8f8cae1c8647">5.9</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODY1NA_4a1f2d6b-cbce-41f4-95ed-b123383665cf">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODY1OA_4429d9fe-c2fc-4725-b602-2b6582c233fd">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODcwNw_c2efa122-f941-4ebd-b726-a05e5ea172d6">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i858f318333da414da051fa53d0aed818_I20200331" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODg1Mw_76cc3c25-6546-4a72-bc40-e303f05d32d2">140.0</ix:nonFraction> million in development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODg5OA_06b079e4-671d-4b8f-acbf-dc6dcb4a491d">4.0</ix:nonFraction> million of which ($<ix:nonFraction unitRef="usd" contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODkxMQ_a27fc0b4-6757-4f65-aa2a-46bd1b26542b">3.6</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODk2MA_1f57fa2d-5104-4f1b-90dd-c2afafafdda5">0.4</ix:nonFraction> million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="i7bbaab8beada4a8e8fd4d70b878b36f9_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfOTExNw_95abfbe8-cbd2-44c0-80fb-427d66755b19">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="ia4f6d5d295fa4f4ab2ad7678c47b90a0_D20180101-20181231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfOTI0MA_76167091-3687-476c-8d2b-37f9b241a5bb">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i000295cc635e4b40a14855976b6ea1ba" continuedAt="i797aa554778340ab88d77f6bcd70b514"><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA1NDA_4429d9fe-c2fc-4725-b602-2b6582c233fd">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id4e465ebe0e74740a272ba2347ea429d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY5MTgxOA_af8d8d17-9f45-43bd-bd0f-8e90e0710fa4">3.6</ix:nonFraction>&#160;million during the six months ended June 30, 2020 under the 2018 Zai Lab Agreement.  There was <ix:nonFraction unitRef="usd" contextRef="i4f0836069df741f4b40628f7e6d2e4cf_I20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI2NTk_8f5619c3-b9ba-420e-8f4f-c4260d1c7d04"><ix:nonFraction unitRef="usd" contextRef="i70c80046e2754387bbfb3a68414afafb_I20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI2NTk_dd36a190-76dd-423c-849d-4ed2170222d8">no</ix:nonFraction></ix:nonFraction> revenue deferred under this agreement as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i718f9275d3084eed957a877fcabb3eed_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjUxOA_88ea5fce-753d-4e0f-af1b-5701f66dfee6">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i624b7721e711450790fb78703bdfac0e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjUyNg_ffdf265f-b322-4642-b1ec-d2aa2cec9490">0.3</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id74f1cf826ca407fb2869bea2077efc9_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjYwMQ_2cd8761d-ba03-49c2-9918-f90efb5ad153">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1fa68fb09ce643209722e4c7061f1dc6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjYwNQ_093044d6-b599-4eb7-9b4f-5958c3cda24c">1.3</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $<ix:nonFraction unitRef="usd" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptInFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzI3Mg_4726a58d-c838-42d4-ad47-cbdeffe03320">85.0</ix:nonFraction>&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab will pay the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzI5Mg_245fb328-42fa-4724-98dd-f58f791d69b8">25.0</ix:nonFraction>&#160;million, which was received in July 2021. Additionally, as part of the consideration for the rights granted to Zai Lab </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i797aa554778340ab88d77f6bcd70b514" continuedAt="i5a097f4b0bf04cd4977831b43df725b7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab agreed to pay the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTgyOQ_9bcad282-3665-4eee-a4ef-4988c1bdca6b">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4ODAwNg_555216f5-7f85-46fc-bf1a-ce33b4b51ff5">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTg5Mg_e633e453-4cf2-4a3b-84a5-928c5caa5eda">31.30</ix:nonFraction> (Offering) which represented a $<ix:nonFraction unitRef="usd" contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTkyNQ_c681adf4-ece1-4f11-940b-b46dcd14a79c">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzMxMg_b737c98f-584f-4c68-9f56-30e134c4e1ef">800.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzMzMw_cf67daf3-3919-4983-8f15-a7f614ab46d9">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQzOA_4fef8785-c958-41eb-b0d4-b5eb180e1ef9">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ1NQ_cfa54518-51f6-43c1-9aff-da4675744aa4">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ3Mg_f7e3f32e-6097-43fd-8493-85140015a13d">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the estimated $<ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ4OA_aa185b4c-6397-4eac-bfe1-46428c769e0b">5.0</ix:nonFraction> million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUwNQ_34b20825-5bf2-437e-977a-17c957abd8fe">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services  performance obligation will be recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i77288252481a45bb8d2a69bd1cc3b2df_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUyMg_67700b62-91bd-43d8-ac8d-e9d85364c5d9"><ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUyMg_f0fe827a-2e62-40fc-a567-cc8d597f8bd9">14.4</ix:nonFraction></ix:nonFraction> million under the 2021 Zai Lab Agreement.  The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUzOQ_60651bbd-7c0f-49c9-b497-d4080eaab55c">25.0</ix:nonFraction> million and the purchase price premium under the Stock Purchase Agreement of $<ix:nonFraction unitRef="usd" contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PremiumReceivedOnStockPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU1Ng_d1442c32-2987-49b2-a671-875d6444ccd9">10.4</ix:nonFraction> million were recorded in Accounts receivable as of June 30, 2021 as the Company has an unconditional right to the payments under the 2021 Zai Lab Agreement and the Stock Purchase Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i8c57174988914ce89f16563fb7997562_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU3Mg_7223eafa-f899-4c82-8228-e1d3bcc6fac9">21.0</ix:nonFraction> million in deferred revenue under the agreements, $<ix:nonFraction unitRef="usd" contextRef="i8c57174988914ce89f16563fb7997562_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU4OQ_cf587f33-58ea-44a9-8303-f9d113cfa66b">13.2</ix:nonFraction> million of which is current and $<ix:nonFraction unitRef="usd" contextRef="i8c57174988914ce89f16563fb7997562_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzYwNQ_4a12d99f-73ef-4c67-b14c-c3e23811dc57">7.8</ix:nonFraction> million of which is non-current.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i5a097f4b0bf04cd4977831b43df725b7" continuedAt="i3a43299148684e80b3afe248350b836c"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQxNzA_e0406597-99ec-4365-acf1-b9cb64eabd8a">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i60c54b835f12476ebcd59fb59d9aee2b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQyOTk_7080cd8a-adba-4bc4-8d2f-88afb3aacab1">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQzNjQ_8a044d3d-f5d5-4c2c-a2ea-01fcb58872da">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i60c54b835f12476ebcd59fb59d9aee2b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTU0NDM_fde69e85-1839-4462-b61f-60f425e9138b">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="iea4736835e9e45ac8018479c040ee6e8_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTcwNTg_759a6ec5-51db-4a3f-bc50-3d878bd1ff29">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $<ix:nonFraction unitRef="usd" contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTcxOTI_dcfecf66-5b26-48b6-9125-47b263c8ea58">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three and six months ended June 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ibfc33644441d49b491f669f6cee3cf52_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDM5ODA0NjU3NTE3NA_26448271-cca6-4da3-ae3f-e378a3a43b00">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib4ee5d7224384f51ae4351da2491f793_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjQ1Mw_205e6dbb-bb59-4a5d-ad16-d6cc3e23c9b1">0.9</ix:nonFraction>&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgxNTE_05681fc6-11b5-4ebc-94e6-7854757cf878">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="ia1829ff483154e78a6241246422a7a16_I20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgyNjA_6f5c5c52-7a14-44b2-9141-0636b8dd52f3">135.0</ix:nonFraction> million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="i08846d12a1824787806650566090f18b_D20190101-20191231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgzODk_6adb7e60-9cdc-47dd-b029-e61dab1f0606">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTkxOTA_05681fc6-11b5-4ebc-94e6-7854757cf878">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTk2MDU_69d676d1-b8be-4cd7-b03e-523ff705e17e">1.0</ix:nonFraction> million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i3a43299148684e80b3afe248350b836c" continuedAt="id6778213f1f44e509eeeca77fa5fb435"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ic1a3cd8312cf4cf6b4d17e604f6ff948_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjgyNg_11b335b3-af48-41a9-8b5b-a89b75b0b7ec">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1a108cdbe85846dcb5a3e8fb692e07e0_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg0Mg_1a4a57e0-114c-4833-ae14-50bbec763f61">1.4</ix:nonFraction> million, respectively, under the I-Mab Agreement.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i4f8bc10e870f423c915193a8d2f50a02_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg1Nw_625affbe-10b1-4e40-a999-b73605330c02">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i05ac94940d774c9cb563d01ff4332791_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg3Mg_d4ec40df-a70b-46bf-8dae-54cb6f9d3ab5">2.5</ix:nonFraction> million, respectively, under the I-Mab Agreement.  At June&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEwOTU_671bf42d-cf9b-463f-b85b-a74732cb2b13">9.0</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjExNDQ_d84a0687-d1c6-40eb-91b7-e0b58ad8c830">3.4</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjExNzI_a6410593-9a86-4941-9fe0-390b3174a5a5">5.6</ix:nonFraction> million of which was non-current.   At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyMTA_a838f044-fee4-44d3-83bf-441c818c11c4">11.4</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyNTk_2ffbba1e-09fa-456c-ad9b-c4b9900517f0">4.5</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyODc_798ac71a-aafa-4863-8a50-15d20bd9b884">6.9</ix:nonFraction> million of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjE1MjM_a55924de-25f2-4ad5-8838-086e90597ce6">two</ix:nonFraction> DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id6778213f1f44e509eeeca77fa5fb435">The NIAID Contract includes a base period of up to $<ix:nonFraction unitRef="usd" contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIwODc_3c3a9764-202d-407c-a3c6-f73967f9226b">7.5</ix:nonFraction> million to support development of MGD014 through Investigational New Drug application submission with the FDA, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIyMTA_4106cce8-7e74-413f-8cf4-1d8169a45cfb">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIzNTg_ec7746bb-0af2-4d2b-bf75-9a32074559a4">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $<ix:nonFraction unitRef="usd" contextRef="i4e56a7a7446f43fe9e4dab1edaa5b3f0_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI1MDg_3ea4bd65-f115-49c0-9fd9-091c70a3d3f7">10.8</ix:nonFraction> million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="idf108d05a1a844ecbaf4f2cf4c8dd881_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI2OTI_011498c4-ad1d-4686-bd25-7e6f04bab9e3">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i85050d9a6f47489bab0765376deae7a9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI2OTk_f3c70ed6-4132-4254-9e04-d8a0de04eaa2">4.6</ix:nonFraction> million, respectively.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="i909de857ac8e40dc9bbdd2e2b24cd20d_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzEzOQ_b25fc4e0-100c-4f7f-a1db-308bee87738d">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i878570654cf7443295140f93cce32043_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzE1NA_fdf7a9f0-8115-423c-85d2-12f762fc8446">5.3</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Nw_8f194eda-9a9c-4296-8c35-1020d0d3975b" continuedAt="i76fc14f06b66458987bed86a9659fc3f" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i76fc14f06b66458987bed86a9659fc3f" continuedAt="ic407635bed50411299f863f08d140605"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="icc441b45390e4e3fbbfbe489832ffed0_I20170531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDI3_a68aa9b2-cb98-41d2-a89d-e54bdf37c2cd">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNjI2_ea7e621d-d608-48a0-94fb-c63012fed5da">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfODcz_478b11f0-1813-4071-8f5d-a4af6c2aabaf">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i0b3e59b96ba24ec9bcac6649b8b2df22_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMTAwMw_d9c82e5b-f229-4710-86f1-60c9f7f308d1">12,305</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMTkyNQ_4a54d5ef-8be8-4ee0-abac-6d0fd99c761c">203,138</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjAwMw_47fb7138-8cab-415e-9f47-ad213aa998cc">2.98</ix:nonFraction> per share.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic407635bed50411299f863f08d140605" continuedAt="i503b8de9ad7c45ea975c01cc3c1781bb"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjQxNQ_7eaa4a29-a749-4078-b76d-e81daedaf61a">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i0031895b9ddb486c9acfd64f0d661e1e_D20210101-20210630" decimals="3" format="ixt:numdotdecimal" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjQzMA_529d534a-c98f-4fd2-8242-145d37039744">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjc4Mg_8a6363bc-85c0-4775-aa70-c25d4096a0e5">13,856,781</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2021, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzM1OA_0d99606b-8d00-44ad-a07d-4d033d29a6b3">8,407,760</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzQzNg_30abb13d-e4e8-4ab0-ad31-88dd52f06b65">21.92</ix:nonFraction> per share under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0NA_cbe5c669-1bfe-4e61-9984-8dbb09fb4430" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda53c5d5b224a6bad5e09031f6b7b9b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi0xLTEtMS0w_2ae0a14f-88cb-4dcc-8ff1-f40267777c78">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7422fa11414ef6a298de5f4f194412_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi0zLTEtMS0w_21be2f55-9927-4575-9d71-f93e28e8c8be">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e4b9564f0e4552a41d250e30a98c66_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi01LTEtMS0w_1d80e66c-f948-4e76-a621-2da41c332945">5,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3aad52d4204392803f61f058015d65_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi03LTEtMS0w_29afd018-ca29-443e-b875-f874d52f7b2e">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbd69658d2544488a8943aea2078bc1_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy0xLTEtMS0w_0ab41700-121a-4f70-91cb-ffdf58e03eef">3,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53482425e144ebf87797a8800447626_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy0zLTEtMS0w_50c08340-8528-4c73-8fa2-801aa26a4d83">2,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8751554712487b9de2c28ecbbfccf0_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy01LTEtMS0w_2a4c2a22-141a-446b-a827-93c391f25ab7">5,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd60f01b1334bea880a5f387322b593_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy03LTEtMS0w_6f8a5563-783e-4390-bf8d-23e49521da1b">4,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC0xLTEtMS0w_de423ed4-aa50-48c4-9d27-536a6d0d2f02">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC0zLTEtMS0w_023a64d2-d7e5-49f4-a035-40a8ba337d20">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC01LTEtMS0w_ffd9e1bc-e91c-46f9-833b-20d096065aa9">11,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC03LTEtMS0w_f6e2e9d9-8791-492d-9442-081b09e8cf9f">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0OQ_087d518a-ea97-4baf-808f-5881c69a3435" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMi0xLTEtMS0w_05b69344-d099-465c-b7cd-4ebc13a4adb2">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMi0zLTEtMS0w_e7600cf2-378a-4e15-8652-de2c69fb074d">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0xLTEtMS0wL3RleHRyZWdpb246MGI3NDE0ODYwOGY1NDYzZDg4ZTc5ZDkwNjcwOWJlNTJfNA_5223ae19-9ca0-4776-b384-60a5232b5854">86.2</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0xLTEtMS0wL3RleHRyZWdpb246MGI3NDE0ODYwOGY1NDYzZDg4ZTc5ZDkwNjcwOWJlNTJfOA_f43be911-a560-4cba-af70-4d041b107c1c">86.7</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0zLTEtMS0wL3RleHRyZWdpb246NTE4NTQ5NmE3ZTBlNGQ4YWE0OTUwYTU5M2JiNTc2OGFfNA_263ed3f2-c7a3-4149-b256-b57d7f98896f">67.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0zLTEtMS0wL3RleHRyZWdpb246NTE4NTQ5NmE3ZTBlNGQ4YWE0OTUwYTU5M2JiNTc2OGFfOQ_efda3646-a582-4c7f-b226-3ff5d4fa0803">108.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0xLTEtMS0wL3RleHRyZWdpb246OTI1MmI0M2EzNGU5NGZmZmEzNGZhMWVkNDc0N2Q0ZTJfNA_c986606c-62d6-429e-9ed0-2a9f7ca81095">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0xLTEtMS0wL3RleHRyZWdpb246OTI1MmI0M2EzNGU5NGZmZmEzNGZhMWVkNDc0N2Q0ZTJfOQ_fe821811-0d61-4ccf-8a79-9b523f781c6f">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0zLTEtMS0wL3RleHRyZWdpb246YjRlNzRlYzBiZjgzNGVlNWE3NjM1Nzc0YmE2NzNiZDZfNA_f4ed76ae-78e1-4ec5-b952-7ae285761ec0">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0zLTEtMS0wL3RleHRyZWdpb246YjRlNzRlYzBiZjgzNGVlNWE3NjM1Nzc0YmE2NzNiZDZfOQ_aea767e9-cc58-414a-8676-cba1e35ed510">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNS0xLTEtMS0w_346d91fe-1f3c-46f7-ad7e-a798645bb8f7">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNS0zLTEtMS0w_ef03166e-c5cd-4303-adb8-6138a1759b34">6.25</ix:nonNumeric> years</span></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM1MQ_a5257f0e-7e0e-4a2e-a9ec-46e04f4f3307" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS0xLTEtMS0w_7d83f83f-c499-4427-ac6a-15cb28b871c9">7,258,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS0zLTEtMS0w_5a0f6b00-5292-4eaa-a089-2ac3be8b1d0c">21.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i801e96d91e944a44bdd5ee5ed3764993_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS01LTEtMS0w_1e19492e-4146-41a9-83ef-c3e0d93d95dc">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMi0xLTEtMS0w_168e115a-5f79-44ae-8a15-6cc1a8658710">1,790,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMi0zLTEtMS0w_389b08a9-5e16-4e57-a478-1fb9283f18b4">20.72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMy0xLTEtMS0w_a4782a1a-e89b-4bb5-8f32-204826d16488">250,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMy0zLTEtMS0w_0137e945-6016-451b-944a-4314f4617942">18.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNC0xLTEtMS0w_ae6ca31f-4f38-46b7-a5dc-82dd23e1fe4e">187,526</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNC0zLTEtMS0w_a2ec16b5-f203-4546-8e83-ceccfba4162c">16.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS0xLTEtMS0w_5b79bcd9-2280-462e-b86d-19b6f772ce67">8,610,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS0zLTEtMS0w_eb18587e-9feb-43bb-b0b4-fc7ec9ee11fa">21.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS01LTEtMS0w_7a3cd65d-07a8-4b3a-90be-19a8a517ce50">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS03LTEtMS0w_66ece1dd-e5ee-49dd-96c2-a5cd457253e2">53,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy0xLTEtMS0w_34c917f3-b5e3-4a8b-a659-d36023acee80">4,957,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy0zLTEtMS0w_1e793352-cee3-46ae-a086-00834161c5c2">22.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy01LTEtMS0w_2b984c12-e4be-4c17-b9ef-ce7fed77c074">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy03LTEtMS0w_8ecfe9d1-3f22-4127-98b8-3a9631192c3b">25,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC0xLTEtMS0w_1531a7bd-dbbf-445a-aa82-c83635bab1d0">8,194,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC0zLTEtMS0w_cab02188-ff20-4625-a294-787fe1fc94ef">21.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC01LTEtMS0w_2c8bbc88-c6c4-47f6-98aa-f582624e52cb">6.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC03LTEtMS0w_6b37240b-d308-428e-a1b8-c7c674dd904e">50,662</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzk3NQ_65e1c13e-6d34-4ab0-a089-5dbaf23608be">15.11</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzk4Mg_5145cf39-bdc4-482d-a11f-775715ad8fcf">8.30</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDEwMg_dfcfa30f-79be-4f33-bac1-d882e122ca0a">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDEwOQ_4d68d9a2-0d2a-4083-b623-05d61e2bd70a">2.6</ix:nonFraction> million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDIyOQ_45712c5e-98a0-44ae-8010-df6ac9351b8b">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDIzNg_405593f0-f7ef-4090-8d38-b562b466b214">2.4</ix:nonFraction> million, respectively.  The total fair value of shares vested in the six months ended June&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDM0NA_95392587-7d76-442a-bb74-76d182270db8">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDM1MQ_8b21d43c-bb2d-47d5-a702-8cb5d4db9e9e">7.4</ix:nonFraction> million, respectively. As of June&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDUxMw_ec93fc5c-9f8e-4732-a4c5-0675ead90185">40.9</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDYwNA_be6693a9-258a-4096-bd06-11014ce9ed19">2.7</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i503b8de9ad7c45ea975c01cc3c1781bb"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Ng_685ac825-d7a8-4da1-aa8f-49f43073bcb3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia217df68ded645e8b6c9001175c243cc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMS0xLTEtMS0w_377af55b-bc02-408e-a9a1-c3df164556da">209,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia217df68ded645e8b6c9001175c243cc_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMS0zLTEtMS0w_6633191c-4be6-49d1-8cf4-788e9d343501">15.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMi0xLTEtMS0w_128e621b-0f5c-484f-9468-1563935b95ae">10,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMi0zLTEtMS0w_2bece42c-22cb-46ac-9a9e-ae3905676ffe">29.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMy0xLTEtMS0w_67d183d2-f57d-482a-a29e-c9441dc9517b">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMy0zLTEtMS0w_3e861b47-64fc-4788-9d0e-42a3bbe49784">23.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNC0xLTEtMS0w_9c8ec305-0ebc-43aa-8fcb-11ad73022e28">17,400</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNC0zLTEtMS0w_df5ca32a-0717-4210-922f-0277bd1cc1fd">15.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNS0xLTEtMS0w_8472aad0-2725-4542-973d-0ea257c74f91">194,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNS0zLTEtMS0w_c97bcb85-1547-4a67-8513-a2a16dfaed23">16.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTE3Ng_c5ee9173-fa57-4e9e-a900-5db74a7db001">0.8</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately <ix:nonNumeric contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Mg_7cfa8f59-a990-4531-a6ca-771a291652b2">1.3</ix:nonNumeric> years.</span></div></ix:continuation><div id="i557d5d473e994fd0b54aa1f596b2fd9c_58"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181OC9mcmFnOmZjZmYyYmQ0Mjg2ZDQ1N2ViYTI4Y2VjNjg0YTVjZThiL3RleHRyZWdpb246ZmNmZjJiZDQyODZkNDU3ZWJhMjhjZWM2ODRhNWNlOGJfMTE3MQ_bca6538c-1649-4c53-8ba6-396f0d822ce5" continuedAt="ie1e508f103434fec9a0ed1aac1ff6281" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1e508f103434fec9a0ed1aac1ff6281">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation>   </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We launched MARGENZA in March 2021.  In addition, we have a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of June&#160;30, 2021, as well as consideration received from Zai Lab in July 2021, anticipated and potential collaboration payments and product revenues, should enable us to fund our operations through 2023, assuming our programs and collaborations advance as currently contemplated. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2021, we had an accumulated deficit of $863.0 million. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials, and incur costs related to commercial product sales.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic and its variants are evolving and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Form 10-Q and "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition. </span></div><div><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. The PDUFA target action date for retifanlimab was July 25, 2021.  On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its BLA for retifanlimab.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones. We received $70.0 million of the total development milestones through June&#160;30, 2021. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement). </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already received $4.0 million ($3.6 million net of foreign withholding tax). In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay us $85.0 million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab will pay us an upfront payment of $25.0 million, which was received in July 2021. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab agreed to pay us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs under the 2021 Zai Lab Agreement, we could receive up to $1.4 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/> <br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay us tiered royalties ranging from mid-teens to 20% on annual net sales in its territories.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. Except as described below with respect to revenue recognition for product revenue and inventory, during the six months ended June 30, 2021, there have been no material changes with respect to our critical accounting policies disclosed in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource the manufacturing of MARGENZA. Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, we began capitalizing MARGENZA inventory costs.  We value our inventories at </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lower of cost and estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. We perform an assessment of the recoverability of capitalized inventory during each reporting period, and we write down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, our inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). We have written contracts with each of our customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell our product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred to ship the product were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may provide customers with discounts which are explicitly stated in our contracts.  These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. We have determined such services received to date are not distinct from the sale of products to our customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, we offer the specialty distributors product return rights pursuant to written contracts and/or our returned goods policies. We estimate the amount of  product sales that may be returned by our customers and record an estimated liability and a reduction of revenue in the period the related product revenue is recognized. We currently estimate product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since we do not have our own returns experience. Our estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to our customers who directly purchase the product from us. In such cases, customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and we generally issue credits for such amounts within a few weeks of the customer&#8217;s notification to us of the resale. Chargebacks consist of credits we expect to issue for units that remain in the distribution channel at each reporting period end that we expect will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which we have not yet issued a credit. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. Our liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:39pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three and six months ended June&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue of $10.5 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $5.0 million development milestone from Incyte</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to retifanlimab;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $14.4 million in revenue from the 2021 Zai Agreement executed in June 2021;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.8 million recognized under the Incyte Commercial Supply Agreement which was executed in late 2020; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.2 million in net product revenue from sales of MARGENZA which was approved by the FDA in December 2020.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition during the three months ended June 30, 2020 of a $12.0 million payment from Boehringer Ingelheim International GmbH for retention of rights to two DART molecules; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $4.2 million in revenue recognized under the National Institute of Allergy and Infectious Diseases (NIAID) contract due to decreased development costs related to the second DART molecule. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue of $13.8 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $15.0 million in development milestones from Incyte</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to retifanlimab;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $14.4 million in revenue from the 2021 Zai Agreement executed in June 2021;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6.0 million recognized under the Incyte Commercial Supply Agreement which was executed in late 2020; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.1 million in net product revenue from sales of MARGENZA which was approved by the FDA in December 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition during the six months ended June 30, 2020 of a $12.0 million payment from Boehringer Ingelheim International GmbH for retention of rights to two DART molecules;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $6.6 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $4.1 million in revenue recognized under the  NIAID contract due to decreased development costs related to the second DART molecule; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $3.6 million in revenue recognized under the 2018 Zai Lab Agreement due to a milestone being recognized in the first quarter of 2020.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the three and six months ended June 30, 2021 consisted primarily of product royalty fees. Product sold during the three and six months ended June 30, 2021 consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA. This minimal cost drug product had a positive impact on our cost of product sales and related product gross margins for the three and six months ended June 30, 2021. No similar cost of product sales was recognized during the three and six months ended June 30, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three and six months ended June&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:34.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  Includes research and discovery projects, as well as early preclinical and terminated molecules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended June 30, 2021 decreased by $1.6 million compared to the three months ended June 30, 2020 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial and Biologics License Application support costs for margetuximab;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to tebotelimab;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to our HIV government contract; and </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial enrollment costs related to enoblituzumab.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These decreases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">increased development, manufacturing and clinical trial costs related to MGC018; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">increased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte under the Incyte supply agreements.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expense for the six months ended June 30, 2021 increased by $2.7 million compared to the six months ended June 30, 2020 primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased MGC018 development, manufacturing and clinical trial costs related to our Phase 1 dose expansion study;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased flotetuzumab development and clinical trial costs related to our Phase 1/2 dose expansion study; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to our MGD019 Phase 1 dose expansion study.</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These increases were partially offset by:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte under the Incyte supply agreements;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial and Biologics License Application support costs for margetuximab;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to tebotelimab; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and manufacturing costs related to our HIV government contract.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our research and development expense will continue to increase as we progress our pipeline of product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $5.0 million for the three months ended June 30, 2021 compared to the three months ended June 30, 2020, and by $9.8 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020, primarily due to costs related to the launch of MARGENZA in 2021.  We expect our selling, general and administrative expense to continue to increase as we continue to launch MARGENZA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income for the three and six months ended June 30, 2021 compared to the three and six months ended June 30, 2020 is primarily due to decreased investment income.</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments,  to support our product development activities. There can be no assurances that new sources of capital will be available to us on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of June&#160;30, 2021, plus consideration received from Zai Lab in July 2021, as well as anticipated and potential collaboration payments, and product revenues should enable us to fund our operations through 2023, assuming our programs and collaborations advance as currently contemplated.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to our business, the COVID-19 pandemic might unfavorably impact our ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic and its variants, we will continue to evaluate the nature and extent of the impact of the pandemic on our business and financial position. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the six months ended June&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was primarily the result of our net loss, adjusted for non-cash items. The six months ended June&#160;30, 2021 benefited from the $15.0 million milestone payment from Incyte and the six months ended June&#160;30, 2020 benefited from the $3.6 million development milestone from Zai Lab.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the six months ended June 30, 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  Net cash provided by investing activities during the six months ended June 30, 2020 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June&#160;30, 2021 reflects net cash proceeds from our securities offerings of approximately $98.2 million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission (SEC).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities of $297.3 million.&#160;&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_85"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2021. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of June&#160;30, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended June 30, 2021 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_88"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_91"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other  intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See note 9, Commitments and Contingencies, to the consolidated financial statements of this Quarterly Report on Form 10-Q for more information.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_94"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_490"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2021, we entered into a stock purchase agreement in which we agreed to issue and sell to Zai Lab an aggregate of 958,467 newly issued shares of our common stock (Shares), with a per share purchase price of $31.30 for aggregate gross proceeds of approximately $30.0 million. We completed the private placement on July 1, 2021. Our offering and sale of the Shares were made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. For more information, please refer to Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation - Collaborations - Zai Lab" in this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101collabliczairdct.htm">Collaboration and License Agreement by and between the Company and Zai Lab US LLC, dated June 15, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102stckprchsagrmntz.htm">Stock Purchase Agreement by and between the Company and Zai Lab Limited, dated June 14, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q22021.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q22021.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q22021.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q22021.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8224;  Portions of this exhibit (indicated by asterisks) have been omitted.</span></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i557d5d473e994fd0b54aa1f596b2fd9c_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: July 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101collabliczairdct.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9d13feba75204fc181fef891e9ff038e_1"></div><div style="min-height:48.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-top:0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.85pt;padding-right:18.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Collaboration and License Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), effective as of June 15, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is entered into by and between MacroGenics, Inc., a Delaware corporation with a place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Zai Lab US LLC, a limited liability company organized under the laws of the State of Delaware, the United States, with a place of business at 1440 O&#8217;Brien Drive, Suite C, Menlo Park, CA 94025 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). MacroGenics and Zai may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.77pt;padding-right:18.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of patients with cancer, inflammatory and infectious diseases&#59;</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zai has expertise in the research, development and commercialization of pharmaceutical products&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zai and MacroGenics desire to enter into a collaboration for the development of certain bi-specific antibodies based on MacroGenics&#8217; proprietary DART&#174; and TRIDENT&#174; platforms, and if approved for commercialization, the commercialization of such bi-specific antibodies in the Territory (as defined below), pursuant to the terms and conditions set forth in this Agreement&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics desires to grant to Zai, and Zai desires to receive, an exclusive license to research, develop, manufacture and commercialize bi-specific antibodies based on MacroGenics&#8217; proprietary DART&#174; and TRIDENT&#174; platforms in the Field in the Territory, pursuant to the terms and conditions set forth in this Agreement&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics desires to grant to Zai, and Zai desires to receive, an option to convert a royalty arrangement into a profit and loss sharing arranging with respect to certain bi-specific antibody- based product(s) on a worldwide basis, pursuant to the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:18.9pt;padding-right:18.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.75pt">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EFINITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set forth below&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a therapeutic bi-specific molecule which binds to &#91;***&#93; and CD3 and is generated from MacroGenics&#8217; proprietary DART or TRIDENT platforms.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Opt-In Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the (a) &#91;***&#93;Territory&#59; (b) the countries, regions and territories of &#91;***&#93;&#59; and (c) Europe.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.05pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Profit Share Option Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (a) eighty-five million US Dollars ($85,000,000) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b) an amount equal to the total </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93; Research Costs incurred by both Parties pursuant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Section 4.2(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">as of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Opt-In date.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a product that incorporates a &#91;***&#93; Molecule as an active ingredient.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_4"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Profit Share Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 5.1(e).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Research Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.2(c)(i).</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Greater China, Japan and Korea.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.55pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the program of activities conducted by the Parties under this Agreement for the Development and Commercialization of the &#91;***&#93; Molecules and &#91;***&#93; Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) with respect to MacroGenics, U.S. generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as consistently applied, and (b) with respect to Zai, International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acting Improperly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(b)(i).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adverse Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any adverse medical occurrence in a patient or clinical investigation subject to whom a Licensed Molecule or Product is administered and which could but does not necessarily have a causal relationship with such Licensed Molecule or Product, including any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the administration of such Licensed Molecule or Product, whether or not considered related to such administration.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means with respect to any Party, any person or entity controlling, controlled by or under common control with such Party. For purposes of this Section 1.12, &#8220;control&#8221; means (a) in the case of a corporate entity, direct or indirect ownership of at least fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such corporate entity and (b) in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all international, national, federal, state, regional, provincial, municipal and local government laws, rules, and regulations that apply to either Party or to the conduct of any Development, Manufacturing or Commercialization activities under this Agreement including cGMP, GCP, GBPS, and the laws, rules and regulations of the ICH, the United States and any country or Region in the applicable Territory, each as may be then in effect, as applicable and amended from time to time.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to a Target selected by a Party in a written notice pursuant to Section 4.1(a) or Section 4.1(b), &#91;***&#93;.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_7"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product sold in a country or Region, a product that&#58; (a) is marketed by a Third Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship with, either Party or any of its Affiliates or Sublicensees&#59; and (b)(i) contains the same or similar amino acid sequence as the applicable Product, or (ii) has been granted Regulatory Approval as a biosimilar or interchangeable biological product by the applicable Regulatory Authority according to a biosimilar regulatory pathway that is materially equivalent to that of Section 351(k) of the US Public Health Service Act (42 U.S.C. &#167; 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Biologics License Application or New Drug Application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) filed with the FDA for marketing approval of a Product or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings with applicable Regulatory Authorities (including the NMPA), for approval to commercially market, import and sell a Product. The term BLA shall exclude pricing and reimbursement approvals.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a day on which banking institutions in Washington, DC, USA, Boston, MA, USA, Hong Kong, and Shanghai, PRC are open for business, excluding any Saturday or Sunday.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the respective periods of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PHS Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and in regulations at 21 C.F.R. Parts 210, 211 and 600, as in effect at the time when any Product is being manufactured for clinical development or commercial use, when any Product is being sold or when any clinical trial regarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are interpreted and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards, and the equivalent legal requirements in other applicable jurisdictions, all as the same may be amended from time to time.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;&#91;***&#93;&#8221; means a therapeutic bi-specific molecule which (a) binds to CD3 and  &#91;***&#93;&#59; (b) is generated from MacroGenics&#8217; proprietary DART or TRIDENT platform&#59; and (c)&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;&#91;***&#93;&#8221; means a product that incorporates a &#91;***&#93; as an active ingredient.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;&#91;***&#93;&#8221; means the program of activities conducted by the Parties under this Agreement for the Development, Manufacture and Commercialization of the &#91;***&#93; and &#91;***&#93; .</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all data generated or arising from the conduct of a Clinical Trial under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Phase IV Clinical Trial or Registration Trial, as applicable.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">3</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_10"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Chemistry Manufacturing and Controls.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a contract manufacturing organization.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Co-Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a written Commercialization plan intended to support Commercialization of &#91;***&#93; Molecules and &#91;***&#93; Products after the Opt-In in the Field worldwide, as may be updated and amended periodically in form and substance approved by the JSC in accordance with Section 7.1(c).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Co-Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a written Development plan intended to support Development and Regulatory Approval of &#91;***&#93; Molecules and &#91;***&#93; Products after the Opt-In in the Field worldwide, as may be updated and amended periodically in form and substance approved by the JSC in accordance with Section 5.1(a)(ii).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Collaboration Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of the &#91;***&#93; Molecule and the MGNX Option Molecule.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Collaboration Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of the &#91;***&#93; Product and the MGNX Option Product.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Collaboration Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each program of activities conducted by the Parties under this Agreement for the Development and Commercialization of the Collaboration Molecules and Collaboration Products.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Collaboration Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) with respect to the &#91;***&#93; Molecule and the &#91;***&#93; Product before the Opt-In, the &#91;***&#93; Territory, (b) with respect to the &#91;***&#93; Molecule and the &#91;***&#93; Product after the Opt-In, the &#91;***&#93; Opt-In Territory, and (b) with respect to the MGNX Option Molecule and MGNX Option Product, the MGNX Option Territory.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; mean (a) any single product comprising both (i) a Licensed Molecule and (ii) one or more other therapies or pharmaceutically active compounds or substances that is not a Licensed Molecule&#59; (b) any sale of a Product with one or more other therapies or products for a single invoice price&#59; or (c) any sale of a Product as part of a bundle with one or more other therapies, products or services (i.e., where a Product and such other therapies, products or services are sold for a single invoice price or where a discount, rebate or other amount that reduces the price of a Product is provided in exchange for, or otherwise conditioned upon, the purchase of such other therapies, products or services), to the extent not described in clause (a) or (b). The Licensed Molecule portion of any Combination Product shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensed Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the other portion of such Combination Product shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, and each Combination Product shall be deemed a Product hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means activities taken before and after obtaining Regulatory Approval relating specifically to the pre-launch, launch, promotion, marketing, sales force recruitment, sale, offering for sale, and distribution of a pharmaceutical product and post-launch medical activities, including&#58; (a) distribution, storage, transportation, importation and exportation&#59; (b) strategic marketing, sales force, detailing, advertising, and market and product support&#59; (c) medical education and liaison and any Phase IV Clinical Trials unless required as a condition for approval, to the extent permitted by this Agreement&#59; (d) all customer support and product distribution, invoicing and sales activities&#59; and (e) all post-approval regulatory activities, including those necessary to maintain Regulatory Approvals. For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; does not include any related Manufacturing activities.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">4</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_13"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective of such Party under similar circumstances, it being understood and agreed that with respect to the Commercialization of Licensed Molecule and Products, such efforts shall be similar to those efforts and resources commonly used by a pharmaceutical or biopharmaceutical company, as applicable, of comparable size and resources to such Party in the applicable country or Region for a similar biological or pharmaceutical product owned by it or to which it has exclusive-rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, other medical and clinical considerations, anticipated or approved labeling, the competitiveness of alternative products in the marketplace, market exclusivity, market potential, financial return, the patent and other proprietary position of the product, and the likelihood of Regulatory Approval given the regulatory structure involved, regulatory environments and other technical, legal, scientific, medical or commercial factors that such a company would reasonably deem to be relevant.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any and all non-public scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information and data, in any tangible or intangible form.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Controlled by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any item of or right under Patents or Know-How, the extent of the ability of a Party (whether through ownership or license, other than pursuant to this Agreement) to grant access to, or a license or sublicense of, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party or creating a payment obligation upon such Party, unless the other Party agrees to bear the applicable Triggered Third Party Payment pursuant to Section 3.8 or otherwise.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a product, technology, process or method, that, in the absence of possession of the right (by ownership, license or otherwise) under a Valid Claim, the practice or exploitation of such product, technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue).</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a clinical research organization.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Data Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period, if any, during which the applicable Regulatory Authority (including the FDA and the NMPA) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that is contained in such BLA and that is not published or publicly available outside of such BLA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deadlock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.2(c).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Depot Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any subcontractor engaged by Zai to store, distribute, handle or otherwise possess Licensed Molecule or Product that was provided by MacroGenics to supply a Clinical Trial.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means research, discovery, and preclinical and clinical drug or biological development activities, including toxicology, formulation, statistical analysis, preclinical and Clinical Trials (but excluding Phase IV Clinical Trials unless required as a condition for Regulatory Approval) and regulatory affairs, approval and registration, in each case, of a Licensed Molecule or a Product in the Field. For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; does not include any related Manufacturing activities.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">5</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_16"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all costs incurred in connection with any Development activities, including (a) site investigator fees and monitoring costs, (b) contract research organization and site management organization fees, (c) data management costs, (d) safety surveillance and reporting costs</font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) patient costs, (f) drug comparator and standard-of-care drug costs, (g) drug administration costs, (h) development, validation, and procurement costs related to any companion diagnostic product, and (i) central and local lab costs.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 5.1(c)(i).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.49.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any dispute, claim, or controversy (other than matters that are within the decision-making authority of a Party pursuant to Section 2.2(c), or are expressly stated herein to require the consent of both Parties) arising from or related to this Agreement or to the interpretation, application, breach, termination, or validity of this Agreement, including any claim of inducement of this Agreement by fraud or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.50.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency, or any successor agency thereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.51.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all countries that are officially recognized as member states of the European Union as of the Effective Date, the United Kingdom, Switzerland, Iceland, Norway and Liechtenstein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.52.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to either Party, the Chief Executive Officer of such Party (or his or her designee who will be a senior executive directly reporting to the Chief Executive Officer of such Party and with authority to bind such Party).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.53.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Failure to Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the failure of MacroGenics or its Affiliates to supply Zai, its Affiliates or Sublicensees with &#91;***&#93;percent (&#91;***&#93;%) &#91;***&#93; be supplied to Zai, its Affiliates or Sublicensees pursuant to a supply agreement between the Parties&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.54.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States Food and Drug Administration, or any successor agency</font></div><div style="margin-top:0.1pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.55.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.56.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the treatment, prevention and diagnosis of all Indications&#59; provided that, in the case of any Licensed Molecule or Product Covered by a Patent or other intellectual property right licensed in one or more MacroGenics Third Party Agreement or Zai Third Party Agreement, &#8220;Field&#8221; in which such Patent or other intellectual property right may be practiced with respect to such Licensed Molecule or Product shall be limited to the minimum extent necessary to comply with the terms of such MacroGenics Third Party Agreement or Zai Third Party Agreement for so long as such limitation is necessary to avoid a breach of the MacroGenics Third Party Agreement or Zai Third Party Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.57.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Product, the first sale to a Third Party for end use or consumption of such Product in a country or Region after Regulatory Approval has been granted by the Regulatory Agency for the Product in such country or Region.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.58.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, &#91;***&#93; hours of work devoted to or in direct support of specified activities under this Agreement, conducted by one or more qualified employees of such Party or its Affiliate. For clarity, any individual contributing less than &#91;***&#93; hours per Calendar Year (or equivalent pro-rata portion thereof for the</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">6</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_19"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">period beginning on the Effective Date and ending on the last day of the first Calendar Year) shall be deemed a fraction of an FTE on a pro-rata basis.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.59.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FTE Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any period and a Party or its Affiliate, the FTE Rate multiplied by the number of FTEs expended by such Party or its Affiliate during such period&#59; provided that a Party shall not charge the other Party more than once for any FTE Cost if such FTE Cost is already included as a component of other expenses payable to such charging Party under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.60.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a rate of &#91;***&#93; US Dollars (US$&#91;***&#93;) per FTE per Calendar Year, pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year&#59; provided, however, that such rate shall be increased or decreased annually beginning on &#91;***&#93;, by the applicable CPI Adjustment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.61.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fully-Burdened Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Collaboration Molecule or Collaboration Product, whether as active pharmaceutical ingredient or finished form, supplied by a Party, &#91;***&#93;percent (&#91;***&#93;%) of either&#58; (i) if Manufactured by a Third Party, &#91;***&#93; for the Manufacture of such Collaboration Molecule or Collaboration Product without mark-up (for clarity, &#91;***&#93;)&#59; or (ii), if Manufactured by such Party or its Affiliate, &#91;***&#93; and applicable FTE costs, and in accordance with such Party&#8217;s Accounting Standards, including the following incurred by or on behalf of such Party or its Affiliate and reasonably allocated to such Collaboration Molecule or Collaboration Product&#58;</font></div><div style="padding-left:40.95pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.62.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Future Third Party Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.8(a).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.63.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.1(c).</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">7</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_22"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.64.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GBPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.65.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means current Good Clinical Practices as set forth in the Applicable Laws and Regulations, such as FDCA and the PHS Act and regulations set forth at 21</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.F.R. Part 312, as well as (but not limited to) the requirements set forth in Directive 2001&#47;20&#47;EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005&#47;28&#47;EC of 8 April 2005, to the extent applicable to a clinical trial regarding any Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority (e.g., FDA and Member States of the European Union), and as interpreted under prevailing industry standards, including standards of medical ethics, applicable guidance documents issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed consent requirements set forth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to Institutional Review Boards set forth in 21</font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.F.R. Part 56 and the equivalent legal requirements in other applicable jurisdictions, as the same may be amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.66.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Branding Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.1(d).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.67.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a written Development plan intended to support Development and Regulatory Approval of Collaboration Molecules and Collaboration Products (other than &#91;***&#93; Molecules and &#91;***&#93; Products after the Opt-In) in the Field both within the Collaboration Territory and outside of the Collaboration Territory, as may be updated and amended periodically in form and substance approved by the JSC in accordance with Section 5.1(a).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.68.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Product Brand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.1(d).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.69.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the recognized rules governing the conduct of non-clinical safety studies and ensuring the quality, integrity and reliability of study data as set forth in Applicable Laws and Regulations, such as 21 C.F.R. Part 58, and the equivalent legal requirements in other applicable jurisdictions, as the same may be amended from time to time.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.70.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person employed by or acting on behalf of a government, government-owned or -controlled entity or public international organization&#59; any political party, party official or candidate&#59; any Person who holds or performs the duties of an appointment, office or position created by custom or convention&#59; and any Person who holds himself out to be the authorized intermediary of any of the foregoing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.71.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Greater China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the PRC, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.72.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ICC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 15.3.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.73.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.74.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">In-License Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.8(a).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.75.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Investigational New Drug application, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">8</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_25"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.76.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Party that is obligated to indemnify the Indemnitee under Article 13.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.77.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means either the Zai Indemnitee or the MacroGenics Indemnitee, as applicable.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.78.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a separate and distinct disease, disorder or medical condition in humans or non-human animals with different tissue origin classified as a three-character category in International Statistical Classification of Diseases and Related Health Problems (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ICD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) 10-CM published by the World Health Organization, for which a Product can be used to diagnose, treat or prevent, which use is the subject of a separate Regulatory Filing to support a Regulatory Approval for such use. Notwithstanding the foregoing, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.79.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a clinical trial of a Product, the first dosing of such Product in the first subject in such clinical trial.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.80.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;&#91;***&#93;&#8221; shall mean an &#91;***&#93; conducted by a Party or its Affiliates that (a) &#91;***&#93;, and (b) has a &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.81.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Commercialization Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section</font></div><div style="margin-top:0.1pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.4(a).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.82.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Research and Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.3(a).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.83.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.2(a).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.84.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Jointly Owned IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, all Know-How and inventions, whether patentable or not, that are (a) conceived or reduced to practice in the course of conducting activities under this Agreement and (b) jointly owned by the Parties pursuant to this Agreement, together with all intellectual property rights therein. For clarity, Jointly Owned IP shall include the Research IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.85.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Jointly Owned Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.2(b)(iv).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.86.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) any proprietary scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data, and (b) any proprietary biological, chemical or physical materials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.87.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License-Only Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">9</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_28"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.88.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License-Only Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.89.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License-Only Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each program of activities conducted by the Parties under this Agreement for the Development, Manufacture and Commercialization of the License-Only Molecules and License-Only Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.90.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License-Only Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means worldwide.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.91.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensed Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of the &#91;***&#93; Molecule, the MGNX Option Molecule, the  &#91;***&#93; and the Zai Selection Molecule.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.92.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.93.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(c)(vi).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.94.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Improvement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(c)(iii)(1).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.95.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.1(c).</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.96.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.97.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Manufacturing In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means agreements executed prior to the Effective Date by MacroGenics with Third Parties to the extent such agreements grant MacroGenics the right to use Patents and&#47;or Know-How controlled by such Third Party for Manufacturing any Licensed Molecule or Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.98.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Know-How (excluding any Patents) that is (a) Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term, and (b) necessary or reasonably useful for Zai to Develop, Manufacture and Commercialize Licensed Molecules and Products in accordance with this Agreement, including MacroGenics&#8217; interest in any Know-How with the Jointly Owned IP or MacroGenics Improvement IP&#59; provided that, MacroGenics Licensed Know-How shall exclude any Know-How &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.99.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Licensed Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Patent that is (a) Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term, and (b) necessary or reasonably useful for Zai to Develop, Manufacture and Commercialize Licensed Molecules and Products in accordance with this Agreement, including any MacroGenics&#8217; interest in any Patent within the Jointly Owned IP or MacroGenics Improvement IP&#59; provided that, MacroGenics Licensed Patent shall exclude &#91;***&#93;. The MacroGenics Licensed Patents Controlled by MacroGenics or any of its Affiliates as of the Effective Date are listed in Exhibit A attached hereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the MacroGenics Licensed Patents and the MacroGenics Licensed Know-How.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.101.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Licensed Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any and all Trademarks &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">10</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_31"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.102.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means MacroGenics&#8217; proprietary DART, TRIDENT and other MacroGenics&#8217; proprietary platforms that are used to generate, evaluate and select bi-specific molecules </font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">comprising one or more covalently-bonded diabody domains including, but not limited to those disclosed in the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A, which may be updated from time to time by MacroGenics.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.103.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Product-Specific Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any MacroGenics Licensed Patent that solely and exclusively Covers the (a) composition of matter of a License-Only Molecule or License-Only Product or (b) the method of using such License-Only Molecule or License-Only Product as a therapeutic, prophylactic or diagnostic, in each case (a)-(b) in the applicable Territory, and does not also Cover the composition of matter of, or the method of using, any other product that is not a License-Only Molecule or License-Only Product. For clarity, MacroGenics Product-Specific Patent shall exclude &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.104.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(c).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.105.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any agreement between MacroGenics and its Third Party licensor that is entered into after the Effective Date and for which Zai elects to obtain a sublicense under Section 3.8.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.106.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Major European Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.107.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Major Safety Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product, any of the following&#58; (a) an adverse safety profile of a Product, or receipt or generation by a Party of any safety, tolerability or other data, indicating, as measured by safety and efficacy evaluation criteria and methodology customarily used by a majority of clinicians conducting studies on similar products for the same or substantially the same Indication as being pursued by such Party for such Product in the applicable country or Region, that such Product has or is reasonably likely to have serious risks for medical applications in humans to require a recall, withdrawal, or similar action&#59; or (b) any notice, information or correspondence received by a Party from &#91;***&#93;, or any action taken by any such Regulatory Authority, in each case, indicates that Regulatory Approval is reasonably unlikely to be granted therefor or, if already granted, the Regulatory Approval therefor would reasonably likely be revoked, or causes the Regulatory Approval therefor not to be granted or, if already granted, to be revoked.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.108.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all operations involved in the manufacturing (including process development activities, quality assurance and quality control testing (including test method development and in-process, release and stability testing, if applicable), storage, releasing, packaging and importation of a Licensed Molecule or a Product) to supply Licensed Molecule and Product for Development and Commercialization under this Agreement. For purposes of clarification, &#8220;Manufacturing&#8221; is not included in Development or Commercialization.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.109.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Marketing Authorization Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a New Drug Application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or any other application to the appropriate Regulatory Authority for approval to market a Product, but excluding pricing approvals.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.110.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MGNX Option Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a therapeutic bi-specific molecule which (a) binds to</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) a Target selected by MacroGenics pursuant to Section 4.1(a) and (ii) CD47&#59; (b) is generated from MacroGenics&#8217; proprietary DART or TRIDENT platform&#59; and (c) comprises a sequence that is the same as or similar to a sequence provided by Zai and encodes a CD47 binding moiety.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">11</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_34"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.111.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MGNX Option Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a product that incorporates a MGNX Option Molecule as an active ingredient.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.112.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MGNX Option Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the program of activities conducted by the Parties under this Agreement for the Development and Commercialization of the MGNX Option Molecules and MGNX Option Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.113.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MGNX Option Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Greater China, Japan and Korea.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.114.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NMPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Medical Products Administration, or any successor agency</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.115.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the gross amount invoiced for Products sold by Zai or its Related Parties directly to Third Parties which are not Related Parties after deducting, if not previously deducted, from the amount invoiced, the following, in each case to the extent included in the gross invoice price&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">reasonable trade, quantity and cash discounts and rebates (including wholesaler inventory management fees), chargebacks, and retroactive price reductions or allowances actually allowed or granted from the billed amount&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">credits or allowances actually granted upon claims, rejections or returns of such sales of Products, including recalls and amounts credited or repaid because of retroactive price reductions specifically identifiable to the Product&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">bad debts written off which are attributable to sales of Products (subject to cap equal to &#91;***&#93; percent (&#91;***&#93;%) of gross amount invoiced for Products sold)&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">taxes imposed on the production, sale, import, delivery or use of the Product (including sales, use, excise or value added taxes but excluding income taxes), duties or other governmental charges (including charges for product testing required for importation) levied on or measured by the billing amount when included in billing, as adjusted for rebates and refunds&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">costs actually incurred for distribution or importing (including transportation, freight and insurance, and warehousing in the Territory).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such amounts shall be determined from the books and records of Zai or its Related Party, maintained in accordance with Zai&#8217;s Accounting Standards, as consistently applied. Zai further agrees, in determining such amounts, it shall use Zai&#8217;s then-current standard procedures and methodology, including Zai &#8217;s then-current standard exchange rate methodology for the translation of foreign currency sales into US Dollars or, in the case of Sublicensees, such similar methodology, consistently applied. Without limiting the generality of the foregoing, non-invoiced transfers or dispositions of Product for charitable, compassionate use, promotional (including samples, in amounts reasonably customary in the industry), non-clinical, clinical, or regulatory purposes shall be excluded from Net Sales, as will sales or transfers of Product among a Party and its Related Parties, unless such Party or Related Party is the end user of such Product, but rather the Net Sales shall be deemed to have arisen upon the subsequent sale or transfer of Product to Third Parties.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Zai or any of its Related Parties sells a Product as a Licensed Component of a Combination Product in a country or Region in any Calendar Quarter, then Net Sales shall be calculated by multiplying the Net Sales of the Combination Product during such Calendar Quarter by the fraction A&#47;(A+B), where </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A is the average Net Sales per unit sold of the Licensed Component when sold separately in such country or</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">13</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_37"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Region during such Calendar Quarter (calculated by determining the Net Sales of the Licensed Component during such Calendar Quarter in accordance with the definition of Net Sales set forth herein and dividing such Net Sales by the number of units of the Licensed Component during such Calendar Quarter) and B is the average Net Sales per unit sold of the Other Component(s) included in the Combination Product when sold separately in such country or Region during such Calendar Quarter (calculated by determining the Net Sales of such Other Component(s) sold during such Calendar Quarter by applying the definition of Net Sales set forth herein as if it applied to sales of such Other Component(s) and dividing such Net Sales by the number of units of such Other Component(s) sold during such Calendar Quarter).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of calculating the average Net Sales per unit sold of a Licensed Component and Other Component(s) of a Combination Product, any of the deductions described herein that apply to such Combination Product shall be allocated among sales of the Licensed Component and sales of the Other Component(s) included in such Combination Product as follows&#58; (i) deductions that are attributable solely to the Licensed Component or one of the Other Component(s) shall be allocated solely to Net Sales of the Licensed Component or such Other Component, as applicable, and (ii) all other deductions shall be allocated among sales of the Licensed Component and sales of the Other Component(s) in proportion to Zai&#8217;s and MacroGenics&#8217; mutual agreement of the fair market value of the Licensed Component and the Other Component(s).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that no separate sales of the Licensed Component or any Other Component(s) included in a Combination Product are made by Zai or its Related Parties, during a Calendar Quarter in which such Combination Product is sold, the average Net Sales per unit sold shall be determined by mutual agreement of the Parties in good faith based on the relative economic value contributions of the Licensed Component and each of the Other Component(s) included in such Combination Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.116.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means Zai&#8217;s exercise of the &#91;***&#93; Profit Share Option in accordance with Section</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.1(e).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.117.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) all patents and patent applications in any country, region (including Region) or supranational jurisdiction and (b) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the like, of any such patents or patent applications.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.118.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the responsibility for (a) preparing, filing, prosecuting, and pursuing registration of, applications (of all types) for any Patent (b) for maintaining any Patent, and (c) for managing any interference or opposition proceeding relating to the foregoing.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.119.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means VAT and income taxes withholding required under Applicable Law to be paid to a tax authority.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.120.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permitted Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 5.1(f)(i).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.121.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.122.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, or the relevant portion of such trial, of a Product in patients in any country (including country or Region) in accordance with GCP that generally provides for the first introduction into humans of a Product and intended to determine safety, </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">metabolism and pharmacokinetic properties and clinical pharmacology of a Product in health patients, or that would</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">15</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_40"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">otherwise satisfy the requirements of Applicable Laws and Regulations for such country in which such human clinical trial is conducted, such as 21 C.F.R. &#167; 312.21(a), relating to human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.123.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, or the relevant portion of such trial, conducted in patients with a Product, in accordance with GCP and intended to demonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit or daily dosage regimen required, or that would otherwise satisfy the requirements of Applicable Laws and Regulations of the country or Region in which such human clinical trial is conducted, such as 21 C.F.R.</font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#167; 312.21(b), relating to human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents. For clarity, a Phase I Clinical Trial with an expansion cohort of patients that meets the descriptions or otherwise satisfies the requirements in the foregoing shall be deemed a Phase II Clinical Trial.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.124.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, or the relevant portion of such trial, in any country that is conducted in accordance with GCPs and the results of which are intended to be used as a pivotal study to establish both safety and efficacy of a Product as a basis for a BLA submitted to the FDA, the NMPA or the appropriate Regulatory Authority of such other country or Region, or that would otherwise satisfy the requirements of 21 C.F.R. &#167; 312.21(c), or any successor regulation thereto or foreign equivalents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.125.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase IV Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial conducted after the Regulatory Approval of a Product in a country or Region, which trial is conducted (a) voluntarily to enhance scientific knowledge of such Product (e.g., for expansion of product labeling or dose optimization)&#59; or (b) conducted due to a request or requirement of a Regulatory Authority of a country or Region.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.126.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means individually and collectively the Research Plans, Global Development Plans, Territory Specific Development Plans, Co-Development Plan and Co-Commercialization Plan.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.127.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">POC Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means one or more Clinical Trials in which patients are treated with the &#91;***&#93; Product that has in aggregate either&#58; (a) &#91;***&#93;, or (b) &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.128.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">POC Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.129.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the People&#8217;s Republic of China, which for purposes of this Agreement, excludes the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.130.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of the Collaboration Products and the License-Only Products.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.131.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Collaboration Program or a License-Only Program.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">16</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_43"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.132.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.133.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of Hong Kong Special Administrative Region and Macau Special Administrative Region.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.134.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Registration Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the first clinical trial which is designed to support Regulatory Approval for the Product in a country or Region. Notwithstanding, any Phase III Clinical Trial shall be deemed a Registration Trial.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.135.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a BLA approval from the relevant Regulatory Authority in a country or Region to market and sell a Product in such country or Region.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.136.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any applicable government regulatory authority involved in granting approvals for the conduct of clinical trials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Product, including in the United States, the FDA and in the PRC, the NMPA, and any successor governmental authority having substantially the same function.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.137.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Submissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any filing, application, or submission with any Regulatory Authority, including authorizations, approvals or clearances arising from the foregoing, including INDs, BLAs, NDAs, and Regulatory Approvals, and all correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences or discussions with the relevant Regulatory Authority, in each case, with respect to a Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.138.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, its Affiliates and Sublicensees.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.139.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Requesting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.7.</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.140.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.1(f).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.141.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.2(a).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.142.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.2(b).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.143.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.144.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ROW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all countries in the world except those in the &#91;***&#93; Opt-In Territory.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.145.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, on a Product-by-Product and country-by-country or Region-by- Region basis, the time period beginning on the First Commercial Sale of such Product in such country or Region and expiring on the latest of the following dates&#58; (a) the twelfth (12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the date of First Commercial Sale of the Product in the applicable country or Region, (b) the expiration of the last-to-</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">17</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_46"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expire MacroGenics Licensed Patent having a Valid Claim Covering the composition, Manufacture, use, sale or importation of the Product in the applicable country or Region, or (c) the expiration of the last-to- expire Data Exclusivity Period for the Product in the applicable country or Region.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.146.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Safety Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities, including any &#8220;adverse events&#8221;, &#8220;adverse drug reactions&#8221;, and &#8220;unexpected adverse drug reactions&#8221; as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management&#58; Definitions and Standards for Expedited Reporting.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.147.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Third Party that is granted a sublicense under the licenses granted to a Party under this Agreement, as permitted herein.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.148.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.149.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 16.1.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.150.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Terminated Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Program that is terminated by a Party pursuant to Section 16.2, Section 16.3, Section 16.4, Section 16.5, Section 16.6 or Section 16.7.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.151.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;&#91;***&#93;&#8221; means each of (a) &#91;***&#93;, (b) &#91;***&#93;, (c) &#91;***&#93;, (d) &#91;***&#93;, (e) &#91;***&#93;, and (f) &#91;***&#93; (a)-(e).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.152.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) with respect to the Collaboration Molecules and Collaboration Products, the applicable Collaboration Territory, and (b) with respect to the License-Only Molecules and License-Only Products, the License-Only Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.153.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Territory-Specific Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a written plan for Development of the Collaboration Molecules and Collaboration Products (other than &#91;***&#93; Molecules and &#91;***&#93; Products after the Opt-In) in the Field in the applicable Collaboration Territory that is primarily intended to support Regulatory Approval of the Collaboration Product in such Collaboration Territory (and not outside such Collaboration Territory) and not otherwise included within the Global Development Plan, as may be updated and amended periodically in form and substance approved by the JSC in accordance with Section 5.1(a).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.154.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an entity other than (a) Zai and its Affiliates, and (b) MacroGenics and its Affiliates.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.155.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications throughout the world.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.156.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trademark Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the responsibility for (a) preparing, filing, and seeking registration of, trademark applications (of all types) for any Trademark, (b) for maintaining any Trademark, and (c) for managing any interference or opposition proceeding relating to the foregoing.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.157.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Triggered Third Party Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Future Third Party Agreement for which a Party elects to obtain a sublicense under Section 3.8, &#91;***&#93;percent (&#91;***&#93;%) of any payments that the In-License Party would be obligated to pay the Third Party licensor of such Future Third Party Agreement as a result of the grant of a sublicense to the other Party, including all royalty</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">18</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_49"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">payments, milestone payments, license maintenance (or similar payment) or sublicense payments payable by the In-License Party pursuant to such Future Third Party Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.158.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States of America and its territories and possessions, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.159.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">US Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means United States Dollars, the lawful currency of the US.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.160.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a claim of&#58; (a) an issued and unexpired Patent included within the MacroGenics Licensed Patents in a country or Region which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and has not been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise&#59; or (b) a pending patent application that has been filed in good faith and that has not been cancelled, withdrawn, or abandoned and has not been pending for more than &#91;***&#93; from the earliest priority date, provided that, if a claim ceases to be a Valid Claim by reason of the foregoing subclause (b), then such claim shall again be deemed a Valid Claim in the event such claim subsequently issues.</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.161.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(b)(vi).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.162.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.1(d).</font></div><div><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.163.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Improvement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(b)(iii)(1).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.164.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.2.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.165.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai License-Only IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.1(e).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.166.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Know-How (excluding any Patent) Controlled by Zai or any of its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful for MacroGenics to (a) conduct the Development activities allocated to it under the applicable Research Plans or (b) Develop, Manufacture and Commercialize Collaboration Molecules and Collaboration Products in accordance with this Agreement, including Zai&#8217;s interest in any Know-How with the Jointly Owned IP or Zai Improvement IP.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.167.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Licensed Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Patent Controlled by Zai or any of its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful for MacroGenics to (a) conduct the Development activities allocated to it under the applicable Research Plans or (b) Develop, Manufacture and Commercialize Collaboration Molecules and Collaboration Products in accordance with this Agreement, including Zai&#8217;s interest in any Patent with the Jointly Owned IP or Zai Improvement IP. &#91;***&#93; and are Controlled by Zai or any of its Affiliates as of the Effective Date are listed in Exhibit C attached hereto.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.168.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Zai Licensed Patents and the Zai Licensed Know-</font></div><div style="margin-top:0.1pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">How.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.169.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">19</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_52"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.170.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Product-Specific Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.171.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.3(b).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.172.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Selection Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.173.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Selection Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a product that incorporates a Zai Selection Molecule as an active ingredient.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.174.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Selection Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the program of activities conducted by the Parties under this Agreement for the Development, Manufacture and Commercialization of the Zai Selection Molecules and Zai Selection Products.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.175.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any agreement between Zai and its Third Party licensor that is entered into after the Effective Date and for which MacroGenics elects to obtain a sublicense under Section 3.8.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">VERVIEW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#59; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVERNANCE</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties intend and have agreed to undertake the Development, Manufacturing and Commercialization activities under this Agreement, consisting of the following components&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.85pt">&#91;***&#93; Collaboration Programs, pursuant to which</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">the Parties will jointly conduct &#91;***&#93; Development activities in accordance with the applicable Research Plans&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-align:justify;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.03pt">with respect to any &#91;***&#93;</font></div><div style="margin-top:0.1pt;padding-left:17.6pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Parties will jointly conduct &#91;***&#93; Development activities in accordance with the applicable Global Development Plan and Territory-Specific Development Plan&#91;***&#93; will have the &#91;***&#93; Development and Commercialization of &#91;***&#93; MGNX Option Territory &#91;***&#93; Development and Commercialization of &#91;***&#93; MGNX Option Territory, in each case of (B) and (C), &#91;***&#93; in the applicable Research Plan, Global Development Plan and Territory-Specific Development Plan&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;text-align:justify;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.98pt">with respect to any &#91;***&#93; Molecule and &#91;***&#93; Product &#91;***&#93;</font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Parties will jointly conduct certain Development activities in accordance with the applicable Global Development Plan and Territory-Specific Development Plan &#91;***&#93; Development and Commercialization of such &#91;***&#93; Molecule and &#91;***&#93; Product Development and Commercialization of such &#91;***&#93; Molecule and &#91;***&#93; Product </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">20</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_55"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;, in each case of (B) and (C), &#91;***&#93; in the applicable Research Plan, Global Development Plan and Territory-Specific Development Plan&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-align:justify;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:7.58pt">with respect to any &#91;***&#93; Molecule and &#91;***&#93; Product  &#91;***&#93;</font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Parties will jointly Develop and Commercialize such &#91;***&#93; Molecule and &#91;***&#93; Product worldwide in accordance with the Co-Development Plan and Co-Commercialization Plan, &#91;***&#93; Development and Commercialization of such &#91;***&#93; Molecule and &#91;***&#93; Product &#91;***&#93; Development and Commercialization of such &#91;***&#93; Molecule &#91;***&#93;, in each case of (B) and (C), &#91;***&#93;Co-Development Plan and Co-</font></div><div style="margin-top:0.05pt;padding-left:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercialization Plan&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#91;***&#93; License-Only Programs, pursuant to which &#91;***&#93;  Development activities in accordance with the applicable Research Plans &#91;***&#93; Zai will have the exclusive rights and be solely responsible for the Development, Manufacturing and Commercialization of License-Only Molecules and License-Only Products in the License-Only Territory.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Joint Steering Committee</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties hereby establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to coordinate and oversee (i) the Parties&#8217; conduct of the Research Plan and subsequent conduct of each Collaboration Program and (ii) the Parties&#8217; conduct of the Research Plan of each License-Only Program during the applicable Research Term. For clarity, neither the JSC nor any other committee established pursuant to this Agreement shall have the right to oversee or have any decision making authority with respect to the Development, Manufacturing or Commercialization of any License- Only Program other than the Parties&#8217; conduct mentioned in (ii) above. The JSC shall consist of &#91;***&#93; representatives &#91;***&#93;. &#91;***&#93; shall designate &#91;***&#93; of its representatives as the initial chairperson of the JSC. Thereafter, the role of chairperson shall alternate between MacroGenics and Zai representatives on a &#91;***&#93;. Each Party may replace its appointed JSC representatives at any time upon reasonable written notice to the other Party. The initial representatives and chair of the JSC shall be established within &#91;***&#93; after the Effective Date. The chair shall have the responsibility to call regular meetings, circulate meeting agendas at least &#91;***&#93; prior to each regular JSC meeting, draft minutes for each JSC meeting and circulate such minutes for both Parties&#8217; written approval. The chair shall have no other authority or special voting power.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The responsibilities of the JSC shall be&#58;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">to provide a forum by which the Parties may share information regarding the overall strategy for the Collaboration Programs&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11.05pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">to facilitate the exchange of information between the Parties with respect to the activities hereunder and to establish procedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect to the Collaboration Programs&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">review, discuss and approve each Research Plan, Global Development Plan and Territory-Specific Development Plan and the Co-Development Plan and Co- Commercialization Plan, and updates or amendments thereto and to share and discuss the progress of activities under the Research Plans, Global Development Plans, Territory-Specific Development Plans, Co-Development Plan and Co-Commercialization Plan on a quarterly basis&#59;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">21</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_58"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">to share and discuss the data generated by or on behalf of the Parties in the course of performance towards the goals set forth in the Research Plans, Global Development Plans, Territory-Specific Development Plans, Co-Development Plan and Co-Commercialization Plan&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">to coordinate Development and Commercialization strategies of the Collaboration Programs, and allocate resources and set timelines for Development and Commercialization activities with respect to the Collaboration Programs&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">to establish an overall regulatory strategy for (1) each &#91;***&#93; Molecule and &#91;***&#93; Product before the Opt-In or (2) any MGNX Option Molecule and MGNX Option Product, in each case of (1) and (2), in the applicable Collaboration Territory that is consistent with and complements the worldwide regulatory strategy being implemented by MacroGenics for the applicable Collaboration Molecule and Product&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.53pt">to establish an overall worldwide regulatory strategy for any &#91;***&#93; Molecule and &#91;***&#93; Product after the Opt-In&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.48pt">to create any subcommittees (including the JRDC and JCC) as agreed in writing by both Parties, to oversee the activities of such subcommittees, and to seek to resolve any issues that such subcommittees cannot resolve&#59;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">to establish an overall strategy for the filing, prosecution and maintenance of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Zai Licensed Patents in the Territory and any applicable Patent and Trademark term extensions&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">to perform such other functions as expressly set forth in this Agreement or as appropriate to further the purposes of this Agreement, as determined by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The JSC shall make decisions unanimously, with each Party&#8217;s representatives collectively having one (1) vote and at least one (1) representative from each Party present. In the event the JSC cannot reach an agreement regarding any matter within the JSC&#8217;s authority for a period of &#91;***&#93; (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deadlock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then either Party may elect to &#91;***&#93;, and if a Party makes an &#91;***&#93;, &#91;***&#93;to resolve promptly such matter, which such &#91;***&#93;shall include at least &#91;***&#93;. If any Deadlock is not resolved after &#91;***&#93;within &#91;***&#93; after its submission to them, such Deadlock shall be finally determined by the applicable Party in accordance with Sections 2.2(c)(i) and 2.2(c)(ii), respectively.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">With respect to any Deadlock pertaining to (A) any &#91;***&#93; Molecule and &#91;***&#93;  Product arising at any time before the Opt-In or (B) any MGNX Option Molecule and MGNX Option Product arising at any time during the Term, if the &#91;***&#93;on any such matter within &#91;***&#93; after its submission to them, the Deadlock shall be resolved in accordance with the provisions of this Section 2.2(c)(i)&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Except for those Deadlocks set forth in Section 2.2(c)(i)(2) for which Zai has the final decision-making authority, MacroGenics shall have the final decision-making authority with respect to all Deadlocks pertaining to any &#91;***&#93;with respect thereto&#59; provided that such decision shall &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Zai shall have the final decision-making authority on all Deadlocks pertaining to any of the following&#58; (A) all Deadlocks &#91;***&#93;, (B) &#91;***&#93;, and (C) &#91;***&#93; in accordance with Section &#91;***&#93; &#59; provided that such decision pursuant to (B) or (C) shall&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Notwithstanding Section 2.2(c)(i)(1) and Section 2.2(c)(i)(2), no exercise of a Party&#8217;s unilateral decision-making authority on any such matters may, without the other Party&#8217;s prior written consent, be used to (A) make a determination as to whether a particular milestone or other criteria has been achieved or that any of its obligations under this Agreement has been fulfilled, (B) amend or add to such Party&#8217;s consent or approval rights or otherwise expand or reduce its obligations provided under this Agreement, (C) impose any requirements that the other Party take or decline to take any action that would result in a violation of Applicable Laws and Regulations or any agreement with any Third Party (including any MacroGenics Third Party Agreements and Zai Third Party Agreements) or the infringement of intellectual property rights of any Third Party, (D) make a decision that is expressly stated to require the consent or approval of the other Party, (E) otherwise conflict with this Agreement, or (F) reduce the other Party&#8217;s rights under this Agreement without such other Party&#8217;s written consent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">With respect to any Deadlock pertaining to any &#91;***&#93; Molecule and &#91;***&#93; Product arising at any time after the Opt-In, if the &#91;***&#93; are unable to reach consensus on any such matter within &#91;***&#93; after its submission to them, the Deadlock shall be resolved in accordance with the provisions of this Section 2.2(c)(ii)&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Subject to Section 2.2(c)(ii)(3) and Section 2.2(c)(ii)(4), &#91;***&#93;shall have the final decision-making authority on all Deadlocks pertaining to all &#91;***&#93;in accordance with Section &#91;***&#93;for &#91;***&#93; Molecules and &#91;***&#93; Products in the &#91;***&#93;&#59; provided that such decision shall &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Subject to Section 2.2(c)(ii)(3) and Section 2.2(c)(ii)(4), &#91;***&#93;shall have the final decision-making authority on all Deadlocks pertaining to all &#91;***&#93;in accordance with Section &#91;***&#93;for &#91;***&#93; Molecules and &#91;***&#93; Products in the Field in the &#91;***&#93; Opt-In Territory&#59; provided that such decision shall&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">In the event that a Party &#91;***&#93;which would cause the &#91;***&#93;percent (&#91;***&#93;%) of the &#91;***&#93; in the &#91;***&#93; (as the case may be), the Parties will discuss any such</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">23</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_61"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">proposal in good faith and attempt to resolve and mitigate such overages related thereto through good faith negotiation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.45pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Notwithstanding Section 2.2(c)(ii)(1) and Section 2.2(c)(ii)(2), no exercise of a Party&#8217;s unilateral decision-making authority on any such matters may, without the other Party&#8217;s prior written consent, be used to (A) &#91;***&#93; that includes at least &#91;***&#93; and where the &#91;***&#93; is expected to &#91;***&#93;of the total &#91;***&#93;, (B) make a determination as to whether a particular milestone or other criteria has been achieved or that any of its obligations under this Agreement has been fulfilled, (C) amend or add to such Party&#8217;s consent or approval rights or otherwise expand or reduce its obligations provided under this Agreement, (D) impose any requirements that the other Party take or decline to take any action that would result in a violation of Applicable Laws and Regulations or any agreement with any Third Party (including any MacroGenics Third Party Agreements and Zai Third Party Agreements) or the infringement of intellectual property rights of any Third Party, (E) make a decision that is expressly stated to require the consent or approval of the other Party, (F) otherwise conflict with this Agreement, or (G) reduce the other Party&#8217;s rights under this Agreement without such other Party&#8217;s written consent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">JSC Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. JSC meetings shall be held &#91;***&#93;, or on any other schedule mutually agreed by the Parties. With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as non-voting observers (provided such non-voting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement). A JSC meeting may be held either in person or by audio, video or internet teleconference with the consent of each Party. Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings. The Parties shall alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JSC meetings.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Duration of JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The JSC shall continue to exist until the first to occur of (i) the Parties mutually agreeing in writing to disband the JSC or (ii) termination of this Agreement in accordance with the terms hereof.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.07pt">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The JSC shall have no authority other than that expressly set forth in this Section 2.1 and, specifically, shall have no authority (i) to amend or interpret this Agreement, or (ii) to determine whether or not a breach of this Agreement has occurred.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any subcommittee (including the JRDC and JCC) established hereunder shall be composed of an equal number of representatives from each Party. Each Party may replace its subcommittee representatives upon written notice to the other Party. All decisions of a subcommittee shall be made by unanimous vote, with each Party&#8217;s representatives having one vote. In the event the Parties are unable to reach a unanimous vote with respect to a matter, such matter shall be referred to the JSC for resolution in accordance with Section 2.2(c).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Joint Research and Development Committee</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within &#91;***&#93; of the Effective Date, the Parties shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Research and Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to oversee (i) the day-to-day Development of the Collaboration Molecules and Collaboration Products, (ii) the day-to-day Development of the License-Only Molecules and License-Only Products as described in the applicable Research Plan(s) during the Research Term, (iii) the execution of the Research Plans, </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Global Development Plans, Territory-Specific Development Plans and Co-Development Plan, (iv) the progress of</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">25</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_64"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Regulatory Approvals and Regulatory Submissions for the Collaboration Molecules and Collaboration Products, (v) sharing of information regarding proposed sites for Clinical Trials of Collaboration Molecules and Collaboration Products in the Territories, and (vi) such other Development related activities pertaining to the Collaboration Molecules and Collaboration Products delegated to it by the JSC. Each Party shall appoint &#91;***&#93; representatives to the JRDC, each of whom shall be an officer or employee of the applicable Party having sufficient knowledge regarding Development of the Collaboration Molecules and Collaboration Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. While the Parties are developing and conducting Clinical Trials for Collaboration Molecules and Collaboration Products in the Territory, the JRDC shall meet at least &#91;***&#93;. The Parties shall endeavor to schedule meetings of the JRDC at least &#91;***&#93; in advance.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Joint Commercialization Committee</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within &#91;***&#93; of initiating a Registration Trial for a Collaboration Product, the Parties shall establish a joint commercialization committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Commercialization Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to oversee and coordinate (i) the day-to-day Commercialization of Collaboration Products in the applicable Collaboration Territory and, in the case of &#91;***&#93; Products after Opt-In, both in and outside the &#91;***&#93; Opt-In Territory, including review of branding, marketing strategy, Product positioning, pricing and reimbursement strategy (to the extent legally permissible), (ii) the progress of Commercialization activities for Collaboration Products in the applicable Collaboration Territory and, in the case of &#91;***&#93; Products after Opt-In, both in and outside the &#91;***&#93; Opt-In Territory, (iii) the execution of the Co-Commercialization Plan, and (iv) such other Commercialization related activities delegated to it by the JSC. Each Party shall appoint &#91;***&#93;representatives to the JCC, each of whom shall be an officer or employee of the applicable Party having sufficient knowledge regarding Commercialization of the Collaboration Products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. While the Parties are Commercializing Collaboration Products in the applicable Collaboration Territory, the JCC shall meet at least &#91;***&#93; . The Parties shall endeavor to schedule meetings of the JCC at least &#91;***&#93; in advance.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ICENSES</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Licenses to Zai</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Research and Development License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Zai a worldwide, royalty-free, co-exclusive (with MacroGenics) license, with the right to grant sublicenses to its Affiliates only, under the MacroGenics Licensed Technology to conduct the Development activities allocated to Zai under the applicable Research Plans, Co-Development Plan, Global Development Plans and Territory-Specific Development Plans.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Development and Commercialization Licenses for Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, MacroGenics hereby grants to Zai an exclusive (even as to MacroGenics except to the extent needed by MacroGenics to perform its assigned responsibilities under the Plans), royalty-bearing license, with the right to grant sublicenses to its Affiliates and Third Party (subject to Section 3.3), under the MacroGenics Licensed Technology and the MacroGenics Licensed Trademarks for the Development, Commercialization, use and otherwise exploitation of </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93; Molecules and &#91;***&#93; Products in the Field in the &#91;***&#93; Territory&#59; provided that, after the Opt-In, the license under this</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">27</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_67"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1(b)(i) shall become royalty-free and the Territory for such license shall be expanded to the &#91;***&#93; Opt-In Territory. Notwithstanding the foregoing, to the extent needed by Zai to perform any responsibility assigned to it under the Co-Development Plan, Co-Commercialization Plan or this Agreement in any country outside the &#91;***&#93; Opt-In Territory after the Opt-In, the license under this Section 3.1(b)(i) shall become royalty-free and co-exclusive (with MacroGenics) for the purpose of performing such responsibility in such country outside the &#91;***&#93; Opt-In Territory.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">MGNX Option Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, effective as of the MGNX Option Target Date, MacroGenics hereby grants to Zai an exclusive (even as to MacroGenics except to the extent needed by MacroGenics to perform its assigned responsibilities under the Plans), royalty-bearing license, with the right to grant sublicenses to its Affiliates and Third Party (subject to Section 3.3), under the MacroGenics Licensed Technology and the MacroGenics Licensed Trademarks for the Development, Commercialization, use and otherwise exploitation of MGNX Option Molecules and MGNX Option Products in the Field in the MGNX Option Territory.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the licenses granted to Zai under this Section 3.1(b) shall (A) &#91;***&#93;&#59; (B) &#91;***&#93;&#59; and (C) be subject to the &#91;***&#93; in the event any such &#91;***&#93;are subject to &#91;***&#93; for which Zai elects to &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">Manufacturing License for Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, &#91;***&#93; with respect to a &#91;***&#93; Product, MacroGenics hereby grants to Zai a co-exclusive (with MacroGenics) license, with the right to grant sublicenses to its Affiliates and Third Parties, under the MacroGenics Licensed Technology for the Manufacture of &#91;***&#93; Molecules and &#91;***&#93; Products in the Field worldwide, solely to Develop, Commercialize, use and otherwise exploit &#91;***&#93; Molecules and &#91;***&#93; Products within the scope of the license grant in Section 3.1(b)(i).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">MGNX Option Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, &#91;***&#93; with respect to a MGNX Option Product, MacroGenics hereby grants to Zai a co-exclusive (with MacroGenics) license, with the right to grant sublicenses to its Affiliates and Third Party, under the MacroGenics Licensed Technology for the Manufacture of the applicable MGNX Option Molecule and MGNX Option Product in the Field in the MGNX Option Territory.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%;padding-left:23.23pt">Development, Manufacturing and Commercialization License for License-</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Only Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, MacroGenics hereby grants to Zai an exclusive (even as to MacroGenics), royalty-bearing license, with the right to grant sublicenses to its Affiliates and Third Party (subject to Section 3.3) under the MacroGenics Licensed Technology, for the Development (other than the Development activities allocated to MacroGenics under the Research Plan for the &#91;***&#93;), Manufacture, Commercialization, use and otherwise exploitation of &#91;***&#93; and &#91;***&#93; in the Field in the License-Only Territory.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">28</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_70"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">Zai Selection Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, effective as of the Zai Selection Target Date, MacroGenics hereby grants to Zai an exclusive (even as to MacroGenics), royalty-bearing license, with the right to grant sublicenses to its Affiliates and Third Parties (subject to Section 3.3), under the MacroGenics Licensed Technology, for the Development (other than the Development activities allocated to MacroGenics under the Research Plan for the Zai Selection Program), Manufacture, Commercialization, use and otherwise exploitation of Zai Selection Molecules and Zai Selection Products in the Field in the License-Only Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the licenses granted to Zai under this Section 3.1(d) shall &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">License to MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Research and Development License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Zai hereby grants to MacroGenics a worldwide, royalty-free, co-exclusive (with Zai) license, with the right to grant sublicenses to its Affiliates only, under the Zai Licensed Patents and Zai Licensed Know-How to conduct the Development activities allocated to MacroGenics under the applicable Research Plans, Co-Development Plan, Global Development Plans and Territory-Specific Development Plans.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Development and Commercialization Licenses for Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Zai hereby grants to MacroGenics an exclusive (even as to Zai except to the extent needed by Zai to perform its assigned responsibilities under the Plans), royalty-free (except as set forth in Section 16.8) license, with the right to grant sublicenses to its Affiliates and Third Party (subject to Section 3.3), under the Zai Licensed Technology for the Development, Commercialization, use and otherwise exploitation of &#91;***&#93; Molecules and &#91;***&#93; Products in the Field outside the &#91;***&#93; Territory&#59; provided that, after the Opt-In, the Territory for the license under this Section 3.2(b)(i) shall be revised to the ROW. Notwithstanding the foregoing, to the extent needed by MacroGenics to perform any responsibility assigned to it under the Co-Development Plan, Co-Commercialization Plan or this Agreement in any country outside the ROW after the Opt-In, the license under this Section 3.1(b)(i) shall become co-exclusive (with Zai) for the purpose of performing such responsibility in such country outside the ROW.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">MGNX Option Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Zai hereby grants to MacroGenics an exclusive (even as to Zai except to the extent needed by Zai to perform its assigned responsibilities under the Plans), royalty- free (except as set forth in Section 16.8) license, with the right to grant sublicenses to its Affiliates and Third Party, under the Zai Licensed Patents and Zai Licensed Know-How for the Development (other than the Development activities allocated to MacroGenics under the Research Plan, Global Development Plan and Territory-Specific Development Plan for the MGNX Option Program), Commercialization, use and otherwise exploitation of MGNX Option Molecules and MGNX Option Products in the Field outside the MGNX Option Territory.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the license granted to MacroGenics under this Section 3.2 shall (i) &#91;***&#93;by reason of &#91;***&#93;, and (ii) be subject to &#91;***&#93;in the event any such &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">29</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_73"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Sublicensees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Sublicenses to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall have the right to grant sublicenses of the licenses granted to such Party in Section 3.1 or Section 3.2 (as applicable), including sublicenses to a subset of the rights granted thereunder, to any of its Affiliates without the other Party&#8217;s consent.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Sublicenses to Third Parties.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Product Before Exercise of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Profit Share Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Before the Opt-In, each Party shall have the right to grant sublicenses of the license granted in Section 3.1(b)(i) or Section 3.2(b)(i) (as applicable), including sublicenses to a subset of the rights granted thereunder, to a third party only with the other Party&#8217;s express prior written consent.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Product After Exercise of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Profit Share Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After the Opt-In, the Parties will jointly decide on any matter in connection with grant of sublicenses of the license granted in Section 3.1(b)(i) or Section 3.2(b)(i) (as applicable), including sublicenses to a subset of the rights granted thereunder.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">MGNX Option Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall have the right to grant sublicenses of the license granted in Section 3.1(b)(ii) or Section 3.2(b)(ii) (as applicable), including sublicenses to a subset of the rights granted thereunder, to a Third Party only with the MacroGenics&#8217; express prior written consent, not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:2.58pt">License-Only Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall have the right to grant sublicenses of the license granted in Section 3.1(d), including sublicenses to a subset of the rights granted thereunder, to any Third Party without MacroGenics&#8217; consent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.63pt">Contractor Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Section 3.3(b), but subject to Section 5.1(f), a Party shall not be required to obtain the other Party&#8217;s consent to grant sublicenses under this Section 3.3(b) to subcontractors subcontracted by such Party to perform responsibilities assigned to such Party under a Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Sublicense Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each sublicense granted by any party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be consistent with this Agreement and subject thereto, and the Licensor shall remain responsible to the other Party for the compliance of each such Sublicensee with the terms and conditions of this Agreement, including, with respect to the financial and other obligations due under this Agreement. Except with respect to sublicenses granted under Section 3.3(b)(v), each sublicense granted by a Licensor pursuant to Section 3.3(b) shall be in writing and the Licensor shall provide a complete copy of each such sublicense (and all amendments or restatements thereof) to the other Party so that the other Party can confirm the Licensor&#8217;s compliance with the foregoing. Each sublicense granted to a Third Party by a Licensor under this Agreement shall permit the conversion of such sublicense to a direct license with the other Party at the other Party&#8217;s sole discretion in the event this Agreement is terminated and, upon such conversion, the other Party shall be responsible for all former obligations of the Licensor under such sublicense. The Licensor shall include in each such sublicense a requirement obligating such Sublicensee to cooperate with the other Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the Term, neither Party may, either by itself or with or through a Related Party or Third Party, (a) Develop or Commercialize any Collaboration Product, (b) &#91;***&#93; or (c) with respect to Zai, practice the MacroGenics Licensed Technology or, with respect to MacroGenics, practice the Zai Licensed Technology, in each case (a)-(c), outside of the scope of this Agreement&#59; provided that MacroGenics shall have the right to practice the Zai Licensed Technology, and</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">30</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_76"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zai shall have the right to practice the MacroGenics Licensed Technology, in each pursuant to the licenses granted under the Collaboration Agreement entered into by the Parties on November 29, 2018.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall retain all rights not otherwise granted to the other Party. For clarity, notwithstanding the licenses granted to Zai pursuant to Section 3.1, no right or license is granted by MacroGenics to Zai under the MacroGenics Licensed Technology or MacroGenics Licensed Trademarks with respect to any molecule or product Covered by such MacroGenics Licensed Technology or MacroGenics Licensed Trademarks other than the Licensed Molecules and Products (including any Other Component of a Combination Product) solely in accordance with Section 3.1, and notwithstanding the licenses granted to MacroGenics pursuant to Section 3.2, no right or license is granted by Zai to MacroGenics under the Zai Licensed Technology with respect to any molecule or product Covered by such Zai Licensed Technology other than the Collaboration Molecules and Collaboration Products (including any Other Component of a Combination Product) solely in accordance with Section 3.2.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Negative Covenant&#59; No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party covenants that, except to the extent Third Parties generally are lawfully permitted to do so without a granted license from or other contractual right with the other Party, it shall not use or practice any of the other Party&#8217;s intellectual property rights licensed to it under this Article except for the purposes expressly permitted in the applicable license grant. Except as explicitly set forth in this Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">All licenses and other rights granted to Zai under this Agreement are subject to the rights and obligations of MacroGenics under the MacroGenics Third Party Agreements. Zai will comply with all applicable provisions of the MacroGenics Third Party Agreements and Zai agrees to (and shall cause its Related Parties to) timely perform and take such actions as may be required to allow MacroGenics to comply with its obligations thereunder, including to provide to MacroGenics such information and reports as it reasonably requires, comply with reasonable requests for access to Zai&#8217;s (and its Related Parties&#8217;) records or facilities or otherwise cooperate with MacroGenics, including with respect to any financial and regulatory reporting, audit and payment obligations under each MacroGenics Third Party Agreement, insofar as they pertain to a Licensed Molecule or any Product or Zai&#8217;s (and its Related Parties&#8217;) activities hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">All licenses and other rights granted to MacroGenics under this Agreement are subject to the rights and obligations of Zai under the Zai Third Party Agreements. MacroGenics will comply with all applicable provisions of the Zai Third Party Agreements and MacroGenics agrees to (and shall cause its Related Parties to) timely perform and take such actions as may be required to allow Zai to comply with its obligations thereunder, including to provide to Zai such information and reports as it reasonably requires, comply with reasonable requests for access to MacroGenics&#8217; (and its Related Parties&#8217;) records or facilities or otherwise cooperate with Zai, including with respect to any financial and regulatory reporting, audit and payment obligations under each Zai Third Party Agreement, insofar as they pertain to a Licensed Molecule or any Product or MacroGenics&#8217; (and its Related Parties&#8217;) activities hereunder</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Future Third Party Agreements</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If, after the Effective Date, either Party enters into a license agreement in which it would Control any Patents or Know-How licensed from a Third Party that would fall under the definitions of (i) in the case of MacroGenics, MacroGenics Licensed Patents or MacroGenics Licensed Know-How, or (ii) in the case of Zai, Zai Licensed Patents or Zai Licensed Know-How (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Future Third </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Party Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such licensee Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">In-License Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall promptly notify the other Party in</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">32</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_79"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">writing of the terms and conditions of such Future Third Party Agreement, including a description of such Patents or Know-How, any restrictions on use, obligations required to be undertaken by, or otherwise applicable to, any (sub)license and any Triggered Third Party Payment that would be payable if the other Party elects to obtain a sublicense under such Patents or Know-How&#59; and upon the other Party&#8217;s reasonable written request, provide a copy of such Future Third Party Agreement, provided that the licensee Party shall have the right to redact confidential, proprietary or sensitive information from such copy.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">Subject to Section 3.8(c), unless the other Party &#91;***&#93;, and subject to all other applicable terms of the Future Third Party Agreement to the extent that would be applicable to the rights (sub)licensed hereunder to such Party, then (i) in the case of MacroGenics as the In-License Party, the MacroGenics Licensed Patents or MacroGenics Licensed Know-How, or (ii) in the case of Zai as the In-License Party, Zai Licensed Patents or Zai Licensed Know-How, in each case (i)-(ii) shall not include such Patents or Know-How in-licensed pursuant to such Future Third Party Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;, with respect to any Patents or Know-How that is (i) licensed to the In-License Party under a Zai Third Party Agreement or MacroGenics Third Party Agreement and (ii) necessary or reasonably useful for the non-In-License Party to perform its obligations under this Agreement or exercise the rights licensed to it under this Agreement with respect to the &#91;***&#93; Program, then&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">any Triggered Third Party Payment that is (A) associated with such Patents or Know-How and (B) payable by the In-License Party after the Opt-In shall be &#91;***&#93;&#59; and</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">such Patents or Know-How shall be &#91;***&#93; (in the case of MacroGenics as the In-License Party) or &#91;***&#93; (in the case of Zai as the In-License Party).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:113pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.23pt">&#91;***&#93;</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARGET </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#59; R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ESEARCH</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Target Nomination</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">MGNX Option Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the period starting from the Effective Date and for &#91;***&#93; thereafter, MacroGenics shall have the right to nominate a Target for the MGNX Option Molecule. To exercise such right, MacroGenics shall notify Zai (or the Gatekeeper, if either Party elects to implement a Gatekeeper pursuant to Section 4.1(c)) in writing of the Target that MacroGenics wishes to be the subject of activities under the Research Plan for the MGNX Option Program. Zai shall notify MacroGenics in writing within &#91;***&#93; following the receipt of MacroGenics&#8217; notice whether it agrees to the inclusion of the selected Target within the MGNX Option Program, provided that Zai may only withhold its consent to such inclusion on the basis that the designated Target is not Available to Zai. If Zai agrees to the inclusion of the selected Target, such Target shall be deemed the Target selected by MacroGenics for the MGNX Option Molecule as of the date of MacroGenics&#8217; receipt of Zai&#8217;s acceptance notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MGNX Option Target Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Zai Selection Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the period starting from the Effective Date and for &#91;***&#93; thereafter, Zai shall have the right to nominate a Target for the Zai Selection Molecule. To exercise such right, Zai shall notify MacroGenics (or the Gatekeeper, if either Party elects to</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">33</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_82"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">implement a Gatekeeper pursuant to Section 4.1(c)) in writing of the Target that Zai wishes to be the subject of activities under the Research Plan for the Zai Selection Program. MacroGenics shall notify Zai in writing within &#91;***&#93; following the receipt of Zai&#8217;s notice whether it agrees to the inclusion of the selected Target within the Zai Selection Program, provided that MacroGenics may only withhold its consent to such inclusion on the basis that the designated Target is not Available to MacroGenics. If MacroGenics agrees to the inclusion of the selected Target, such Target shall be deemed the Target selected by Zai for the Zai Selection Molecule as of the date of Zai&#8217;s receipt of MacroGenics&#8217; acceptance notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Selection Target Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Target Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon either Party&#8217;s reasonable request, the Parties shall mutually agree upon an independent, nationally-recognized law firm to act as a gatekeeper (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) solely for purposes of facilitating Target nomination and verifying whether or not a Target is Available, as further described in this Section 4.1(c), and the Parties shall  &#91;***&#93; the Gatekeeper in connection therewith. At the nominating Party&#8217;s request, the non-nominating Party shall provide the nominating Party (or, at non-nominating Party&#8217;s discretion, the Gatekeeper) with &#91;***&#93;&#59; provided that, the non-nominating Party shall not be obligated to provide to the nominating Party any confidential information of a Third Party, or to breach the terms of any agreement with a Third Party in providing such information. The Parties shall agree upon and enter into a customary three-way agreement with the Gatekeeper, whereby (i) the nominating Party will provide the Gatekeeper with the proposed Target, (ii) the non-nominating Party will provide the Gatekeeper with a list of Targets that are not Available, and (iii) upon review of both lists, the Gatekeeper will inform the nominating Party (and only the nominating Party) of whether the proposed Target is Available&#59; provided that the nominating Party&#8217;s proposed Target shall be the Confidential Information of nominating Party, and the non-nominating Party&#8217;s list of Targets shall be the Confidential Information of the non-nominating Party. In the event of any dispute with respect to the Availability of a Target under this Section 4.1, whether or not a Gatekeeper is implemented to facilitate the Target nomination process, either Party may submit such dispute for resolution pursuant to Article 15.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Research</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the Research Term, the Parties will jointly conduct early Development activities pursuant to a Research Plan for each of the Programs. Within (i) &#91;***&#93; following the Effective Date with respect to the &#91;***&#93; Program, (ii) &#91;***&#93; following the Effective Date with respect to the &#91;***&#93;, and (iii) &#91;***&#93; following the MGNX Option Target Date with respect to the MGNX Option Program, and (iv) &#91;***&#93; following the Zai Selection Target Date with respect to the Zai Selection Program, the Parties shall mutually agree to a research and early development plan and budget (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for the applicable Program, which shall set forth the deliverables, timelines, responsibilities of each Party, criteria for selecting development candidates, and budgeted FTEs and out-of-pocket costs for Development activities. Each Research Plan shall set forth the Development activities to be conducted by the Parties for the applicable Program which extend through &#91;***&#93;(including completion of &#91;***&#93;, &#91;***&#93;, and &#91;***&#93;) during the Research Term. The JSC shall review each Research Plan no less than &#91;***&#93;  during the Research Term, and make updates as appropriate. During the Research Term, each Party shall use Commercially Reasonable Efforts to conduct the activities allocated to such Party in each Research Plan, and the JRDC shall oversee and facilitate the conduct of such activities.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Records&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall maintain complete, current and accurate records of (i) all activities conducted pursuant to the Research Plan and (ii) other pre-IND activities that are mutually agreed upon by the Parties and conducted after the Effective Date (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and all data and other information resulting from such Research Plan Activities. Such</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">34</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_85"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">records shall fully and properly reflect all work performed and results achieved in the performance of such Research Plan Activities in good scientific manner appropriate for regulatory and patent purposes. During each JRDC meeting, each Party shall provide the JRDC with an update on the progress of Research Plan Activities and any information and data generated from such Research Plan Activities since the prior JRDC meeting.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">Research Costs</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; MacroGenics and Zai &#91;***&#93; with Research Plan Activities for the &#91;***&#93; Product in the &#91;***&#93; Program &#91;***&#93; Molecule or &#91;***&#93; Product under the Research Plan (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Research Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93;  Program, &#91;***&#93;  Research Plan Activities for the applicable Product in the applicable Program.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Program, &#91;***&#93;Research Plan Activities &#91;***&#93; Program.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall have the right to engage Third Party contractors to perform any portion of its obligations under the Research Plans without the other Party&#8217;s consent&#59; provided that any subcontractor engaged by a Party pursuant to this Section 4.2(d) shall be required to agree in writing to be bound by terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this Agreement. Use of subcontractors for the foregoing purposes by any Party shall not relieve it of any of its obligations pursuant to this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EVELOPMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#59; R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EGULATORY</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Collaboration Programs</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:113pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">Development Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Option Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. &#91;***&#93;, the Parties will jointly conduct Development activities pursuant to a Global Development Plan and a Territory-Specific Development Plan for such Collaboration Program&#59; provided that, with respect to the &#91;***&#93; Program, the Parties will so conduct the Development activities unless and until Zai elects to exercise its Opt-In pursuant to Section 5.1(e). Subject to Section 5.1(a)(ii), no later than &#91;***&#93; prior to the date the Parties reasonably &#91;***&#93;, the Parties shall mutually prepare a Global Development Plan and a Territory-Specific Development Plan for such Collaboration Program for the JSC&#8217;s review and approval. Each Global Development Plan and Territory-Specific Development Plan shall set forth in reasonable detail the major</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">35</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_88"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Development and regulatory activities to be conducted by or on behalf of each Party (or its Affiliates or Sublicensees) and the estimated timelines for achieving such activities to obtain Regulatory Approval in each country or Region in the applicable Collaboration Territory. Pursuant to each Global Development Plan and Territory-Specific Development Plan for a Collaboration Program Zai shall be primarily responsible for conducting Clinical Trials in the applicable Collaboration Territory, and MacroGenics shall be primarily responsible for conducting Clinical Trials outside the applicable Collaboration Territory. The JSC shall review each Global Development Plan and Territory-Specific Development Plan no less than &#91;***&#93; and make updates as appropriate, and the JRDC shall oversee and facilitate cooperation and information transfer between the Parties in conducting the activities set forth in the Global Development Plan and Territory-Specific Development Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Zai exercises the &#91;***&#93; Profit Share Option pursuant to Section 5.1(e) the Parties shall mutually prepare a Co-Development Plan within &#91;***&#93;</font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  of Zai&#8217;s exercise of the &#91;***&#93; Profit Share Option for the JRDC&#8217;s review and approval&#59; provided that, if there is a Global Development Plan or Territory Specific Development Plan in effect at such time, the Co-Development Plan shall replace such Global Development Plan or Territory Specific Development Plan. The Co-Development Plan shall set forth in reasonable detail (1) the major Development and regulatory activities to be conducted by or on behalf of each Party (or its Affiliates or Sublicensees), (2) the estimated timelines for achieving such activities to obtain Regulatory Approval in each country or Region in the world, and (3) the respective budgets for the Development of the applicable &#91;***&#93; Product (A) under the Research Plan, if ongoing, (B) in the &#91;***&#93; Opt-In Territory, and (C) in the ROW. Pursuant to the Co-Development Plan and unless otherwise specified therein, Zai shall be primarily responsible for finishing all Clinical Trials it is conducting in the &#91;***&#93; Territory at the time of the Opt-In and conducting Clinical Trials in the &#91;***&#93; Opt-In Territory that will be initiated after the Opt- In, and MacroGenics shall be primarily responsible for finishing all Clinical Trials it is conducting outside the &#91;***&#93; Territory at the time of the Opt-In and conducting Clinical Trials in all countries in the ROW that will be initiated after the Opt-In. The JSC shall review the Co-Development Plan no less than &#91;***&#93; and make updates as appropriate, and the JRDC shall oversee and facilitate cooperation and information transfer between the Parties in conducting the activities set forth in the Co- Development Plan.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Diligence&#59; Standards</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Zai&#8217;s Responsibilities for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Option Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall use Commercially Reasonable Efforts to conduct the Development activities allocated to Zai under the Global Development Plans and Territory-Specific Development Plans for (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Option Program, and to achieve the Development goals as described in each Global Development Plan and Territory-Specific Development Plan. Without limiting the generality of the foregoing, with respect to each such Collaboration Program, Zai shall use Commercially Reasonable Efforts to either (y) &#91;***&#93; or (z) include the &#91;***&#93;. Further, Zai shall provide reasonable assistance to MacroGenics with submissions to and interactions with the FDA and other Regulatory Authorities outside of the applicable Collaboration Territory, at MacroGenics&#8217; request and expense&#59; provided that, with respect to the provision of data, information and materials, such obligation to assist shall not require Zai to generate any data not within its possession or control.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.5pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:5.03pt">MacroGenics&#8217; Responsibilities for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> Program Before Opt-In and MGNX Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. MacroGenics shall use Commercially Reasonable Efforts to conduct the Development activities allocated to MacroGenics under the Global Development Plans and Territory-</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">36</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_91"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Specific Development Plans for (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Program, and to achieve the Development goals as described in the Global Development Plan and Territory-Specific Development Plan. Further, MacroGenics shall provide reasonable assistance to Zai with submissions to and interactions with the NMPA and other Regulatory Authorities in the applicable Collaboration Territory, at Zai&#8217;s request and expense&#59; provided that, with respect to the provision of data, information and materials, such obligation to assist shall not require MacroGenics to generate any data not within its possession or control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Parties&#8217; Responsibilities for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After Opt-In, each Party shall use Commercially Reasonable Efforts to conduct the Development activities allocated to it under the Co-Development Plan for the &#91;***&#93; Program, and to achieve the Development goals as described in the Co-Development Plan. Each Party shall provide reasonable assistance to the other Party with submissions to and interactions with the Regulatory Authorities that the other Party is responsible for under the Co-Development Plan, at the other Party&#8217;s request&#59; provided that (a) any cost incurred by such other Party in connection therewith &#91;***&#93;, and (b) with respect to the provision of data, information and materials, such obligation to assist shall not require such other Party to generate any data not within its possession or control.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:2.58pt">Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall conduct all Development Plan Activities in compliance with&#58; (A) the terms and conditions of this Agreement&#59; (B) as may be updated from time to time, the Global Development Plans, Territory Specific Development Plans and Co-Development Plan&#59;</font></div><div style="padding-left:17.6pt;padding-right:11.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C) all applicable GLP, GCP and applicable cGMP requirements, including those specified by the ICH&#59; and (D) all Applicable Laws and Regulations.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">Records&#59; Data&#59; Information Sharing</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Records&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall maintain complete, current and accurate records of all activities conducted pursuant to each Global Development Plan, each Territory- Specific Development Plan and the Co-Development Plan (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development Plan Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and all data and other information resulting from such Development Plan Activities. Such records shall fully and properly reflect all work performed and results achieved in the performance of such Development Plan Activities in good scientific manner appropriate for regulatory and patent purposes. During each JRDC meeting, each Party shall provide the JRDC with an update on the progress of Development Plan Activities and any information and data generated from such Development Plan Activities since the prior JRDC meeting.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.03pt">Ownership of Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">&#91;***&#93;. Subject to Section&#91;***&#93;,  &#91;***&#93; shall be (A) the sole owner of &#91;***&#93; generated or arising &#91;***&#93;(x) the &#91;***&#93; in the Field &#91;***&#93;, (y) the &#91;***&#93; in the Field  &#91;***&#93;and (z) the &#91;***&#93;in the Field &#91;***&#93;&#59; (B) the &#91;***&#93; mentioned in Section &#91;***&#93; above&#59; and (C) to the extent permitted under the Applicable Laws and Regulations, the&#91;***&#93;, as appliable, &#91;***&#93;, outside the &#91;***&#93; and in the &#91;***&#93;as set forth in clause (A) above.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:185.05pt;text-align:justify;text-indent:-23.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.58pt">&#91;***&#93;. Subject to Section &#91;***&#93;, &#91;***&#93; shall be</font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.14pt">the sole owner of &#91;***&#93;generated or arising &#91;***&#93;(x) the &#91;***&#93;in the Field &#91;***&#93;, (y) the &#91;***&#93;in the Field &#91;***&#93; and (z) the &#91;***&#93; in the Field &#91;***&#93;&#59; (B) the &#91;***&#93; mentioned in Section &#91;***&#93; above&#59; and (C) to the extent permitted under the Applicable Laws and Regulations, the &#91;***&#93; in, as applicable, the &#91;***&#93;, the &#91;***&#93; and the &#91;***&#93; as set forth in clause (A) above.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">&#91;***&#93;. &#91;***&#93; shall be (A) the sole owner of &#91;***&#93; generated in the conduct of any &#91;***&#93; that is &#91;***&#93; for (x) any &#91;***&#93;and at least &#91;***&#93;, (y) any &#91;***&#93;  and at least &#91;***&#93;, or (z) any &#91;***&#93; in at least &#91;***&#93;and at least &#91;***&#93;&#59; and (B) the &#91;***&#93; mentioned in clause (A) above.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.58pt">Assignment Obligation and License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party hereby assigns, transfers and conveys (and to the extent a present assignment is prohibited by Applicable Laws and Regulations, shall assign) to the other Party its, its Affiliates&#8217; and its Sublicensees&#8217; right, title and interest in and to the data generated or arising after the Research Term from the Collaboration Programs in such a way as to effectuate the terms set forth in this Section 5.1(c)(ii). For clarity, all such Data solely owned by a Party shall be deemed to be such Party&#8217;s Licensed Know-How, under which such Party shall grant to the other Party a license pursuant to Section 3.1 or Section 3.2.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:6.98pt">Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.58pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to each Party&#8217;s rights and obligations set forth in Section 5.1(c)(i) and Section 5.1(c)(ii), each Party shall use Commercially Reasonable Efforts to provide to the other Party summaries of data generated from its conduct of Development Plan Activities. Upon a Party&#8217;s reasonable request, and at such Party&#8217;s cost and expense, the other Party shall, to the extent permitted by the Applicable Laws and Regulations, provide more detailed information and data (including Clinical Data) that is reasonably available to such other Party and in support of such summary data provided by such other Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (A) the &#91;***&#93; Program before the Opt-In and (B) the MGNX Option Program, Zai shall, to the extent permitted by the Applicable Laws and Regulations, have the right to use any information or data so provided by MacroGenics to Develop and obtain Regulatory Approval for the applicable Collaboration Molecules and Collaboration Products in the Field in the applicable Collaboration Territory under the applicable Territory Specific Development Plan, and MacroGenics shall, to the extent permitted by the Applicable Laws and Regulations, have the right to use any information or data so provided by Zai to Develop and obtain Regulatory Approval for the applicable Collaboration Molecules and Collaboration Products in the Field outside the applicable Collaboration Territory under the applicable Global Development Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Program after the Opt-In, each Party shall, to the extent permitted by the Applicable Laws and Regulations, have the right to use any information or data so provided by the other Party to carry out the Development and regulatory activities with respect to the &#91;***&#93; Molecules and &#91;***&#93; Products solely in accordance with the Co-Development Plan under the &#91;***&#93; Opt-In Territory and the ROW.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">38</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_94"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Development Costs for &#91;***&#93; Program Before Opt-In and MGNX Program</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Within the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Territory and MGNX Option Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (A) &#91;***&#93;, and (B) the &#91;***&#93;, &#91;***&#93; shall be responsible &#91;***&#93;  Development Costs incurred by &#91;***&#93; in connection with the conduct of any Development Plan Activities that are &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">Outside the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Territory and MGNX Option Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (A) &#91;***&#93;, and (B) the &#91;***&#93;, &#91;***&#93;shall be responsible &#91;***&#93; Development Costs incurred by &#91;***&#93; in connection with the conduct of any Development Plan Activities that are &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Global Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (A) the &#91;***&#93;, and (B) &#91;***&#93;, &#91;***&#93;Development Costs incurred by &#91;***&#93; in connection with the conduct of any Development Plan Activities that (A) are &#91;***&#93;, and (B) &#91;***&#93; (e.g. &#91;***&#93;), as follows&#58; (x) &#91;***&#93; such Development Costs, and (y) &#91;***&#93;such Development Costs.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">&#91;***&#93; Profit Share Option.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Subject to the terms and conditions of this Agreement (including Section 5.1(e)(ii)), MacroGenics hereby grants Zai an option (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Profit Share Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">share in the profit and losses with respect to the &#91;***&#93; Product on a worldwide basis, as set forth in more detail in Exhibit D&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:185.05pt;text-align:justify;text-indent:-23.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.58pt">&#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">Zai may exercise the &#91;***&#93; Profit Share Option only during the period &#91;***&#93;by providing a written notice to MacroGenics and paying MacroGenics the  Profit Share Option Payment within &#91;***&#93; after providing such notice.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.07pt">Subcontractors for Collaboration Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (i) the &#91;***&#93; Program before the Opt-In and (ii) the MGNX Program, each Party shall have the right to engage Third Party contractors to perform any portion of its obligations under this Agreement (each such subcontractor, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permitted Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that &#91;***&#93; to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Program after the Opt-In, each Party shall have the right to engage Third Party contractors to perform any portion of its</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">39</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_97"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">obligations under this Agreement&#59; provided, however, that (A) any such Third Party contractor for which such Party is engaging to conduct services &#91;***&#93;, and (B) &#91;***&#93;, in each case (A)-(B) &#91;***&#93; to be unreasonably withheld, conditioned or delayed (any such subcontractor, as permitted under this Section 5.1(f)(ii), also a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permitted Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Subcontract Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Permitted Subcontractor engaged by a Party pursuant to Section 5.1(f)(i) or Section 5.1(f)(ii) shall be required to agree in writing to be bound by terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this Agreement. Use of Permitted Subcontractors by any Party shall not relieve it of any of its obligations pursuant to this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">License-Only Programs</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Following expiration of the applicable Research Term with respect to a License-Only Program, as between the Parties, Zai shall be solely responsible for the Development of License-Only Molecules and License-Only Products for such License-Only Program in the Field in the License-Only Territory and be the sole owner of all data (including Clinical Data) generated or arising from any License-Only Program after the Research Term. Zai shall use Commercially Reasonable Efforts to Develop License-Only Molecules and License-Only Products in the Field in the License-Only Territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall conduct all Development activities under this Section 5.2 in compliance with&#58; (i) the terms and conditions of this Agreement&#59; (ii) all applicable GLP, GCP and applicable cGMP requirements, including those specified by the ICH&#59; and (iii) all Applicable Laws and Regulations.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Records&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall maintain complete, current and accurate records of all Development activities conducted pursuant to this Section 5.2, and all data and other information resulting from such Development activities. Such records shall fully and properly reflect all work performed and results achieved in the performance of such Development activities in good scientific manner appropriate for regulatory and patent purposes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall have the right to engage Third Party contractors to perform any portion of its obligations with respect to the License-Only Program, other than those under the Research Plans, without MacroGenics&#8217; consent.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EGULATORY</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Collaboration Program</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Option Program within the Collaboration Territory</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Regulatory Submissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Option Program, as between the Parties, subject to this Section 6.1(a)(i), Zai shall be solely responsible for, at &#91;***&#93;, preparing, translating (to the extent required by the applicable Regulatory Authority in the applicable Collaboration Territory) and filing all Regulatory Submissions, and obtaining and maintaining Regulatory Approvals, for the Collaboration</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">40</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_100"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Products in the applicable Collaboration Territory, in compliance with all Applicable Laws and Regulations. MacroGenics shall have the right, but not the obligation, to review and comment on all Regulatory Submissions for any Collaboration Product to any Regulatory Authority in the applicable Collaboration Territory, and Zai shall reasonably consider any such comments in such Regulatory Submissions prior to filing thereof and shall promptly provide copies of any Regulatory Submissions (including all updates thereof) to MacroGenics. MacroGenics shall cooperate with Zai in all material respects and be actively involved in Zai&#8217;s efforts with respect to such Regulatory Submissions, including without limitation providing to Zai any revisions to the investigator&#8217;s brochure and CMC information required for Regulatory Submissions to Regulatory Authorities in the applicable Collaboration Territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Option Program, as between the Parties, subject to this Section 6.1(a)(ii), Zai shall be responsible for, at &#91;***&#93;, responding to inquiries and correspondence from the applicable Regulatory Authorities with respect to Collaboration Products in the applicable Collaboration Territory. MacroGenics (or its designee) shall have a right to be present at (but not participate in, unless otherwise requested by Zai or the applicable Regulatory Authority) meetings with the Regulatory Authorities if (1) it is reasonably likely that there would be discussions on the agenda about the Collaboration Product beyond the scope of Zai&#8217;s Development of the Collaboration Product in the applicable Collaboration Territory (e.g., CMC matters, Clinical Data generated by MacroGenics),</font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) MacroGenics&#8217; (or its designee&#8217;s) attendance is permitted under the Applicable Laws and Regulations and by the Regulatory Authorities, and (3) MacroGenics&#8217; (or its designee&#8217;s) attendance would not delay any such meetings. Following each substantive communication (whether by phone or in person) with a Regulatory Authority with respect to a Collaboration Product, Zai shall prepare a record of such meeting in accordance with its standard business practices (e.g., written minutes) and provide to MacroGenics a copy of such record.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program outside the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Option Program, as between the Parties, MacroGenics shall be solely responsible for, at &#91;***&#93;, (i) preparing, translating and filing all Regulatory Submissions, and obtaining and maintaining Regulatory Approvals, for the Collaboration Products outside the applicable Collaboration Territory, in compliance with all Applicable Laws and Regulations, and (ii) responding to inquiries and correspondence from the applicable Regulatory Authorities with respect to Collaboration Products outside the applicable Collaboration Territory. MacroGenics or its designee shall own and hold all Regulatory Approvals for Collaboration Products outside the applicable Collaboration Territory. Zai shall cooperate with MacroGenics in all material respects and be actively involved in MacroGenics&#8217; efforts with respect to such Regulatory Submissions, including without limitation providing to MacroGenics any revisions to the investigator&#8217;s brochure and pharmacovigilance information required for Regulatory Submissions to Regulatory Authorities in the applicable jurisdiction outside the Collaboration Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Program after the Opt-In, subject to the Co-Development Plan, Zai shall be responsible for the regulatory activities in the &#91;***&#93; Opt-in Territory and MacroGenics shall be responsible for the regulatory activities in the ROW (each such Party responsible for regulatory activities, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Subject to the Co-Development Plan, (1) the Responsible Party shall comply with Sections 6.1(a)(i) and 6.1(a)(ii), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, with respect to the conduct of regulatory activities in the country or Region allocated to it&#59; and (2) the other Party shall have the same rights and obligations set forth in Sections 6.1(a)(i) and 6.1(a)(ii), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, with respect to such country or Region&#59; provided that, in each case of (1) and (2), any cost incurred by any Party in connection therewith will &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">41</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_103"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Market Authorization Applications and Regulatory Approvals in Greater China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (i) the &#91;***&#93; Program (whether before or After the Opt-In) and (ii) the MGNX Program, unless otherwise required by Applicable Laws and Regulations, &#91;***&#93; shall file all MAAs for Collaboration Products as imported products in Greater China, in &#91;***&#93; name. For clarity, such Regulatory Approvals shall be deemed &#91;***&#93; for so long as such Regulatory Approvals are in &#91;***&#93; name, under which &#91;***&#93; shall grant to &#91;***&#93; a license pursuant to Section &#91;***&#93;. For so long as such Regulatory Approvals are in &#91;***&#93; name, &#91;***&#93; hereby designates &#91;***&#93; as &#91;***&#93; regulatory agent and exclusive general distributor for each Collaboration Product in Greater China. In the event later permitted by Applicable Laws or Regulations, and upon &#91;***&#93;  reasonable request, &#91;***&#93; shall promptly assist and cooperate with &#91;***&#93; and transfer and assign all MAAs or Regulatory Approvals for each Collaboration Product in Greater China to &#91;***&#93; to allow &#91;***&#93; to be the holder and sole owner of the Regulatory Approval for each Collaboration Product in Greater China within the scope of the license granted to &#91;***&#93; under Section &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">Pharmacovigilance</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Pharmacovigilance and Safety Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics shall establish and maintain, at &#91;***&#93;, a global drug safety database for the Collaboration Products. Zai shall have the right to access from such global drug safety database all Safety Data necessary for Zai to comply with all Applicable Laws and Regulations in the applicable Collaboration Territory. Zai may establish and maintain, at &#91;***&#93;, a local drug safety database for the Collaboration Products in the applicable Collaboration Territory. Each Party will be responsible, at its sole cost and expense, for&#58; (A) collecting all pharmacovigilance and other Safety Data for the Collaboration Products in its respective territory as required by Applicable Laws and Regulations&#59; and</font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:3.75pt">reporting any such pharmacovigilance and other Safety Data, including Adverse Events in its respective territory, for the Collaboration Products to the applicable Regulatory Authorities in its respective territory, as appropriate to be in compliance with all Applicable Laws and Regulations, including reporting Safety Data to the other Party in XML files (or CIOMS format) (in English) for entry into the global safety database&#59; provided that any cost incurred by any Party in connection therewith with respect to the &#91;***&#93; Program &#91;***&#93;. Each Party expressly acknowledges that the other Party may provide information it receives pursuant to this Section 6.1(e)(i) to appropriate Regulatory Authorities within its respective territory by itself or through any of its Affiliates or Sublicensees engaged in Development and Commercialization activities of the Collaboration Products in its respective territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within &#91;***&#93; following the Effective Date, or such other period as the Parties may agree (but in any case before the first IND filing of the first Product in the applicable Collaboration Territory), the Parties shall enter into a mutually acceptable pharmacovigilance agreement setting forth the Parties&#8217; respective obligations in detail regarding pharmacovigilance and the exchange of Safety Data for the Collaboration Programs during the period before the First Commercial Sale of a first Collaboration Product in the applicable Collaboration Territory. Further, no less than &#91;***&#93; before the estimated date of the first Regulatory Approval of a first Collaboration Product in the applicable Collaboration Territory, the Parties shall amend such pharmacovigilance agreement to set forth the Parties&#8217; respective obligations in the detail regarding pharmacovigilance and the exchange of Safety Data during the period after the First Commercial Sale of a first Collaboration Product in the applicable Collaboration Territory. In the event Zai elects to Opt-In with respect to the &#91;***&#93; Program, the Parties will determine the need to amend the pharmacovigilance agreement in view of the Parties&#8217; responsibilities set forth in the Co-Development Plan and Co-Commercialization Plan.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">42</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_106"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.07pt">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a Party is required by a Regulatory Authority of competent jurisdiction a recall, withdrawal, or correction (including the dissemination of relevant information) of any Collaboration Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or if a Recall is deemed advisable by a Party in its sole discretion, then such Party shall so notify the other Party no later than &#91;***&#93; hours in advance of the earlier of (i) initiation of Recall, or (ii) the submission of plans for such Recall to a Regulatory Authority. Promptly after being notified of a Recall, each Party shall provide the other Party with such assistance in connection with such Recall as may be reasonably requested by such other Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Program, Zai shall handle exclusively the organization and implementation of any Recalls of any Collaboration Product in the applicable Collaboration Territory, at &#91;***&#93;, and MacroGenics shall handle exclusively the organization and implementation of any Recalls of any Collaboration Product outside the Collaboration Territory, at &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Program after the Opt-In, Zai shall handle exclusively the organization and implementation of any Recalls of any &#91;***&#93; Product in the &#91;***&#93; Opt-In Territory, and MacroGenics shall handle exclusively the organization and implementation of any Recalls of any &#91;***&#93; Product in the ROW&#59; provided that any cost incurred by any Party in connection therewith will &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">License-Only Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As between the Parties, Zai shall &#91;***&#93;, (a) preparing, translating and filing all Regulatory Submissions, and obtaining and maintaining Regulatory Approvals, for the License-Only Products in the License-Only Territory, in compliance with all Applicable Laws and Regulations, (b) responding to inquiries and correspondence from the applicable Regulatory Authorities with respect to License-Only Products in the License-Only Territory, and (c) handling exclusively the organization and implementation of any Recalls of any License-Only Products &#91;***&#93;.  Zai or its designee shall own and hold all Regulatory Approvals for License-Only Products.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OMMERCIALIZATION</font></div><div><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Collaboration Programs</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program Within the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Program, as between the Parties, subject to this Section 7.1, Zai shall be solely responsible for the Commercialization of Collaboration Products in the applicable Collaboration Territory, at &#91;***&#93;, including developing and executing a plan for commercial launch, obtaining all required approvals from Regulatory Authorities for Commercialization (including reimbursement activities), marketing and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related functions. Following Regulatory Approval of a Collaboration Product in the Field in any country or Region in the applicable Collaboration Territory, (i) Zai shall use Commercially Reasonable Efforts to Commercialize such Collaboration Product in the Field in such country or Region, and (ii) at each JCC meeting, Zai shall provide the JCC with an update with respect to its Commercialization activities for such Collaboration Product in the Field in such country or Region, and</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">43</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_109"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">consider in good faith any comments thereto provided by the JCC. As between the Parties, Zai shall book all sales of Collaboration Products in any country or Region in the applicable Collaboration Territory, and shall have the sole right to determine all pricing of Collaboration Products in such country or Region.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Program Outside the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to (1) the &#91;***&#93; Program before the Opt-In and (2) the MGNX Program, as between the Parties, subject to this Section 7.1, MacroGenics shall be solely responsible for the Commercialization of Collaboration Products in the Field outside the applicable Collaboration Territory.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Zai elects to Opt-In with respect to the &#91;***&#93; Program pursuant to Section 5.1(e), no later than &#91;***&#93; prior to the anticipated First Commercial Sale of the first &#91;***&#93; Product worldwide, the Parties shall mutually prepare a Co- Commercialization Plan for the JCC&#8217;s review and approval. The Co-Commercialization Plan shall set forth in reasonable detail the major Commercialization activities to be conducted by or on behalf of each Party (or its Affiliates or Sublicensees), (2) the estimated timelines for achieving such activities in each country or Region in the world, and (3) the respective budgets for the Commercialization of the applicable &#91;***&#93; Product in (A) the &#91;***&#93; Opt-in Territory, and (B) the ROW. The JSC shall review the Co-Commercialization Plan on a regular basis and make updates as appropriate. The Parties hereby agree that, after the Opt-In, as between the Parties, &#91;***&#93; shall book all sales of &#91;***&#93; Products in &#91;***&#93; and &#91;***&#93; shall book all sales of &#91;***&#93; Products in &#91;***&#93;. Each Party shall use Commercially Reasonable Efforts to conduct the Commercialization activities allocated to it under the Co-Commercialization Plan for the &#91;***&#93; Program. At each JCC meeting, each Party shall provide the JCC with an update with respect to its Commercialization activities for the &#91;***&#93; Product in the Field worldwide, and consider in good faith any comments thereto provided by the JCC.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Global Branding&#59; Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program Before Opt-In and MGNX Option Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to each &#91;***&#93; Product before the Opt-In and MGNX Option Product, Zai shall reasonably cooperate with MacroGenics and its designees to establish a global branding strategy worldwide (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Branding Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Zai shall Commercialize each such Collaboration Product in the applicable Collaboration Territory under a worldwide brand (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Product Brand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) specified by MacroGenics consistent with the Global Branding Strategy, except to the extent such Global Product Brand is not practicable in the applicable Collaboration Territory or not permitted by any applicable Regulatory Authority in such Collaboration Territory, in which case MacroGenics and Zai shall agree on an alternate product brand specific to such Collaboration Territory or MacroGenics may make adjustments to the Global Branding Strategy, as MacroGenics deems appropriate.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that Zai elects to Opt-In with respect to the &#91;***&#93; Program pursuant to Section 5.1(e), each Party shall Commercialize each &#91;***&#93; Product in accordance with a Global Branding Strategy jointly established by the Parties after the Opt-In and under the Global Product Brand jointly specified by the Parties after the Opt-In, except to the extent such Global Product Brand is not practicable or not permitted by in any country or Region in the world, in which case the Party responsible for Commercialization of &#91;***&#93; Products in such country shall decide on an alternate product brand specific to such country or Region.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Zai&#8217;s Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except for any Trademarks that are intended to identify MacroGenics&#8217; as the manufacturer or owner of a Collaboration Product, and subject to Section 7.1(d)(i) and Section 7.1(d)(ii), Zai shall be responsible for the following aspects of Commercialization of the Collaboration Products&#58; (i) the design and supply of printable artworks and labels in promotional materials for Collaboration Products for the applicable Collaboration Territory (and other countries</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">44</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_112"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">allocated to Zai under the Co-Commercialization Plan with respect to the &#91;***&#93; Program after the Opt-In),</font></div><div style="padding-left:17.6pt;padding-right:10.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) determining the product names of the Collaboration Products in a local language and how the Collaboration Products shall be presented and described in any promotional materials to the medical community in the applicable Collaboration Territory (and other countries allocated to Zai under the Co- Commercialization Plan with respect to the &#91;***&#93; Program after the Opt-In), (iii) the placement of the name and logos of Zai in any such promotional materials and (iv) branding the Collaboration Products in the applicable Collaboration Territory (and other countries allocated to Zai under the Co- Commercialization Plan with respect to the &#91;***&#93; Program after the Opt-In) using any trademarks it determines appropriate, which branding may vary by country or Region, in each case (i)-(iii) as permitted by Applicable Laws and Regulation and consistent with the applicable Global Branding Strategy. Except with respect to the MacroGenics Licensed Trademarks, Zai will own all rights in all other trademarks it creates for the &#91;***&#93; Products and MGNX Option Products for use in the applicable Collaboration Territory, and register and maintain such trademarks in the applicable Collaboration Territory, where and how it determines appropriate.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.85pt">No Diversion</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Each Party hereby covenants and agrees that it shall not, either directly or indirectly, promote, market, distribute, import, sell or have sold Collaboration Products, including via the Internet or mail order, to any Third Party, address or Internet Protocol address in the other Party&#8217;s territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">If any of the Collaboration Products are diverted into the other Party&#8217;s territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unauthorized Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for use (excluding use by or on behalf of any Party, its Affiliates and Sublicensees for activities permitted under this Agreement) or sale therein (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unauthorized Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the following shall apply&#58; (1) if such Collaboration Products were diverted by an identifiable customer, distributor, employee, consultant or agent of the source Party (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unauthorized Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) then, upon the request of the other Party, the source Party shall not sell such Collaboration Products to, or allow the sale of such Collaboration Products by, such Unauthorized Person (including by requiring the discontinuation of sales of such Collaboration Product or enforcement of contractual obligations against such Unauthorized Person) for the remaining Term and shall use Commercially Reasonable Efforts to buy back all such Collaboration Products from such Unauthorized Person within &#91;***&#93; of such request from the other Party&#59; or (2) the source Party shall use Commercially Reasonable Efforts to investigate the location of such diverted Collaboration Products and buy them back&#59; but, if and to the extent that, the source Party elects not to, or is unable to, buy back the applicable diverted Collaboration Products, then the other Party may, in its sole discretion, buy back the applicable diverted Collaboration Products, and the source Party shall reimburse the other Party for all reasonable costs incurred by such other Party in connection with the buy-back or lost sales of any such diverted Collaboration Products. Notwithstanding the foregoing, any cost incurred by any Party in connection with (1) or (2) above with respect to the &#91;***&#93; Program after the Opt-In &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">License-Only Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As between the Parties, Zai shall be solely responsible for the Commercialization of License-Only Products in the Field in the License-Only Territory. Following the Regulatory Approval of a License-Only Product in the Field in any country or Region in the License-Only Territory, Zai shall use Commercially Reasonable Efforts to Commercialize such License-Only Product in the Field in such country or Region. Zai will own all rights in all other trademarks it creates for the License- Only Products for use in the License-Only Territory, and register and maintain such trademarks in the License-Only Territory, where and how it determines appropriate</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">45</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_115"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall comply with the terms of this Agreement and all Applicable Laws and Regulations relating to activities performed or to be performed by such Party (or its Affiliates, contractor(s) or Sublicensee(s)) under or in relation to the Commercialization of Products pursuant to this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Zai&#8217;s Covenants, Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Without limiting the generality of Section 7.3(a), Zai agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants, and Subcontractors (together with Zai, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that for the performance of its obligations hereunder&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">The Zai Representatives shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to&#58; (1) any Government Official in order to influence official action&#59;</font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) any Person (whether or not a Government Official) (a) to influence such Person to act in breach of a duty of good faith, impartiality or trust (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acting Improperly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (b) to reward such Person for Acting Improperly, or (c) where such Person would be Acting Improperly by receiving the money or other thing of value&#59; (3) any other Person while knowing or having reason to know that all or any portion of the money or other thing of value shall be paid, offered, promised or given to, or shall otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement&#59; or (4) any Person to reward that Person for Acting Improperly or to induce that Person to Act Improperly.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">The Zai Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">Zai and the other Zai Representatives shall comply with the Anti- Corruption Laws and shall not take any action that shall, or would reasonably be expected to, cause either Party (or its Affiliates) to be in violation of any such laws. In furtherance of the foregoing, Zai acknowledges and confirms the following&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">Zai has reviewed its internal programs in relation to the Anti- Corruption Laws and the ability of the Zai representatives to adhere to such laws in performance of its obligations hereunder in advance of the signing of this Agreement and warrants that it and the other Zai Representatives can and shall continue to comply with such Anti-Corruption Laws in performance of its obligations hereunder and further represents and warrants that should either Party identify in writing to the other Party any measures that should be reasonably taken to improve Zai Representatives&#8217; compliance with such Anti-Corruption Laws for the performance of its obligations hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Improvement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Zai shall use Commercially Reasonable Efforts to implement such Zai Improvement Plan within an agreed reasonable timeframe (which shall in any event not be in excess of &#91;***&#93;) from the date the Zai Improvement Plan is delivered to the receiving Party. In the absence of the full implementation by Zai of such Zai Improvement Plan within the aforesaid &#91;***&#93; period, MacroGenics shall be entitled to terminate this Agreement, upon written notice to Zai with immediate effect, to be relieved of any obligations, and to seek compensation from Zai&#59;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">To the best of Zai&#8217;s and its Affiliates&#8217; knowledge after reasonable diligence, no Zai Representative that shall participate or support Zai&#8217;s performance of its obligations hereunder has, directly or indirectly, (x) paid, offered or promised to pay, or authorized the payment of</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">46</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_118"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">any money&#59; (y) given, offered or promised to give, or authorized the giving of anything else of value&#59; or</font></div><div style="padding-left:17.6pt;padding-right:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.2pt">solicited, received or agreed to accept any payment of money or anything else of value, in each case ((x), (y) and (z)), in violation of the Anti-Corruption Laws during the &#91;***&#93; preceding the date of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">To the best of Zai &#8217;s and its Affiliates&#8217; knowledge, none of its intellectual property rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement, other than those provided by or on behalf of MacroGenics, were procured in violation of any Anti-Corruption Laws.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Zai, on behalf of itself and the Zai Representatives, represents and warrants to MacroGenics that all information provided by Zai and the Zai Representatives to MacroGenics in any anti-bribery and corruption due diligence checklist, similar due diligence process performed by MacroGenics or its Affiliates or inquiry by MacroGenics related to Zai &#8217;s or the Zai Representatives compliance with Anti-Corruption Laws is true, complete and correct in all material respects at the date it was provided and that any material changes in circumstances relevant to the answers provided in such exercise shall be promptly disclosed to MacroGenics.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">Zai shall promptly provide MacroGenics with written notice of the following events&#58; (i) upon becoming aware of any actual, alleged, or potential breach or violation by Zai or any Zai Representative of any representation, warranty or undertaking set forth in this Section 0&#59; or</font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.98pt">upon receiving a formal notification that it is the target of a formal investigation by a government authority for any violation of any Anti-Corruption Law or upon receipt of information from any of the Zai Representatives that any of them is the target of a formal investigation by a government authority for a violation of any Anti-Corruption Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">For the Term and for &#91;***&#93; following the expiration or earlier termination of the Agreement, Zai shall for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly this Section 0 permit MacroGenics, its Affiliates, any auditors of any of them and any government authority to have reasonable access to any premises of Zai or other Zai Representatives used in connection with this Agreement, together with a right to reasonably access personnel and records that relate to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Zai shall provide or procure that the Zai Representatives shall provide all co-operation as reasonably requested by MacroGenics for the purposes of the Zai Audit, with the understanding that MacroGenics shall be responsible for all costs and fees of any Zai Audit and MacroGenics shall procure that any auditor enters into a confidentiality agreement consistent with the confidentiality provisions elsewhere in this Agreement in all material respects.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.53pt">If (A) MacroGenics becomes aware of, whether or not through a Zai Audit, that Zai (or any other Zai Representative) is in breach or violation of any representation, warranty or undertaking in Section 0 or of the Anti-Corruption Laws&#59; or (B) MacroGenics receives notification that a suspected or actual violation of an Anti-Corruption Law has occurred by Zai or any other Zai Representative, in each case of (A)-(B), MacroGenics shall have the right, in addition to any other rights or remedies under this Agreement or to which MacroGenics may be entitled in law or equity, to take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by MacroGenics or any of its Affiliates of the Anti-Corruption Laws, including by requiring that Zai agrees to and uses Commercially Reasonable Efforts to implement any curative actions requested by MacroGenics. In the event that Zai refuses to agree to all of the curative actions requested by MacroGenics (and provided that MacroGenics has (x) provided Zai with an explanation in reasonable detail as to why MacroGenics considers such actions necessary, (y) given Zai a </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reasonable opportunity to review and comment upon the proposed actions and to provide its view as to the necessity or</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">48</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_121"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">usefulness of these to address the event concerned, and (z) considered such comments in good faith), MacroGenics shall be entitled to terminate this Agreement in its entirety with immediate effect. Any termination of this Agreement pursuant to this Section 0 shall be treated as a termination for breach by Zai of this Agreement and the consequences of termination shall apply and additionally&#58; (1) subject to the accrued rights of the Parties prior to termination, MacroGenics shall have no liability to Zai for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination&#59; and (2) any amounts that would otherwise be payable to Zai pursuant to this Agreement in its entirety, as applicable, including any then outstanding and unpaid claims for payment shall be null and void to the extent permissible under Applicable Laws and Regulations.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.48pt">Zai shall be responsible for any breach of any representation, warranty or undertaking in this Section 0 or of the Anti-Corruption Laws by any Zai Representative.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">MacroGenics may disclose the terms of this Agreement or any action taken under this Section 0 to prevent a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of Zai and the payment terms, to any government authority if MacroGenics determines, upon advice of counsel, that such disclosure is necessary.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">MacroGenics&#8217;s Covenants, Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Without limiting the generality of Section 7.3(a), MacroGenics agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants, and Subcontractors (together with MacroGenics, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that for the performance of its obligations hereunder&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">The MacroGenics Representatives shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to&#58; (1) any Government Official in order to influence official action&#59; (2) any Person (whether or not a Government Official) (a) to influence such Person to act in breach of a duty of good faith, impartiality or trust, (b) to reward such Person for Acting Improperly, or (c) where such Person would be Acting Improperly by receiving the money or other thing of value&#59;</font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3) any other Person while knowing or having reason to know that all or any portion of the money or other thing of value shall be paid, offered, promised or given to, or shall otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement&#59; or (4) any Person to reward that Person for Acting Improperly or to induce that Person to Act Improperly.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">The MacroGenics Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti- Corruption Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">MacroGenics and the other MacroGenics Representatives shall comply with the Anti-Corruption Laws and shall not take any action that shall, or would reasonably be expected to, cause either Party (or its Affiliates) to be in violation of any such laws. In furtherance of the foregoing, MacroGenics acknowledges and confirms the following&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">MacroGenics has reviewed its internal programs in relation to the Anti-Corruption Laws and the ability of the MacroGenics representatives to adhere to such laws in performance of its obligations hereunder in advance of the signing of this Agreement and warrants that it and the other MacroGenics Representatives can and shall continue to comply with such Anti- </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">49</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corruption Laws in performance of its obligations hereunder and further represents and warrants that should either Party identify in writing to the other Party any measures that should be reasonably taken</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">50</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_124"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to improve MacroGenics Representatives&#8217; compliance with such Anti-Corruption Laws for the performance of its obligations hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Improvement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), MacroGenics shall use Commercially Reasonable Efforts to implement such MacroGenics Improvement Plan within an agreed reasonable timeframe (which shall in any event not be in excess of &#91;***&#93;) from the date the MacroGenics Improvement Plan is delivered to the receiving Party. In the absence of the full implementation by MacroGenics of such MacroGenics Improvement Plan within the aforesaid &#91;***&#93; period, Zai shall be entitled to terminate this Agreement, upon written notice to MacroGenics with immediate effect, to be relieved of any obligations, and to seek compensation from MacroGenics&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.58pt">To the best of MacroGenics&#8217;s and its Affiliates&#8217; knowledge after reasonable diligence, no MacroGenics Representative that shall participate or support MacroGenics&#8217;s performance of its obligations hereunder has, directly or indirectly, (x) paid, offered or promised to pay, or authorized the payment of any money&#59; (y) given, offered or promised to give, or authorized the giving of anything else of value&#59; or (z) solicited, received or agreed to accept any payment of money or anything else of value, in each case ((x), (y) and (z)), in violation of the Anti-Corruption Laws during the </font></div><div style="padding-left:17.6pt;padding-right:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93; preceding the date of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3) To the best of MacroGenics &#8217;s and its Affiliates&#8217; knowledge, none of its intellectual property rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement, other than those provided by or on behalf of Zai, were procured in violation of any Anti-Corruption Laws.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">MacroGenics, on behalf of itself and the MacroGenics Representatives, represents and warrants to Zai that all information provided by MacroGenics and the MacroGenics Representatives to Zai in any anti-bribery and corruption due diligence checklist, similar due diligence process performed by Zai or its Affiliates or inquiry by Zai related to MacroGenics &#8217;s or the MacroGenics Representatives compliance with Anti-Corruption Laws is true, complete and correct in all material respects at the date it was provided and that any material changes in circumstances relevant to the answers provided in such exercise shall be promptly disclosed to Zai.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">MacroGenics shall promptly provide Zai with written notice of the following events&#58; (i) upon becoming aware of any actual, alleged, or potential breach or violation by MacroGenics or any MacroGenics Representative of any representation, warranty or undertaking set forth in this Section 0&#59; or (ii) upon receiving a formal notification that it is the target of a formal investigation by a government authority for any violation of any Anti-Corruption Law or upon receipt of information from any of the MacroGenics Representatives that any of them is the target of a formal investigation by a government authority for a violation of any Anti-Corruption Law.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">For the Term and for &#91;***&#93; following the expiration or earlier termination of the Agreement, MacroGenics shall for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly this Section 0 permit Zai, its Affiliates, any auditors of any of them and any government authority to have reasonable access to any premises of MacroGenics or other MacroGenics Representatives used in connection with this Agreement, together with a right to reasonably access personnel and records that relate to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). MacroGenics shall provide or procure that the MacroGenics Representatives shall provide all co-operation as reasonably requested by Zai for the purposes of the MacroGenics Audit, with the understanding that Zai shall be responsible for all costs and fees of any MacroGenics Audit and Zai shall procure that any auditor enters into a confidentiality agreement consistent with the confidentiality provisions elsewhere in this Agreement in all material respects.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">51</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_127"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.53pt">If (A) Zai becomes aware of, whether or not through a MacroGenics Audit, that MacroGenics (or any other MacroGenics Representative) is in breach or violation of any representation, warranty or undertaking in Section 0 or of the Anti-Corruption Laws&#59; or (B) Zai receives notification that a suspected or actual violation of an Anti-Corruption Law has occurred by MacroGenics or any other MacroGenics Representative, in each case of (A)-(B), Zai shall have the right, in addition to any other rights or remedies under this Agreement or to which Zai may be entitled in law or equity, to take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by Zai or any of its Affiliates of the Anti-Corruption Laws, including by requiring that MacroGenics agrees to and uses Commercially Reasonable Efforts to implement any curative actions requested by Zai. In the event that MacroGenics refuses to agree to all of the curative actions requested by Zai (and provided that Zai has (x) provided MacroGenics with an explanation in reasonable detail as to why Zai considers such actions necessary, (y) given MacroGenics a reasonable opportunity to review and comment upon the proposed actions and to provide its view as to the necessity or usefulness of these to address the event concerned, and (z) considered such comments in good faith), Zai shall be entitled to terminate this Agreement in its entirety with immediate effect. Any termination of this Agreement pursuant to this Section 0 shall be treated as a termination for breach by MacroGenics of this Agreement and the consequences of termination shall apply and additionally&#58; (1) subject to the accrued rights of the Parties prior to termination, Zai shall have no liability to MacroGenics for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination&#59; and (2) any amounts that would otherwise be payable to MacroGenics pursuant to this Agreement in its entirety, as applicable, including any then outstanding and unpaid claims for payment shall be null and void to the extent permissible under Applicable Laws and Regulations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.48pt">MacroGenics shall be responsible for any breach of any representation, warranty or undertaking in this Section 0 or of the Anti-Corruption Laws by any MacroGenics Representative.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Zai may disclose the terms of this Agreement or any action taken under this Section 0 to prevent a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of MacroGenics and the payment terms, to any government authority if Zai determines, upon advice of counsel, that such disclosure is necessary.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANUFACTURE AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UPPLY</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Supply of &#91;***&#93; Products Before Opt-In and MGNX Products</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">MacroGenics Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the &#91;***&#93; Products before the Opt-In and the MGNX Products, subject to other provisions in this Agreement (including Section 4.2(c)(i) and Section 8.3), MacroGenics shall be solely responsible for the Manufacture, either by itself or through one or more Third Parties selected by MacroGenics at its sole discretion, of (i) all such Collaboration Molecules and Collaboration Products required for the Clinical Trials described in each Global Development Plan or Territory-Specific Development Plan, at MacroGenics&#8217; Fully-Burdened Manufacturing Cost, and (ii) all commercial supplies of Collaboration Products required by Zai for the Commercialization of Collaboration Products in the applicable Collaboration Territory, at MacroGenics&#8217; Fully-Burdened Manufacturing Cost.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Supply Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No later than &#91;***&#93; before the first anticipated IND filing for a Collaboration Molecule or Collaboration Product in the applicable Collaboration Territory, the Parties shall enter into negotiations for a supply agreement governing the clinical supply to Zai for its requirements of such Collaboration Molecule and Collaboration Product required for Development </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">52</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereunder in the applicable Collaboration Territory. Within &#91;***&#93; (but no later than &#91;***&#93;) prior to the projected date of First Commercial Sale of a Product in any country or</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">53</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_130"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Region in the applicable Collaboration Territory, the Parties shall negotiate and enter into a supply agreement governing the commercial supply of such Collaboration Product to Zai for its requirements of such Collaboration Product for Commercialization in the applicable Collaboration Territory. Each supply agreement shall provide customary terms and conditions, such as acceptance and rejection procedures, forecast and order procedures, release documentations and audit rights by Zai and for MacroGenics and Zai to discuss and agree upon a Third Party supplier for Products in the event of certain material supply failures, as determined in accordance with criteria to be mutually agreed by the Parties thereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Manufacturing Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All clinical and commercial supplies of Collaboration Molecules and Collaboration Product supplied by MacroGenics shall be manufactured in accordance with the specifications (i) determined by MacroGenics, (ii) subject to Section 8.1(d), consistent with those specifications required by the applicable Regulatory Authority in the Territory provided by Zai to MacroGenics in writing, and (iii) in compliance with all regulatory requirements and all Applicable Laws and Regulations, as further set forth in the supply agreements and related quality agreements.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Change of Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics shall reasonably inform Zai of developments in matters of process development and Manufacture of the Collaboration Products, and shall consult with Zai with respect to the development and Manufacture processes of the Collaboration Products adopted by MacroGenics to the to obtain Regulatory Approval(s) of the same in the Collaboration Territory, all as described in further detail in the supply agreements and quality agreements. In addition, MacroGenics shall implement changes required by Regulatory Authority in the Collaboration Territory to the extent commercially practicable, provided that Zai shall bear any and all incremental costs resulting from any changes to the manufacturing specifications required by the applicable Regulatory Authority in the Collaboration Territory but not by any of the Regulatory Authorities outside the Collaboration Territory, and the supply agreements and quality agreements shall provide the mechanism for such implementation. In the event it is not commercially practicable for MacroGenics or its supplier to implement a change required by a Regulatory Authority in the Collaboration Territory, the Parties shall explore the potential engagement of any other Third Party supplier or &#91;***&#93;. Each Party shall promptly notify the other Party of any information that may impact approvability or regulatory status (before or after approval) of Collaboration Products of which it is aware and reasonably believes may impact the regulatory status before or after Regulatory Approval of a Product in the Collaboration Territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Supply of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to each &#91;***&#93; Product after the Opt- In, the Parties will &#91;***&#93; .</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">&#91;***&#93;Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#91;***&#93;. In the event that &#91;***&#93; Collaboration Molecule  or Collaboration Product other than because of (1) &#91;***&#93;or (2) &#91;***&#93;, or (ii) following the &#91;***&#93;,</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">54</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_133"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then in each case of (i) or (ii) Zai may, upon written notice to MacroGenics &#91;***&#93; request MacroGenics to initiate, or cause its applicable Affiliate or designated Third Party to &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#91;***&#93;. &#91;***&#93;the Parties will &#91;***&#93;. MacroGenics will use Commercially Reasonable Efforts to &#91;***&#93;. Among other things, &#91;***&#93;will provide that MacroGenics will, or will cause its applicable Affiliate or designated Third Party to, &#91;***&#93; Collaboration Molecule and Collaboration Product &#91;***&#93; such Collaboration Molecule and Collaboration Product &#91;***&#93; Zai, its Affiliates or Sublicensees as &#91;***&#93;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If Zai, its Affiliate &#91;***&#93;, MacroGenics shall have the right &#91;***&#93;. MacroGenics may exercise such right by providing written notice to Zai of its intent to do so, and promptly following Zai&#8217;s receipt thereof, the Parties shall &#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.55pt">Supply of cGMP Materials for the First Phase I Clinical Trial of MGNX Option Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary in this Agreement, &#91;***&#93; the Manufacture and supply of the cGMP materials for the first Phase I Clinical Trial of the MGNX Option Product at its own cost and expense.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Supply of License-Only Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall be solely responsible for the manufacture of clinical and commercial supply of License-Only Molecules and License-Only Products, at its sole cost and expense. Zai shall ensure that all clinical and commercial supplies of License-Only Molecules and License- Only Products are manufactured in accordance with the specifications in compliance with all regulatory</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">55</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_136"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">requirements and all Applicable Laws and Regulations in the applicable country or Region in the License- Only Territory.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AYMENTS</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, Zai shall pay to MacroGenics Twenty-Five Million US Dollars (US$25,000,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which shall be non-creditable, non-refundable against any other payments due under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Equity Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As partial consideration for the rights granted to Zai hereunder, the Parties are entering into separate stock issuance and related agreements concurrently with the execution of this Agreement whereby Zai will purchase Thirty Million Seventeen US Dollars and Ten Cents (US$30,000,017.10) of MGNX stock at Thirty-One US Dollars and Thirty Cents ($31.30) per share.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Development and Regulatory Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On a Program-by-Program basis, Zai shall pay to MacroGenics the non-creditable, non-refundable milestone payments listed set forth in the table below within &#91;***&#93; after the first achievement of the applicable milestone events by the first Product in such Program, whether by or on behalf of Zai, its Affiliate or any Sublicensee. For clarity, each of the following milestone payments shall be payable only once per Program, regardless of the number of times such milestone is achieved.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:10.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.074%"><tr><td style="width:1.0%"></td><td style="width:32.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc2e4;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Milestone Event</font></div></td><td colspan="9" style="background-color:#9cc2e4;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:106.9pt;padding-right:106.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Milestone Payment</font></div></td></tr><tr><td colspan="12" style="background-color:#d0cece;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For each of the Collaboration Programs</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:117.7pt;padding-right:97.75pt;text-indent:-18.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:117.7pt;padding-right:98pt;text-indent:-18.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 30.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 28.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.25pt;padding-right:8.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.22pt;padding-right:8.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.35pt;padding-right:7.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.2pt;padding-right:8.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.95pt;padding-right:15.95pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.27pt;padding-right:7.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.2pt;padding-right:8.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.95pt;padding-right:15.95pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.27pt;padding-right:7.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">56</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_139"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:10.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.074%"><tr><td style="width:1.0%"></td><td style="width:32.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.22pt;padding-right:8.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.8pt;padding-right:13.8pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.22pt;padding-right:8.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.8pt;padding-right:13.8pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="background-color:#d0cece;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For each of the License-Only Programs</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:117.7pt;padding-right:98pt;text-indent:-18.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:117.7pt;padding-right:98pt;text-indent:-18.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 30.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 28.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided that, after Zai exercises the &#91;***&#93; Profit Share Option, &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The milestone events above are intended to be successive with respect to each Product and each Program, such that if a particular milestone event set forth in the table above for a Product for an Indication is not achieved prior to the achievement of the next milestone event set forth in the table above for such Product in such Indication (and with respect to the BLA submission acceptance and Regulatory Approval milestones, in the corresponding country or Region) (such non-achieved milestone event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Skipped Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such Skipped Milestone shall be deemed to have been achieved upon the achievement of such next milestone event to occur, and the milestone payment for such Skipped Milestone shall be due and payable by Zai to MacroGenics at the time the milestone payment is due and payable for such next milestone event. For example, if a Registration Trial for a Collaboration Product for an Indication has not been Initiated in the applicable Collaboration Territory prior to the acceptance of a BLA submission for such Collaboration Product for such Indication in China, then the milestone payment for both milestone events shall be due and payable by Zai to MacroGenics at the time the milestone payment for the BLA acceptance milestone event is due and payable under this Section 9.3.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Commercial Milestone Payments for License-Only Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to each License-Only Program, Zai shall pay to MacroGenics the non-creditable, non-refundable milestone payments set forth in the table below within &#91;***&#93;after the first achievement of aggregate annual Net Sales for all License-Only Products for a License-Only Program in a Calendar Year of the applicable sales milestone event. For clarity, the milestone payments in this Section 9.4 shall be additive such that if multiple milestone events specified below are achieved in the same Calendar Year, then the milestone payments for all such milestone events shall be payable with respect to such Calendar Year. For clarity, each of the following milestone payments shall be payable only once for each License-Only Program regardless of the number of times such milestone is achieved.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:10.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.919%"><tr><td style="width:1.0%"></td><td style="width:67.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc2e4;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:90.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Commercial Milestone Event</font></div></td><td colspan="3" style="background-color:#9cc2e4;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:26.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:11.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.75pt;padding-right:6.85pt;text-indent:-32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:11.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.75pt;padding-right:24.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">57</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_142"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:10.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.919%"><tr><td style="width:1.0%"></td><td style="width:67.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:11.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.75pt;padding-right:5.85pt;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:10.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#91;***&#93;)</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:37.75pt;padding-right:19.5pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Royalties on Net Sales of Products Other Than &#91;***&#93; Products After Opt-In</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On a Product-by-Product basis, other than any &#91;***&#93; Product in the event that Zai elects to Opt-In pursuant to Section 5.1(e), subject to the terms and conditions of this Section 9.5, for each Calendar Quarter during the Royalty Term, Zai shall pay to MacroGenics non-creditable, non- refundable royalties on Net Sales of such Product (excluding any &#91;***&#93; Product in the event that Zai elects to Opt-In pursuant to Section 5.1(e)) in the Territory during such Calendar Quarter, as calculated by multiplying the applicable royalty rate by the corresponding amount of incremental Net Sales of such Product in the Territory, as follows&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:10.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.004%"><tr><td style="width:1.0%"></td><td style="width:71.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc2e4;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:52.97pt;padding-right:52.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Annual Net Sales of each Product in the Territory</font></div></td><td colspan="3" style="background-color:#9cc2e4;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.32pt;padding-right:9.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Royalty Rate</font></div></td></tr><tr><td colspan="6" style="background-color:#d0cece;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For each of the &#91;***&#93; Products prior to the Opt-In</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:30.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product less than or equal to &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.32pt;padding-right:9.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product greater than &#91;***&#93;Dollars ($&#91;***&#93;) but less than or equal to &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.27pt;padding-right:9.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">For that portion of annual Net Sales of a Product greater than &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.35pt;padding-right:9.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="background-color:#d0cece;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For each of the MGNX Option Products, &#91;***&#93; and Zai Selection Products</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product less than or equal to &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.35pt;padding-right:9.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:26.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product greater than &#91;***&#93;Dollars ($&#91;***&#93;) but less than or equal to &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.27pt;padding-right:9.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product greater than &#91;***&#93;Dollars ($&#91;***&#93;) but less than or equal to &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.32pt;padding-right:9.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:9.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For that portion of annual Net Sales of a Product greater than &#91;***&#93;Dollars ($&#91;***&#93;)</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.27pt;padding-right:9.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">58</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_145"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Royalty Reduction</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Biosimilar Product Market Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 9.5(c), with respect to a Product in a country or Region in the Territory, (1) if, in any Calendar Quarter, one or more Biosimilar Products for such Product are on the market in such country or Region and the sales of such Biosimilar Products in such country or Region constitute &#91;***&#93;percent (&#91;***&#93;%) or more of the total sales &#91;***&#93;in such country or Region, the royalty payment for such Product in such country or Region for such Calendar Quarter shall be reduced to &#91;***&#93;&#91;***&#93;% of the amount otherwise payable with respect to such Product in the absence of such Biosimilar Product(s)&#59; or (2) if, in any Calendar Quarter, one or more Biosimilar Products for such Product are on the market in such country or Region and the sales &#91;***&#93;in such country or Region constitute &#91;***&#93;percent (&#91;***&#93;%) or more of the total sales &#91;***&#93; in such country or Region, the royalty payments for such Product in such country or Region for such Calendar Quarter shall be reduced to &#91;***&#93;percent (&#91;***&#93;%) of the amount otherwise payable with respect to such Product in the absence of such Biosimilar Product(s).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">Valid Claim Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 9.5(c), if, in any Calendar Quarter, a Product in a country or Region in the Territory is not Covered by a Valid Claim within any MacroGenics Licensed Patent under which Zai is granted an effective license pursuant to this Agreement, then the royalty payments for Net Sales for such Product in such country or Region shall be reduced by &#91;***&#93;percent (&#91;***&#93;%) in such Calendar Quarter.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Third Party Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 9.5(c), if Zai obtains a license to any &#91;***&#93; rights owned by a Third Party that is necessary for Zai to (1) Develop or Commercialize a Collaboration Product in a country or Region in the applicable Collaboration Territory,</font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) Manufacture a Collaboration Product in a country or Region in the applicable Collaboration Territory after the date of the &#91;***&#93;, or (3) Develop, Manufacture or Commercialize a License-Only Product in a country or Region in the applicable License-Only Territory, then the royalties payable by Zai to MacroGenics with respect to Net Sales of the applicable Product in such country or Region in any Calendar Quarter shall be reduced, on a Product-by-Product and country-by-country or Region-by-Region basis, by &#91;***&#93;percent (&#91;***&#93;%) of the &#91;***&#93;paid by Zai to such Third Party with respect to such Product in such country or Region in such Calendar Quarter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Royalty Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In no event shall the royalty reductions available to Zai under Section 9.5(b), collectively or individually, reduce the royalties payable to MacroGenics for a given Calendar Quarter to less than &#91;***&#93;percent (&#91;***&#93;%) of the amount otherwise payable under Section 9.5 with respect to an applicable Product&#59; provided that &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Triggered Third Party Payments for Products Other Than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products After Opt- In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that a Party will be obligated to reimburse the other Party for any Triggered Third Party Payments, the obligated Party shall reimburse the other Party at least &#91;***&#93; prior to the applicable payment date for such Triggered Third Party Payment specified under the applicable Future Third Party Agreement. Such Party&#8217;s obligation under this Section 9.6 with respect to the payment of Triggered Third Party Payments under a given Future Third Party Agreement for which such Party elects to obtain a sublicense pursuant to Section 3.8 shall terminate upon termination of the In-License Party&#8217;s obligation to pay such Triggered Third Party Payments under the terms of such Future Third Party Agreement.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">59</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_148"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Profit Sharing for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Program After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After the Opt-In, the Parties shall share the profit and loss for the &#91;***&#93; Program equally in accordance with the terms set forth in Exhibit D.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">Payments&#59; Reports&#59; Records&#59; Audits</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Net Sales Quarterly Reports for Products Other Than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Products After Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the Term, for each Calendar Quarter following the First Commercial Sale of a Product, other than &#91;***&#93; Product after the Opt-In, in the Territory, Zai shall furnish to MacroGenics&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">a quarterly written report for the Calendar Quarter showing, on a country-by- country and Region-by-Region basis, the Net Sales of all Products subject to royalty payments sold by Zai and its Related Parties in the Territory during the reporting period and the royalties payable under this Agreement&#59; and</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">a quarterly report for the Calendar Quarter showing, on a country-by-country and Region-by-Region basis, the Triggered Third Party Payments, Zai&#8217;s royalties payable to Third Parties on Net Sales made during such Calendar Quarter and any royalty adjustments taken by Zai pursuant to Section 9.5(b), with such detail as shall reasonably allow MacroGenics to determine the basis for such quarterly costs.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.372%"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:4.6pt;padding-left:41pt;padding-right:10.7pt;text-align:right;text-indent:-41.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font></div></div><div style="display:inline-block;max-width:3.254%;min-width:2.254%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.374%"><div style="padding-left:41pt;padding-right:10.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Submission and Payment Schedule for Products Other Than &#91;***&#93; Products After Opt-</font></div><div><font><br></font></div><div style="margin-top:10.6pt;padding-left:77pt;padding-right:10.6pt;text-align:right;text-indent:-77.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:64.85pt">Reports under this Article 10 shall be due on the &#91;***&#93; Calendar Day</font></div></div></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">following the close of each Calendar Quarter.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">Royalties (including those within the Triggered Third Party Payments) shown to have accrued by each report shall, unless otherwise specified under this Agreement, be due and payable &#91;***&#93; after the date such report is due.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Payment Exchange Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All payments to be made by one Party to the other Party under this Agreement shall be made in US Dollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by such other Party. For invoices that a Party shall forward to the other Party, such first Party shall use an exchange rate as published by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as of the close of business on the last business day of the preceding month, or such other source as the Parties may agree in writing. Each Party shall take all possible steps to ensure all payments are made to the other Party under this Agreement, including by paying from non-Territory sources.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event any withholding, value added, or other tax is required to be withheld and deducted from payments by Zai pursuant to this Agreement under Applicable Laws and Regulations, notwithstanding anything to the contrary herein, Zai will make such deduction and withholding and will pay the remainder to MacroGenics, and any amounts so withheld and deducted will be remitted by Zai to the appropriate governmental authority(ies) for the account of MacroGenics and Zai will provide MacroGenics reasonable evidence of the remittance within &#91;***&#93; thereof. If &#91;***&#93;, then &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">60</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_151"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.8pt">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Research, Development, Manufacturing and Commercialization Activities. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall maintain appropriate records of&#58; (i) all research, Development, Manufacturing and Commercialization events and activities conducted by it or on its behalf related to a Product, and all costs in connection therewith, as applicable&#59; and (ii) all information generated by it or on its behalf in connection with Development of Licensed Molecules and Products under this Agreement, in each case in accordance with such Party&#8217;s usual documentation and record retention practices. Such records shall be in sufficient detail to properly reflect, in good scientific manner, all significant work done and results of studies and trials undertaken, and further shall be at a level of detail appropriate for patent and regulatory purposes. Upon the reasonable request of a Party, the other Party shall make such records available to the requesting Party. Each Party shall cause its Related Parties and Permitted Subcontractors to comply with this Section 10.5(a).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Zai Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Without limiting the foregoing under Section 10.5(a), Zai shall keep complete and accurate records in sufficient detail to allow MacroGenics to determine the basis for any amounts payable to or by Zai under this Agreement. At the reasonable request of MacroGenics, Zai shall make such records available to MacroGenics.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">MacroGenics Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Without limiting the foregoing under Section 10.5(a), MacroGenics shall keep complete and accurate records in sufficient detail to allow Zai to determine the basis for any amounts payable to or by MacroGenics under this Agreement. At the reasonable written request of Zai, MacroGenics shall make such records available to Zai.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that any payment due under this Agreement is not sent to the payee Party when due in accordance with the applicable provisions of this Article 10 &#91;***&#93;, the payment shall accrue interest from the date due at the prime rate as reported by Citibank N.A., plus &#91;***&#93;percent (&#91;***&#93;%)&#59; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit the payee Party from exercising any other rights it may have as a consequence of the lateness of any payment.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the written request of a Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Requesting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with reasonable advance notice and not more than &#91;***&#93; in each Calendar Year, the other Party shall permit an independent certified public accounting firm of internationally recognized standing selected by Requesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal business hours to such records as may be reasonably necessary to verify the that the correct amounts have been paid to such Party under or in connection with this Agreement during any Calendar Year ending not more than &#91;***&#93; prior to the date of such request. The accounting firm shall disclose to the Requesting Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with this audit right. This right to audit shall remain in effect throughout the life of this Agreement and for a period of &#91;***&#93; after the termination of this Agreement. If such accounting firm identifies a discrepancy, the other Party shall pay Requesting Party the amount of the discrepancy within &#91;***&#93; of the date Requesting Party delivers to the other Party such accounting firm&#8217;s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by Requesting Party unless the underpayment by the other Party exceeded &#91;***&#93;percent (&#91;***&#93;%) of the amount owed for such Calendar Year, in which case the other Party shall pay to Requesting Party the reasonable fees charged by such accounting firm.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall treat all information of the other Party subject to review under this Article 10 in accordance with the confidentiality and non-use provisions of this Agreement, and</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">61</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_154"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:11.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party and any applicable Related Parties, obligating it or them to retain all such information in confidence pursuant to such confidentiality agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ONFIDENTIALITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#59; P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UBLICATION</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.05pt">Nondisclosure Obligation</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Definition and Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All Confidential Information disclosed by one Party to the other Party at any time, including before the Effective Date or after the expiration or termination of this Agreement, shall be maintained in confidence by the receiving Party and shall not be disclosed by the receiving Party to any Third Party or used by the receiving Party for any purpose except as set forth herein without the prior written consent of the disclosing Party, during the Term and for a period of &#91;***&#93; thereafter&#59; provided that, with respect to Confidential Information that is confidential information of a Third Party to which a Party has an obligation of confidentiality or non-use under an agreement with such Third Party, the confidentiality and non-use obligations in this Agreement shall (A) further include such additional confidentiality and non-use obligations as such Party is required to undertake with respect to such confidential information pursuant to such Third Party agreement, and (B) continue beyond such &#91;***&#93; period for so long as such Party is required to maintain such confidential information as confidential pursuant to such Third Party agreement (including any MacroGenics Third Party Agreement and Zai Third Party Agreement). The following shall not be deemed Confidential Information of the disclosing Party for purposes of the restrictions set forth in this Section 11.1(a)&#58;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Information that is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#8217;s business records&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">Information that is or becomes part of the public domain through no wrongful act or fault on the part of the receiving Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">Information that is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Information that is developed by the receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party&#8217;s business records.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any combination of features or disclosures shall not be deemed to fall within the exclusions set forth in Section 11.1(a) merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding the restrictions   set   forth   in Section 11.1(a), the receiving Party may disclose Confidential Information of the other Party to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:11pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct clinical trials or to market Products, but such disclosure may be only to the extent reasonably necessary to obtain Patents or authorizations&#59; or</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">62</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_157"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">as the receiving Party deems necessary to be disclosed, to its Affiliates, agents, consultants, or other Third Parties for the Development, Manufacture or Commercialization of Product(s), or in connection with a potential or actual licensing transaction or contractual obligation related to such Product(s) or potential or actual loan, financing or investment or acquisition, merger, consolidation or similar transaction (or for such entities to determine their interest in performing such activities or to determine their rights and obligations as a result of completing such transactions) or in order to perform its obligations or exercise its rights under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement&#59; provided that the term of confidentiality and non-use applicable to such Third Parties shall be no less than &#91;***&#93; (but of shorter duration if customary given the nature of such Person (i.e., investors, lenders and banking institutions) from the date of disclosure to them, provided further, that with respect to Confidential Information of a Party that constitutes (a) a trade secret, such confidentiality and non-use obligations shall apply for so long as such information constitutes a trade secret under Applicable Laws and Regulations, or (b) confidential information of a Third Party, such confidentiality and non-use obligations shall apply for so long as such Party is required to keep such information confidential under such Third Party agreement (including any MacroGenics Third Party Agreement and  Zai Third Party Agreement), but only if such Party informs the other Party in writing of such additional obligations and identifies to the other Party at the time of disclosure the information subject to such additional obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Disclosure Required by Judicial or Administrative Process. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a Party is required by judicial or administrative process to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section 11.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 11.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information, including, by using not less than the same level of efforts to secure such confidential treatment of such information as it would to protect its own Confidential Information of like nature from disclosure.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Obligations Upon Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the termination or expiration of this Agreement, or upon the earlier request of either Party, the receiving Party shall return to the disclosing Party, all of the disclosing Party&#8217;s Confidential Information, including all copies thereof, provided that the receiving Party may retain one copy for archival purposes, and provided further, that a receiving Party shall not be required to destroy electronic files containing such Confidential Information of the disclosing Party that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information, and any such retained copies shall continue to be subject to the confidentiality and non-use obligations in accordance with this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Publication</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Publication of Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai and MacroGenics each acknowledge the other Party&#8217;s interest in publishing the results of its activities under the Programs in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. The JSC shall establish procedures for review of publications related to the Collaboration Programs and License-Only Programs, ensuring that, except for disclosures permitted pursuant to</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">63</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_160"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 11.1, either Party and its employees wishing to make a publication related to work performed under this Agreement (including under a License-Only Program) shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least &#91;***&#93; prior to submission for publication or for presentation. Notwithstanding the foregoing, (i) no Party may publish any results of the Parties&#8217; activities conducted under any Research Plan without the other Party&#8217;s prior written consent&#59;</font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) subject to the review procedures established by the JSC, Zai may publish any results related to any License-Only Program generated after the Research Term for such License-Only Program without MacroGenics&#8217; consent&#59; (iii) MacroGenics shall not publish any results of the Parties&#8217; activities related to any License-Only Program without Zai&#8217;s prior written consent&#59; and (ii) no Party may publish any results of the Parties&#8217; activities related to any Collaboration Program without the other Party&#8217;s prior written consent.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Review of Publications and Presentations</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">The reviewing Party shall have the right (A) to propose modifications to the publication or presentation for patent reasons, trade secret reasons, or for purposes of removing the Confidential Information of the reviewing Party, or (B) to request a reasonable delay in publication or submission for presentation in order to protect trade secret or patentable information.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">If the reviewing Party requests the removal of the reviewing Party&#8217;s Confidential Information or a delay, the publishing Party shall remove such Confidential Information and if requested by the reviewing Party delay submission for publication or submission for presentation for a period of &#91;***&#93; to enable patent applications protecting each Party&#8217;s rights in such Confidential Information to be filed in accordance with Article 14 below.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">Upon expiration of such &#91;***&#93; and satisfaction of any other conditions imposed by the JSC, the publishing Party shall be free to proceed with the publication or submission for presentation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11.05pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Upon request of the Party seeking publication, the reviewing Party shall consider expediting the time frames set forth in this Section 11.2.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">If the reviewing Party requests modifications to the publication or submission for presentation, the publishing Party shall edit such publication to prevent disclosure of the Confidential Information of the reviewing Party.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Publicity&#59; Use of Names</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties shall issue the press release included in this Agreement as Exhibit E announcing the execution of this Agreement. A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder upon prior written approval of the other Party, such approval not to be unreasonably withheld or delayed&#59; provided, however, that no approval of the other Party shall be required if a subsequent press release or securities filing solely discloses the information that</font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1) a milestone under this Agreement has been achieved or any payments associated therewith have been received&#59; (2) the filing or approval of a BLA generally has occurred (provided, however, that specific dates of filing shall not be disclosed)&#59; (3) initiation of any clinical trial&#59; and (4) commercial launch of a Product or any information that has previously been approved and disclosed as permitted by this Section 11.3(a). In the case of items (1) to (4) of the preceding sentence, the disclosing Party shall provide the other Party a copy of such proposed disclosures at least &#91;***&#93; prior to the proposed release and consider in </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">64</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under Applicable Laws and Regulations, including the rules</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">65</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_163"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and regulations promulgated by the United States Securities and Exchange Commission or any other relevant stock exchange or governmental agency.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">No Other Use of Company Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter without the prior express written permission of the other Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Approved Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition and notwithstanding anything to the contrary herein, (a) if the relevant text of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republished in such proposed press release provided that the Party issuing such press release provides notice to the other Party of such press release at least &#91;***&#93; prior to the issuance of such press release, where practicable, and (b) if the relevant text of a proposed public announcement such as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior approved presentation materials, Q&#38;A script or the like) then such text may be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Existence of Agreement</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">No Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither Party shall disclose the existence or terms of this Agreement pursuant to a press release or otherwise except as provided in this Section 11.3(d).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.03pt">Permitted Disclosures</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.74pt">Notwithstanding the terms of this Article 11, either Party shall be permitted to disclose the existence and terms of this Agreement and the conduct of the Programs under this Agreement, to the extent required, in the reasonable opinion of such Party&#8217;s legal counsel, to comply with Applicable Laws and Regulations, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any other relevant stock exchange or governmental agency. The disclosing Party shall take reasonable and lawful actions to avoid or minimize the degree of such disclosure.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.35pt">Either Party may also disclose the existence and terms of this Agreement to its attorneys, accountants and advisors, and to potential acquirors, in connection with a potential acquisition or other change of control transaction and to existing and potential investors or lenders of such Party, as a part of their due diligence investigations, or to potential licensees or to potential and current permitted assignees in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.35pt">Each Party may also disclose the existence and terms of this Agreement pursuant to transactions related to the research, Development, Manufacture or Commercialization or exploitation of a Licensed Molecule or any Product, in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">66</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_166"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EPRESENTATIONS AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARRANTIES</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Representations and Warranties of MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics represents and warrants to Zai that, as of the Effective Date, and covenants, that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">it is duly organized and validly existing under the Applicable Laws and Regulations of the jurisdiction of its incorporation and has the full right, power and authority to enter into this Agreement, to perform the Programs, and to grant the licenses contemplated under Article 3&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and fulfillment of its obligations and performance of its activities hereunder do not conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which MacroGenics is bound, nor violate any material Application Laws and Regulations&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained by MacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it is not aware of any action, suit or inquiry or investigation instituted by any Person which could question or threaten the validity of this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">in the conduct of any activities under this Agreement, it shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws and Regulations, including all export control, anti-corruption and anti-bribery laws and regulations, and shall not cause Zai&#8217;s Indemnitees to be in violation of any Applicable Laws and Regulations or otherwise cause any reputational harm to Zai&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.07pt">it Controls the right, title and interest in and to the MacroGenics Platform, MacroGenics Licensed Patents, MacroGenics Licensed Know-How and MacroGenics Licensed Trademarks, and has the right to grant to Zai the licenses that it purports to grant hereunder&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it has not granted, and shall not grant during the Term, any Third Party rights and has not taken, and shall not take during the Term, any other action which would be inconsistent or interfere with Zai&#8217;s rights hereunder, including Zai&#8217;s &#91;***&#93; Profit Share Option&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">the MacroGenics Platform, MacroGenics Licensed Patents, MacroGenics Licensed Know-How and MacroGenics Licensed Trademarks are not subject to any other Third Party agreements or existing royalty or other payment obligations to any Third Party&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">it is the sole and exclusive owner of the entire right, title and interest in the MacroGenics Licensed Patents. All MacroGenics Licensed Patents owned by MacroGenics as of the Effective Date are listed in Exhibit A. All MacroGenics Licensed Patents are (i) subsisting and in good standing and (ii) being diligently prosecuted in the respective patent offices in accordance with Applicable Laws and Regulations, and have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment. To its knowledge after due investigation, the issued Patents in the MacroGenics Licensed Patents are valid and enforceable&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">to its knowledge, no Third Party is infringing or misappropriating any MacroGenics Platform, MacroGenics Licensed Technology or MacroGenics Licensed Trademarks&#59;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">67</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_169"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">there is no action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing by any Third Party that challenges or threatens the validity, enforceability or MacroGenics&#8217; Control of any of the MacroGenics Licensed Patents or MacroGenics Licensed Trademarks. In the event that MacroGenics receives notice of any such action or proceeding, it shall notify Zai promptly in writing&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">there is no action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing by any Third Party (and it is not aware of any grounds therefor) that alleges the use of the MacroGenics Platform, MacroGenics Licensed Technology or MacroGenics Licensed Trademarks or the development, manufacture, commercialization, and use of the Products would infringe intellectual property rights or misappropriate any Know-How of any Third Party (and it has not received any notice alleging such an infringement). In the event that MacroGenics receives notice of any such action or proceeding, it shall notify Zai promptly in writing&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.18pt">to MacroGenics knowledge, no material breach of confidentiality has been committed by any Person with respect to the MacroGenics Licensed Know-How that is maintained as a trade secret and MacroGenics has used reasonable measures to protect the confidentiality thereof&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it has obtained or shall obtain written agreements from each of its employees, consultants and contractors who perform any activities pursuant to this Agreement, which agreements shall obligate such persons to obligations of confidentiality and non-use and to assign Inventions in a manner consistent with the provisions of this Agreement&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">neither it nor any of its or its Affiliates&#8217; employees or agents performing under this Agreement has ever been, or is currently&#58; (i) debarred under 21 U.S.C. &#167; 335a or by any Regulatory Authority&#59; (ii) excluded, debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs&#59; (iii) listed on the FDA&#8217;s Disqualified and Restricted Lists for clinical investigators&#59; or (iv) convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167; 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. MacroGenics further covenants that if, during the Term, it becomes aware that it or any of its or its Affiliates&#8217; employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, MacroGenics will promptly notify Zai. The foregoing sentence will survive termination or expiration of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Representations and Warranties of Zai</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai represents and warrants to MacroGenics that, as of the Effective Date&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">it is duly organized and validly existing under the Applicable Laws and Regulations of the jurisdiction of its incorporation and has the full right, power and authority to enter into this Agreement, to perform the Programs, and to grant the licenses contemplated under Article 3&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and fulfillment of its obligations and performance of its activities hereunder do not conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which Zai is bound, nor violate any material Application Laws and Regulations&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained by Zai as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained&#59;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">68</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_172"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">the Zai Platform, Zai Licensed Patents and Zai Licensed Know-How are not subject to any other Third Party agreements or existing royalty or other payment obligations to any Third Party&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">it is not aware of any action, suit or inquiry or investigation instituted by any Person which questions or threatens the validity of this Agreement&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.07pt">in the conduct of any activities under this Agreement, it shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws and Regulations, including all export control, anti-corruption and anti-bribery laws and regulations, and shall not cause MacroGenics&#8217; Indemnitees to be in violation of any Applicable Laws and Regulations or otherwise cause any reputational harm to MacroGenics</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it Controls the right, title and interest in and to the Zai Platform, Zai Licensed Patents and Zai Licensed Know-How, and has the right to grant to MacroGenics the licenses that it purports to grant hereunder&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it has not granted, and shall not grant during the Term, any Third Party rights and has not taken, and shall not take during the Term, any other action which would be inconsistent or interfere with MacroGenics rights hereunder&#59;</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">to its knowledge, no Third Party is infringing or misappropriating any Zai Platform or Zai Licensed Technology&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">there is no action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing by any Third Party (and it is not aware of any grounds therefor) that alleges the use of the Zai Platform or Zai Licensed Technology would infringe intellectual property rights or misappropriate any Know-How of any Third Party (and it has not received any notice alleging such an infringement). In the event that Zai receives notice of any such action or proceeding, it shall notify MacroGenics promptly in writing&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">it has obtained or shall obtain written agreements from each of its employees, consultants and contractors who perform any activities pursuant to this Agreement, which agreements shall obligate such persons to obligations of confidentiality and non-use and to assign Inventions in a manner consistent with the provisions of this Agreement&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">neither it nor any of its or its Affiliates&#8217; employees or agents performing under this Agreement has ever been, or is currently&#58; (i) debarred under 21 U.S.C. &#167; 335a or by any Regulatory Authority&#59; (ii) excluded, debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs&#59; (iii) listed on the FDA&#8217;s Disqualified and Restricted Lists for clinical investigators&#59; or (iv) convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167; 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. Zai further covenants that if, during the Term, it becomes aware that it or any of its or its Affiliates&#8217; employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, Zai will promptly notify MacroGenics. The foregoing sentence will survive termination or expiration of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party hereby covenants to the other Party that it will not, and will not permit its Affiliates, (Sub)licensees or anyone acting on its or their behalf to, grant or otherwise convey to any Third Party any rights that would interfere or be inconsistent with such other Party&#8217;s rights hereunder.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">69</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_175"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">No Other Representations or Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NDEMNIFICATION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">By Zai</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai agrees to indemnify and hold harmless MacroGenics, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Indemnitee(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from and against all losses, liabilities, damages and expenses (including reasonable attorneys&#8217; fees and costs) incurred in connection with any claims, demands, actions or other proceedings by any Third Party (individually and collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) first arising after the Effective Date to the extent arising from (a) activities by Zai or any of its Related Parties, or any Zai Representatives with respect to the research, Development, use, Manufacture, Commercialization, import, distribution, or sale of Licensed Molecules or Products or the exercise of their rights or performance of their obligations related thereto, (b) the use by Zai or any of its Related Parties, or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed Know-How pursuant to this Agreement, (c) the negligence, illegal conduct or willful misconduct of Zai, or (d) Zai&#8217;s breach of this Agreement&#59; provided, however, that Zai&#8217;s obligations pursuant to this Section 13.1 will not apply to the extent such Losses result from Losses for which MacroGenics has an obligation to indemnify Zai pursuant to Section 13.2.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">By MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics agrees to indemnify and hold harmless Zai, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Indemnitee(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from and against all Losses to the extent arising from (a) activities by MacroGenics or any of its Related Parties or Permitted Subcontractors or MacroGenics Representatives with respect to the research, Development, use, Manufacture, Commercialization or sale of Licensed Molecules or Products or the exercise of their rights or performance of their obligations related thereto, (b) the negligence, illegal conduct or willful misconduct of MacroGenics, (c) the use by MacroGenics or any of its Related Parties or Permitted Subcontractors of the Zai Licensed Patents or Zai Licensed Know-How pursuant to this Agreement, or (d) MacroGenics&#8217; breach of this Agreement&#59; provided, however, that MacroGenics&#8217; obligations pursuant to this Section 13.2 will not apply to the extent such Losses result from Losses for which Zai has an obligation to indemnify MacroGenics pursuant to Section 13.1.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any such claims or actions are made, the Indemnitee shall be defended at the Indemnifying Party&#8217;s sole expense by counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee, provided that the Indemnitee may, at its own expense, also be represented by counsel of its own choosing. The Indemnifying Party shall have the sole right to control the defense of any such claim or action, subject to the terms of this Section 13.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Indemnifying Party may settle any such claim, demand, action or other proceeding or otherwise consent to an adverse judgment (a) with prior written notice to the Indemnitee but without the consent of the Indemnitee where the only liability to the Indemnitee is the payment of money and the Indemnifying Party makes such payment, provided such settlement would not subject the Indemnitee to an injunction or otherwise adversely impact any of the Indemnitee&#8217;s rights under this Agreement or constitute an admission of guilt or wrongdoing by the Indemnitee, or (b) in all other cases, only with the prior written consent of the Indemnitee, such consent not to be unreasonably withheld. The Indemnitee may not settle any such claim, demand, action or other proceeding or otherwise consent to an</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">70</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_178"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">adverse judgment in any such action or other proceeding or make any admission as to liability or fault without the express written permission of the Indemnifying Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Indemnitee shall notify the Indemnifying Party promptly of any claim, demand, action or other proceeding under Section 13.1 or Section 13.2 and shall reasonably cooperate with all reasonable requests of the Indemnifying Party with respect thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Limitation of Liability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 13.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 13, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 11.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NTELLECTUAL </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ROPERTY</font></div><div><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.05pt">Ownership of Intellectual Property</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Ownership of current MacroGenics IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As between MacroGenics and Zai, MacroGenics shall remain the sole and exclusive owner of all MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and MacroGenics Licensed Know-How that exist as of the Effective Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Ownership of current Zai IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As between Zai and MacroGenics, Zai shall remain the sole and exclusive owner of all Zai Licensed Patents and Zai Licensed Know-How that exists as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">MacroGenics Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Research Plan for any Licensed Molecule or Product or in the course of either Party conducting Development, Manufacturing or Commercialization of a Collaboration Molecule or Collaboration Product, in each case that is solely and specifically related to the MacroGenics Platform, together with all intellectual property rights therein (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Zai shall, and hereby does (and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to), assign to MacroGenics all of its and their right, title and interest in and to MacroGenics Improvement IP. Upon MacroGenics&#8217;s written request, Zai shall, and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as MacroGenics may reasonably request to effectuate and confirm the vesting of all right, title and interest in and to the MacroGenics Improvement IP in MacroGenics.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Zai Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Research Plan for a Program for any Licensed Molecule or Product or in the course of either Party conducting Development, Manufacturing or Commercialization of a Collaboration Compound or Collaboration Product, in each case that is solely and specifically related to the Zai Platform, together with all intellectual property rights therein (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) . MacroGenics shall, and hereby does (and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">71</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subcontractors to), assign to Zai all of its and their right, title and interest in and to Zai Improvement IP. Upon Zai&#8217;s written</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">72</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_181"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">request, MacroGenics shall, and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as Zai may reasonably request to effectuate and confirm the vesting of all right, title and interest in and to the Zai Improvement IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Zai License-Only IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 14.1(c) and Section 14.1(f), Zai shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting Development, Manufacturing or Commercialization of any License-Only Molecule or License- Only Product and any other activities within the License-Only Programs, together with all intellectual property rights therein (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai License-Only IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, notwithstanding the foregoing, &#91;***&#93;. Subject to this Section 14.1(e), MacroGenics shall, and hereby does (and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to), assign to Zai all of its and their right, title and interest in and to Zai License-Only IP. Upon Zai&#8217;s written request, MacroGenics shall, and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as Zai may reasonably request to effectuate and confirm the vesting of all right, title and interest in and to the Zai License-Only in Zai.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.07pt">Research IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms of this Agreement, and other than MacroGenics Improvement IP and Zai Improvement IP, MacroGenics and Zai shall jointly own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting Research Plan Activities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with each Party owning an undivided half interest and the right to exploit without the duty of accounting or seeking consent from the other Party to the extent to be permitted under Applicable Laws and Regulations.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Ownership of All Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms of this Agreement and other than MacroGenics Improvement IP, Zai Improvement IP, Zai License-Only IP and Research IP, ownership of data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting Development, Manufacture or Commercialization of a Licensed Molecule or Product shall be based upon inventorship, as determined in accordance with U.S. patent law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Jointly Owned IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall promptly disclose any Joint Owned IP developed by or on behalf of it to the other Party. Each Party shall, and hereby does (and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to), assign to the other Party an undivided half interest of its and their right, title and interest in and to Jointly Owned IP. Upon either Party&#8217;s written request, the other Party shall, and shall cause its employees, agents, and subcontractors to, and shall cause its Affiliates and their respective employees, agents and subcontractors to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as the requesting Party may reasonably request to effectuate and confirm the vesting of such right, title and interest in and to the Jointly Owned IP.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Patent and Trademark Filing, Prosecution and Maintenance</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Overall Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The JSC shall establish an overall strategy for the filing, prosecution and maintenance of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, Jointly Owned Patents and Zai Licensed Patents in the Territory.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">73</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_184"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Prosecution</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.08pt">Solely Owned Patents &#8211; General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 14.2(b)(ii) and Section 14.2(b)(iii), the responsibility for Patent Prosecution and Trademark Prosecution related to a Patent or Trademark that is within the MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and the Zai Licensed Patents that is owned solely by a Party shall be the responsibility of such Party. Zai has the sole right to prepare, file, prosecute, maintain or abandon any Patent that is within the Zai License-Only IP.</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.03pt">MacroGenics Product-Specific Patents for License-Only Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Zai shall have the first right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain, in the name of MacroGenics, (A) MacroGenics Product-Specific Patents, and (B) MacroGenics Licensed Trademarks for a License-Only Product. In the event that Zai elects not to undertake the Patent Prosecution for such MacroGenics Product-Specific Patents, Zai shall notify MacroGenics at least &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and MacroGenics shall have the right (but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such MacroGenics Product-Specific Patents. Thereafter, any MacroGenics Product-Specific Patents that are the subject of such opt-out notice by Zai shall cease to be MacroGenics Licensed Patents for all purposes under this Agreement, including for purposes of the license granted by MacroGenics to Zai under Section 3.1. The right to assume Patent Prosecution of a MacroGenics Product-Specific Patent shall not apply in the event such a patent application would become abandoned or otherwise forfeited as a result of the prosecuting Party (x) discontinuing Patent Prosecution of such patent application but also filing a continuation application claiming the same invention or (y) settling an opposition to obtain a license to a competing patent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:1.98pt">Zai Product-Specific Patents for Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics shall have the first right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain, in the name of Zai, Zai Product-Specific Patents within the scope of the exclusive license granted by Zai to MacroGenics pursuant to Section 3.2. In the event that MacroGenics elects not to undertake the Patent Prosecution for such Zai Product-Specific Patents, MacroGenics shall notify Zai at least &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and Zai shall have the right (but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such Zai Product-Specific Patents. Thereafter, any Zai Product-Specific Patents that are the subject of such opt-out notice by MacroGenics shall cease to be Zai Licensed Patents for all purposes under this Agreement, including for purposes of the license granted by Zai to MacroGenics under Section 3.2. The right to assume Patent Prosecution of a Zai Product-Specific Patent shall not apply in the event such a patent application would become abandoned or otherwise forfeited as a result of the prosecuting Party (A) discontinuing Patent Prosecution of such patent application but also filing a continuation application claiming the same invention or (B) settling an opposition to obtain a license to a competing patent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:2.58pt">Jointly Owned Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 14.2(b)(ii) and Section 14.2(b)(iii), MacroGenics shall be responsible for undertaking the Patent Prosecution with respect to Patents jointly owned by the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Jointly Owned Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (i) with respect to Jointly Owned Patents generated or developed under a Collaboration Program, &#91;***&#93;, and (ii) with respect to Jointly Owned Patents generated or developed under a License-Only Program, at Zai&#8217;s sole cost and expense. With respect to Jointly Owned Patents, in the event that MacroGenics elects not to undertake the Patent Prosecution for the Jointly Owned Patents, MacroGenics shall notify Zai at least &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and Zai shall have the right (but not the obligation), to undertake the Patent Prosecution of such Jointly Owned Patents and become the prosecuting Party therefor. The right to assume Patent Prosecution of a</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">74</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_187"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jointly Owned Patent shall not apply in the event such a patent application would become abandoned or otherwise forfeited as a result of the prosecuting Party (A) discontinuing Patent Prosecution of such patent application but also filing a continuation application claiming the same invention or (B) settling an opposition to obtain a license to a competing patent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.63pt">Prosecuting Party Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The prosecuting Party shall keep the JSC and the other Party informed of the status of all matters affecting Patent Prosecution and Trademark Prosecution of MacroGenics Product-Specific Patents, MacroGenics Licensed Trademarks, Jointly Owned Patents, and the Zai Product-Specific Patents, including providing a copy of all patent applications filed hereunder and any material correspondence from or with any governmental authorities (including the applicable patent office) to the IP Coordinator and the other Party in sufficient time to allow for review and comment by the non-prosecuting Party, and timely consulting with the non- prosecuting Party and its patent counsel on the strategy and content of submissions to such governmental authorities in advance of any submissions. Timely advice and suggestions of the non-prosecuting Party and its patent counsel shall be taken into consideration in good faith by the prosecuting Party and its patent counsel in connection with such filing.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:2.58pt">IP Coordinators&#59; Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall designate one (1) qualified and experienced intellectual property professional to serve as that Party&#8217;s primary contact and coordinator regarding Patent Prosecution and Trademark Prosecution within this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IP Coordinator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Each Party may replace its IP Coordinator with an alternative representative at any time with prior written notice to the other Party. The IP Coordinators shall be responsible for facilitating information exchange and discussion between the Parties regarding Patent Prosecution and Trademark Prosecution under this Agreement. Each Party will be responsible for all of its own costs with respect to its IP Coordinator. Any dispute regarding Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, Zai Product-Specific Patent or Jointly Owned Patents that cannot be resolved by intellectual property counsel of the Parties shall be resolved by the IP Coordinators, and the IP Coordinator of the applicable prosecuting Party shall have final say with respect to any such disputes.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:35.53pt">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party&#8217;s rights and obligations under this Section 14.2 with respect to MacroGenics Licensed Patents and Zai Licensed Patents are secondary to and shall be subject to any Third Party rights and obligations under the applicable MacroGenics Third Party Agreements and Zai Third Party Agreements.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Patent and Trademark Invalidations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The JSC shall decide whether and how to undertake activities intended to invalidate pending or issued Third Party Patents in the Territory that Cover the composition, use or manufacture of Licensed Molecules or Products.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Costs of Patent and Trademark Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 14.2(b)(iv), all out-of-pocket costs for Patent Prosecution and Trademark Prosecution of any Patent or Trademark shall be solely incurred by and the sole responsibility of the prosecuting Party, except that (a) if MacroGenics is conducting the Patent Prosecution of the Zai Product-Specific Patents pursuant to Section 14.2(b)(iii), Zai shall be responsible for the out-of-pocket costs for Patent Prosecution of such Zai Product-Specific Patents in the Collaboration Territory, and (b) if Zai assumes the responsibility to conduct the Patent Prosecution of such Zai Product-Specific Patents pursuant to Section 14.2(b)(iii), the costs of such activities conducted by or on behalf of Zai shall be borne solely by Zai. Notwithstanding the foregoing, all such costs incurred by the Parties with respect to the &#91;***&#93; Program after the Opt-In shall be &#91;***&#93;.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">75</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_190"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Patent and Trademark Prosecution Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to all Patent Prosecution and Trademark Prosecution related to pending or issued Patents and Trademarks included in Jointly Owned Patents, MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, MacroGenics Product-Specific Patents, or Zai Product-Specific Patents, each Party shall&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">execute all further instruments to document their respective ownership consistent with this Agreement as reasonably requested by the other Party&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">make its employees, agents and consultants reasonably available to the other Party (or to the other Party&#8217;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its Patent Prosecution and Trademark Prosecution responsibilities&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">cooperate, if necessary and appropriate, with the other Party in gaining Patent and Trademark term extensions&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">endeavor in good faith to coordinate its efforts under this Agreement with the other Party to minimize or avoid interference with the Patent Prosecution and Trademark Prosecution of the other Party&#8217;s Patents and Trademarks.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Enforcement</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall promptly provide, but in no event later than &#91;***&#93;, the other with written notice reasonably detailing any known or alleged infringement of any Patent or Trademark owned by the other Party and subject to a license under this Agreement. The notifying Party will provide the other Party with all evidence available to it supporting its belief of such infringement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.23pt">Enforcement of Intellectual Property Rights</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Except as expressly set forth in this Section 14.3, the sole owner (as between the Parties) of a Patent, Trademark, Know-How or Confidential Information shall have the exclusive right to institute and direct legal proceedings against any Third Party believed to be infringing such Patent or Trademark or misappropriating or otherwise violating such Know-How or Confidential Information.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">Zai shall have the initial right (but not the obligation) to institute and direct legal proceedings in the applicable Territory against any Third Party believed to be infringing (A) Collaboration Product-specific claims within other MacroGenics Licensed Patents (in each case within the scope of the exclusive license granted by MacroGenics to Zai under this Agreement) or Jointly Owned Patents, with respect to the &#91;***&#93; Program before the Opt-In or MGNX Option Program in the applicable Collaboration Territory, (B) Collaboration Product-specific claims within other MacroGenics Licensed Patents (in each case within the scope of the exclusive license granted by MacroGenics to Zai under this Agreement) or Jointly Owned Patents, with respect to the &#91;***&#93; Program after the Opt-In in the &#91;***&#93;  Opt-In Territory, or (C) (1) MacroGenics Product-Specific Patents and (2) License-Only Product- specific claims within MacroGenics Licensed Patents or Jointly Owned Patents, in the License-Only Territory. Zai agrees to discuss the foregoing in good faith with MacroGenics. If Zai (x) does not initiate any action against such violation of any such Patent or claim, including by commencement of a lawsuit against the accused person if necessary or obtain settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such infringement of such Patent or claim, or (y) if such action is initiated within such period, ceases to pursue or </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">76</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:17.6pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">withdraws from such action, then in each case ((x) and (y)) MacroGenics shall be entitled (but shall not be obligated) to take all actions reasonably</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">77</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_193"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">necessary to abate such violation in the applicable Territory, including commencement of a lawsuit against the accused Third Party if necessary.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">MacroGenics shall have the first right (but not the obligation) to institute and direct legal proceedings against any Third Party believed to be infringing (1) Zai Product-Specific Patents, Collaboration Product-specific claims within other Zai Licensed Patents (each within the scope of the exclusive license granted by Zai to MacroGenics under this Agreement) or Jointly Owned Patents, with respect to the &#91;***&#93; Program before the Opt-In or MGNX Option Program outside the applicable Collaboration Territory, or (2) Zai Product-Specific Patents, Collaboration Product-specific claims within other Zai Licensed Patents (each within the scope of the exclusive license granted by Zai to MacroGenics under this Agreement), or Jointly Owned Patents, with respect to the &#91;***&#93; Program after the Opt-In in the ROW. MacroGenics agrees to discuss the foregoing in good faith with Zai. If MacroGenics (x) does not initiate any action against such violation of any such Patent or claim, including by commencement of a lawsuit against the accused person if necessary or obtain settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such infringement of such Patent or claim, or (y) if such action is initiated within such period, ceases to pursue or withdraws from such action, then in each case ((x) and (y)) Zai shall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation outside the applicable Territory, including commencement of a lawsuit against the accused Third Party if necessary.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">All amounts recovered from enforcement of any such rights by either Party in accordance with Section 14.3(b)(ii) or 14.3(b)(iii) relating to the intellectual property licensed under this Agreement shall be first used to reimburse each Party&#8217;s costs and expenses incurred in connection with such action, and any remainder of such recovery, other than amounts recovered as lost profits, shall be (A) retained by Zai if Zai is the Party instituting the action, provided that any remainder retained by Zai shall be treated as Net Sales and shall be subject to Zai&#8217;s royalty payment obligations at the applicable rate specified in Section 9.5 to the extent such action is related to any Product that is subject to royalty payments pursuant to Section 9.5&#59; (B) shared between MacroGenics and Zai equally if MacroGenics is the Party instituting the action during the Term in the Territory where MacroGenics has the first right to enforce, or retained by MacroGenics if MacroGenics is the Party instituting the action during the Term in the Territory where MacroGenics exercised its backup right to enforce&#59; and (C) MacroGenics if MacroGenics is the Party instituting the action with respect to a Zai Product-Specific Patent outside the applicable Territory or Collaboration Product-specific claims within Zai Licensed Patents outside the applicable Territory (x) during the Term or (y) after the Term and MacroGenics has exercised its option under Section 16.8(a)(iv) or Section 16.8(b)(ii), provided that any remainder retained by MacroGenics shall be treated in the same as Net Sales were treated during the Term and shall be subject to MacroGenics royalty payment obligations or Third Party Triggered Payments, to the extent applicable, at the applicable rate specified in Section 16.8(a)(iv) or Section 16.8(b)(ii). Notwithstanding the foregoing, any costs and expenses incurred by the Parties or amounts recovered from enforcement with respect to the &#91;***&#93; Program after the Opt-In pursuant to this Section 14.3(b)(iv) &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Cooperation in Enforcement Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For any action by a Party pursuant to subsection (b) above, in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party shall join such action voluntarily and shall execute all documents necessary for such Party to initiate, prosecute and maintain such action. If either Zai or MacroGenics initiates an enforcement action pursuant to Section 14.3(b), then the other Party shall cooperate to the extent reasonably necessary and at the first Party&#8217;s sole expense (except for the expenses of the non-controlling Party&#8217;s counsel, if any). Upon the reasonable request of the Party instituting any such action, such other Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">78</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_196"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subject thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Status&#59; Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties shall keep each other informed of the status of and of their respective activities regarding any enforcement action pursuant to Section 14.3(b). Neither Party shall settle any litigation or legal proceeding (i) in the Territory to enforce MacroGenics Licensed Patents against a Third Party selling a Product or MacroGenics Licensed Trademarks without the other Party&#8217;s written authorization or (ii) outside the Territory to enforce Zai Licensed Patents against a Third Party selling a Product without the other Party&#8217;s written authorization. Zai will not enter into any settlement of any action described in this Section 14.3 that admits to the invalidity, unpatentability, narrowing of scope or unenforceability of the MacroGenics Licensed Patents or the Jointly Owned Patents in any manner, incurs any financial liability on the part of MacroGenics or requires an admission of liability, wrongdoing or fault on the part of MacroGenics, in each case without MacroGenics&#8217; prior written consent. MacroGenics will not enter into any settlement of any action described in this Section 14.3 that admits to the invalidity, unpatentability, narrowing of scope or unenforceability of the Zai Licensed Patents or the Jointly Owned Patents in any manner, incurs any financial liability on the part of Zai or requires an admission of liability, wrongdoing or fault on the part of Zai, in each case without Zai&#8217;s prior written consent.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Defense</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Notice of Allegations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall notify the other in writing of any allegations it receives from a Third Party that the manufacture, production, use, development, sale, offer for sale, import or distribution of any Product or practice of any MacroGenics Licensed Technology or Zai Licensed Patents or Zai Licensed Know-How licensed by a Party under this Agreement or Jointly Owned Patents infringes the intellectual property rights of such Third Party in the Territory or with respect to the Zai Licensed Patents, Zai Licensed Know-How or Jointly Owned Patents outside the Territory. Such notice shall be provided promptly, but in no event after more than &#91;***&#93;, following receipt of such allegations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.23pt">Notice of Suit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that a Party receives notice that it or any of its Affiliates have been individually or collectively named as a defendant (or defendants) in a legal proceeding by a Third Party alleging infringement of a Third Party&#8217;s Patents issued (i) in the Territory as a result of the manufacture, production, use, development, sale, offer for sale, import or distribution of Products or any MacroGenics Licensed Technology or Zai Licensed Technology licensed by a Party under this Agreement or Jointly Owned Patents, or (ii) outside the Territory as a result of the practice of any Zai Licensed Technology or Jointly Owned Patents, such Party shall immediately notify the other Party in writing and in no event notify such other Party later than &#91;***&#93; after the receipt of such notice. Such written notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subject thereof. In such event, the Parties shall agree how best to mitigate or control the defense of any such legal proceeding&#59; provided however, that if either Party or any of its Affiliates have been individually named as a defendant in a legal proceeding relating to the alleged infringement of a Third Party&#8217;s issued Patents in the Territory as a result of the manufacture, production, use, development, sale or distribution of Products, the other Party shall be allowed to join in such action, at its own expense.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.85pt">Status&#59; Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties shall keep each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party as contemplated under Section 14.4(a) or Section 14.4(b)&#59; provided, however, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section 14.4(c) may be undertaken by a</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">79</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_199"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Party without the consent of the other Party which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ISPUTE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ESOLUTION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Exclusive Dispute Resolution Mechanism</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties agree that the procedures set forth in this Article 15 shall be the exclusive mechanism for resolving any Dispute between the Parties that may arise from time to time pursuant to this Agreement relating to either Party&#8217;s rights or obligations hereunder that is not resolved through good faith negotiation between the Parties. For the avoidance of doubt, this Article 15 shall not apply to any decision with respect to which a Party has final decision-making authority hereunder. Any Dispute, including Disputes that may involve the parent company, subsidiaries, or Affiliates under common control of any Party, shall be resolved in accordance with this Article 15.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Resolution by Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Article 15, in the event of any Dispute, either Party may, by written notice to the other Party, refer the Dispute to the Executive Officer of each Party for attempted resolution by good faith negotiation within &#91;***&#93; after such notice is received (unless otherwise agreed by the Parties). Each Party may, in its discretion, seek resolution of any and all Disputes that are not resolved under this Section 15.2 in accordance with Section 15.3.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Executive Officers of the Parties fail to resolve (a) the Dispute pursuant to Section 15.2 or (b) a Deadlock pursuant to Section 2.2(c), and a Party desires to pursue resolution of such Dispute or Deadlock, such Dispute or Deadlock shall be referred to and finally resolved by arbitration in accordance with the International Chamber of Commerce Rules (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ICC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for the time being in force, which rules are deemed incorporated by reference in this clause. The seat of the arbitration shall be in New York, New York, the United States, and the arbitration tribunal shall consist of three arbitrators, of whom each Party shall designate one in accordance with the appointment procedures provided in the ICC Rules and the chairs shall be selected by the tribunal in accordance the ICC Rules. The language of the arbitration shall be English. Notwithstanding the foregoing or anything to the contrary in this Agreement,</font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) if any matter is within the scope of the JSC&#8217;s authority, the provisions of Section 2.2(c) will initially apply with respect to such matter&#59; and (b) if this Agreement expressly provides that such matter is subject to a Party&#8217;s discretion or a Party&#8217;s sole or final decision-making authority (including the matters set forth in Sections 2.2(c)(i) and 2.2(c)(ii)), such matter shall not be subject to dispute resolution under this Section</font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.3 and shall be finally determined by such Party in accordance with the terms of this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Costs of Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall be solely responsible for the costs it incurs to resolve a Dispute except for the costs of engaging arbitrators which shall be &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ERMS AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ERMINATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless earlier terminated, this Agreement shall continue in effect, on a Program- by-Program and country-by-country or Region-by-Region basis, until the expiration of the applicable Royalty Term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except that, with respect to the &#91;***&#93; Program after the Opt-In, this Agreement shall continue in effect until the expiration of all payment obligations of each Party under this Agreement. Upon the expiration (but not early termination) of this Agreement with respect to a Program (other than the &#91;***&#93; Program after the Opt-In), on a country-by-country or Region-by-Region basis, the licenses </font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">80</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">granted hereunder by MacroGenics to Zai shall become fully paid-up, royalty-free, irrevocable and perpetual.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be terminated in its entirety or on a Program-by-Program basis at any time during the Term upon written notice by either Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">81</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_202"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) if the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is in material breach of this Agreement and, in each case, has not cured such breach within &#91;***&#93; after notice requesting cure of the breach (other than for non-payment which shall be cured within &#91;***&#93;. Notwithstanding the foregoing, in the event there is a good faith dispute as to whether a material breach exists, the dispute shall be resolved pursuant to Section 15.3. During the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. If (a) as a result of the application of such dispute resolution procedures, the Breaching Party is determined to be in material breach of one (1) or more of its obligations under this Agreement, and (b) the Breaching Party fails to complete the actions specified by such adverse ruling to cure such material breach in accordance with any procedures or timeframes established by the tribunal, then the Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Termination for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">At any time after (i) the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Effective Date with respect to the &#91;***&#93; Program (&#91;***&#93;), or any of the License-Only Programs, or (ii) the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Effective Date with respect to the MGNX Option Program, Zai may terminate this Agreement (A) in its entirety, (B) on a Program-by-Program basis, or (C) solely with respect to the &#91;***&#93;, in each case (i)-(iii) for any or no reason upon ninety (90) days&#8217; written notice to MacroGenics.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">At any time after the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Effective Date with respect to the &#91;***&#93; Program &#91;***&#93;, Zai may terminate this Agreement with respect to the &#91;***&#93; Program for any or no reason upon one hundred and eighty (180) days&#8217; written notice to MacroGenics.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Termination for Safety and End of Global Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">MacroGenics may terminate this Agreement on a Collaboration Product-by- Collaboration Product basis upon ninety (90) days&#8217; written notice if a Major Safety Issue has occurred with respect to a Collaboration Product (other than any &#91;***&#93; Product after the Opt-In) before First Commercial Sale of the Product in the Territory and MacroGenics, its Affiliates and other licensees have all discontinued the global Development, Manufacturing and Commercialization activities with respect to such Collaboration Product and announced such discontinuation through a press release or other public announcement&#59; provided that such written notice shall set forth with reasonably details the basis of such Major Safety Issue. &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">With respect to any &#91;***&#93; Product after the Opt-In, either Party may terminate this Agreement pursuant to the procedures set forth in Section 16.4(a)&#59; provided that (i) &#91;***&#93; and (ii) &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Termination for Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be terminated in its entirety, to the extent permitted by the Applicable Laws and Regulations, by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">82</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_205"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">portion of the assets for the benefit of creditors by the other Party&#59; provided, however, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding, such right to terminate will only become effective if the Party subject to such proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed within &#91;***&#93; after the filing thereof.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except to the extent the following is unenforceable under the Applicable Laws and Regulations of a particular jurisdiction in the Territory, MacroGenics may terminate this Agreement (other than with respect to the &#91;***&#93; Program after the Opt-In) upon &#91;***&#93;&#8217; prior written notice to Zai if Zai, its Affiliates, or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any MacroGenics Licensed Patent in a court or other governmental agency of competent jurisdiction, including a reexamination or opposition proceeding&#59; provided that if (i) Zai or its Affiliates, or Sublicensees withdraws such legal action within such &#91;***&#93;&#8217; notice period or (ii) with respect to a such interference, opposition or challenge brought by a Sublicensee, if the applicable Sublicense is terminated within such &#91;***&#93;&#8217; notice period, then MacroGenics shall not have the right to terminate this Agreement under this Section 16.6.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Termination for Collaboration Program Cessation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On a Collaboration Program-by- Collaboration Program basis (other than the &#91;***&#93; Program after the Opt-In), &#91;***&#93;, if &#91;***&#93; under a Collaboration Program, in each case, in the Collaboration Territory for &#91;***&#93; other than because of (a) any &#91;***&#93;, (b) any &#91;***&#93;, (c) any &#91;***&#93; or &#91;***&#93;, or (d) any &#91;***&#93;shall have the right to terminate this Agreement with respect to such Collaboration Program (other than the &#91;***&#93; Program after the Opt-In) upon &#91;***&#93;&#8217; prior written notice to Licensee.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Effect of Termination for Collaboration Programs</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If MacroGenics terminates this Agreement with respect to a Collaboration Program (other than the &#91;***&#93; Program after the Opt-In) pursuant to &#91;***&#93;, or if Zai terminates this Agreement with respect to a Collaboration Program (other than the   &#91;***&#93; Program after the Opt-In) pursuant to &#91;***&#93;&#58;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Each Party shall pay any amounts due pursuant to, as applicable, Section 5.1(d) (solely for all Development Costs and non-cancellable commitments such Party actually incurred for such Terminated Program prior to such termination) or &#91;***&#93; (with respect to all costs, solely for all costs (as applicable) and non-cancellable commitments such Party actually incurred for such Terminated Program prior to such termination) and Zai shall pay any amounts due pursuant to Article 9 prior to the date of termination&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">For the avoidance of doubt, the applicable licenses and sublicenses granted to Zai with respect to such Terminated Program under Sections 3.1 shall terminate&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:11pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">&#91;***&#93;shall survive&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">&#91;***&#93;with respect to such Terminated Program under Section &#91;***&#93;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">83</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_208"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to include the &#91;***&#93; within &#91;***&#93; of the effective date of termination of this Agreement. In the event that &#91;***&#93; hereunder within such &#91;***&#93;, then the &#91;***&#93;  with respect to such Terminated Program pursuant to Section &#91;***&#93;shall automatically &#91;***&#93; of such notice, and thereafter, &#91;***&#93; , &#91;***&#93;, a &#91;***&#93;of the applicable Products &#91;***&#93;in the Territory during the &#91;***&#93;, which &#91;***&#93; shall further be subject to Section &#91;***&#93; (in which case &#91;***&#93; , provided that, for clarity, that subsection (b) of the defined &#91;***&#93; shall be based on the &#91;***&#93; (for which &#91;***&#93; maintains the &#91;***&#93; ) and not the &#91;***&#93;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">Zai shall return to MacroGenics or its designee all Products (including all Licensed Molecules) of the Terminated Program within its possession or control and arrange for the Zai Sublicensees to return to MacroGenics or its designee all Products (including all Licensed Molecules) of the Terminated Program within such Zai Sublicensees&#8217; possession or control&#59;</font></div><div><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Zai shall cease to Develop and Commercialize all Licensed Molecules and Products (including all Combination Products) of the Terminated Program, including immediately stopping enrollment of subjects (unless otherwise directed in writing by MacroGenics) into any Clinical Trial being conducted by the Parties and at MacroGenics&#8217; sole election either wind-down (including to cease administering Licensed Molecules or Products to Clinical Trial subjects and conducting Clinical Trial procedures on Clinical Trial subjects, to the extent medically advisable) or transition to MacroGenics (or its designee) any Clinical Trial then being conducted by Zai, but in all cases in a timely manner and in accordance with all Applicable Laws and Regulations&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.53pt">for the Products (including Licensed Molecules) of the Terminated Program, to the extent &#91;***&#93;, Zai will &#91;***&#93;, for the purpose of the &#91;***&#93; of the &#91;***&#93;, to &#91;***&#93; (A) all Regulatory Submissions (such as Regulatory Approvals, INDs, BLAs, NDAs, and drug master files) and clinical trial agreements (to the extent assignable and not cancelled) for such Product(s), to the extent that &#91;***&#93;&#59; (B) all data, including clinical data, materials and information of any kind or nature whatsoever, in Zai &#8217;s possession or in the possession of its Affiliates or its or their respective agents related to such Product(s)&#59; (C) all trademarks related to such Products (if such termination occurs after approval of such trademark by a Regulatory Authority)&#59; and (D) all material information, and any other information reasonably requested and required by MacroGenics, relating to the manufacture of such Products&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.48pt">all sublicenses under the license granted pursuant to Section 3.3 shall terminate, unless converted to a direct license upon the mutual agreement between MacroGenics and the applicable sublicensee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">MacroGenics shall revoke (and Zai shall allow revocation of) any powers of attorney for any MacroGenics Licensed Patents that Zai holds as of the time of such termination&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">If Zai terminates this Agreement with respect to a Collaboration Program (other than the &#91;***&#93; Program after the Opt-In) pursuant to &#91;***&#93;, the following shall apply&#58;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">84</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_211"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">Section 16.8(a)(i), Section 16.8(a)(ii), Section 16.8(a)(vi), Section 16.8(a)(viii) and Section 16.8(a)(ix) shall apply, and Section 16.8(a)(v) shall apply subject to MacroGenics&#8217; payment to Zai for the Fully Burdened Manufacturing Costs for the Products transferred to MacroGenics thereunder&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">&#91;***&#93;with respect to such Terminated Program by within &#91;***&#93;of the effective date of termination of this Agreement. In the event that &#91;***&#93;hereunder within such &#91;***&#93;, then the &#91;***&#93;with respect to the Terminated Program under Section &#91;***&#93; shall survive (subject to &#91;***&#93;) and &#91;***&#93; if &#91;***&#93; of and the applicable Products &#91;***&#93;, which  &#91;***&#93;shall further be subject to Section  (in which case  &#91;***&#93;, provided that, for clarity, that subsection (b) of the defined &#91;***&#93; shall be based on the &#91;***&#93; (for which &#91;***&#93;maintains the &#91;***&#93;) and not the &#91;***&#93;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">Section 16.8(a)(vii) will apply if &#91;***&#93; set forth in Section 16.8(b)(ii).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If Zai terminates this Agreement with respect to the &#91;***&#93; Program after the Opt-In pursuant to &#91;***&#93;or if MacroGenics terminates this Agreement with respect to the &#91;***&#93; Program after the Opt-In pursuant to &#91;***&#93;, then MacroGenics may elect one of the following&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.08pt">MacroGenics may elect to also terminate this Agreement with respect to the &#91;***&#93; Program, in which case (x) all licenses granted under this Agreement with respect to the &#91;***&#93; Program shall terminate, and (y) each Party shall cease to Develop and Commercialize all &#91;***&#93; Molecules and &#91;***&#93; Products, including immediately stopping enrollment of subjects into any Clinical Trial being conducted by such Party for &#91;***&#93; Products, and wind-down (including to cease administering &#91;***&#93; Molecules or Products to Clinical Trial subjects and conducting Clinical Trial procedures on Clinical Trial subjects, to the extent medically advisable) then be conducted by such Party, but in all cases in a timely manner and in accordance with all Applicable Laws and Regulations, at such Party&#8217;s sole cost and expense&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">MacroGenics may &#91;***&#93;, in which case (A) &#91;***&#93;, and &#91;***&#93; the &#91;***&#93; (&#8220;&#91;***&#93;&#8221;), &#91;***&#93;&#59; and (B) &#91;***&#93; shall&#91;***&#93;, &#91;***&#93;&#58; (x) the &#91;***&#93;, (y) the &#91;***&#93; of the &#91;***&#93; Product &#91;***&#93;, or</font></div><div style="padding-left:32.6pt;text-align:justify;text-indent:-15.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.85pt">the &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">If Zai terminates this Agreement with respect to the &#91;***&#93; Program after the Opt-In pursuant to &#91;***&#93;, then &#91;***&#93;</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">85</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_214"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, except that in the event that Zai &#91;***&#93;, then the &#91;***&#93;mentioned therein shall be &#91;***&#93;, and thereafter, &#91;***&#93;, during the period set forth in &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If this Agreement is terminated with respect to one or more Programs or one or more &#91;***&#93; (but not in the case of any termination of this Agreement in its entirety or all Programs), then Section 16.8 shall apply solely with respect to such Terminated Program(s) or such&#91;***&#93;, as applicable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.55pt">Effect of Termination for License-Only Programs</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If MacroGenics terminates this Agreement with respect to a License-Only Program pursuant to &#91;***&#93;, or if Zai terminates this Agreement with respect to a License-Only Program pursuant to &#91;***&#93;&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:149.05pt;text-align:justify;text-indent:-23.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.08pt">Zai shall pay any amounts due pursuant to Article 9 prior to the date of</font></div><div style="padding-left:17.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">termination&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.03pt">For the avoidance of doubt, the applicable licenses and sublicenses granted to Zai with respect to such Terminated Program under Sections 3.1 shall terminate&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.98pt">Zai &#91;***&#93;Affiliates and Third Party (subject to Section &#91;***&#93;) &#91;***&#93;for the Terminated Program, by providing written notice &#91;***&#93;. In the event that &#91;***&#93;hereunder &#91;***&#93;, then the &#91;***&#93; in the preceding sentence shall be &#91;***&#93;, and thereafter, &#91;***&#93; will (A) &#91;***&#93;by or on behalf of &#91;***&#93;after the &#91;***&#93;, and (B) have the option to purchase any of Zai&#8217;s inventory of the applicable License-Only Molecule and License-Only Product, at Zai&#8217;s Fully-Burdened Manufacturing Cost&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">Zai shall cease to Develop and Commercialize all Licensed Molecules and Products (including all Combination Products) of the Terminated Program, including immediately stopping enrollment of subjects (unless otherwise directed in writing by MacroGenics) into any Clinical Trial being conducted by the Parties and at MacroGenics&#8217; sole election either wind-down (including to cease administering Licensed Molecules or Products to Clinical Trial subjects and conducting Clinical Trial procedures on Clinical Trial subjects, to the extent medically advisable) or transition to MacroGenics (or its designee) any Clinical Trial then be conducted by Zai, but in all cases in a timely manner and in accordance with all Applicable Laws and Regulations&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.6pt;padding-right:10.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.63pt">all sublicenses under the license granted pursuant to Section 3.3 shall terminate, unless converted to a direct license upon the mutual agreement between MacroGenics and such sublicensee&#59; and</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">86</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_217"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:17.6pt;padding-right:10.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.58pt">MacroGenics shall revoke (and Zai shall allow revocation of) any powers of attorney for any MacroGenics Licensed Patents that Zai holds as of the time of such termination.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">If Zai terminates this Agreement with respect to a License-Only Program pursuant to &#91;***&#93;, the provisions in Section &#91;***&#93;, except that in the event that &#91;***&#93; pursuant to Section 16.9(a)(iii), then &#91;***&#93;therein shall be &#91;***&#93;, and thereafter, &#91;***&#93; achieved by or on &#91;***&#93;and &#91;***&#93; the License-Only Products &#91;***&#93; that are&#91;***&#93; .</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">If this Agreement is terminated with respect to one or more Programs or one or more &#91;***&#93; (but not in the case of any termination of this Agreement in its entirety or all Programs), then Section 16.9 shall apply solely with respect to such Terminated Program(s) or such &#91;***&#93;, as applicable.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The following provisions shall survive the termination or expiration of this Agreement for any reason&#58; Articles </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d13feba75204fc181fef891e9ff038e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, 13, 15 and 17, and Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d13feba75204fc181fef891e9ff038e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.1(c)(ii), </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.3(b)(vi), 7.3(c)(vi), 10.3- 10.8 (solely with respect to any amounts due but unpaid), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9d13feba75204fc181fef891e9ff038e_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, 11.3(b), 11.3(d), 12.4, 14.1, 16.1, 16.4, 16.8,</font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.9 and 16.10, and, in the event Zai exercises the &#91;***&#93; Profit Share Option, Section 4 of Exhibit D-1, and Sections 6 and 7 of Exhibit D-2. In addition, the other applicable provisions of Article 10 and Exhibit D, in the event Zai exercises the &#91;***&#93; Profit Share Option, shall survive such expiration or termination of this Agreement in its entirety to the extent required to make final reimbursements, reconciliations or other payments incurred or accrued prior to the date of termination or expiration. Any expiration or termination of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.3pt">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ISCELLANEOUS</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date may be invoked as a Force Majeure Event for the purposes of this Agreement solely to the extent those effects are not reasonably foreseeable by the Parties as of the Effective Date. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. In the event a Party is unable to perform its obligations under a Program due to Force Majeure for a period of &#91;***&#93;, the Parties will discuss in good faith to seek an equitable remedy for such nonperformance, including the possibility of the termination of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code or comparable provision of</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">87</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_220"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable bankruptcy or insolvency laws. The Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, and that upon commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Involved Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, the other Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Noninvolved Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectual property and all embodiments of such intellectual property, provided the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all embodiments thereof shall be promptly delivered to the Noninvolved Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party, unless the Involved Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request therefor by Noninvolved Party. The foregoing is without prejudice to any rights the Noninvolved Party may have arising under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, or other Applicable Laws and Regulations.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither Party may assign this Agreement or any right or obligation under this Agreement without the prior written consent of the other Party, provided that each Party may assign this Agreement and its rights and obligations under this Agreement, without such consent from the other Party, to its Affiliate or any successor in interest in connection with the sale of all or substantially all of its assets or a sale of all or substantially of the business related to a Licensed Molecule or a Product, or a merger, acquisition or other similar transactions. For the avoidance of doubt, the terms and conditions of this Agreement shall be binding on the permitted successors and assignees of each Party and any permitted successor and assignee shall assume all obligations of the assigning Party under this Agreement and shall agree in writing to be bound by the terms and conditions of this Agreement. Any assignment not in accordance with this Section 17.3 shall be null and void.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:57.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if to MacroGenics, to&#58;&#160;&#160;&#160;&#160;9704 Medical Center Drive</font></div><div style="padding-left:187.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rockville, MD 20850</font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer &#91;***&#93;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.793%"><div style="margin-top:4.55pt;padding-left:57.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">with copy to&#58;</font></div><div style="padding-left:57.2pt;padding-right:-0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(which shall not constitute notice)</font></div><div style="margin-top:4.55pt;padding-left:12pt;padding-right:174.65pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.413%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.794%"><div style="padding-left:12pt;padding-right:174.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9704 Medical Center Drive Rockville, MD 20850 &#91;***&#93;&#91;***&#93;</font></div></div></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">88</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_223"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:57.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if to Zai, to&#58;&#160;&#160;&#160;&#160;Zai Lab (Hong Kong) Limited</font></div><div style="padding-left:187.65pt;padding-right:127.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Room 2301, 23&#47;F, Island Place Tower 510 King&#8217;s Road, North Point</font></div><div style="padding-left:187.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hong Kong</font></div><div style="margin-top:0.05pt;padding-left:187.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.793%"><div style="margin-top:4.6pt;padding-left:57.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with copy to&#58;</font></div><div style="margin-top:0.05pt;padding-left:57.2pt;padding-right:-0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(which shall not constitute notice)</font></div><div style="margin-top:4.6pt;padding-left:12pt;padding-right:208.6pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.413%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.794%"><div style="padding-left:12pt;padding-right:208.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93; &#91;***&#93;Zai Lab Limited</font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:128.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">314 Main Street, 4th Floor Cambridge, MA 02142 &#91;***&#93;</font></div><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></div></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given upon receipt.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Applicable Intellectual Property Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All questions of inventorship shall be determined in accordance with U.S. patent laws. In respect to all other Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or granted shall govern. Except as otherwise indicated, in all other respects, the right and obligations of the Parties under this Agreement shall be governed by and construed in accordance with the laws of the State of New York, US.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agreement contains the entire understanding of the Parties with respect to the subject matter hereof, including the Programs and licenses granted hereunder. All express or implied agreements and understandings, either oral or written, with regard to the subject matter hereof, including the Programs and the licenses granted hereunder, are superseded by the terms of this Agreement, including the Existing CDA. The Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Existing CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Mutual Confidentiality Agreement between the Parties effective as of &#91;***&#93;. Any confidential information disclosed by the Parties pursuant to the Existing CDA shall be deemed to constitute Confidential Information under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The captions to the several Sections hereof are not a part of the Agreement, but are merely for convenience to assist in locating and reading the several Sections and Sections of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.55pt">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. It is expressly agreed that MacroGenics and Zai shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor Zai shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The waiver by either Party of any right hereunder, or the failure of the other Party to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.</font></div><div><font><br></font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.05pt">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">90</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_226"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.8pt">Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.8pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.8pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.8pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and&#47;or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. References to &#8220;Section&#8221; or &#8220;Sections&#8221; are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are United States Dollars. Unless the context otherwise requires, countries shall include territories. References to any specific law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement law thereto.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8pt;padding-left:155.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Remainder of page intentionally left blank)</font></div><div style="height:49pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">91</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_229"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.75pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-top:10.45pt;padding-left:10.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zai Lab US LLC&#160;&#160;&#160;&#160;MacroGenics, Inc.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Samantha Du&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="margin-top:4.55pt;padding-left:10.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> Samantha Du&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Name&#58;  Scott Keonig</font></div><div style="margin-top:5.95pt;padding-left:10.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> CEO&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> CEO&#160;&#160;&#160;&#160;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">92</font></div><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_232"></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_235"></div><hr style="page-break-after:always"><div style="min-height:32pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.75pt;padding-right:10.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONFIDENTIAL</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:18.77pt;padding-right:18.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:18.82pt;padding-right:18.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Licensed Trademarks</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:225%">DART&#174; TRIDENT&#174;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_238"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_241"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:18.77pt;padding-right:18.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit D</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:18.82pt;padding-right:18.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; Profit Share Option</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> covers the financial planning, accounting policies and procedures to be followed in determining the Development Cost Share and Profit &#38; Loss Share, and the Parties&#8217; other rights and obligations, upon Zai&#8217;s exercise of the &#91;***&#93; Profit Share Option.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit D-1. Development Cost Share</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Research and Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to this Paragraph 1 and Paragraph 2 of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, upon exercise of the &#91;***&#93; Profit Share Option, the Parties shall share all Research and Development Costs incurred on or after the exercise of the &#91;***&#93; Profit Share Option in connection with the Development of the &#91;***&#93;  Product(s), including preclinical, CMC, clinical development, and companion diagnostic development but excluding, for clarity, any Research and Development Costs incurred with respect to a Competing Study or Proprietary Compound Combination Study, as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.75pt">Research and Development Costs shall be borne fifty percent (50%) by MacroGenics and fifty percent (50%) by Zai&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">&#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.8pt">&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.08pt">&#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.74pt">&#91;***&#93; </font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">&#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(k)</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_244"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.74pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:13.74pt">&#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit D-2. Profit &#38; Loss Share</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.05pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.75pt">&#91;***&#93;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_247"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.7pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.08pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.05pt">&#91;***&#93;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:22pt">&#91;***&#93;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_250"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.05pt;text-decoration:underline">Net Profits&#47;Losses Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">Upon Zai&#8217;s exercise of the &#91;***&#93; Profit Share Option, during the Profit &#38; Loss Share Term, &#91;***&#93;, the Parties agree to share equally (which, for clarity, shall mean that MacroGenics shall bear (and be entitled to) fifty percent (50%), and Zai will bear (and be entitled to) fifty percent (50%) of the Net Profits&#47;Losses with respect to &#91;***&#93; Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Profit &#38; Loss Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.05pt">&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22pt">&#91;***&#93;.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_253"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.75pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:19.08pt">&#91;***&#93; </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_256"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-right:10.9pt;text-align:justify"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.74pt">&#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.74pt">&#91;***&#93;&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.63pt">&#91;***&#93;&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.58pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.74pt">&#91;***&#93;.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_259"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.74pt">&#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.08pt">&#91;***&#93;.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_262"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:5pt;padding-right:10.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.41pt">&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.74pt">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.41pt">&#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:17.07pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:5pt;padding-right:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z) &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(aa) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(bb)   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_265"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:18.72pt;padding-right:18.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit E</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:18.82pt;padding-right:18.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Press Release</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18.95pt;padding-right:18.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:133%">Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:10.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%;padding-left:11.33pt">Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules</font></div><div style="padding-left:41pt;padding-right:10.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:134%;padding-left:11.33pt">MacroGenics provides rights to Zai Lab for its DART&#174; and TRIDENT&#174; multi- specific platforms and a lead research program targeting solid tumors</font></div><div style="padding-left:41pt;padding-right:11.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%;padding-left:11.33pt">Zai Lab provides rights to MacroGenics for certain intellectual property related to CD47 for select tumor targets</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE</font></div><div style="margin-top:2.05pt;padding-left:5pt;padding-right:10.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">NEWSWIRE) &#8211; Zai Lab Limited (NASDAQ&#58; ZLAB&#59; HKEX&#58; 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ&#58; MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, announced today that the companies have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">The first collaboration program covers a lead research molecule that incorporates MacroGenics&#8217; DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors. The next-generation CD3 component of the DART bispecific molecule has been designed to minimize cytokine-release syndrome while maintaining anti-tumor cytolytic activity. The second collaboration program will cover a target to be designated by MacroGenics. For both molecules, Zai receives commercial rights in Greater China, Japan, and Korea and MacroGenics receives commercial rights in all other territories. For the lead molecule, Zai Lab receives an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50&#47;50 profit share.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules. For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_268"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8220;We are very pleased to be expanding our existing relationship with Zai Lab, which already includes regional rights in Greater China for two clinical-stage programs,&#8221; said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. &#8220;Zai has a strong track record of rapidly progressing the development of innovative product candidates in China. This new partnership enables us to jointly discover, develop and deliver potentially best-in-class therapeutics to address patients&#8217; unmet medical needs.&#8221;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8220;MacroGenics has been a great partner and one of the leading companies in the immuno- oncology field,&#8221; said Samantha Du, Ph.D., Founder, Chairperson, Chief Executive Officer of Zai Lab. &#8220;We are pleased to expand our strategic collaboration, which leverages both companies&#8217; unique research capabilities and gives Zai Lab access to MacroGenics&#8217; proprietary technologies to expand our innovative oncology portfolio on a global basis.&#8221;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Under the terms of the agreement, MacroGenics receives initial consideration from Zai Lab of $55 million, including an upfront payment of $25 million and an equity investment of $30 million in MacroGenics&#8217; common stock at $31.30 per share. In addition, MacroGenics is eligible to receive up to $1.4 billion in potential development, regulatory and commercial milestone payments for the four programs. If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Lab&#8217;s territories.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Zai Lab</font></div><div style="margin-top:2.1pt;padding-left:5pt;padding-right:10.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Zai Lab (NASDAQ&#58; ZLAB&#59; HKEX&#58; 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. Our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of potentially innovative, marketed products and product candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to positively impact human health worldwide.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com&#47;ZaiLab_Global.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About MacroGenics, Inc.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_271"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:10.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, DART and TRIDENT are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Zai Lab Forward-Looking Statements</font></div><div style="margin-top:2pt;padding-left:5pt;padding-right:18.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects and plans for developing and commercializing the preclinical bispecific molecules monoclonal</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:17.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">antibodies and other statements containing words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221;</font></div><div style="padding-left:5pt;padding-right:31.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking</font></div><div style="padding-left:5pt;padding-right:10.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">statements are based on Zai Lab&#8217;s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including but not limited to</font></div><div style="padding-left:5pt;padding-right:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">(1) Zai Lab&#8217;s ability to successfully commercialize and generate revenue from its approved products&#59; (2) Zai Lab&#8217;s ability to finance its operations and business initiatives and obtain funding for such activities, (3) Zai Lab&#8217;s results of clinical and pre-clinical development of its product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab&#8217;s product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions and (6) the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab&#8217;s expectations and assumptions to change and undertakes no obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_274"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:14.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">relied upon as representing Zai Lab&#8217;s views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Forward-Looking Statements</font></div><div style="margin-top:2.05pt;padding-left:5pt;padding-right:11.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div style="margin-top:1.2pt;padding-left:5pt;padding-right:262.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:230%">For more information, please contact&#58; Zai Lab Contacts</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Billy Cho, CFO</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">+86 137 6151 2501</font></div><div style="padding-left:5pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">billy.cho&#64;zailaboratory.com</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:5pt;padding-right:269.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Media&#58; Ryo Imai &#47; Robert Flamm, Ph.D. Burns McClellan, on behalf of Zai Lab 212-213-0006 ext. 315 &#47; 364</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d13feba75204fc181fef891e9ff038e_277"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rimai&#64;burnsmc.com &#47; rflamm&#64;burnsmc.com</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investors&#58; Mike Zanoni</font></div><div style="padding-left:5pt;padding-right:258.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Endurance Advisors, on behalf of Zai Lab 610-442-8570</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mzanoni&#64;enduranceadvisors.com</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Contacts</font></div><div style="margin-top:2pt;padding-left:5pt;padding-right:264.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Jim Karrels, Senior Vice President, CFO 1-301-251-5172</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:113%">info&#64;macrogenics.com</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102stckprchsagrmntz.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i75d044c9ff86424aa5a9ecf0f42d8a38_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:120pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STOCK PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">By and Between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ZAI LAB LIMITED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AND</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dated as of June 14, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i75d044c9ff86424aa5a9ecf0f42d8a38_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1......... Definitions.......................................................................................................................... 1</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.1...... Defined Terms........................................................................................................ 1</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.2...... Additional Defined Terms...................................................................................... 4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2......... Purchase and Sale of Common Stock................................................................................ 5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3......... Closing Date&#59; Deliveries.................................................................................................... 5</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.1...... Closing Date........................................................................................................... 5</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.2...... Deliveries............................................................................................................... 5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4......... Representations and Warranties of the Company.............................................................. 6</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.1...... Organization, Good Standing and Qualification.................................................... 6</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.2...... Capitalization and Voting Rights........................................................................... 6</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.3...... Subsidiaries............................................................................................................ 7</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.4...... Authorization.......................................................................................................... 7</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.5...... No Defaults............................................................................................................ 8</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.6...... No Conflicts........................................................................................................... 8</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.7...... No Governmental Authority or Third Party Consents........................................... 8</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.8...... Valid Issuance of Shares........................................................................................ 9</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.9...... Litigation................................................................................................................ 9</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.10.... Licenses and Other Rights&#59; Compliance with Laws.............................................. 9</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.11.... Company SEC Documents&#59; Financial Statements&#59; Nasdaq Stock Market............ 9</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.12.... Absence of Certain Changes................................................................................ 11</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.13.... Offering................................................................................................................ 11</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.14.... No Integration...................................................................................................... 11</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.15.... Brokers&#8217; or Finders&#8217; Fees..................................................................................... 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.16.... Investment Company............................................................................................ 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.17.... No General Solicitation........................................................................................ 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.18.... Foreign Corrupt Practices.................................................................................... 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.19.... Regulation M Compliance. ................................................................................. 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.20.... Office of Foreign Assets Control......................................................................... 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.21.... Intellectual Property............................................................................................. 12</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.22.... Full Disclosure..................................................................................................... 13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5......... Representations and Warranties of the Investor............................................................... 13</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.1...... Organization&#59; Good Standing............................................................................... 13</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.2...... Authorization........................................................................................................ 13</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.3...... No Conflicts......................................................................................................... 14</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.4...... No Governmental Authority or Third Party Consents......................................... 14</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.5...... Purchase Entirely for Own Account.................................................................... 14</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.6...... Disclosure of Information.................................................................................... 14</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.7...... Investment Experience and Accredited Investor Status....................................... 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.8...... Acquiring Person.................................................................................................. 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.9...... Restricted Securities............................................................................................. 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.10.... Legends................................................................................................................ 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.11.... Financial Assurances............................................................................................ 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.12.... Stock Ownership.................................................................................................. 15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6......... Investor&#8217;s Conditions to Closing...................................................................................... 15</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.1...... Representations and Warranties........................................................................... 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.2...... Representations and Warranties in the Collaboration Agreement....................... 16</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.3...... Covenants............................................................................................................. 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.4..................................................................................................................................... 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.5...... Collaboration Agreement..................................................................................... 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.6...... No Material Adverse Effect................................................................................. 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.7...... Listing................................................................................................................... 16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7......... Company&#8217;s Conditions to Closing................................................................................... 16</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.1...... Representations and Warranties........................................................................... 17</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.2...... Covenants............................................................................................................. 17</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.3..................................................................................................................................... 17</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.4...... Collaboration Agreement..................................................................................... 17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8......... Mutual Conditions to Closing.......................................................................................... 17</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.1...... Absence of Litigation........................................................................................... 17</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.2...... No Prohibition...................................................................................................... 17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9......... Termination...................................................................................................................... 18</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.1...... Ability to Terminate............................................................................................. 18</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.2...... Effect of Termination........................................................................................... 18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10....... Additional Covenants and Agreements............................................................................ 19</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.1.... Market Listing...................................................................................................... 19</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.2.... Assistance and Cooperation................................................................................. 20</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.3.... Legend Removal.................................................................................................. 20</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.4.... Conduct of Business............................................................................................. 21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11....... Miscellaneous................................................................................................................... 21</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.1.... Governing Law&#59; Submission to Jurisdiction........................................................ 21</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.2.... Waiver.................................................................................................................. 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.3.... Notices.................................................................................................................. 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.4.... Entire Agreement................................................................................................. 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.5.... Amendments......................................................................................................... 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.6.... Headings&#59; Nouns and Pronouns&#59; Section References.......................................... 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.7.... Severability.......................................................................................................... 22</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.8.... Assignment........................................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.9.... Successors and Assigns........................................................................................ 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.10.. Counterparts......................................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.11.. Third Party Beneficiaries..................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.12.. No Strict Construction.......................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.13.. Survival of Warranties......................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.14.. Remedies.............................................................................................................. 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.15.. Expenses............................................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.16.. No Publicity.......................................................................................................... 23</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.17.. Limitation of Liability.......................................................................................... 24</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Exhibit A &#8211; Notices</font></div><div><font><br></font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i75d044c9ff86424aa5a9ecf0f42d8a38_137"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STOCK PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS STOCK PURCHASE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of June 14, 2021, by and between Zai Lab Limited (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), an exempted company with limited liabilities incorporated under the Laws of Cayman Islands</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with its principal place of business at Fourth Floor, Building 1,4560 Jinke Road, Pudong District, Shanghai 201210, China, and MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), a Delaware corporation, with its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the terms and subject to the conditions set forth in this Agreement, the Company desires to issue and sell to the Investor, and the Investor desires to subscribe for and purchase from the Company, certain shares of common stock, par value $0.01 per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, simultaneously with the execution of this Agreement, the Company and the Investor, are entering into the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for good and valuable consideration, the adequacy and sufficiency of which are hereby acknowledged, the Investor and the Company agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  When used in this Agreement, the following terms shall have the respective meanings specified therefor below&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, another Person that controls, is controlled by or is under common control with such Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that with respect to the Investor, &#8220;Affiliate&#8221; shall mean the Investor&#8217;s subsidiaries that are wholly-owned directly or indirectly, by the Investor and any Person that wholly-owns, directly or indirectly, the Investor.  A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.  Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met&#58; (i) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.  For the purposes of this Agreement, in no event shall the Investor or any of its Affiliates be deemed Affiliates of the Company or any of its Affiliates, nor shall the Company or any of its Affiliates be deemed Affiliates of the Investor or any of its Affiliates.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Preamble, including all Exhibits attached hereto.</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a shall mean a day on which banking institutions in Washington, DC, USA and Shanghai, China are generally open for business, excluding any Saturday or Sunday.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Collaboration and License Agreement, of even date herewith, between the Investor and the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Collaboration Products, as defined in the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any effect that, individually or when taken together with all other Effects, has had, or would reasonably be expected to have, (i) a material adverse effect on the Collaboration Assets, taken as a whole, or (ii) a material adverse effect on the Company&#8217;s ability to perform its obligations under the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any agreement, contract, lease, indenture, instrument, note, debenture, bond, mortgage or deed of trust or other agreement, commitment, arrangement or understanding.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Department of Justice.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the definition of &#8220;Material Adverse Effect.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Federal Trade Commission.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational organization of which any such country is a member.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean trademarks, trade names, trade dress, service marks, copyrights, and similar rights (including registrations and applications to register or renew the registration of any of the foregoing), patents and patent applications, trade secrets, and any other similar intellectual property rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any license, permit, authorization, approval, contract or consent granted, issued by or with any Person relating to the use of Intellectual Property.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions and&#47;or ordinances of any Governmental Authority.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any change, event or occurrence (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that, individually or when taken together with all other Effects, has had, or would reasonably be expected to have, (i) a material adverse effect on the business, financial condition, assets or results of operations of the Company and its subsidiaries, taken as a whole, or (ii) a </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">material adverse effect on the Company&#8217;s ability to perform its obligations, or consummate the Transaction, in accordance with the terms of this Agreement, except in the case of (i) to the extent that any such Effect results from or arises out of&#58; (A) changes in conditions in the United States or global economy or capital or financial markets generally, including changes in interest or exchange rates, (B) changes in general legal, regulatory, political, economic or business conditions or changes in generally accepted accounting principles in the United States or interpretations thereof, (C) acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism, (D) earthquakes, hurricanes, floods or other natural disasters, (E) the announcement of this Agreement or the Transaction, (F) any change in the Company&#8217;s stock price or trading volume or any failure to meet internal projections or forecasts or published revenue or earnings projections of industry analysts (provided that the underlying events giving rise to any such change shall not be excluded), (G) any breach, violation or non-performance by the Investor or any of its Affiliates under the Collaboration Agreement (provided that this item (G) will not apply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if such breach, violation or non-performance by the Investor or any of its Affiliates was primarily caused by the failure of the Company to perform of the covenants or agreements under the Collaboration Agreement or this Agreement to be performed by the Company), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Effects excluded in clauses (A), (B), (C) and (D) shall only be excluded to the extent such Effects are not disproportionately adverse on the Company and its subsidiaries as compared to other companies operating in the Company&#8217;s industry.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organizational Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the Restated Certificate of Incorporation of the Company, as amended through the date of this Agreement and (ii) the Amended and Restated Bylaws of the Company, as amended through the date of this Agreement.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Per Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean $31.30&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in the event of any stock dividend, stock split, combination of shares, recapitalization or other similar change in the capital structure of the Company after the date hereof and on or prior to the Closing which affects or relates to the Common Stock, the Per Share Purchase Price shall be appropriately adjusted.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, partnership, limited liability company, firm, corporation, trust, unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Person (other than a Governmental Authority) other than the Investor, the Company or any Affiliate of the Investor or the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means The Nasdaq Stock Market.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the issuance and sale of the Shares by the Company, and the purchase of the Shares by the Investor, in accordance with the terms hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Additional Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to the terms defined in Section&#160;1.1, the following terms shall have the respective meanings assigned thereto in the sections indicated below&#58;</font></div><div style="margin-bottom:6pt;padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.346%"><tr><td style="width:1.0%"></td><td style="width:57.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Term</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Aggregate Purchase Price</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Closing</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Closing Date</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company Rights</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.21(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company SEC Documents</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.11(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exchange Act</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.11(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAAP</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.11(c)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HSR Act</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investor</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LAS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Permits</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proprietary Rights</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.21(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 144</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities Act</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.11(a)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subsidiaries</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination Date</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.1(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transfer Agent</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.3(c)</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Purchase and Sale of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, at the Closing, the Company shall issue and sell to the Investor, free and clear of all liens, other than any liens arising as a result of any action by the Investor, and the Investor shall purchase from the Company, a number of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) equal to the amount obtained by dividing the aggregate purchase price of US $30,000,017.10 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Aggregate Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by the Per Share Purchase Price.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Closing Date&#59; Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the satisfaction or waiver of all the conditions to the Closing set forth in Sections 6, 7 and 8 hereof, the closing of the purchase and sale of the Shares hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be held on the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Business Day after the satisfaction of the conditions to Closing set forth in Sections 6, 7 and 8 (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction at such time of such conditions), at 9&#58;00 a.m. New York time, at the offices of Cooley LLP, 55 </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hudson Yards, New York, New York 10001, or at such other time, date and location as the parties may agree.  The date the Closing occurs is hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Deliveries by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Closing, the Company shall deliver to the Investor the Shares in book-entry form, registered in the name of the Investor, and the Company shall instruct its transfer agent to register such issuance at the time of such issuance, evidenced by an issuance statement or equivalent document issued by such transfer agent to be delivered to the Investor at Closing.  The Company shall also deliver at the Closing&#58; (i) a certificate in form and substance reasonably satisfactory to the Investor and duly executed on behalf of the Company by an authorized executive officer of the Company, certifying that the conditions to Closing set forth in Sections 6 and 8.2 of this Agreement have been fulfilled&#59;&#59; and (ii) a certificate of the secretary of the Company dated as of the Closing Date certifying (A) that attached thereto is a true and complete copy of the Amended and Restated Bylaws of the Company as in effect at the time of the actions by the Board of Directors of the Company referred to in clause (B) below, and on the Closing Date&#59; (B) that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors of the Company authorizing the execution, delivery and performance of the this Agreement and the Transaction and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby as of the Closing Date&#59; (C) that attached thereto is a true and complete copy of the Company&#8217;s Restated Certificate of Incorporation as in effect at the time of the actions by the Board of Directors of the Company referred to in clause (B) above, and on the Closing Date&#59; and (D) as to the incumbency and specimen signature of any officer of the Company executing this Agreement on behalf of the Company.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Deliveries by the Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Closing, the Investor shall deliver, or cause to be delivered, to the Company the Aggregate Purchase Price by wire transfer of immediately available United States funds to an account designated by the Company.  The Company shall notify the Investor in writing of the wiring instructions for such account not less than five (5) Business Days before the Closing Date.  The Investor shall also deliver, or cause to be delivered, at the Closing&#58; (i) a certificate in form and substance reasonably satisfactory to the Company duly executed by an authorized executive officer of the Investor certifying that the conditions to Closing set forth in Section 7 of this Agreement have been fulfilled&#59; and (ii) a certificate of the secretary or assistant secretary of the Investor dated as of the Closing Date certifying as to the incumbency and specimen signature of any officer executing this Agreement on behalf of the Investor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby represents and warrants to the Investor as of the date hereof and as of the Closing Date that&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Organization, Good Standing and Qualification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company and each of the Subsidiaries is a corporation duly incorporated or otherwise organized, validly existing and in good standing under the laws of the </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.  The Company and each of the Subsidiaries has all requisite corporate power and corporate authority to own, lease and operate its properties and assets, to carry on its business as now conducted, and as proposed to be conducted as described in the Company SEC Documents, the Company has all requisite corporate power and corporate authority to enter into the this Agreement and the Collaboration Agreement, to issue and sell the Shares and to perform its obligations under and to carry out the other transactions contemplated by the this Agreement and the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company and each of the Subsidiaries is qualified to transact business and is in good standing in each jurisdiction in which the character of the properties owned, leased or operated by the Company or Subsidiary, as applicable, or the nature of the business conducted by the Company or Subsidiary, as applicable, makes such qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Capitalization and Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The authorized capital of the Company as of June 10, 2021 consists of&#58; (i) 125,000,000 shares of Common Stock of which, as of the date of this Agreement, (x) 60,108,325 shares are issued and outstanding and (y) 13,808,200 shares are reserved for issuance pursuant to the Company&#8217;s stock incentive plans, of which 8,835,532 shares are issuable upon the exercise of stock options outstanding on the date hereof and (ii) 5,000,000 shares of preferred stock, par value $0.01 per share, of which no shares are issued and outstanding as of the date of this Agreement.  All of the issued and outstanding shares of Common Stock (A) have been duly authorized and validly issued, (B) are fully paid and non-assessable and (C) were issued in compliance with all applicable federal and state securities Laws and not in violation of any preemptive rights.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All of the authorized shares of Common Stock are entitled to one (1) vote per share.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as described or referred to in Section 4.2(a) above, there are not&#58; (i) any outstanding equity securities, options, warrants, rights (including conversion or preemptive rights) or other agreements pursuant to which the Company is or may become obligated to issue, sell or repurchase any shares of its capital stock or any other securities of the Company or (ii) any restrictions on the transfer of capital stock of the Company other than pursuant to state and federal securities Laws.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Except as disclosed in the Company SEC Documents, the Company is not a party to or subject to any agreement or understanding relating to the voting of shares of capital stock of the Company or the giving of written consents by a stockholder or director of the Company.</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Except as disclosed in the Company SEC Documents, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such registration.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has disclosed all of its subsidiaries required to be disclosed pursuant to Item 601(b)(21) of Regulation S-K in an exhibit to its Annual Report on Form 10-K (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All requisite corporate action on the part of the Company, its directors and stockholders required by applicable Law for the authorization, execution and delivery by the Company of the this Agreement and the Collaboration Agreement, and the performance of all obligations of the Company hereunder and thereunder, including the authorization, issuance and delivery of the Shares, has been taken.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Collaboration Agreement has been, and upon the execution and delivery of this Agreement by the Company and upon the due execution and delivery of this Agreement by the Investor and the Collaboration Agreement by the Investor, this Agreement and the Collaboration Agreement will constitute, valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms (except with respect to the Investor Agreement and the Collaboration Agreement as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other Laws of general application relating to or affecting enforcement of creditors&#8217; rights and (ii) rules of Law governing specific performance, injunctive relief or other equitable remedies and limitations of public policy).</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No stop order or suspension of trading of the Common Stock has been imposed by Nasdaq, the SEC or any other Governmental Authority and remains in effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Defaults</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not in default under or in violation of (a) its Organizational Documents, (b) any provision of applicable Law or any ruling, writ, injunction, order, Permit, judgment or decree of any Governmental Authority or (c) any agreement, arrangement or instrument, whether written or oral, by which the Company or any of its assets are bound, except, in the case of subsections (b) and (c), as would not have a Material Adverse Effect.  There exists no condition, event or act which after notice, lapse of time, or both, would </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">constitute a default or violation by the Company under any of the foregoing, except, in the case of subsections (b) and (c), as would not have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution, delivery and performance of the this Agreement and the Collaboration Agreement, and compliance with the provisions hereof and thereof by the Company do not and shall not&#58; (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b) constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether written or oral, by which the Company or any of its assets are bound, (c) violate or conflict with any of the provisions of the Company&#8217;s Organizational Documents or (d) result in any encumbrance upon any of the Shares, other than restrictions pursuant to this Agreement or securities Laws, or on any of the properties or assets of the Company or any Subsidiary, except, in the case of subsections (a) and (b), as would not have a Material Adverse Effect with respect to this Agreement or a Collaboration Material Adverse Effect with respect to the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Governmental Authority or Third Party Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No consent, approval, authorization or other order of, or filing with, or notice to, any Governmental Authority or other Third Party is required to be obtained or made by the Company in connection with the authorization, execution and delivery by the Company of any of the this Agreement or the Collaboration Agreement, or with the authorization, issue and sale by the Company of the Shares, except such filings as may be required to be made with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and with any state blue sky or securities regulatory authority, which filings shall be made in a timely manner in accordance with all applicable Laws and.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Valid Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  When issued, sold and delivered at the Closing in accordance with the terms hereof for the Aggregate Purchase Price, the Shares shall be duly authorized, validly issued, fully paid and nonassessable, free from any liens, encumbrances or restrictions on transfer, including preemptive rights, rights of first refusal or other similar rights, other than as arising pursuant to the this Agreement, as a result of any action by the Investor or under federal or state securities Laws.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in the Company SEC Documents filed prior to the date of this Agreement (excluding (i) any amendment thereto filed on or after the date of this Agreement, (ii) disclosures of non-specific risks faced by the Company included in any forward-looking statement, disclaimer, risk factor disclosure or other similarly non-specific statements that are predictive, general or forward-looking in nature, and (iii) disclosures in any Company SEC Documents filed on or after the date of this Agreement but are incorporated by reference into the Company SEC Documents filed prior to the date of this Agreement ((i), (ii) and (iii), collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), there is no action, suit, proceeding or investigation pending (of which the Company has received notice or otherwise has knowledge) or, to the Company&#8217;s knowledge, threatened, against the Company or which the Company </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">intends to initiate which has had or is reasonably likely to have a Material Adverse Effect or Collaboration Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Licenses and Other Rights&#59; Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has all franchises, permits, licenses, authorizations, consents, approvals and other rights and privileges (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and has made all filings, applications and registrations with any Governmental Authority, that are necessary to permit it to own its properties and to conduct its business as presently conducted and is in compliance thereunder, except where the failure to be in compliance does not and would not have a Material Adverse Effect or Collaboration Material Adverse Effect.  All such Permits are in full force and effect and, to the knowledge of the Company, no suspension or cancellation of any of them is threatened, and all such filings, applications and registrations are current. The Company has not taken any action that would interfere with the Company&#8217;s ability to renew all such Permit(s).  The Company is and has been in compliance in all material respects with all Laws applicable to its business, properties and assets, and to the products and services sold by it, except where the failure to be in compliance does not and would not have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Company SEC Documents&#59; Financial Statements&#59; Nasdaq Stock Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Since January 1, 2020, the Company has timely filed or furnished, as applicable, all required reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, with the SEC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company SEC Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  As of their respective filing dates, each of the Company SEC Documents complied in all material respects with the requirements of the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the rules and regulations of the SEC promulgated thereunder and the rules and regulations of The Nasdaq Stock Market, and no Company SEC Documents when filed, declared effective or mailed, as applicable, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC or its staff.  As of the date of this Agreement, none of the Company&#8217;s Subsidiaries is subject to the reporting requirements of Section 13(a) or 15(d) under the Exchange Act.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The consolidated financial statements of the Company included in its Annual Report on Form 10-K for the fiscal years ended December 31, 2019 and December 31, 2020 and in its quarterly reports on Form 10-Q for the quarterly period ended March 31, 2021 comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with United States generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly present in all material respects the financial position of the Company as of the dates thereof </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the results of its operations and cash flows for the periods then ended.  Except (i) as set forth in the Company SEC Documents filed prior to the date of this Agreement (excluding the Excluded Disclosures) or (ii) for liabilities incurred in the ordinary course of business subsequent to the date of the most recent balance sheet contained in the Company SEC Documents, none of which would, individually or in the aggregate, have a Material Adverse Effect, the Company has no liabilities, whether absolute or accrued, contingent or otherwise, other than those that would not, individually or in the aggregate, have a Material Adverse Effect.  There are no unconsolidated subsidiaries of the Company or any material off-balance sheet arrangements of any type (including any off balance sheet arrangements required to be disclosed pursuant to Item 303(a)(4) of Regulation S-K promulgated under the Securities Act) that have not been so described in the Company SEC Documents filed prior to the date hereof (excluding the Excluded Disclosures) nor any obligations to enter into any such arrangements. </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Common Stock is listed on The Nasdaq Global Select Market, and the Company has taken no action or inaction designed to, or which is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from The Nasdaq Global Market.  The Company has not received any notification that, and has no knowledge that, the SEC or The Nasdaq Stock Market LLC is contemplating terminating such listing or registration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e)&#160;&#160;&#160;&#160;The Company has implemented and maintains a system of internal control over financial reporting (to the extent required by Rule 13a-15(a) under the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes, and such system of internal control over financial reporting is effective.  The Company has implemented and maintains disclosure controls and procedures (to the extent required by Rule 13a-15(a) of the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the timeframes specified by the SEC&#8217;s rules and forms (and such disclosure controls and procedures are effective), and has disclosed, based on its most recent evaluation of its system of internal control over financial reporting prior to the date of this Agreement, to the Company&#8217;s outside auditors and the audit committee of the Company Board (i) any significant deficiencies and material weaknesses known to it in the design or operation of its internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that would reasonably be expected to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information and (ii) any fraud known to it, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(f)&#160;&#160;&#160;&#160;To the knowledge of the Company, as of the date hereof, no employee of the Company or its subsidiaries has provided since January 1, 2019 or is providing information to any law enforcement agency regarding the violation of any applicable Law of the type described in Section 806 of the Sarbanes-Oxley Act by the Company or its Subsidiaries.  Neither the Company nor its Subsidiaries have discharged, demoted or suspended an employee </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Company or its Subsidiaries in the terms and conditions of employment because of any lawful act of such employee described in Section 806 of the Sarbanes-Oxley Act.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Absence of Certain Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as disclosed in the Company SEC Documents filed prior to the date of this Agreement (excluding the Excluded Disclosures), since December 31, 2020, to the Company&#8217;s knowledge there has not occurred any event that has caused or would reasonably be expected to cause a Material Adverse Effect or a Collaboration Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except as set forth in the Company SEC Documents filed prior to the date hereof (excluding the Excluded Disclosures), since December 31, 2020, the Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, or (ii) sold, exchanged or otherwise disposed of any of its material assets or rights.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Since December 31, 2020, the Company has not admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated a bankrupt, or filed a petition or answer seeking reorganization or arrangement under the federal bankruptcy laws or any other laws of the United States or any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the accuracy of the Investor&#8217;s representations set forth in Sections 5.5, 5.6, 5.7, 5.9 and 5.10, the offer, sale and issuance of the Shares to be issued in conformity with the terms of this Agreement constitute transactions which are exempt from the registration requirements of the Securities Act and from all applicable state registration or qualification requirements.  Neither the Company nor any Person acting on its behalf will take any action that would cause the loss of such exemption.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">No Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has not, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated with the Shares sold pursuant to this Agreement in a manner that would require the registration of the Shares under the Securities Act.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Brokers&#8217; or Finders&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No broker, finder, investment banker or other Person is entitled to any brokerage, finder&#8217;s or other fee or commission from the Company in connection with the transactions contemplated by the this Agreement and the Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Investment Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended.  </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">No General Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Shares by any form of general solicitation or general advertising.  The Company has offered the Shares for sale only to the Investor.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Foreign Corrupt Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Anti-Money Laundering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Neither the Company nor, to the knowledge of the Company, any of its directors, officers, employees, or agents, has&#58; (i) directly or indirectly, made, offered, promised, or authorized any unlawful contributions, gifts, entertainment or other payments related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is  in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any applicable non-U.S. anti-bribery Law.  Neither the Company nor, to the knowledge of the Company, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other applicable anti-bribery Law.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Regulation M Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Office of Foreign Assets Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor, to the Company's knowledge, any director, officer, agent, employee or Affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Company is, and for the past five (5) years has been, in material compliance with all OFAC regulations and any other applicable sanctions </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Laws in all material respects, and there are no pending or, to the Company&#8217;s knowledge, threatened claims against the Company, nor, to the Company&#8217;s knowledge, any actions, conditions, facts, or circumstances that would reasonably be expected to give rise to any material future claims with respect to such Laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Intellectual Property that is owned by the Company or any subsidiary is owned free from any liens or restrictions (other than any restrictions set forth in any Intellectual Property License relating to such Intellectual Property), and all of the Company&#8217;s and its subsidiaries&#8217; material Intellectual Property Licenses are in full force and effect in accordance with their terms, are free of any liens or restrictions, and neither the Company nor to the Company&#8217;s knowledge any other party thereto, is in breach of any such material Intellectual Property License, and no event has occurred that with notice or lapse of time or both would constitute such a breach or default thereunder or would result in the termination thereof or would cause or permit the acceleration or other change of any right or obligation of the loss of any benefit thereunder by the Company except for such failures to be in full force and effect, such liens or restrictions, and such material breaches that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or a Collaboration Material Adverse Effect. Except as set forth in the Company SEC Documents filed prior to the date hereof (excluding the Excluded Disclosures), there is no material legal claim or demand of any Person pertaining to, or any proceeding which is pending (of which the Company has received notice or otherwise has knowledge) or, to the knowledge of the Company, threatened, (i) challenging the right of the Company in respect of any Company Intellectual Property, or (ii) that claims that any default exists under any Intellectual Property License.<br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as set forth in the Company&#8217;s SEC Documents filed prior to the date hereof (excluding the Excluded Disclosures)&#58; (i) the Company or one of its subsidiaries owns, free and clear of any lien or encumbrance, or has a valid license to, or has an enforceable right to use, as it is used or held for use, all material U.S. and non-U.S. patents, trade secrets, know-how, trademarks, service marks, copyrights, and other proprietary and intellectual property rights, and all grants and applications with respect to the foregoing (collectively, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Proprietary Rights&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) necessary for the conduct of the Company's business (such Proprietary Rights owned by or licensed to the Company collectively, the</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Company Rights&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59; and (ii) the Company and its subsidiaries have taken reasonable measures to protect the Company Rights, consistent with prudent commercial practices in the  biotechnology industry.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Full Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the date hereof, and other than the transactions that are the subject of this Agreement and the Collaboration Agreement, no material fact or circumstance exists that would be required to be disclosed in a current report on Form 8-K or in a registration statement filed under the Securities Act, were such a registration statement filed on the date hereof, that has not been disclosed in an SEC Report filed on or after June 14, 2021.</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company and each of its Subsidiaries (a) has made or filed in a timely manner (within any applicable extension periods) and in the appropriate jurisdictions all foreign, federal and state income and all other tax returns, reports, information statements and other documentation (including any additional or supporting materials) required to be filed or maintained in connection with the calculation, determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties, governmental fees and charges of whatever kind (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including all amended returns required as a result of examination adjustments made by any Governmental Authority responsible for the imposition of any Tax (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and such Returns are true, correct and complete in all material respects, (b) has paid all Taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such Returns, except those being contested in good faith, not finally determined, and (c) has set aside on its books provision reasonably adequate for the payment of all Taxes for periods subsequent to the periods to which such Returns apply. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Labor and Employment Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No labor disturbance by or dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its Subsidiaries&#8217; principal suppliers, contractors or customers, except as would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title to Property and Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the Company and its Subsidiaries has good and marketable title to, or a legal and valid right to use, all properties and assets (whether tangible or intangible) that it purports to own or that it leases or otherwise uses, free and clear of any and all Encumbrances, except for any defects in title or right or any Encumbrances that would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole.  Such properties and assets collectively represent in all material respects all properties and assets necessary for the conduct of the business of the Company and its Subsidiaries as presently conducted.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  True and correct copies (or excerpt thereof) of all material Contracts of the Company and its Subsidiaries have either been disclosed to the Investor or disclosed in the SEC Company Documents (subject to redactions as permitted under applicable law), and since the date of this Agreement, there has been no acceleration, termination, material modification to or cancellation of any such Contracts that would, individually or in the aggregate, be or reasonably expected to have a Material Adverse Effect or Collaboration Material Adverse Effect.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor hereby represents and warrants to the Company as of the date hereof and as of the Closing Date that&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Organization&#59; Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor is an exempted company with limited liability duly organized, validly existing and in good standing under the Laws of Cayman </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Islands.  The Investor has or will have all requisite power and authority to enter into the this Agreement, to purchase the Shares and to perform its obligations under and to carry out the other transactions contemplated by the this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All requisite action on the part of the Investor and its directors and shareholders, required by applicable Law for the authorization, execution and delivery by the Investor of the this Agreement, and the performance of all of its obligations thereunder, including the subscription for and purchase of the Shares, has been taken.  This Agreement has been  duly executed and delivered by the Investor and, upon the due execution and delivery thereof by the Company, will constitute a valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with its terms (except as such enforceability may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other Laws of general application relating to or affecting enforcement of creditors&#8217; rights and (b) rules of Law governing specific performance, injunctive relief or other equitable remedies and limitations of public policy).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution, delivery and performance of the this Agreement and compliance with the provisions thereof by the Investor do not and shall not&#58; (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b) constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether written or oral, by which the Investor or any of its assets, are bound, or (c) violate or conflict with any of the provisions of the Investor&#8217;s organizational documents (including any articles or memoranda of organization or association, charter, bylaws or similar documents), and except, in the case of subsections (a), (b) and (c) as would not have a material adverse effect on the Investor&#8217;s ability to perform its obligations or consummate the Transaction in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Governmental Authority or Third Party Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No consent, approval, authorization or other order of any Governmental Authority or other Third Party is required to be obtained by the Investor in connection with the authorization, execution and delivery of this Agreement or with the subscription for and purchase of the Shares.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Purchase Entirely for Own Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Shares shall be acquired for investment for the Investor&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling, granting any participation or otherwise distributing the Shares.  The Investor does not have and will not have as of the Closing any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participation to a Person any of the Shares.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Disclosure of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor has been furnished access to all materials and information the Investor has requested relating to the Company and its Subsidiaries in order to evaluate the transactions contemplated by this Agreement.  </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Investment Experience and Accredited Investor Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor is an &#8220;accredited investor&#8221; (as defined in Regulation D under the Securities Act).  The Investor has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares to be purchased hereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">&#91;Reserved.&#93;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor understands that the Shares, when issued, shall be &#8220;restricted securities&#8221; under the federal securities Laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such Laws the Shares may be resold without registration under the Securities Act only in certain limited circumstances.  The Investor represents that it is familiar with Rule 144 of the Securities Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as presently in effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor understands that any certificates representing the Shares shall bear the following legends&#58;</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;These securities have not been registered under the Securities Act of 1933.  They may not be sold, offered for sale, pledged or hypothecated  except pursuant to a registration statement in effect with respect to the securities under the Securities Act, in accordance with Rule 144 of the Securities Act or pursuant to an available exemption from registration under the Securities Act of 1933.&#8221;&#59; and</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any legend required by applicable state securities Laws.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Financial Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Closing Date, the Investor has and will have access to cash in an amount sufficient to pay to the Company the Aggregate Purchase Price.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the date hereof, neither the Investor nor any of its Affiliates (excluding for this purpose any employee benefit plan of the Investor) own any shares of capital stock of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Investor&#8217;s Conditions to Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor&#8217;s obligation to purchase the Shares at the Closing is subject to the fulfillment as of the Closing of the following conditions (unless waived in writing by the Investor)&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The representations and warranties made by the Company in Section 4 hereof shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that for purposes of this Section 6.1, all such representations and warranties of the Company (other than Sections 4.1(a), 4.2, 4.3, 4.4, 4.5(a), 4.6(c), 4.8, and 4.11 of this Agreement) shall be deemed to be true and correct for purposes of this Section 6.1 unless the failure or failures of such representations and warranties to be so true and correct, without regard to any &#8220;material,&#8221; </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; qualifiers set forth therein, constitute a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Representations and Warranties in the Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The representations and warranties made by the Company in Section 12.1 of the Collaboration Agreement shall be true and correct as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that for purposes of this Section 6.2, all such representations and warranties of the Company shall be deemed to be true and correct for purposes of this Section 6.2 unless the failure or failures of such representations and warranties to be so true and correct, without regard to any &#8220;material&#8221; or &#8220;materiality&#8221; qualifiers set forth therein, individually or in the aggregate, has had or would reasonably be expected to have a Collaboration Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All covenants and agreements contained in this Agreement to be performed or complied with by the Company on or prior to the Closing Date shall have been performed or complied with in all material respects.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have duly executed and delivered to the Investor the Collaboration Agreement, and there shall have been no termination of the Collaboration Agreement that, as of the Closing, is effective.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From and after the date of this Agreement until the Closing Date, there shall have occurred no event that has caused a Material Adverse Effect or a Collaboration Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Shares shall be eligible and approved for listing on the Nasdaq Global Select Market.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Company&#8217;s Conditions to Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company&#8217;s obligation to issue and sell the Shares at the Closing is subject to the fulfillment as of the Closing of the following conditions (unless waived in writing by the Company)&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The representations and warranties made by the Investor in Section 5 hereof shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of such Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date, in the case of Sections 5.1-5.4, and 5.11, except where any failure to be true and correct would not have a material adverse effect on the Investor&#8217;s ability to perform its obligations, or consummate the Transaction in accordance with the terms of this Agreement, in the case of Section 5.5, 5.6 and 5.7, except where any inaccuracy would not result in the issuance of the Shares hereunder failing to qualify as an offering of securities not involving any public offering under the federal securities Laws, and in the case of Section 5.12, except where any inaccuracy would not be material on the </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investor&#8217;s ability to perform its obligations, or consummate the Transaction in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All covenants and agreements contained in this Agreement to be performed or complied with by the Investor on or prior to the Closing Date shall have been performed or complied with in all material respects.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Investor shall have duly executed and delivered to the Company the Collaboration Agreement, and there shall have been no termination of the Collaboration Agreement that, as of the Closing, is effective.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Mutual Conditions to Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The obligations of the Investor and the Company to consummate the Closing are subject to the fulfillment as of the Closing Date of the following conditions&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Absence of Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There shall be no action, suit, proceeding or investigation by a Governmental Authority pending or currently threatened in writing against the Company or the Investor that questions the validity of any of the this Agreement, the right of the Company or the Investor to enter into this Agreement or to consummate the transactions contemplated hereby or thereby or which, if determined adversely, would impose substantial monetary damages on the Company or the Investor as a result of the consummation of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Prohibition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of any applicable Law and no judgment, injunction (preliminary or permanent), order or decree that prohibits, makes illegal or enjoins the consummation of the Transaction shall be in effect.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Ability to Terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be terminated at any time prior to the Closing by&#58;</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;mutual written consent of the Company and the Investor&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;either the Company or the Investor, upon written notice to the other no earlier than June 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), if the Transaction shall not have been consummated by the Termination Date&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;either the Company or the Investor, upon written notice to the other, if any of the mutual conditions to the Closing set forth in Section 8 shall have become incapable of fulfillment by the Termination Date and shall not have been waived in writing by the other party within ten business days after receiving receipt of written notice of an intention to terminate pursuant to this clause (c) provided, however, that the right to terminate this Agreement under this Section 9.1(c) shall not be available to any party whose failure to fulfill </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any obligation under this Agreement has been the cause of, or resulted in, the failure to consummate the transactions contemplated hereby prior to the Termination Date&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Company, upon written notice to the Investor, so long as the Company is not then in breach of its representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section 6, could not be satisfied by the Termination Date, (i) upon a material breach of any covenant or agreement on the part of the Investor set forth in this Agreement, or (ii) if any representation or warranty of the Investor shall have been or become untrue, in each case such that any of the conditions set forth in Section 7, could not be satisfied by the Termination Date&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the Investor, upon written notice to the Company, so long as the Investor is not then in breach of its representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section 7, could not be satisfied by the Termination Date, (i) upon a breach of any covenant or agreement on the part of the Company set forth in this Agreement, or (ii) if any representation or warranty of the Company shall have been or become untrue, in each case such that any of the conditions set forth in Section 6, could not be satisfied by the Termination Date.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of the termination of this Agreement pursuant to Section 9.1 hereof, (a) this Agreement (except for this Section 9.2 and Section 11 hereof (other than Section 11.13), and any definitions set forth in this Agreement and used in such sections) shall forthwith become void and have no effect, without any liability on the part of any party hereto or its Affiliates, and (b) all filings, applications and other submissions made pursuant to this Agreement, to the extent practicable, shall be withdrawn from the agency or other Person to which they were made or appropriately amended to reflect the termination of the transactions contemplated hereby&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that nothing contained in this Section 9.2 shall relieve any party from liability for fraud or any intentional or willful breach of this Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Additional Covenants and Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Market Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From the date hereof through the Closing Date, Company shall use all reasonable efforts to maintain the listing and trading of the Common Stock on The Nasdaq Global Market.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Assistance and Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the Closing, upon the terms and subject to the conditions set forth in this Agreement, each of the parties agrees to use all reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, and to assist and cooperate with the other party in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement, including using all reasonable efforts to accomplish the following&#58; (a) taking all reasonable acts necessary to cause the conditions precedent set forth in Sections 6, 7 and 8 to be satisfied&#59; (b) taking all reasonable actions necessary to obtain all </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">necessary actions or non-actions, waivers, consents, approvals, orders and authorizations from Governmental Authorities and the making of all necessary registrations, declarations and filings (including registrations, declarations and filings with Governmental Authorities, if any)&#59;  (c) taking all reasonable actions necessary to obtain all necessary consents, approvals or waivers from Third Parties&#59; and (d) except as otherwise provided for in Section 10.2, defending any suits, claims, actions, investigations or proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated hereby, including seeking to have any stay or temporary restraining order entered by any court or other Governmental Authority vacated or reversed.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Legend Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Certificates evidencing the Shares shall not contain the legend set forth in Section 5.10(a)&#58; (i) following any sale of such Shares pursuant to Rule 144, (ii) if such Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iii) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC).  </font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Certificates evidencing the Shares shall not contain the legend set forth in Section 5.10(c) following any sale of such Shares pursuant to Rule 144.  </font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Company agrees that at such time as any legend set forth in Section 5.10 is no longer required under this Section 10.4, the Company will, no later than three (3) Business Days following the delivery by the Investor to the Company or the Company&#8217;s transfer agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of a certificate representing Shares issued with such legend, deliver or cause to be delivered to the Investor a certificate representing such Shares that is free from such legend, or, in the event that such shares are uncertificated, remove any such legend in the Company&#8217;s stock records.  The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in Section 5.10.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Conduct of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the period from the date hereof until the Closing, except as consented to in writing by the Investor, the Company shall not (i) declare, set aside or pay any dividend or make any other distribution or payment (whether in cash, stock or property or any combination thereof) in respect of its capital stock, or establish a record date for any of the foregoing, or (ii) make any other actual, constructive or deemed distribution in respect of any shares of its capital stock or otherwise make any payments to stockholders in their capacity as such, except pursuant to repurchases of equity pursuant to the terms of its equity compensation plans. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Governing Law&#59; Submission to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction.  Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees not to assert, as a defense in any action, suit or proceeding in which any such claim is made that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof may not be appropriate or that this agreement may not be enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of the State of Delaware jurisdiction over such parties and over the subject matter of any such claim and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 11.3 or in such other manner as may be permitted by law, shall be valid and sufficient thereof. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Waiver by a party of a breach hereunder by the other party shall not be construed as a waiver of any subsequent breach of the same or any other provision.  No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such party.  No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party granting the waiver.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent to the address of the relevant party set forth on Exhibit A attached hereto and shall be (a) delivered personally, (b) sent by registered or certified mail, return receipt requested, postage prepaid, (c) sent via a reputable nationwide overnight courier service or (d) sent by facsimile transmission or electronic mail, with a confirmation copy to be sent by registered or certified mail, return receipt requested, postage prepaid.  Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1) Business Day after it is sent via a reputable nationwide overnight courier service or when transmitted with electronic confirmation of receipt, if transmitted by facsimile or electronic mail (if such transmission is made during regular business hours of the recipient on a Business Day&#59; or otherwise, on the next Business Day following such transmission).  Either party may change its address by giving notice to the other party in the manner provided above.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Collaboration Agreement, contain the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or oral, with respect hereto and thereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision in this Agreement shall be supplemented, deleted or amended except in a writing executed by an authorized representative of each of the Investor and the Company.</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Headings&#59; Nouns and Pronouns&#59; Section References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Headings in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement.  Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa.  References in this Agreement to a section or subsection shall be deemed to refer to a section or subsection of this Agreement unless otherwise expressly stated.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, under applicable Laws, any provision hereof is invalid or unenforceable, or otherwise directly or indirectly affects the validity of any other material provision(s) of this Agreement in any jurisdiction (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Modified Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, it is mutually agreed that this Agreement shall endure and that the Modified Clause shall be enforced in such jurisdiction to the maximum extent permitted under applicable Laws in such jurisdiction&#59; provided that the parties shall consult and use all reasonable efforts to agree upon, and hereby consent to, any valid and enforceable modification of this Agreement as may be necessary to avoid any unjust enrichment of either party and to match the intent of this Agreement as closely as possible, including the economic benefits and rights contemplated herein.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except for an assignment of this Agreement or any rights hereunder by the Investor to an Affiliate, neither this Agreement nor any of the rights or obligations hereunder may be assigned by either the Investor or the Company without (a) the prior written consent of Company in the case of any assignment by the Investor or (b) the prior written consent of the Investor in the case of an assignment by the Company.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of any party hereto.  No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against any party hereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been prepared jointly and will not be construed against either party.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Survival of Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The representations and warranties of the Company and the Investor contained in this Agreement shall survive the Closing and the delivery of the Shares. </font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The rights, powers and remedies of the parties under this Agreement are cumulative and not exclusive of any other right, power or remedy which such parties may have under any other agreement or Law.  No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party shall pay its own fees and expenses in connection with the preparation, negotiation, execution and delivery of the this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">No Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties hereto agree that the provisions of Section 11.3 of the Collaboration Agreement shall be applicable to the parties to this Agreement with respect to any public disclosures regarding the proposed transactions contemplated by the Purchase Agreement and the Collaboration Agreement or regarding the parties hereto or their Affiliates (it being understood that the provisions of Section 11.3 of the Collaboration Agreement shall be read to apply to disclosures of information relating to this Agreement and the transactions contemplated hereby).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Adjustment of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each reference to a number of shares of Common Stock in this Agreement shall be adjusted proportionately to reflect any stock dividend, subdivision, split or reverse split or the like affected with respect to all outstanding shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Electronic Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed by facsimile signature or any other form of electronic transmission of signature and a facsimile or any other form of electronically transferred signature shall constitute an original for all purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#8217;S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)</font></div><div style="height:83.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i75d044c9ff86424aa5a9ecf0f42d8a38_140"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ZAI LAB LIMITED</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Samantha Du</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Samantha Du</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;CEO</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Scott Koenig</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;CEO</font></div><div style="height:122.05pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Stock Purchase Agreement</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div></div></div><div id="i75d044c9ff86424aa5a9ecf0f42d8a38_143"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTICES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If to the Investor&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Zai Lab Limited</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fourth Floor, Building 1,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4560 Jinke Road, Pudong District, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shanghai 201210, China</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; CEO</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Goodwin Procter (Hong Kong) LLP</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38th Floor, Edinburgh Tower, The Landmark</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15 Queen's Road Central, Hong Kong</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Wendy Pan</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; WPan&#64;goodwinlaw.com</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If to the Company&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics, Inc.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9704 Medical Center Drive</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rockville, MD  20850</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  CEO </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP<br>55 Hudson Yards<br>New York, NY 10001<br>Attention&#58;  Eric Blanchard</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31-1q22021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ieb43e2a47b0d47cbbbda02573aa2f222_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; July&#160;29, 2021 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31-2q22021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iede13dbad63c4470969006fc0e6605b8_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2021 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; July&#160;29, 2021 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32-1q22021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic14925f16ed04e66982e372542e9b506_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;June&#160;30, 2021&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;29, 2021 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit32-2q22021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7d05351804da4abf935ae04278198a0e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;June&#160;30, 2021&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;29, 2021 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mgnx-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://macrogenics.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://macrogenics.com/role/Inventory">
        <link:definition>2110105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://macrogenics.com/role/InventoryTables">
        <link:definition>2311303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://macrogenics.com/role/InventoryDetails">
        <link:definition>2412403 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2113106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2414404 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2115107 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails">
        <link:definition>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2121108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2127109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012SupplyAgreementMember" abstract="true" name="IncyteMGA012SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenuesNetOfTaxWithholding" abstract="false" name="RevenuesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesTaxWithholding" abstract="false" name="RevenuesTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_OptInFee" abstract="false" name="OptInFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RetirementOfTreasuryStock" abstract="false" name="RetirementOfTreasuryStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mgnx-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_09a52997-56fb-4e51-bad7-acf8487eaf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3cbc1a23-6301-4bb1-af67-2bf1457d8da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_09a52997-56fb-4e51-bad7-acf8487eaf17" xlink:to="loc_us-gaap_AccountsPayableCurrent_3cbc1a23-6301-4bb1-af67-2bf1457d8da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_07533224-b42a-4ac7-8e39-2ea010888f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_09a52997-56fb-4e51-bad7-acf8487eaf17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_07533224-b42a-4ac7-8e39-2ea010888f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b741860-5b8d-48ec-aab7-51f71a5f7e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_09a52997-56fb-4e51-bad7-acf8487eaf17" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b741860-5b8d-48ec-aab7-51f71a5f7e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81671cd5-ef9f-4ee8-83bc-8abd66b49903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_09a52997-56fb-4e51-bad7-acf8487eaf17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_81671cd5-ef9f-4ee8-83bc-8abd66b49903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_af3b7dae-86bc-47e3-a0e2-0e0c96eb4831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_86ceffdb-01b3-4e6d-9051-2261a1987141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af3b7dae-86bc-47e3-a0e2-0e0c96eb4831" xlink:to="loc_us-gaap_AssetsCurrent_86ceffdb-01b3-4e6d-9051-2261a1987141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2557036f-70ef-41de-8ead-5ef39ad59eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af3b7dae-86bc-47e3-a0e2-0e0c96eb4831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2557036f-70ef-41de-8ead-5ef39ad59eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d1bb384d-4046-4398-8502-df00b462ab79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_af3b7dae-86bc-47e3-a0e2-0e0c96eb4831" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d1bb384d-4046-4398-8502-df00b462ab79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f232f792-511f-4c70-9af7-1cbda989c272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_891b5dfa-01bc-4439-9a41-0516a81b7100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f232f792-511f-4c70-9af7-1cbda989c272" xlink:to="loc_us-gaap_LiabilitiesCurrent_891b5dfa-01bc-4439-9a41-0516a81b7100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_61f51abb-eb5d-403f-9937-08bff0065d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f232f792-511f-4c70-9af7-1cbda989c272" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_61f51abb-eb5d-403f-9937-08bff0065d36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19a9b610-171d-48a4-9d42-c0e925b707c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f232f792-511f-4c70-9af7-1cbda989c272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19a9b610-171d-48a4-9d42-c0e925b707c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ec42b4e-a4cc-4a7d-b51a-e49fde6b326d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f232f792-511f-4c70-9af7-1cbda989c272" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ec42b4e-a4cc-4a7d-b51a-e49fde6b326d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b679535-435d-44c9-9312-69b0e35b81d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e34645c7-05ed-436e-924d-a01fd23c8b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b679535-435d-44c9-9312-69b0e35b81d3" xlink:to="loc_us-gaap_Liabilities_e34645c7-05ed-436e-924d-a01fd23c8b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14e4bb47-6cb8-4f05-b508-23eab7641ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9b679535-435d-44c9-9312-69b0e35b81d3" xlink:to="loc_us-gaap_StockholdersEquity_14e4bb47-6cb8-4f05-b508-23eab7641ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db2d1aa2-b553-4380-8611-053c195ad2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_083b9be5-0adb-4c0e-a02a-9d982b6782a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_db2d1aa2-b553-4380-8611-053c195ad2f1" xlink:to="loc_us-gaap_CommonStockValue_083b9be5-0adb-4c0e-a02a-9d982b6782a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_53a08e7c-62b4-40a1-af0c-c6df4a2aee1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_db2d1aa2-b553-4380-8611-053c195ad2f1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_53a08e7c-62b4-40a1-af0c-c6df4a2aee1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68055c1b-9874-4650-9cbd-415ee3ab0a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_db2d1aa2-b553-4380-8611-053c195ad2f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68055c1b-9874-4650-9cbd-415ee3ab0a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_54f60380-a784-4bdf-806a-c123ddf60e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_db2d1aa2-b553-4380-8611-053c195ad2f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_54f60380-a784-4bdf-806a-c123ddf60e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_3afe003b-79d2-4d9c-aa85-d422c43875c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:to="loc_us-gaap_Investments_3afe003b-79d2-4d9c-aa85-d422c43875c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d58def8d-6b74-4e7b-b81d-0aae8804ebe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d58def8d-6b74-4e7b-b81d-0aae8804ebe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_748d044d-d053-4e22-bb68-9808993d27ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:to="loc_us-gaap_InventoryNet_748d044d-d053-4e22-bb68-9808993d27ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ed8bae6b-d5aa-4fee-b02c-c79f111f8d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ed8bae6b-d5aa-4fee-b02c-c79f111f8d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_313543bf-e26b-49c2-88df-27462084dd5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b4ff0c8e-0c3b-4c71-a2a5-cbd6e7c94078" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_313543bf-e26b-49c2-88df-27462084dd5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3d422185-6c65-4121-995d-51b8063248fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_912c62f2-58a8-4fc8-bf2c-f8200f8b77c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3d422185-6c65-4121-995d-51b8063248fb" xlink:to="loc_us-gaap_NetIncomeLoss_912c62f2-58a8-4fc8-bf2c-f8200f8b77c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_104d967e-9a2d-4745-bc05-78c92989f7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3d422185-6c65-4121-995d-51b8063248fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_104d967e-9a2d-4745-bc05-78c92989f7cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_97e08767-9173-4ccc-95d8-e2a18436e3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ca0599c9-8d4b-4922-acc4-aac777e9026d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97e08767-9173-4ccc-95d8-e2a18436e3e2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ca0599c9-8d4b-4922-acc4-aac777e9026d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5c1dcd9d-6e5e-45f7-a4c5-6ffbdb8b87fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97e08767-9173-4ccc-95d8-e2a18436e3e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5c1dcd9d-6e5e-45f7-a4c5-6ffbdb8b87fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_54c742cb-1c14-4221-9b9b-0a6177d10d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_97e08767-9173-4ccc-95d8-e2a18436e3e2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_54c742cb-1c14-4221-9b9b-0a6177d10d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4dec70a9-b86c-4ac1-ab56-66df29e150ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dc89a974-8837-4e63-b7d9-ff26cd4c968b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4dec70a9-b86c-4ac1-ab56-66df29e150ed" xlink:to="loc_us-gaap_Revenues_dc89a974-8837-4e63-b7d9-ff26cd4c968b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b95895ba-be27-4828-92ae-f18fe92d4d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4dec70a9-b86c-4ac1-ab56-66df29e150ed" xlink:to="loc_us-gaap_CostsAndExpenses_b95895ba-be27-4828-92ae-f18fe92d4d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_171bf34b-b82f-43cc-a959-e9cba6fb5963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0dcd9e77-8810-44aa-9292-6597c52263d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_171bf34b-b82f-43cc-a959-e9cba6fb5963" xlink:to="loc_us-gaap_OperatingIncomeLoss_0dcd9e77-8810-44aa-9292-6597c52263d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8cc9ea95-4a02-41d4-839d-181177834b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_171bf34b-b82f-43cc-a959-e9cba6fb5963" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8cc9ea95-4a02-41d4-839d-181177834b34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a3252d-9f64-449d-b34f-74f46fb08264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_de81e683-3045-468a-931b-3284951e0e4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a3252d-9f64-449d-b34f-74f46fb08264" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_de81e683-3045-468a-931b-3284951e0e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e2e5e7a2-e759-4844-8a2c-7c8cb265629e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a3252d-9f64-449d-b34f-74f46fb08264" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e2e5e7a2-e759-4844-8a2c-7c8cb265629e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_51b09afc-38bd-4a84-a51c-1fdaa5a88367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98a3252d-9f64-449d-b34f-74f46fb08264" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_51b09afc-38bd-4a84-a51c-1fdaa5a88367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2010e96d-773c-4ec5-9738-3b77a9f2b9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625fcab2-44dc-4154-8473-144dd128e134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2010e96d-773c-4ec5-9738-3b77a9f2b9e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625fcab2-44dc-4154-8473-144dd128e134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_98c13e50-c473-4cc1-8053-29b682bea487" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2010e96d-773c-4ec5-9738-3b77a9f2b9e4" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_98c13e50-c473-4cc1-8053-29b682bea487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock_5fda8c04-5179-4e9d-93ce-02082108ab4d" xlink:href="mgnx-20210630.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2010e96d-773c-4ec5-9738-3b77a9f2b9e4" xlink:to="loc_mgnx_RetirementOfTreasuryStock_5fda8c04-5179-4e9d-93ce-02082108ab4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43f857e5-29b6-44af-b455-7106fd1d6e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e91e695-60f0-48cb-9113-81c75ea7acec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43f857e5-29b6-44af-b455-7106fd1d6e6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e91e695-60f0-48cb-9113-81c75ea7acec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05ea0c10-f612-442a-8f4b-e35c2d49f037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43f857e5-29b6-44af-b455-7106fd1d6e6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_05ea0c10-f612-442a-8f4b-e35c2d49f037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2fcff85-4c0b-4d28-ba3e-9c8c07e39d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43f857e5-29b6-44af-b455-7106fd1d6e6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2fcff85-4c0b-4d28-ba3e-9c8c07e39d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dd371f5f-de9d-4670-b62d-ab244765b33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_NetIncomeLoss_dd371f5f-de9d-4670-b62d-ab244765b33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6a1fa97a-a6e4-4ae8-b679-3d66d7cb19a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6a1fa97a-a6e4-4ae8-b679-3d66d7cb19a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_db4b8f48-b83d-4e29-b31d-e818bd997432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_db4b8f48-b83d-4e29-b31d-e818bd997432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ef45ea25-62b3-4332-9418-8a26182b2e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_ShareBasedCompensation_ef45ea25-62b3-4332-9418-8a26182b2e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe9b4be5-0167-49f5-b69b-fe3c448a2471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe9b4be5-0167-49f5-b69b-fe3c448a2471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f10cd138-742b-43e6-aa62-3ebc395f24dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f10cd138-742b-43e6-aa62-3ebc395f24dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_576cbcef-760c-4250-adf4-9d283f7566ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_576cbcef-760c-4250-adf4-9d283f7566ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_50594dea-acef-438d-a351-9df51849cc7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_50594dea-acef-438d-a351-9df51849cc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2b356a5d-44d5-4512-a5e3-a5f1f6eabb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2b356a5d-44d5-4512-a5e3-a5f1f6eabb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_695741c9-e031-47db-b060-75b10c439f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_695741c9-e031-47db-b060-75b10c439f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_4e9b9abd-3103-49e0-98c8-9dfa712e09a3" xlink:href="mgnx-20210630.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_4e9b9abd-3103-49e0-98c8-9dfa712e09a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01a1d1b1-2e67-4e4c-b99f-516a13bd8e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01a1d1b1-2e67-4e4c-b99f-516a13bd8e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b2fa262c-a3ea-41af-9ca3-625fd88fd729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15ce4381-fd27-4db6-bda6-b8875abc9972" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b2fa262c-a3ea-41af-9ca3-625fd88fd729" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_42d742dc-c999-4d50-95fd-192095e04d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6d7d172-f150-4577-bbe8-bfc11bca565d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_42d742dc-c999-4d50-95fd-192095e04d6e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6d7d172-f150-4577-bbe8-bfc11bca565d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16380cc4-f3a9-4d20-9480-d0ad7d2960de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_42d742dc-c999-4d50-95fd-192095e04d6e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16380cc4-f3a9-4d20-9480-d0ad7d2960de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_142a61ee-4fff-4aaf-99a2-ba659f993d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9d5fc1a1-72e5-452d-8e5f-6f747962880c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_142a61ee-4fff-4aaf-99a2-ba659f993d87" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9d5fc1a1-72e5-452d-8e5f-6f747962880c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_18f97cbc-4dd2-475f-83cf-9990853573b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_142a61ee-4fff-4aaf-99a2-ba659f993d87" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_18f97cbc-4dd2-475f-83cf-9990853573b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc15072-233b-4718-95f9-9b5105c8f797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_142a61ee-4fff-4aaf-99a2-ba659f993d87" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc15072-233b-4718-95f9-9b5105c8f797" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_10248370-56a7-40e3-bb3c-2f86a963ea12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a0f78035-2726-4b41-ab61-4fd75b4db27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_10248370-56a7-40e3-bb3c-2f86a963ea12" xlink:to="loc_us-gaap_InventoryWorkInProcess_a0f78035-2726-4b41-ab61-4fd75b4db27e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_07f373b9-a9dd-4f3b-ba89-dc4e6ba006ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_10248370-56a7-40e3-bb3c-2f86a963ea12" xlink:to="loc_us-gaap_InventoryRawMaterials_07f373b9-a9dd-4f3b-ba89-dc4e6ba006ed" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mgnx-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ia88de1681cbe4721b404470a670371a2_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cfc4c22c-e9d4-47aa-be50-03d3c42be8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:to="loc_us-gaap_Revenues_cfc4c22c-e9d4-47aa-be50-03d3c42be8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9a0d6403-f122-4af3-a6f8-eafa6276e1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9a0d6403-f122-4af3-a6f8-eafa6276e1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ce1654bb-4f80-4786-9bdf-3c35e08ea1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ce1654bb-4f80-4786-9bdf-3c35e08ea1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1fa1e52a-1914-4e53-86dd-d8d71cda842f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1fa1e52a-1914-4e53-86dd-d8d71cda842f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0a84b595-0c43-4a6c-afb1-a900fd64128f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_CostsAndExpenses_0a84b595-0c43-4a6c-afb1-a900fd64128f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2e84136a-c6be-4a57-812f-d345927f76f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_OperatingIncomeLoss_2e84136a-c6be-4a57-812f-d345927f76f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d2a14dd-68ea-46c2-9a9a-124d90838f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d2a14dd-68ea-46c2-9a9a-124d90838f5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_636774bc-1446-4e0c-8490-ee9527790a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_NetIncomeLoss_636774bc-1446-4e0c-8490-ee9527790a0f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3af1a99c-f76f-4b72-9139-d544aa5df219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3af1a99c-f76f-4b72-9139-d544aa5df219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_936f4025-c9e3-4e1d-b4df-bace370794b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_936f4025-c9e3-4e1d-b4df-bace370794b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffd8c977-ebe6-4fa5-879e-d340fde5340e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffd8c977-ebe6-4fa5-879e-d340fde5340e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4718bfb1-706d-4f98-be1d-e7c9cc40e990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4718bfb1-706d-4f98-be1d-e7c9cc40e990" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42ba65bc-66a2-458f-80e2-8ebeaeab44e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42ba65bc-66a2-458f-80e2-8ebeaeab44e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b03f17d-0a90-4161-9c13-fe24b8602427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b03f17d-0a90-4161-9c13-fe24b8602427" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:to="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc08bb7f-9d76-4566-ae29-145f579d3831_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:to="loc_srt_ProductsAndServicesDomain_bc08bb7f-9d76-4566-ae29-145f579d3831_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:to="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_3a9a3d57-1e58-4e9e-9b32-da73a1823415" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_3a9a3d57-1e58-4e9e-9b32-da73a1823415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_17a5fc15-46d8-4cc4-8b58-71544eac68b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_us-gaap_ProductMember_17a5fc15-46d8-4cc4-8b58-71544eac68b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_91ac0a78-e17e-42d3-ab60-e03d22d6489c" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_91ac0a78-e17e-42d3-ab60-e03d22d6489c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="idf446de9d2944c6dbeede8caa25bfe7c_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ae9897f6-1e4b-445b-a718-e6eaa54323fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_SharesIssued_ae9897f6-1e4b-445b-a718-e6eaa54323fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b2af66-4b15-4dba-9b8d-844663e2ec4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b2af66-4b15-4dba-9b8d-844663e2ec4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2053756-a3bf-48ce-b7aa-afc16ce8b04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2053756-a3bf-48ce-b7aa-afc16ce8b04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_18886136-ba4d-47ef-9dba-d8043fe8397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_ProfitLoss_18886136-ba4d-47ef-9dba-d8043fe8397f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3856465a-e912-4a23-8ccc-6dbebc740f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3856465a-e912-4a23-8ccc-6dbebc740f9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25782568-cf6e-41c5-918a-e1e2815975a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25782568-cf6e-41c5-918a-e1e2815975a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50ab8539-b3bc-40a2-802c-00b6562c74e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50ab8539-b3bc-40a2-802c-00b6562c74e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_fbae33da-dae8-43da-aa4e-09d20f9d7526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_fbae33da-dae8-43da-aa4e-09d20f9d7526" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ccd056cd-4783-41e7-b3ad-3d0f75e29ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ccd056cd-4783-41e7-b3ad-3d0f75e29ebd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5412d276-94d9-413c-8d02-a34f0d5ce9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_NetIncomeLoss_5412d276-94d9-413c-8d02-a34f0d5ce9ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5b910964-72c4-4034-98ac-88a601b27e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e009787-cdf1-4029-a0a2-4e1db0ec759a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:to="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33dd40e8-6f02-4172-b908-773b7a7a52fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:to="loc_us-gaap_EquityComponentDomain_33dd40e8-6f02-4172-b908-773b7a7a52fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:to="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2402a85a-86ff-495b-8d02-ba2833f06541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_CommonStockMember_2402a85a-86ff-495b-8d02-ba2833f06541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f02b0fd7-da59-4af7-9e2c-b4aa465d9657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f02b0fd7-da59-4af7-9e2c-b4aa465d9657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43774b14-9040-47f4-856e-786143f2e097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_RetainedEarningsMember_43774b14-9040-47f4-856e-786143f2e097" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3c72f6c4-11ce-4d2c-af59-b151e44dabe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3c72f6c4-11ce-4d2c-af59-b151e44dabe1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ib18622bd30274f2eb2cc6af17b2853e5_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91c4fe83-03bb-4691-8e9d-fbe2b6b79b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91c4fe83-03bb-4691-8e9d-fbe2b6b79b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd82fa4-b3c0-4dd7-ba79-f08e208850e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd82fa4-b3c0-4dd7-ba79-f08e208850e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8350e9a1-200e-4426-b283-1554530fe12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8350e9a1-200e-4426-b283-1554530fe12e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0700b48e-cc09-4d12-a2bf-890b58182b8d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0700b48e-cc09-4d12-a2bf-890b58182b8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3289c525-4395-4893-9b1b-a7f8347540f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3289c525-4395-4893-9b1b-a7f8347540f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_30e233d0-534f-4947-97c2-27d4d25cb7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_MoneyMarketFundsMember_30e233d0-534f-4947-97c2-27d4d25cb7af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_04468f4f-e85d-4307-8ffa-c401d0bbeb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_04468f4f-e85d-4307-8ffa-c401d0bbeb54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5cc740c0-2f57-4e14-ac24-cb2f0469db24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5cc740c0-2f57-4e14-ac24-cb2f0469db24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9c650429-088f-47f7-a608-390492dc3e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9c650429-088f-47f7-a608-390492dc3e0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b59eb36-eed8-4b38-ade8-b57eeb5cc74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b59eb36-eed8-4b38-ade8-b57eeb5cc74d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25742a5f-471a-48eb-a64b-4e31df9370fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25742a5f-471a-48eb-a64b-4e31df9370fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="ia6e8d84ebc5b43869daf33293a7c9d58_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a37b8659-08a1-4b53-831b-18e19a6ea748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a37b8659-08a1-4b53-831b-18e19a6ea748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_966053bd-e6d3-4429-84db-f3f822336232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_966053bd-e6d3-4429-84db-f3f822336232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da5719f4-d9e4-40b1-a248-aff77d705da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da5719f4-d9e4-40b1-a248-aff77d705da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb5303fa-a834-4df9-8b97-0ce83f246dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb5303fa-a834-4df9-8b97-0ce83f246dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_501584df-3809-4d40-b86e-860ed0380964_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_501584df-3809-4d40-b86e-860ed0380964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0bd86391-f43e-44ca-b9b0-143e6438a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0bd86391-f43e-44ca-b9b0-143e6438a5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6d31e164-978c-4bb1-8f3e-11446ca61449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6d31e164-978c-4bb1-8f3e-11446ca61449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ddf373ef-d9a3-459c-91a1-a14583c7e8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ddf373ef-d9a3-459c-91a1-a14583c7e8db" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i7722193379b0469aaf7126507c4716cf_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_562bda9e-fa89-4e42-9612-5dd9c875d451" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_562bda9e-fa89-4e42-9612-5dd9c875d451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_40d66748-3d30-440f-9779-696826dea04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_40d66748-3d30-440f-9779-696826dea04b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b5ec40c1-b82c-4ed8-b1bd-d0f750d6fb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b5ec40c1-b82c-4ed8-b1bd-d0f750d6fb4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1790b5ff-21ea-4a37-8e98-b5dab1c7d465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1790b5ff-21ea-4a37-8e98-b5dab1c7d465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_d3cf2208-fad0-4a44-a5c4-a08448dee978" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_d3cf2208-fad0-4a44-a5c4-a08448dee978" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3951b75a-1496-482d-8de8-f7e4d0a0f6b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3951b75a-1496-482d-8de8-f7e4d0a0f6b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_f557156b-72d1-46db-b560-374e32a7d001" xlink:href="mgnx-20210630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:to="loc_mgnx_AtTheMarketOfferingMember_f557156b-72d1-46db-b560-374e32a7d001" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i5509570f785e4a16b1084cb5aa012cc0_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a3837772-fa6c-436f-8079-08e6b4ce3e56" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a3837772-fa6c-436f-8079-08e6b4ce3e56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f0b0a61e-5eda-400b-8326-70cd7d62ea63" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f0b0a61e-5eda-400b-8326-70cd7d62ea63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ed90eb2b-12fa-4529-8362-0289c3319a2f" xlink:href="mgnx-20210630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ed90eb2b-12fa-4529-8362-0289c3319a2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7a3f0688-b98b-4a10-af41-f9049bfe8815" xlink:href="mgnx-20210630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7a3f0688-b98b-4a10-af41-f9049bfe8815" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_08b0a612-70b2-4aa7-a50e-a06cd03a7985" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_08b0a612-70b2-4aa7-a50e-a06cd03a7985" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_05511da4-241d-42eb-a6d6-09d5bab6d399" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_NumberOfPerformanceObligations_05511da4-241d-42eb-a6d6-09d5bab6d399" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_74a224d6-2140-40c0-a840-5857eaab1c87" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_74a224d6-2140-40c0-a840-5857eaab1c87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4a619f2-c31d-4ff4-8d9b-683ec6ee151e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_us-gaap_Revenues_d4a619f2-c31d-4ff4-8d9b-683ec6ee151e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fd63114e-d739-49fa-b5ef-70053cf398de" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fd63114e-d739-49fa-b5ef-70053cf398de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e7455c3-8228-4116-ae25-eb222ce0f564_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:to="loc_srt_ProductsAndServicesDomain_8e7455c3-8228-4116-ae25-eb222ce0f564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:to="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_1829f259-f536-4c19-b495-999cfc452c26" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_1829f259-f536-4c19-b495-999cfc452c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd291b56-5e0f-444a-8ec4-53e8b05f3033_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:to="loc_srt_RangeMember_dd291b56-5e0f-444a-8ec4-53e8b05f3033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:to="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6bd3ce47-5078-421a-b834-004cfbb2f8af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:to="loc_srt_MaximumMember_6bd3ce47-5078-421a-b834-004cfbb2f8af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6749cc46-d59a-4aa5-864d-ccca225bfd8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:to="loc_srt_MinimumMember_6749cc46-d59a-4aa5-864d-ccca225bfd8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b555fa0-5fee-4848-b304-5fa2607088a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b555fa0-5fee-4848-b304-5fa2607088a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_02a231f9-3022-4c4d-9579-67739db29a64" xlink:href="mgnx-20210630.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:to="loc_mgnx_IncyteCorporationMember_02a231f9-3022-4c4d-9579-67739db29a64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b92d423c-f8fc-424d-bf52-0ecb920e1914_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b92d423c-f8fc-424d-bf52-0ecb920e1914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_080cd897-8782-4777-b18b-eda7a6c9c9a3" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_080cd897-8782-4777-b18b-eda7a6c9c9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_970c06e1-f9c1-4af5-a9d0-3be7440ec4da" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_970c06e1-f9c1-4af5-a9d0-3be7440ec4da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_ac892ea6-05cd-47de-9477-9572f802a35a" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_ac892ea6-05cd-47de-9477-9572f802a35a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i27cef8a5e67c4e6db69ba5060a6911ab_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5cf007db-68a6-4aee-b95c-4f00f583fa75" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5cf007db-68a6-4aee-b95c-4f00f583fa75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_154f96c8-15c5-4f83-8b33-9753d196e930" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_154f96c8-15c5-4f83-8b33-9753d196e930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_24aa4995-b2ed-447f-9e6a-295f68421b7a" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_24aa4995-b2ed-447f-9e6a-295f68421b7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4197d3a5-26bb-4fa9-a63f-9ad8c6eb9662" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4197d3a5-26bb-4fa9-a63f-9ad8c6eb9662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ba5a8ea1-2b2b-43f4-bf5b-a5d4ba01dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_Revenues_ba5a8ea1-2b2b-43f4-bf5b-a5d4ba01dc97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_5af44356-4add-40c7-8fe2-3d46d7410b6a" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_5af44356-4add-40c7-8fe2-3d46d7410b6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_5cab7980-1eb2-493d-93e7-2cdecdf623ed" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenuesTaxWithholding_5cab7980-1eb2-493d-93e7-2cdecdf623ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_e952fb4b-e0a7-486f-b032-9e687ef5f11a" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_e952fb4b-e0a7-486f-b032-9e687ef5f11a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a6543ad-de6f-4069-85a8-008eef3f6525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a6543ad-de6f-4069-85a8-008eef3f6525" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_31f8b49a-fa62-4b54-80b9-afe426b7047b" xlink:href="mgnx-20210630.xsd#mgnx_OptInFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_OptInFee_31f8b49a-fa62-4b54-80b9-afe426b7047b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9cfdeae9-9a02-48ad-88ac-8b4c31f25993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9cfdeae9-9a02-48ad-88ac-8b4c31f25993" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3a6e7316-f7ca-4df6-8612-d1b4116571e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3a6e7316-f7ca-4df6-8612-d1b4116571e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4c4b2dc0-41e9-4ade-babe-6eb2e4e15af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4c4b2dc0-41e9-4ade-babe-6eb2e4e15af1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_3128d624-8ac9-4ad7-84cc-eec45213feec" xlink:href="mgnx-20210630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_3128d624-8ac9-4ad7-84cc-eec45213feec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_6ac9370c-5ac6-4315-a5d6-48b4e8b2d72a" xlink:href="mgnx-20210630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_6ac9370c-5ac6-4315-a5d6-48b4e8b2d72a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0de3b9e7-3b80-480f-b15d-0f7e1b736255" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0de3b9e7-3b80-480f-b15d-0f7e1b736255" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a9e03ba8-4694-4d57-a0bf-a0a87446e5c4" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a9e03ba8-4694-4d57-a0bf-a0a87446e5c4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ba4d11e0-f2f2-4633-9d95-32e73b234912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ba4d11e0-f2f2-4633-9d95-32e73b234912" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f2427843-206c-45fa-b39a-f61260bc19d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f2427843-206c-45fa-b39a-f61260bc19d8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b5dd19b4-21bb-4601-bfc3-06644ff81d32_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:to="loc_srt_ProductsAndServicesDomain_b5dd19b4-21bb-4601-bfc3-06644ff81d32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:to="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_818f4abc-865c-4db1-9d1b-811c0dd1a569" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_818f4abc-865c-4db1-9d1b-811c0dd1a569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_18c3b96b-6000-4e6b-9120-272a21b0fb56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_18c3b96b-6000-4e6b-9120-272a21b0fb56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_509a535e-fc88-420e-ae8e-86cddb648487" xlink:href="mgnx-20210630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_509a535e-fc88-420e-ae8e-86cddb648487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_2152a76d-4228-45aa-b4f9-d3bc1a099bef" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_2152a76d-4228-45aa-b4f9-d3bc1a099bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_1a01bb8e-0351-4881-b097-a59f7f207ebc" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_1a01bb8e-0351-4881-b097-a59f7f207ebc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_b3e7be2c-1417-4cab-8039-81f1a6fc23cf" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_b3e7be2c-1417-4cab-8039-81f1a6fc23cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_9758f6f8-202e-4666-80e1-8243b70b7c37" xlink:href="mgnx-20210630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_9758f6f8-202e-4666-80e1-8243b70b7c37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9277e744-c85d-4257-a8c5-e476334f82ab_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9277e744-c85d-4257-a8c5-e476334f82ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_dc0f36ad-3a13-4c0e-bc7f-c8494775dd90" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:to="loc_mgnx_ZaiLabMember_dc0f36ad-3a13-4c0e-bc7f-c8494775dd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b561ddc3-4800-412d-bff9-5086fe68368b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:to="loc_srt_RangeMember_b561ddc3-4800-412d-bff9-5086fe68368b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:to="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dee41ba4-503a-4cec-89a5-1e1f73c96eaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:to="loc_srt_MaximumMember_dee41ba4-503a-4cec-89a5-1e1f73c96eaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_994495eb-7eb7-448e-ab29-b46b909baaa3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:to="loc_us-gaap_EquityComponentDomain_994495eb-7eb7-448e-ab29-b46b909baaa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:to="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ac70197d-509e-488d-afbf-c21a855731aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ac70197d-509e-488d-afbf-c21a855731aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended" id="if790343137e941d2a186a58b325d95e9_CollaborationandOtherAgreementsJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c43c5b87-31a0-4b6f-8607-a0453fe687aa" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c43c5b87-31a0-4b6f-8607-a0453fe687aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_15146f00-8d25-45b7-b241-6654b65c0e85" xlink:href="mgnx-20210630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_15146f00-8d25-45b7-b241-6654b65c0e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_911b5c25-514b-4a59-bb9e-de581658cecb" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_911b5c25-514b-4a59-bb9e-de581658cecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ebf2682b-335d-4438-b75a-8d8bcbc0385e" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ebf2682b-335d-4438-b75a-8d8bcbc0385e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_131b6813-f33a-45a5-8013-2d41c6f1069c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_us-gaap_Revenues_131b6813-f33a-45a5-8013-2d41c6f1069c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_731b7589-a0f8-4d76-b753-de1cd05af4df" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_731b7589-a0f8-4d76-b753-de1cd05af4df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02193bbf-c4c6-4bf4-a582-bb12ca1fca02_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02193bbf-c4c6-4bf4-a582-bb12ca1fca02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_6d3e762f-4bad-40d5-934e-f49adb187912" xlink:href="mgnx-20210630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:to="loc_mgnx_JanssenBiotechIncMember_6d3e762f-4bad-40d5-934e-f49adb187912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a3f2efff-00b4-4ff4-b721-be7ca9f2940c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a3f2efff-00b4-4ff4-b721-be7ca9f2940c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_b092eb9a-816a-4191-8a86-ad1482fb168c" xlink:href="mgnx-20210630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_b092eb9a-816a-4191-8a86-ad1482fb168c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be9ea227-7b9a-4ef3-95bf-b2054dd308a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:to="loc_srt_ProductsAndServicesDomain_be9ea227-7b9a-4ef3-95bf-b2054dd308a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:to="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b8217b47-93a7-4e2f-a52f-45272224d5a5" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b8217b47-93a7-4e2f-a52f-45272224d5a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_e0cdcf61-c648-4aba-85de-4ec1d10d580d" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_e0cdcf61-c648-4aba-85de-4ec1d10d580d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i979c9e99624544f4a6349aa71c8169c0_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ebf029b0-3b70-4cf7-aee9-e327b8b03e4d" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ebf029b0-3b70-4cf7-aee9-e327b8b03e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cd72f838-173b-4b83-889c-7c94f85313c7" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cd72f838-173b-4b83-889c-7c94f85313c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_bccd6917-78bd-4b59-ab29-2051c9f09c63" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_bccd6917-78bd-4b59-ab29-2051c9f09c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_f905ca80-97d6-4a94-9cf9-20397ccfb1c8" xlink:href="mgnx-20210630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_f905ca80-97d6-4a94-9cf9-20397ccfb1c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b8de4b3-1771-4848-88b7-55a464fa713c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_Revenues_9b8de4b3-1771-4848-88b7-55a464fa713c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7336b08e-1e5e-4d04-889a-e5ad61579aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7336b08e-1e5e-4d04-889a-e5ad61579aaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0fb660c7-df17-429d-b677-0d62ac9e2cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0fb660c7-df17-429d-b677-0d62ac9e2cb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0e4a57bd-112b-4b2e-8d3f-9094139fb65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0e4a57bd-112b-4b2e-8d3f-9094139fb65e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9da15f2-06ac-4b40-86ef-d43266e4653a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9da15f2-06ac-4b40-86ef-d43266e4653a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_8af26637-03f2-4715-a86a-def3136cf195" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:to="loc_mgnx_IMabBiopharmaMember_8af26637-03f2-4715-a86a-def3136cf195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_f28f005c-d49e-4390-9fbd-626b8b980322" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_f28f005c-d49e-4390-9fbd-626b8b980322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:to="loc_srt_RangeMember_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:to="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b3dd03c-2083-4a23-ac8e-45efbc4a20c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:to="loc_srt_MaximumMember_7b3dd03c-2083-4a23-ac8e-45efbc4a20c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="i015b6fb78d514a69ab5eec7854fef30d_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_e5e1efee-f31b-4676-abf6-c464afb7c761" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_e5e1efee-f31b-4676-abf6-c464afb7c761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_67e3649e-5743-4ec7-a688-a3740a4f6586" xlink:href="mgnx-20210630.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_FundedValueOfBasePeriod_67e3649e-5743-4ec7-a688-a3740a4f6586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_f63eb9b9-87db-4a2c-97eb-2183a8f3b221" xlink:href="mgnx-20210630.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_f63eb9b9-87db-4a2c-97eb-2183a8f3b221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_2fe59faa-d621-4114-90ae-373639f35d68" xlink:href="mgnx-20210630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_2fe59faa-d621-4114-90ae-373639f35d68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_e09cf2e3-3d0b-48d6-bea4-c71067e0b28f" xlink:href="mgnx-20210630.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_e09cf2e3-3d0b-48d6-bea4-c71067e0b28f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0feb12d0-08c7-42fc-b6c9-369efe961798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_us-gaap_Revenues_0feb12d0-08c7-42fc-b6c9-369efe961798" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90baae65-2100-4275-b640-873d49965228_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:to="loc_srt_ProductsAndServicesDomain_90baae65-2100-4275-b640-873d49965228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:to="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_84393c78-486d-44b4-a32b-fd14d3952756" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:to="loc_mgnx_RevenuesFromGrantsMember_84393c78-486d-44b4-a32b-fd14d3952756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3702e441-7691-4fea-bb6c-6f4a9c6d46c8" xlink:href="mgnx-20210630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3702e441-7691-4fea-bb6c-6f4a9c6d46c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2d77b1a-3679-4834-96b7-1c68c5accf9c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:to="loc_srt_RangeMember_b2d77b1a-3679-4834-96b7-1c68c5accf9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:to="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8102c271-cd35-4e88-8796-0e5316c0070d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:to="loc_srt_MaximumMember_8102c271-cd35-4e88-8796-0e5316c0070d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="iff7c70fdca7a4802ba6e0c97057bf28f_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9bfe5a7a-5b58-4f20-95f3-260a6c94e9a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9bfe5a7a-5b58-4f20-95f3-260a6c94e9a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_53eddb75-0006-4192-95bd-d3cf01afd9f2" xlink:href="mgnx-20210630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_53eddb75-0006-4192-95bd-d3cf01afd9f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5f0fef0a-632d-485a-b807-08cf9b2fc656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5f0fef0a-632d-485a-b807-08cf9b2fc656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cad628c6-ac75-4c24-891a-9b7ef5293eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cad628c6-ac75-4c24-891a-9b7ef5293eed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_3ac9497f-d567-4be1-8000-6a0eda5bf481" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_3ac9497f-d567-4be1-8000-6a0eda5bf481" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6889b9fa-0378-4d73-8aff-68e88933b410" xlink:href="mgnx-20210630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6889b9fa-0378-4d73-8aff-68e88933b410" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acbfe63b-1a02-4294-af51-14976f287ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acbfe63b-1a02-4294-af51-14976f287ce4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d51b7bce-60ff-4ed0-ba36-7eb99ddc39fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d51b7bce-60ff-4ed0-ba36-7eb99ddc39fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:to="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_73bd4d97-c40b-4452-8efb-9fbedafe0be1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:to="loc_us-gaap_PlanNameDomain_73bd4d97-c40b-4452-8efb-9fbedafe0be1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:to="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_533052d9-f9f7-45e1-86bb-5a32cda19af3" xlink:href="mgnx-20210630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_533052d9-f9f7-45e1-86bb-5a32cda19af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_f8fdcf36-e421-4abc-92f9-c73c6fd8c7ca" xlink:href="mgnx-20210630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_f8fdcf36-e421-4abc-92f9-c73c6fd8c7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_61002a07-4e08-473d-a03a-861ba9171d3d" xlink:href="mgnx-20210630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_StockIncentivePlan2013Member_61002a07-4e08-473d-a03a-861ba9171d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe3ee574-1968-4af8-9893-29142018e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe3ee574-1968-4af8-9893-29142018e87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_182a1e81-56cb-4b9c-b148-65e28501d9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_182a1e81-56cb-4b9c-b148-65e28501d9c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_495039eb-5da2-4dd4-ad69-26e4a3084432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_495039eb-5da2-4dd4-ad69-26e4a3084432" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="iaf0137a829144fc9a9cd56008f89669f_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75ad6e5a-5848-4017-9eb7-2dd640f9bcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75ad6e5a-5848-4017-9eb7-2dd640f9bcfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45ace583-b71a-4fd8-9f92-37d58e3d555b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45ace583-b71a-4fd8-9f92-37d58e3d555b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6505fda5-bed3-4377-88a3-0ae4a88299fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6505fda5-bed3-4377-88a3-0ae4a88299fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95d78e90-bcd9-4c36-b4e4-5d67deef7de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95d78e90-bcd9-4c36-b4e4-5d67deef7de0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:to="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cce88f00-e299-4684-8f95-0df7fd7806f0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:to="loc_srt_RangeMember_cce88f00-e299-4684-8f95-0df7fd7806f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:to="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6adf50c9-cca5-44ea-826b-1c50a838e919" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:to="loc_srt_MinimumMember_6adf50c9-cca5-44ea-826b-1c50a838e919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1181661-3591-4f72-964e-0475f08d01b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:to="loc_srt_MaximumMember_d1181661-3591-4f72-964e-0475f08d01b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="ibbb2b79d6f1c4fe1862c460e4dd20eee_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb6398fa-ff00-4752-ba55-915c4be4c86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb6398fa-ff00-4752-ba55-915c4be4c86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_26ec94a3-b60a-4921-9a69-d857280e21c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_26ec94a3-b60a-4921-9a69-d857280e21c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7a357af1-c281-4fd5-9088-1c7962c42ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7a357af1-c281-4fd5-9088-1c7962c42ccf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a688071c-dd08-4164-8023-2c05531ccf19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a688071c-dd08-4164-8023-2c05531ccf19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b2fb23d-60f4-4a1d-89f5-facbf28b2e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_28654b80-36e2-4b38-affa-10fc5debef65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_28654b80-36e2-4b38-affa-10fc5debef65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ef3f83d-fed5-4acb-8999-30fba7ceed29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ef3f83d-fed5-4acb-8999-30fba7ceed29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e00f37fc-1f3c-4bf4-bb2b-f690dae425f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e00f37fc-1f3c-4bf4-bb2b-f690dae425f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_292f74a5-cfcc-44c7-bd65-056fe79e7a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_292f74a5-cfcc-44c7-bd65-056fe79e7a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4bfcb7e-3830-4c0b-97bd-24b117b1d0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e19e1cd8-ba4d-4d61-a62e-06f495167774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_95f7c07c-e5b2-4ab7-8f16-ccfa4b833069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_95f7c07c-e5b2-4ab7-8f16-ccfa4b833069" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43377e6e-87ae-4c40-ae2f-42d51ef28425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43377e6e-87ae-4c40-ae2f-42d51ef28425" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:to="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f311251-0a3f-4c36-994c-46fd10d89df2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f311251-0a3f-4c36-994c-46fd10d89df2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_554b22a5-5326-4a47-bf80-d68753c4c5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_554b22a5-5326-4a47-bf80-d68753c4c5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:to="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_255acb9f-366f-4388-af6c-800b76b9b059_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:to="loc_us-gaap_PlanNameDomain_255acb9f-366f-4388-af6c-800b76b9b059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:to="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_d0d4a754-c0ee-4808-824b-d057bb4974e9" xlink:href="mgnx-20210630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:to="loc_mgnx_StockIncentivePlan2013Member_d0d4a754-c0ee-4808-824b-d057bb4974e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mgnx-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d318c617-a4cf-4218-b38a-4efe0e9b36c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a4d2b92c-4ecb-4c4b-8c28-6f01f9e6ef7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ea6c7da9-16fa-4a20-a8b0-8cefda23a477_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c39e3ad2-8a66-4e26-8290-3ccd023e9e45_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e074e81b-9770-40ab-915a-cf0f0cd226b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fee6e04b-797f-48de-97b4-452a645db1e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_72a7cdba-86fb-42e5-9983-97437e1516d4_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d9e57dc1-8d45-46dc-8d60-7dc61919ebe6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a0ab1303-ad53-4d30-9a95-c2ad0814c327_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0372a928-3b8a-44c3-bd20-a510f8592848_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_44738550-84db-4eca-9fc9-4950c8366152_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_af00e779-a6da-4c8d-b541-26461e5de061_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdbb18f6-1e7e-4776-90b5-55f05420ee64_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61736dc7-61b5-463e-884a-c65bed8c24bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3cdeb6f6-4e25-4b57-9157-717062b09586_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2d4513f3-429d-4dcb-863e-e78c729d208d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b4d0fd4b-5e3a-465c-a557-29c930913d94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_41c3e5da-d811-4537-af69-9ee7712aa6dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_77d4cb7b-c284-47a6-99f6-09809b670df8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_70604772-ff35-4fe5-896c-c451386d6cbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_af47a2c8-59ae-40f4-a576-888f86df0846_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_5d4b01c3-c9d7-4589-a7ff-0791b4c863ba_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20210630.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_a6d6901a-329c-43f5-a810-9e49e4071b77_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cd2e147f-0486-4993-9010-7cfcb805f733_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79ef7b5e-f59d-459e-abd9-aa6d9f10c7ed_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2098b4-b9b1-46d6-9988-8eab8a8bd00d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c091d9f0-7555-483f-b659-5dae5b579331_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a7a0de27-b361-433c-b373-d7d6e4bb87ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c49c57ca-e680-4b16-87e2-bd8e854de203_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20210630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_24c8dc5a-a23b-4685-b9fb-67fd6706130d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_79eb5053-662c-4435-a483-9442e99d3647_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9e7b7c3a-4383-4281-a32f-fcd918505e38_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3fd79df8-af69-41ef-ad3d-c529e8987a90_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_320125ef-d1d6-4dc0-8cb5-dcb0bc196544_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_db73c7dd-3b0c-4fed-aeae-4c9ea5e4e775_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2ebcdb61-8dce-475d-a3a2-c89b051bffea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_ef391063-0a1c-4da9-8b4a-abb85838b7d9_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3278e1e9-bab4-4e8a-b1db-b3267c215ea8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_47d596a4-9271-4a04-b595-ee55f47100b0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_5857e356-079e-4381-b89b-f375c37e3ee8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2bcb7270-dae2-4616-b547-bd8923111c90_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_25982df0-61e8-4264-8d8a-d4cfc1c9df50_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22f0016b-7a5a-4b1d-bb07-90fc6ff0d3a0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_167602c8-245e-46a0-bba5-63181cbc92a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b63090e-7db8-415f-b6c4-b929b873d110_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_8cc50e9a-4351-4094-97e1-50d1adf4724b_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesTaxWithholding" xlink:to="lab_mgnx_RevenuesTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_29a29a26-18ed-4452-97c7-afabcf2a23c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d127621-b44f-43eb-8e76-48621a1ce44a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_2382e35b-1d74-48c6-a760-6c2027c6c011_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012SupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012SupplyAgreementMember" xlink:to="lab_mgnx_IncyteMGA012SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_019dcd03-1a7d-45a7-aed3-1491359f38b8_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_00d8ea78-4fa4-4cc9-8491-dad9b884eac6_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39256c74-c78c-4af0-a0a9-dd8c0dd62d99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_55ef8577-92da-4613-913a-c3c1c0337d17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f4096698-3b2f-4655-a546-a63046c4f8b1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_781816bb-03f1-43b1-aa1d-c51a82d23d59_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_654abd18-da20-41c0-b75f-e6b6cfca7d1f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c5aaa118-7574-447d-9df3-4be1a1f79575_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cbd516b0-f962-4fdf-8515-f59fb032ece4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_60687b89-30d4-4aa0-a29c-be5c93234489_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_86434a34-34a5-40a2-b36b-bbc86ede5349_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="mgnx-20210630.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a83b9ded-1a44-48e2-848f-7e5bf6af885d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a41490e-190e-4375-89ae-6e4f51c8e069_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa97f26a-bd54-4347-aaec-489cc89a69cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a231d79-9b7e-4eda-839a-d9998c0557db_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d0ce9063-9840-4852-8aba-4fe8be4018ed_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_82726a9e-4619-4734-86cb-511a48e78ea4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_238da6e8-a89c-4d27-bef6-e58e44f31a24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cc4e2ef0-dbf6-4a3f-a3a3-8904e593e2a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6363ff3b-9e0c-4a40-92f0-8b519be10499_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_81733894-58b1-4cb2-8224-cf99cf5510c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_2ec39085-4103-4794-985e-fd01894032ab_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7922c16e-2913-4583-8c08-69b7ee58ccba_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a66d62e1-3088-4ac4-87af-c92de10d59d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_789af07c-6246-4360-b892-2927d5f8ad42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f49a544f-8107-4df3-9ef6-69dcd896e6fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2cf1140a-6ed1-45d5-bba9-d4b1f22e9e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65546a94-e0a5-4e92-9eb4-5421d3cd0ed4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8930313a-acdc-4693-a2fe-654bc6a2525e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fb06a02-f14a-40a5-b8b4-a91084ebf96a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ee24e92e-530f-4c0b-8e7b-e38f1e5cc3f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6a90e094-49d5-4585-b8c7-ad69e5b42e25_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_6658af02-cbec-4633-859a-6092b58b32a0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a58d726b-4ca7-49bc-b309-d5f85b11d224_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6c872a59-2dd7-4cb0-b471-0d028efcdf89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_228ddb4a-a666-45e9-b097-8268d94a42d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2963361b-089b-47cd-bbee-161fd0e80c94_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_15b4c3ec-87c6-4d8b-80cf-256114ff7f20_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_92b479f2-872a-4f3e-bef8-7dbae3eb0baa_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_977136ac-0186-42be-995a-eccf9ade3ffd_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20210630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a5544270-7572-42e6-81b7-2f0252eb2bc3_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7240f5c1-6e0c-4ff3-816a-a3392adfd59f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_29457b29-e881-4644-bd09-17402355d55f_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_4a5517d0-2b1a-4993-867f-70b8bd951d3b_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b960ae6f-b7d6-4e20-9562-1be704655f10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f2b11294-927d-40d0-9325-f89385a989b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ddda2d47-2129-4be2-836c-44d432cbbcdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4c6d5400-0e41-424b-b6c4-7025af380f11_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_24e4d9c6-4cf6-4a81-bc1f-1bcbcc8448c4_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_76de0554-9147-4a78-bb95-b61f2861b74d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d1814f6c-7c73-4a6d-a59b-5d542d3c4476_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_33e52595-346b-4777-b723-393b7051f98e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a7cdeac-e5f6-4aa2-880b-4d1c955296ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4e0525a3-8295-4a1f-af12-9cd363548fba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b381c7d-eb3d-453c-bcd8-a53f6c28be5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_98b38b06-dd4a-4718-bae6-4a6ea44e1ece_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e3b607e8-c7a6-4765-a44f-26fb802d3958_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_08bdd416-8f3c-4f36-8f93-ffd6f0515242_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c15eb01d-58aa-41e6-89fa-715bee2f435f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dec968be-bd55-440c-85fc-209947cf92b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5104096b-2408-4623-870c-69bab8db6877_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b8367419-8389-4d61-acf8-dccd84518e41_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_92b7be0c-7809-4066-b8f5-16ccb6e3e295_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_db138526-9d78-4267-bfbf-8944c2b7923d_negatedTerseLabel_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_label_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_documentation_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock" xlink:href="mgnx-20210630.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RetirementOfTreasuryStock" xlink:to="lab_mgnx_RetirementOfTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1c1663ce-529c-4821-a508-7bfd1779992e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cdda3c4b-028b-4a3e-a7d0-560e41b66ee3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 60,133,447 and 56,244,771 shares outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_2f1a1557-660f-4e35-95de-d74c83df73ab_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20210630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_638a8021-27a3-46f8-a5fc-313b4077e7c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cf27edf0-3a9f-455a-ae92-1d85ca6f5a88_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a12388c7-39b2-440c-b08f-8118e5b88fb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c2abac85-0b3e-46d9-b92e-feeb3048b8d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_d8132d44-5382-4d78-934d-e47dfa7d455a_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PremiumReceivedOnStockPurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20210630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_3038c88a-82cf-4503-aa99-c00ebd7e5de5_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35080a47-86f8-46fc-b951-6da056bdbf8f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d99c2a4c-6a4d-45b3-bc63-84441361c6df_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8b9dad42-b262-4cf5-8c15-3704f153dd0a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7571b924-7c92-4194-b1b1-07d7955dec97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77984cc0-0235-434d-bd2b-74d8c620322b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_7489422d-2f17-4656-92b4-ed1ef7b81d74_terseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period amount</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FundedValueOfBasePeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20210630.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cce4346e-6d1f-4ead-97d1-21e8e0ef43f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_49229e2d-980a-4e99-acb2-51aeacdfa801_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3a408392-2f80-43fa-b94a-daa040f64d13_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_31d270de-24e8-41bc-94d6-86a399fb7247_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_78ac83e4-469b-4c4f-9dc0-83c30a4a92d2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f29ee29e-c41b-40b4-b9ab-745dfa02e5ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_507ec9a3-5baa-4aad-813e-6d145b42d381_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_08702904-ee2a-47a4-9e4d-a55a9bb7f0c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_079d5cc6-e64b-4fb5-9228-88661d6b234e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_cae8b4a8-0cea-4f21-96ae-10b70cc1645f_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20210630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_79463d61-f9e5-4a42-8a20-4c9fa7457e58_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_5b778d10-b045-46ae-829d-25e0e6c4d5df_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative and other agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_a0b5c877-aea8-44db-9e94-7cb50f2d9429_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_54b6ed0c-0a6b-4885-8c6f-7d9532e73555_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e1cc4e2e-0495-4879-a5da-0a8462719ea1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_88a4e28e-a917-44cc-bc5b-6d5f02f5edd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_eec6902b-6ba2-4112-a040-261239cf15d2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c7cf6d72-5cc2-4fd4-b2f9-c3a58ad442e7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b373255b-c38a-476c-841c-46f9ac3f578d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d9d8fd54-5987-46ff-8ace-3c64d6984e01_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7e03adc9-08e2-457b-9768-f0be17d9c356_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_7450ef86-7e8a-4ba9-aacb-ffe7dab3ac6b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_92536d96-2910-45b0-b2f3-aea123970faa_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software included in accounts payable or accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a3882bfd-ae04-406e-a989-098fcbf0fd35_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_78fde673-57b5-4373-b925-84d4a9ae99df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_56a44c64-6358-4692-8d51-72dab925b7f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1f1790f5-ce24-4312-8d60-45cdd56f63c1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_3d724b37-5ec4-4ffd-9c8f-8fe53e36df61_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_95513e65-d71a-427a-83ef-97c022e63947_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_58bfe47a-c4a7-4f31-85a5-20a81f2bc759_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f0aec9b-d1ec-4d16-bf92-2e022e4c0f9c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9a0e488c-ef64-4028-9bd7-f8f3d813809e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_35c53f61-5b84-47a4-a05e-3529efa5cf2e_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20210630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0d6e66c8-e817-4451-b2ce-e759fa773bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9baea993-9ddd-4738-ab1d-8c3d4c2cff3f_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20210630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_08d3e9c8-7b6a-42de-a307-2cad21a8c454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e28059a8-752e-4ff2-8fcb-064db6006d46_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2825c5a2-2390-4242-95c9-3cf634a782b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b5bb55ac-4f19-42ac-9604-abee4497ea72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e75d6ee7-cd07-49c7-af36-d9658b65b16c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_fe08e563-4187-4076-b62a-94cd15a5fae7_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c00d96ee-a1fd-45b6-b2ab-b01681418a53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_39e70c50-c143-466b-bc67-fc567ed140fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9574ab10-58fb-4403-bf63-ecfe6f36b0b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d7ee1148-e658-4e06-a4d4-e89106412da8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_ff574ec3-b349-4edc-8d93-031b43d36d2e_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_7ce6d772-dd64-4208-a1cf-944da69da016_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20210630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cb5102dc-fb70-40d2-a381-eb3d7b52cfa2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4e78f44-e8ee-483d-b315-37c377274d53_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2f00d653-48a9-4af8-bde4-3f373150e0c9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_278ea233-6bbf-4f63-b10f-c634530738e8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f95f83-b1d9-4216-9864-f4ee54e4fe5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6f07b122-63e6-4d70-92e7-176dd5ca11f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0d7e1964-537e-4097-a822-81c46d4d4de0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_881ea622-76ad-4d8e-a463-4de2488236f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_dfaa9fc6-872e-4e26-9485-68d517482d63_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_18910aa2-fbd5-4dcd-9489-b596f6e679a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_db7cac27-4d28-4bd5-9a55-e91a137fd609_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5cbccad-e58b-4c0d-9e3a-9b8bf7ac125e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_03d32815-f1bc-47b8-bb98-caff72cd592a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_254cc98e-b9c2-4e09-b5a4-a46cbb6767ee_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3958a255-c220-410b-a2e1-6ac519f6e554_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5e61a26d-c8ba-45c2-9cd1-1f2d92381c34_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f046f351-5ebb-44bc-9bb7-f37bd7e05758_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb9d2687-465e-4701-8940-1fec167fbe92_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_86890d46-8057-4fdb-ace6-83fe0134bbae_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20210630.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_850281cf-59d0-4a26-9e2f-c1affe265a3f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_7c968895-b3d0-488d-b97f-24e2c7eb06b9_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, net of tax withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:to="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb3e7a6-45a0-4948-9b61-a18f368678b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_a3d335fe-dd56-445a-adcf-a6af2470f1f1_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_687d2459-82c4-484b-801c-92f114f2aa8d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9df40a34-8335-4ffd-af45-ae78ca8c8f94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_64ba43f9-d079-451e-9fa9-6006cd72680e_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20210630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6a5b8f25-20c5-47ae-b179-0d12a2e6957d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7dc931d0-bb85-4984-878e-1e934f1693aa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_dfd10a2c-2900-4098-a404-b37bf6abfc3f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_2b7bfc8c-a0e6-4f97-9af3-718ef3c1c4df_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction discount</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20210630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c6648661-5f2d-45b0-a760-c8569f37e5df_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_716d1bb6-8aa2-41dd-afb9-e434015bfd8b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_5462436e-0c8a-460a-a397-0639bcaef7cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_ea2b4cf0-a339-42b9-9f9b-47856d50e068_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_426ed520-a70a-4989-8dc1-8d229e01557e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bf6d8011-8f1b-40a7-b61a-8378309a58b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f6cab01e-f5d3-4b13-86ac-b63f1fd364dd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1d7243f8-6c4f-436d-a134-9e67cce71139_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4f93aedd-001d-4139-9296-c79a12780153_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_306a1f8e-4c8b-4daf-8d6b-fb8f440d821f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3e6c559c-dfe4-43f3-8adc-8f521064f5be_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f984033f-40a7-4dac-bec0-fc14736a1dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_49e6d2e9-46ab-467a-bf02-efc2f4afe763_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b7933d90-5266-4c49-9b77-9c38612f15e0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1970a306-66a4-4dd1-99a9-21fe711d4d48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9d00bc18-9c20-417a-82e1-4fe67dd8311f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01bbedaa-f318-4b42-991e-9f09254c007c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8c5f3600-9463-4764-ad6d-e03cab133101_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_d57d788c-19b2-4271-9596-5a3de7fca4fb_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_432869bd-f1cd-4ad3-be45-ed1c9b8d15a4_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_440c8ec5-fdef-455b-a252-536cddf1945f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_c67d8591-d863-4698-b147-08ee7c77bb93_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_68d0bc9b-ed2b-4599-86f5-88fcd3251dde_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e25358a3-a888-4845-b560-c1d452674e80_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_37aaeecc-987e-44fa-9761-578e6e522f5d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_60207b7f-0f84-4547-836b-34e8d780f2d7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f6066cfe-9c39-47cf-ae0c-e9fab32f0d6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c95ba43b-b6c7-43ff-9907-23ce60abc6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_fd35ed95-675f-4204-81e8-56abb0c9a361_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_69deb34a-e4dd-49dd-b67b-121cffb973b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_a87ca694-4329-41ef-833f-8e93ae55a99a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c50b041d-9973-4d44-8a5b-64fc273a6914_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e3f2b6c-a9eb-4097-ac16-05fa5a900246_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c712fa46-9a0e-4880-bb0c-442efd7606bf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e772d0a2-77fd-4329-acf7-ca327fc80680_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dc956d61-9b59-40d9-8575-800f6e09d99b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fe9e661e-f9c8-4d96-8e42-8c6cfba00338_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15f983ce-fb80-474d-ad83-0e08900fcd45_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c4f0f079-1f70-4a23-ad30-21f9b2ff33b7_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_38f1ac84-bd08-441f-ac36-cbcec71f20b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0edd9d13-8b15-4ebb-a504-91ea0d58246b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_35d7dd70-0425-453f-8a16-74fc1297294f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3f10cc8-35c8-4138-95fc-0ddce6027bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_354dacb6-1411-4885-919d-7b407123665c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90ea8ef1-d27d-4c06-9227-6410852e54e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b111ab70-5a70-4d79-91e2-b0967d9c2271_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_41f25246-f405-49a4-94af-f600c4846639_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_79b22ead-585e-4b25-bbfe-450d9269bc60_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1e915594-d21f-4b0a-b7c6-842c9646b640_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_84bea62c-a8d2-4515-aa8d-f242ea187d53_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_5791d2cf-9d3e-43b8-80f5-6e3da84cfad6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_8aa587ca-a1d5-4a9a-9846-c9397a62ec3d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Reserves for Variable Consideration, Customer Discounts and Services Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_261425c1-4d40-47fe-b2da-6559f63dffa0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e825ffb0-8174-42f7-8b03-3e0ef4fc14ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a0142547-ef6b-4627-97ba-9ea01a563325_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_842eb335-59e3-44c7-bc75-42e6fd1e120f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_42ecf225-a7d4-4f95-b81d-124a72077fe9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_bd1c1cf0-5d6d-4bab-bb70-2dcdf5b32694_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance of the Research and Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_132d9cb8-88ef-49b2-909c-bb7b98f444a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f89b2ca8-ed8b-467f-bbcb-e4782936ba00_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_36cc4c69-9ef9-4f69-86f3-d7be638f4abd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6f540661-1244-4b14-947d-5c87ab9bfb89_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_ee4ce96d-2ccb-4f31-bc91-fee053a5a77e_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be2ca3d1-5c96-41d0-a4f3-d693697622f2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2d08c9bb-b3e2-461c-ac5d-7305a3bc9da2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bbd8334e-d0e0-47d1-9b72-73bc14c50246_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a72d1981-89d1-4108-9b57-40ee441830c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bb4bf069-4ca8-4225-aa33-e5b91faec11a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_02185bce-06e6-4e4a-9fea-0ee86f8b0f26_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9373a948-76a8-434b-95ca-2ec6587cffb7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_18cebd31-2705-490b-9e11-bc03ebe09490_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_09809b4d-757c-4699-a9dc-b4c71227a38c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_07d331da-717b-426c-8c15-d8b599587f18_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c8f2004a-7677-41f6-8320-52d36fa9536a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_71edff4e-31a9-4836-abe9-e2cc0330e88b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_ea19674c-7f82-4009-9d27-5aeda1caac5f_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_06e2367e-9671-4fc7-9e20-5f1b9a3dc75c_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_77196407-892e-4e45-aa7d-d13bc999c050_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9b393c6-264b-4bb8-8e45-221110abd948_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_218bc9eb-9982-468d-938e-fbd1c6349cda_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_7b2af6e0-dc62-4e0b-a9a0-87a35f139665_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20210630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f42c38bf-9f76-4489-934d-f8a61a449fb8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f40438d1-83fc-471a-aefd-05ea977a88f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_28f2231e-5022-4821-affc-976e81174516_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_b34917e2-ba7f-4211-9028-c2678abbb0d2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptInFee_1927378f-999a-45d0-acd2-19331a800f78_terseLabel_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in fee</link:label>
    <link:label id="lab_mgnx_OptInFee_label_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:label id="lab_mgnx_OptInFee_documentation_en-US" xlink:label="lab_mgnx_OptInFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee" xlink:href="mgnx-20210630.xsd#mgnx_OptInFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptInFee" xlink:to="lab_mgnx_OptInFee" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7029cd78-5863-42cd-8bc4-82bfc4436cac_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d2d78335-b432-41cc-b75b-f7ef81493a6d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8941e124-ed66-4c93-bdc8-ad5b429e172b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_e9726e56-dbed-43a5-9aa6-00cb84683060_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_e3a654ac-fa58-43aa-8eef-fec582a45497_verboseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_11684bd0-5154-478f-b41c-0abeb83b63a2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9a3cf066-502a-4bb9-8387-911a6c708fad_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b8a913e2-2f19-444d-9319-f37449f657d8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_363d5361-b051-4a81-b4dc-2e78f303fed9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac405cdd-d6f5-4426-9776-b42e895bd585_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_26cfe274-d34d-4b4b-8f47-0c97f0337a8a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_aa79920f-189c-44f5-930f-8324c92814e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5ad7d5e0-e6d3-4cd7-b62d-26fbbf46dd60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_95049c2e-b6dc-445f-8d49-1f412dbd6f0a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0be4a28b-e5f5-4eb3-87ce-6f4a538897e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_90853f71-f29b-4029-9d8d-29bae30600c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d06f580c-6720-42cb-a808-94a91fef2fb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_5cb4225c-1146-42c5-ba56-6dd0fc4ec347_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20210630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_5a95b5ee-d4d8-4cb2-ab9d-de820cdfdf9f_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20210630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_ed2ec417-279b-498a-bbd6-390737f8e8ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fc25138c-c92a-4f2f-ad62-39c1e8d0bb87_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a4aa240a-a9d3-42ed-8c88-186e8f1b066e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a0ad733f-d88b-4e26-bfd8-ecf35a702fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_ba381376-2f6f-49aa-a368-ac474bf19d20_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available for issuance, increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_dc3c6de1-2be3-4612-827b-beba21a81bdb_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_50c4dc22-22c6-4371-bcc2-f20e2735e2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ba58a935-a394-4b2c-b0e7-ce45d0afbb7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_1963ac8f-dfce-4f6e-a205-913c8ace73af_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20210630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b99f6dc4-7947-4628-b8f8-169df835ef47_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_bf462eff-d71d-474d-ab9a-366ba9e759b6_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6e2b2a29-7248-4119-a68a-6eb0c13b835d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7820f6e2-ab43-460c-876d-6fe256c3120b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a8693cd0-45b6-4a91-b2d3-45145cbc4765_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6aa215a7-5cb4-413b-8567-4e54d3d83659_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mgnx-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:25dea74e-b208-4a37-85a5-525bfa10ac16,g:344be16d-ba3d-41b6-9609-593178175f39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bd9c927b-a3ae-41ce-9dd5-64c1d043597d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentType_bd9c927b-a3ae-41ce-9dd5-64c1d043597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0de55277-9de0-4d83-9db5-8f44ce30a441" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentQuarterlyReport_0de55277-9de0-4d83-9db5-8f44ce30a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b8f8f56-284f-407e-a298-25681a2d558e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentPeriodEndDate_2b8f8f56-284f-407e-a298-25681a2d558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_36417802-3088-4de6-a42e-5d9d8b9fc7f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentTransitionReport_36417802-3088-4de6-a42e-5d9d8b9fc7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a600314f-4056-44cb-b177-cfdd70d04cba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityFileNumber_a600314f-4056-44cb-b177-cfdd70d04cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f9db4240-4d9d-4b53-bdbe-dfc1d15804d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityRegistrantName_f9db4240-4d9d-4b53-bdbe-dfc1d15804d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7fd71919-6698-442c-aa4d-6fc6827b524e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7fd71919-6698-442c-aa4d-6fc6827b524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_803fdb0f-e5ee-47cd-ad57-8e2226a422db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityTaxIdentificationNumber_803fdb0f-e5ee-47cd-ad57-8e2226a422db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ff442f11-9129-496a-8c5b-188e09cb9421" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityAddressAddressLine1_ff442f11-9129-496a-8c5b-188e09cb9421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3277d9f9-46c1-4602-aca2-8cd3078f408f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityAddressCityOrTown_3277d9f9-46c1-4602-aca2-8cd3078f408f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_70dbae9b-99ea-4f88-834e-00e77220d1f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityAddressStateOrProvince_70dbae9b-99ea-4f88-834e-00e77220d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_08848fd7-b4d4-41eb-ae23-8c76fd9c546a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityAddressPostalZipCode_08848fd7-b4d4-41eb-ae23-8c76fd9c546a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_98c262a9-7bc7-4519-80e5-7467a77aa507" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_CityAreaCode_98c262a9-7bc7-4519-80e5-7467a77aa507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4faba684-d5a6-4e47-ab66-55bd4a1340f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_LocalPhoneNumber_4faba684-d5a6-4e47-ab66-55bd4a1340f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2e4f6127-2632-478c-ba12-cc50f82bf7fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_Security12bTitle_2e4f6127-2632-478c-ba12-cc50f82bf7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_739b526b-feeb-4429-b58c-e54c73453886" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_TradingSymbol_739b526b-feeb-4429-b58c-e54c73453886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_aadb2c67-cdfe-4d8c-952c-7d0447fa6e53" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_SecurityExchangeName_aadb2c67-cdfe-4d8c-952c-7d0447fa6e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_025116aa-5f00-4edb-b345-89d3936f5495" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityCurrentReportingStatus_025116aa-5f00-4edb-b345-89d3936f5495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fdf365ef-558f-4755-b3f5-39f4acd98092" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityInteractiveDataCurrent_fdf365ef-558f-4755-b3f5-39f4acd98092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_02330768-2786-400b-a539-cd8cd030cfc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityFilerCategory_02330768-2786-400b-a539-cd8cd030cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c5aee92a-4360-4d7e-9f80-eb53f4d42461" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntitySmallBusiness_c5aee92a-4360-4d7e-9f80-eb53f4d42461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ef889829-ec0b-4570-91ce-b7436b14924f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityEmergingGrowthCompany_ef889829-ec0b-4570-91ce-b7436b14924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b77835a-deb7-4f07-ad40-2136228a45cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityShellCompany_5b77835a-deb7-4f07-ad40-2136228a45cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f274b9f6-79bb-47cc-a4af-e94577ef1c71" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f274b9f6-79bb-47cc-a4af-e94577ef1c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4a84b9bd-926f-419d-acf5-5aeaf877ab9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_AmendmentFlag_4a84b9bd-926f-419d-acf5-5aeaf877ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_965f6666-ef29-4cd0-8e17-e15614ff7e70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentFiscalYearFocus_965f6666-ef29-4cd0-8e17-e15614ff7e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13a0ec6c-4f14-40c9-8e1e-80c9e780b64f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13a0ec6c-4f14-40c9-8e1e-80c9e780b64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_87a76db9-eb86-423e-91f4-5f3368027bac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_EntityCentralIndexKey_87a76db9-eb86-423e-91f4-5f3368027bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2a91e1d8-691e-439e-8d80-7c0dbc689e7d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8703d0cc-94bb-4baf-b577-fdb9258bbef3" xlink:to="loc_dei_CurrentFiscalYearEndDate_2a91e1d8-691e-439e-8d80-7c0dbc689e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_67700d4c-d5c8-4388-ac02-5d359898a67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_67700d4c-d5c8-4388-ac02-5d359898a67c" xlink:to="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_45327897-2e4a-4ce8-b9ad-4c6b6547fa65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_45327897-2e4a-4ce8-b9ad-4c6b6547fa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_35b70671-fa6a-45c5-80f0-a07320f33e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_Investments_35b70671-fa6a-45c5-80f0-a07320f33e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2a771372-9924-4e7f-899b-80c7adb02a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2a771372-9924-4e7f-899b-80c7adb02a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2309549a-9ebc-4e8e-a71d-b0144c5fa242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_InventoryNet_2309549a-9ebc-4e8e-a71d-b0144c5fa242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf748faa-7023-4e9e-9b6c-fa3cff6cb03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf748faa-7023-4e9e-9b6c-fa3cff6cb03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11cf0fb0-133c-4487-a87d-5573853c6dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c8daa79-0cb1-4372-a1b8-f58f3aa62391" xlink:to="loc_us-gaap_AssetsCurrent_11cf0fb0-133c-4487-a87d-5573853c6dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8aa5e21c-8016-40de-94b6-ded3806afc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8aa5e21c-8016-40de-94b6-ded3806afc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_48e85844-5891-4462-8c37-513a3e3e6ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_48e85844-5891-4462-8c37-513a3e3e6ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bfe6e03d-aa24-4c64-a234-8b4ce07d71c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c813475c-26e2-46e7-b253-fb92facc8c78" xlink:to="loc_us-gaap_Assets_bfe6e03d-aa24-4c64-a234-8b4ce07d71c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_67700d4c-d5c8-4388-ac02-5d359898a67c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_995cf873-6e63-4b09-b418-f4bd405d5d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:to="loc_us-gaap_AccountsPayableCurrent_995cf873-6e63-4b09-b418-f4bd405d5d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bb64648c-0777-4a6b-bd54-6c0fb0f3c00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bb64648c-0777-4a6b-bd54-6c0fb0f3c00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1293d014-6074-478b-8950-289b3e48f6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1293d014-6074-478b-8950-289b3e48f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5578e78b-e850-4675-8f73-5be6a7af1714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5578e78b-e850-4675-8f73-5be6a7af1714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_33d49055-7d83-4123-9c72-e6ba627f1a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45401c39-f9b3-4208-a53b-b71fa674b089" xlink:to="loc_us-gaap_LiabilitiesCurrent_33d49055-7d83-4123-9c72-e6ba627f1a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_94e6c169-b17a-47da-b7e5-449ad57996da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_94e6c169-b17a-47da-b7e5-449ad57996da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11562eca-42fb-41f0-81f7-d2e6c81bfbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11562eca-42fb-41f0-81f7-d2e6c81bfbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_09950762-3cef-4aac-a3ad-c81e45ed4856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_09950762-3cef-4aac-a3ad-c81e45ed4856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_77728f75-0a73-4df7-a953-f59628949bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_Liabilities_77728f75-0a73-4df7-a953-f59628949bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5604b4b5-6b05-4bb2-93f7-e5739db4f6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:to="loc_us-gaap_CommonStockValue_5604b4b5-6b05-4bb2-93f7-e5739db4f6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_052d7164-cb09-481b-afc3-c698d866be61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_052d7164-cb09-481b-afc3-c698d866be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a79740c0-4712-42f9-8e62-8b4910770b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a79740c0-4712-42f9-8e62-8b4910770b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_60455c5d-fd79-42f8-97f6-b9bc0af0a531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_60455c5d-fd79-42f8-97f6-b9bc0af0a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a498d902-1528-47a7-8d1f-a2b7b8239b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ca93f82c-1381-4c37-b450-9233d930fe91" xlink:to="loc_us-gaap_StockholdersEquity_a498d902-1528-47a7-8d1f-a2b7b8239b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_372e9542-72db-408c-8755-5d514f32e74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c55dbc4f-c0ad-450c-b502-9ba4316db9ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_372e9542-72db-408c-8755-5d514f32e74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bd910a45-13cc-4bc6-8201-cd63b1948bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ccbef881-cac4-4249-a70d-912f387d9802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bd910a45-13cc-4bc6-8201-cd63b1948bc9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ccbef881-cac4-4249-a70d-912f387d9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_31e1a1aa-9993-4ffa-a050-19a49af89fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ccbef881-cac4-4249-a70d-912f387d9802" xlink:to="loc_us-gaap_StockholdersEquityAbstract_31e1a1aa-9993-4ffa-a050-19a49af89fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_01e28dd2-c482-4b78-8310-8822ba810851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31e1a1aa-9993-4ffa-a050-19a49af89fa6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_01e28dd2-c482-4b78-8310-8822ba810851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2791b468-5c28-461a-ac1f-37123a29f20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31e1a1aa-9993-4ffa-a050-19a49af89fa6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2791b468-5c28-461a-ac1f-37123a29f20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e7891bf7-1967-4f50-aa85-594f812f7171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31e1a1aa-9993-4ffa-a050-19a49af89fa6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e7891bf7-1967-4f50-aa85-594f812f7171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8c7c018a-9700-444e-955d-8d31a2aee265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8c7c018a-9700-444e-955d-8d31a2aee265" xlink:to="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:to="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bc08bb7f-9d76-4566-ae29-145f579d3831" xlink:to="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_3a9a3d57-1e58-4e9e-9b32-da73a1823415" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_3a9a3d57-1e58-4e9e-9b32-da73a1823415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_17a5fc15-46d8-4cc4-8b58-71544eac68b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_us-gaap_ProductMember_17a5fc15-46d8-4cc4-8b58-71544eac68b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_91ac0a78-e17e-42d3-ab60-e03d22d6489c" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_28942d7b-bf51-4e76-844d-65b27c3c6c6c" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_91ac0a78-e17e-42d3-ab60-e03d22d6489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52026522-40bd-4922-a09b-93f75f244dc3" xlink:to="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cfc4c22c-e9d4-47aa-be50-03d3c42be8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6b84fcd8-e5a6-4ef9-a956-f4ac086a5197" xlink:to="loc_us-gaap_Revenues_cfc4c22c-e9d4-47aa-be50-03d3c42be8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9a0d6403-f122-4af3-a6f8-eafa6276e1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9a0d6403-f122-4af3-a6f8-eafa6276e1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ce1654bb-4f80-4786-9bdf-3c35e08ea1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ce1654bb-4f80-4786-9bdf-3c35e08ea1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1fa1e52a-1914-4e53-86dd-d8d71cda842f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1fa1e52a-1914-4e53-86dd-d8d71cda842f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0a84b595-0c43-4a6c-afb1-a900fd64128f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_CostsAndExpenses_0a84b595-0c43-4a6c-afb1-a900fd64128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2e84136a-c6be-4a57-812f-d345927f76f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_OperatingIncomeLoss_2e84136a-c6be-4a57-812f-d345927f76f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d2a14dd-68ea-46c2-9a9a-124d90838f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d2a14dd-68ea-46c2-9a9a-124d90838f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_636774bc-1446-4e0c-8490-ee9527790a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7bfea77d-6218-4044-bdd0-4bdc74b8bca1" xlink:to="loc_us-gaap_NetIncomeLoss_636774bc-1446-4e0c-8490-ee9527790a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3af1a99c-f76f-4b72-9139-d544aa5df219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a50bd842-9a5a-4455-8f33-9cb056c6b4f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3af1a99c-f76f-4b72-9139-d544aa5df219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_936f4025-c9e3-4e1d-b4df-bace370794b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_936f4025-c9e3-4e1d-b4df-bace370794b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffd8c977-ebe6-4fa5-879e-d340fde5340e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffd8c977-ebe6-4fa5-879e-d340fde5340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4718bfb1-706d-4f98-be1d-e7c9cc40e990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4718bfb1-706d-4f98-be1d-e7c9cc40e990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42ba65bc-66a2-458f-80e2-8ebeaeab44e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42ba65bc-66a2-458f-80e2-8ebeaeab44e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b03f17d-0a90-4161-9c13-fe24b8602427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13657ab4-1957-4c7e-9d83-1c1b872de29b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b03f17d-0a90-4161-9c13-fe24b8602427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f0b19335-f211-4e0b-9b95-59ab3e622456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f0b19335-f211-4e0b-9b95-59ab3e622456" xlink:to="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33dd40e8-6f02-4172-b908-773b7a7a52fa" xlink:to="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2402a85a-86ff-495b-8d02-ba2833f06541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_CommonStockMember_2402a85a-86ff-495b-8d02-ba2833f06541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f02b0fd7-da59-4af7-9e2c-b4aa465d9657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f02b0fd7-da59-4af7-9e2c-b4aa465d9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_43774b14-9040-47f4-856e-786143f2e097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_RetainedEarningsMember_43774b14-9040-47f4-856e-786143f2e097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3c72f6c4-11ce-4d2c-af59-b151e44dabe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ba3e59e-d85b-4a44-b8e5-0038b1fe9787" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3c72f6c4-11ce-4d2c-af59-b151e44dabe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1b2f59f-1037-4aa5-b812-46e98e2484af" xlink:to="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9b48c7f5-4da7-44d9-aba9-c064556c4107" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ae9897f6-1e4b-445b-a718-e6eaa54323fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_SharesIssued_ae9897f6-1e4b-445b-a718-e6eaa54323fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b2af66-4b15-4dba-9b8d-844663e2ec4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4b2af66-4b15-4dba-9b8d-844663e2ec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2053756-a3bf-48ce-b7aa-afc16ce8b04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2053756-a3bf-48ce-b7aa-afc16ce8b04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_18886136-ba4d-47ef-9dba-d8043fe8397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_ProfitLoss_18886136-ba4d-47ef-9dba-d8043fe8397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3856465a-e912-4a23-8ccc-6dbebc740f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3856465a-e912-4a23-8ccc-6dbebc740f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25782568-cf6e-41c5-918a-e1e2815975a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25782568-cf6e-41c5-918a-e1e2815975a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50ab8539-b3bc-40a2-802c-00b6562c74e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50ab8539-b3bc-40a2-802c-00b6562c74e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_fbae33da-dae8-43da-aa4e-09d20f9d7526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_fbae33da-dae8-43da-aa4e-09d20f9d7526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ccd056cd-4783-41e7-b3ad-3d0f75e29ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ccd056cd-4783-41e7-b3ad-3d0f75e29ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5412d276-94d9-413c-8d02-a34f0d5ce9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_NetIncomeLoss_5412d276-94d9-413c-8d02-a34f0d5ce9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5b910964-72c4-4034-98ac-88a601b27e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_SharesIssued_5b910964-72c4-4034-98ac-88a601b27e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e009787-cdf1-4029-a0a2-4e1db0ec759a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23003076-0bc7-4120-869c-2c270ad195d2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e009787-cdf1-4029-a0a2-4e1db0ec759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8afd79db-2bd6-490a-b6b5-dbb8c7e9ff3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8afd79db-2bd6-490a-b6b5-dbb8c7e9ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7aa66655-5ff0-4f30-99fb-5008239a0372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8afd79db-2bd6-490a-b6b5-dbb8c7e9ff3f" xlink:to="loc_us-gaap_NetIncomeLoss_7aa66655-5ff0-4f30-99fb-5008239a0372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8afd79db-2bd6-490a-b6b5-dbb8c7e9ff3f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_82297e0d-c04f-4c66-aee8-30625f3b2f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_82297e0d-c04f-4c66-aee8-30625f3b2f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cc7f7ea3-57f9-4e96-91d0-4f8dea18d3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cc7f7ea3-57f9-4e96-91d0-4f8dea18d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20efbe37-efa3-4e2a-93ce-26e466dec0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:to="loc_us-gaap_ShareBasedCompensation_20efbe37-efa3-4e2a-93ce-26e466dec0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcfd8b8f-6c18-4062-a0f0-a834c1d93d54" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff77dcd1-4f3c-47e7-b529-f8be00949699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff77dcd1-4f3c-47e7-b529-f8be00949699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf50a6ea-a318-4398-9ab1-0885635c5f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf50a6ea-a318-4398-9ab1-0885635c5f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1d6918b-3eec-47bd-9544-cb961a4edef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1d6918b-3eec-47bd-9544-cb961a4edef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82f08594-a400-4562-8412-31a59cde6e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_82f08594-a400-4562-8412-31a59cde6e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_24330b1c-d01a-463f-9590-c86e4c5157e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_24330b1c-d01a-463f-9590-c86e4c5157e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f1a2d2ec-bb33-42e3-82fc-185b2ce23717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f1a2d2ec-bb33-42e3-82fc-185b2ce23717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_23e3079a-a7ef-403f-87a6-abfcc9b8ba9f" xlink:href="mgnx-20210630.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_23e3079a-a7ef-403f-87a6-abfcc9b8ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7a30e1eb-938e-450d-ba11-69cd22d8c65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7a30e1eb-938e-450d-ba11-69cd22d8c65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_46431516-eae7-435a-9e7e-9ae285bde39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5cf71ca0-7e1c-4586-8404-a3c90c6ba2d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_46431516-eae7-435a-9e7e-9ae285bde39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_835f26ef-2347-4c01-a35a-1dc353999d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8afd79db-2bd6-490a-b6b5-dbb8c7e9ff3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_835f26ef-2347-4c01-a35a-1dc353999d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_82eea3ce-4b56-42bd-b73a-65a4cf1ef0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_82eea3ce-4b56-42bd-b73a-65a4cf1ef0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c7be4611-9f3e-4498-aed4-8c82209f3613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c7be4611-9f3e-4498-aed4-8c82209f3613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eadc1e6d-f6a4-4734-82e2-5949c4d2b7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eadc1e6d-f6a4-4734-82e2-5949c4d2b7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96e84e94-4934-429f-ab38-5b9a0fb1257c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4d9eea3e-acbf-4d6c-8ab1-2c59caf8f9bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96e84e94-4934-429f-ab38-5b9a0fb1257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cbf2e08-a483-4665-86b1-1875f528c47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cbf2e08-a483-4665-86b1-1875f528c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a246809c-8128-4dba-9ece-cc1aa68a0db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cbf2e08-a483-4665-86b1-1875f528c47b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a246809c-8128-4dba-9ece-cc1aa68a0db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_75204d9a-8793-4a0f-9fac-d96b710eb42b" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cbf2e08-a483-4665-86b1-1875f528c47b" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_75204d9a-8793-4a0f-9fac-d96b710eb42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eda743e2-2a27-4639-abcb-5ef62998c48d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cbf2e08-a483-4665-86b1-1875f528c47b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eda743e2-2a27-4639-abcb-5ef62998c48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca778a8c-e387-4170-95b2-4566135c10a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca778a8c-e387-4170-95b2-4566135c10a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_476539bb-a531-4a34-bf00-6b0a68ef81f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_476539bb-a531-4a34-bf00-6b0a68ef81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7eeba802-7d43-4b02-96c9-9497187c3d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7eeba802-7d43-4b02-96c9-9497187c3d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_089664c7-4363-40e4-bd03-1cfb8c56c298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_089664c7-4363-40e4-bd03-1cfb8c56c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9c84f705-8ecf-4280-84e7-8645d881ed35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_089664c7-4363-40e4-bd03-1cfb8c56c298" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9c84f705-8ecf-4280-84e7-8645d881ed35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock_118b2c30-e9f2-43cd-9b7f-3a814dbc607b" xlink:href="mgnx-20210630.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0fd0d8d5-1206-4330-9517-ded0ebd84e78" xlink:to="loc_mgnx_RetirementOfTreasuryStock_118b2c30-e9f2-43cd-9b7f-3a814dbc607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/NatureofOperations" xlink:type="simple" xlink:href="mgnx-20210630.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5334c8ce-c5a5-4016-a50e-2344fa2ed3be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5f4638b8-9c16-455c-a31c-4f690ac0041b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5334c8ce-c5a5-4016-a50e-2344fa2ed3be" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5f4638b8-9c16-455c-a31c-4f690ac0041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ca4a2ed-ce7a-446c-b0a9-96c31cc6148c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_090bc717-f33e-4f19-8092-6766d77fc20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ca4a2ed-ce7a-446c-b0a9-96c31cc6148c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_090bc717-f33e-4f19-8092-6766d77fc20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20210630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_af746f96-bdeb-4ec7-a7fe-1c4534edb8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_af746f96-bdeb-4ec7-a7fe-1c4534edb8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_66bd5e18-bbe3-4e6c-b61c-c928c7b3456f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_66bd5e18-bbe3-4e6c-b61c-c928c7b3456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2871bb17-e586-470a-9364-fa6733f0c5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2871bb17-e586-470a-9364-fa6733f0c5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_d623879e-da76-46a2-9f41-d5eff18310e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_d623879e-da76-46a2-9f41-d5eff18310e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac099360-5bd6-4d02-b80b-6d93526070de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac099360-5bd6-4d02-b80b-6d93526070de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_cc6eb0e7-7255-4464-a3c1-b151ee424a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ba3d861-90ed-42cc-ada9-c0f1adad3488" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_cc6eb0e7-7255-4464-a3c1-b151ee424a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20210630.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71b29681-f3ff-4b41-bf97-a376a5ae894d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_dcddf6c0-37c0-4640-8fa6-96a7ef2337f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71b29681-f3ff-4b41-bf97-a376a5ae894d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_dcddf6c0-37c0-4640-8fa6-96a7ef2337f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20210630.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5af0eddf-069f-45ec-b6ce-65758c280136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_94e4c55a-d27a-400b-9078-4b5697f5885f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5af0eddf-069f-45ec-b6ce-65758c280136" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_94e4c55a-d27a-400b-9078-4b5697f5885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dd77bba1-2e6f-4e7d-a62a-5e4998119462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd77bba1-2e6f-4e7d-a62a-5e4998119462" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0700b48e-cc09-4d12-a2bf-890b58182b8d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3289c525-4395-4893-9b1b-a7f8347540f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_faa3d03c-e54a-4e16-90d5-c1a2bda09fef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3289c525-4395-4893-9b1b-a7f8347540f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e482ec4f-23df-4a7c-8d93-acdcf7a60c2e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_30e233d0-534f-4947-97c2-27d4d25cb7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_MoneyMarketFundsMember_30e233d0-534f-4947-97c2-27d4d25cb7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_04468f4f-e85d-4307-8ffa-c401d0bbeb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_04468f4f-e85d-4307-8ffa-c401d0bbeb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5cc740c0-2f57-4e14-ac24-cb2f0469db24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5cc740c0-2f57-4e14-ac24-cb2f0469db24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9c650429-088f-47f7-a608-390492dc3e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20337af4-57a6-497c-843f-2995eaf67223" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9c650429-088f-47f7-a608-390492dc3e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe75a48e-d7f2-45b7-ad44-e20f6b7875fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b59eb36-eed8-4b38-ade8-b57eeb5cc74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b59eb36-eed8-4b38-ade8-b57eeb5cc74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25742a5f-471a-48eb-a64b-4e31df9370fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cfdb1ed-50a4-4322-b6bf-e7bdb3530999" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25742a5f-471a-48eb-a64b-4e31df9370fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85175d50-d342-43eb-848a-9a283b892f1a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18cd04dc-8b3e-466c-a775-275543b37cfa" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91c4fe83-03bb-4691-8e9d-fbe2b6b79b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91c4fe83-03bb-4691-8e9d-fbe2b6b79b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd82fa4-b3c0-4dd7-ba79-f08e208850e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd82fa4-b3c0-4dd7-ba79-f08e208850e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8350e9a1-200e-4426-b283-1554530fe12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5993af46-3f1b-4ce0-97f6-60e2173fefed" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8350e9a1-200e-4426-b283-1554530fe12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20210630.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66da4976-cb50-48cf-945e-bcb468e1df9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4abfe677-7d14-4e7f-85b7-ea1c5a706dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66da4976-cb50-48cf-945e-bcb468e1df9e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4abfe677-7d14-4e7f-85b7-ea1c5a706dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20210630.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0a3575ec-7b92-4fc6-bbc2-415052eeadc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_1555c33e-e00c-40e2-b00e-4222a344dffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0a3575ec-7b92-4fc6-bbc2-415052eeadc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_1555c33e-e00c-40e2-b00e-4222a344dffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c921544-1be5-4988-a0bb-b8d44f152ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c921544-1be5-4988-a0bb-b8d44f152ae2" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_501584df-3809-4d40-b86e-860ed0380964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0bd86391-f43e-44ca-b9b0-143e6438a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0bd86391-f43e-44ca-b9b0-143e6438a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6d31e164-978c-4bb1-8f3e-11446ca61449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6d31e164-978c-4bb1-8f3e-11446ca61449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ddf373ef-d9a3-459c-91a1-a14583c7e8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8c53dc5-6df2-49da-9bcb-c59518f3fa93" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ddf373ef-d9a3-459c-91a1-a14583c7e8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_0d13fb41-3de6-431f-9e50-15daaf91cd4f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a37b8659-08a1-4b53-831b-18e19a6ea748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a37b8659-08a1-4b53-831b-18e19a6ea748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_966053bd-e6d3-4429-84db-f3f822336232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_966053bd-e6d3-4429-84db-f3f822336232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da5719f4-d9e4-40b1-a248-aff77d705da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da5719f4-d9e4-40b1-a248-aff77d705da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb5303fa-a834-4df9-8b97-0ce83f246dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50fc0276-0b2f-43ef-9b21-77e97a3756b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb5303fa-a834-4df9-8b97-0ce83f246dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_be3fb4f8-951e-4af1-992a-8867492ef1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c921544-1be5-4988-a0bb-b8d44f152ae2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_be3fb4f8-951e-4af1-992a-8867492ef1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Inventory" xlink:type="simple" xlink:href="mgnx-20210630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_64b65886-3fbc-418b-815b-a8d29e15d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9957dff3-3690-438c-b735-f32780faf400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64b65886-3fbc-418b-815b-a8d29e15d5f5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9957dff3-3690-438c-b735-f32780faf400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryTables" xlink:type="simple" xlink:href="mgnx-20210630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_65db12d5-beb8-4652-ab45-012417f50a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c4da433d-4477-4ff6-9924-9c5f5303564a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_65db12d5-beb8-4652-ab45-012417f50a9e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c4da433d-4477-4ff6-9924-9c5f5303564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8453730c-b91f-4d1a-8d1d-dddb518e0bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_bf520f11-e2f3-4a40-a205-955f02c0f2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8453730c-b91f-4d1a-8d1d-dddb518e0bc5" xlink:to="loc_us-gaap_InventoryRawMaterials_bf520f11-e2f3-4a40-a205-955f02c0f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d5f8bf78-7b14-4e37-a0d3-2b48e190fb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8453730c-b91f-4d1a-8d1d-dddb518e0bc5" xlink:to="loc_us-gaap_InventoryWorkInProcess_d5f8bf78-7b14-4e37-a0d3-2b48e190fb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_74dad40a-e1ad-4461-8eb7-7e2dc6c88af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8453730c-b91f-4d1a-8d1d-dddb518e0bc5" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_74dad40a-e1ad-4461-8eb7-7e2dc6c88af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8523e065-b514-43a5-9583-da438bf574b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2bb9b811-92dc-435b-a227-47ed499e123c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8523e065-b514-43a5-9583-da438bf574b6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2bb9b811-92dc-435b-a227-47ed499e123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_96aeeafc-beb5-4adb-b4cb-cf5a594939ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_96aeeafc-beb5-4adb-b4cb-cf5a594939ae" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3951b75a-1496-482d-8de8-f7e4d0a0f6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_f557156b-72d1-46db-b560-374e32a7d001" xlink:href="mgnx-20210630.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008b78c6-6c26-43e5-b43b-a6a1a4356aa2" xlink:to="loc_mgnx_AtTheMarketOfferingMember_f557156b-72d1-46db-b560-374e32a7d001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a8f2ba86-3e53-4d2c-849d-bb87704e891c" xlink:to="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_562bda9e-fa89-4e42-9612-5dd9c875d451" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_562bda9e-fa89-4e42-9612-5dd9c875d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_40d66748-3d30-440f-9779-696826dea04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_40d66748-3d30-440f-9779-696826dea04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b5ec40c1-b82c-4ed8-b1bd-d0f750d6fb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b5ec40c1-b82c-4ed8-b1bd-d0f750d6fb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1790b5ff-21ea-4a37-8e98-b5dab1c7d465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1790b5ff-21ea-4a37-8e98-b5dab1c7d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_d3cf2208-fad0-4a44-a5c4-a08448dee978" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9ca2f3cd-8a64-49a6-ab61-855821c4ec50" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_d3cf2208-fad0-4a44-a5c4-a08448dee978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f2b93b58-adc8-4c86-90bd-a2d860fcd3f2" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_2753b24e-32d1-4a48-bd57-82bcccca35e5" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f2b93b58-adc8-4c86-90bd-a2d860fcd3f2" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_2753b24e-32d1-4a48-bd57-82bcccca35e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a053e399-9802-46dd-b316-59bcb54e55c4" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a053e399-9802-46dd-b316-59bcb54e55c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e7455c3-8228-4116-ae25-eb222ce0f564" xlink:to="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_1829f259-f536-4c19-b495-999cfc452c26" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c73ade85-b74f-4a67-ae36-083924984c6f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_1829f259-f536-4c19-b495-999cfc452c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dd291b56-5e0f-444a-8ec4-53e8b05f3033" xlink:to="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6bd3ce47-5078-421a-b834-004cfbb2f8af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:to="loc_srt_MaximumMember_6bd3ce47-5078-421a-b834-004cfbb2f8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6749cc46-d59a-4aa5-864d-ccca225bfd8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e7c25a0-91be-4e1c-8bf4-f4be7f9f9331" xlink:to="loc_srt_MinimumMember_6749cc46-d59a-4aa5-864d-ccca225bfd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2b555fa0-5fee-4848-b304-5fa2607088a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_02a231f9-3022-4c4d-9579-67739db29a64" xlink:href="mgnx-20210630.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28a2a21b-3ad1-47a3-8321-e0b44868ded0" xlink:to="loc_mgnx_IncyteCorporationMember_02a231f9-3022-4c4d-9579-67739db29a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b92d423c-f8fc-424d-bf52-0ecb920e1914" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_080cd897-8782-4777-b18b-eda7a6c9c9a3" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_e7f9f56e-85d3-468a-acd8-4a4686d07bb7" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_080cd897-8782-4777-b18b-eda7a6c9c9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_970c06e1-f9c1-4af5-a9d0-3be7440ec4da" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_970c06e1-f9c1-4af5-a9d0-3be7440ec4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012SupplyAgreementMember_ac892ea6-05cd-47de-9477-9572f802a35a" xlink:href="mgnx-20210630.xsd#mgnx_IncyteMGA012SupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a39b8802-352e-4a5f-a983-bb6c44706075" xlink:to="loc_mgnx_IncyteMGA012SupplyAgreementMember_ac892ea6-05cd-47de-9477-9572f802a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_548f989f-277b-4bb2-b21b-984d92a072f1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a3837772-fa6c-436f-8079-08e6b4ce3e56" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a3837772-fa6c-436f-8079-08e6b4ce3e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f0b0a61e-5eda-400b-8326-70cd7d62ea63" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f0b0a61e-5eda-400b-8326-70cd7d62ea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ed90eb2b-12fa-4529-8362-0289c3319a2f" xlink:href="mgnx-20210630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ed90eb2b-12fa-4529-8362-0289c3319a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7a3f0688-b98b-4a10-af41-f9049bfe8815" xlink:href="mgnx-20210630.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_7a3f0688-b98b-4a10-af41-f9049bfe8815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_08b0a612-70b2-4aa7-a50e-a06cd03a7985" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_08b0a612-70b2-4aa7-a50e-a06cd03a7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_05511da4-241d-42eb-a6d6-09d5bab6d399" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_NumberOfPerformanceObligations_05511da4-241d-42eb-a6d6-09d5bab6d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_74a224d6-2140-40c0-a840-5857eaab1c87" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_74a224d6-2140-40c0-a840-5857eaab1c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4a619f2-c31d-4ff4-8d9b-683ec6ee151e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_us-gaap_Revenues_d4a619f2-c31d-4ff4-8d9b-683ec6ee151e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fd63114e-d739-49fa-b5ef-70053cf398de" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e7630289-7bce-4308-849f-c014754daad9" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_fd63114e-d739-49fa-b5ef-70053cf398de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0c63d7cf-941c-4a8e-ba5c-0ce56f18dfe5" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0c63d7cf-941c-4a8e-ba5c-0ce56f18dfe5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b5dd19b4-21bb-4601-bfc3-06644ff81d32" xlink:to="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_818f4abc-865c-4db1-9d1b-811c0dd1a569" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e5c9be2-e66d-48fc-9930-3407709fbd24" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_818f4abc-865c-4db1-9d1b-811c0dd1a569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18c3b96b-6000-4e6b-9120-272a21b0fb56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_509a535e-fc88-420e-ae8e-86cddb648487" xlink:href="mgnx-20210630.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_509a535e-fc88-420e-ae8e-86cddb648487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_2152a76d-4228-45aa-b4f9-d3bc1a099bef" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_2152a76d-4228-45aa-b4f9-d3bc1a099bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_1a01bb8e-0351-4881-b097-a59f7f207ebc" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_1a01bb8e-0351-4881-b097-a59f7f207ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_b3e7be2c-1417-4cab-8039-81f1a6fc23cf" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_b3e7be2c-1417-4cab-8039-81f1a6fc23cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_9758f6f8-202e-4666-80e1-8243b70b7c37" xlink:href="mgnx-20210630.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2587ca69-c63c-4501-946d-94e33f25b742" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_9758f6f8-202e-4666-80e1-8243b70b7c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9277e744-c85d-4257-a8c5-e476334f82ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_dc0f36ad-3a13-4c0e-bc7f-c8494775dd90" xlink:href="mgnx-20210630.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e1e744f-918d-473e-99b7-668729f1e1c9" xlink:to="loc_mgnx_ZaiLabMember_dc0f36ad-3a13-4c0e-bc7f-c8494775dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b561ddc3-4800-412d-bff9-5086fe68368b" xlink:to="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dee41ba4-503a-4cec-89a5-1e1f73c96eaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6df89b4f-1ab9-4ffa-bf6f-9d1d2b391017" xlink:to="loc_srt_MaximumMember_dee41ba4-503a-4cec-89a5-1e1f73c96eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_994495eb-7eb7-448e-ab29-b46b909baaa3" xlink:to="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ac70197d-509e-488d-afbf-c21a855731aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_22e7e9dd-d3ce-401c-aba0-541437fc522d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ac70197d-509e-488d-afbf-c21a855731aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecf0992e-2d90-4ffe-b9b0-1e4e8d2fb6f6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5cf007db-68a6-4aee-b95c-4f00f583fa75" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5cf007db-68a6-4aee-b95c-4f00f583fa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_154f96c8-15c5-4f83-8b33-9753d196e930" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_154f96c8-15c5-4f83-8b33-9753d196e930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_24aa4995-b2ed-447f-9e6a-295f68421b7a" xlink:href="mgnx-20210630.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_24aa4995-b2ed-447f-9e6a-295f68421b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4197d3a5-26bb-4fa9-a63f-9ad8c6eb9662" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4197d3a5-26bb-4fa9-a63f-9ad8c6eb9662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ba5a8ea1-2b2b-43f4-bf5b-a5d4ba01dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_Revenues_ba5a8ea1-2b2b-43f4-bf5b-a5d4ba01dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_5af44356-4add-40c7-8fe2-3d46d7410b6a" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_5af44356-4add-40c7-8fe2-3d46d7410b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_5cab7980-1eb2-493d-93e7-2cdecdf623ed" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenuesTaxWithholding_5cab7980-1eb2-493d-93e7-2cdecdf623ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_e952fb4b-e0a7-486f-b032-9e687ef5f11a" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_e952fb4b-e0a7-486f-b032-9e687ef5f11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a6543ad-de6f-4069-85a8-008eef3f6525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a6543ad-de6f-4069-85a8-008eef3f6525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptInFee_31f8b49a-fa62-4b54-80b9-afe426b7047b" xlink:href="mgnx-20210630.xsd#mgnx_OptInFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_OptInFee_31f8b49a-fa62-4b54-80b9-afe426b7047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9cfdeae9-9a02-48ad-88ac-8b4c31f25993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9cfdeae9-9a02-48ad-88ac-8b4c31f25993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3a6e7316-f7ca-4df6-8612-d1b4116571e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3a6e7316-f7ca-4df6-8612-d1b4116571e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4c4b2dc0-41e9-4ade-babe-6eb2e4e15af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4c4b2dc0-41e9-4ade-babe-6eb2e4e15af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_3128d624-8ac9-4ad7-84cc-eec45213feec" xlink:href="mgnx-20210630.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_3128d624-8ac9-4ad7-84cc-eec45213feec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_6ac9370c-5ac6-4315-a5d6-48b4e8b2d72a" xlink:href="mgnx-20210630.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_6ac9370c-5ac6-4315-a5d6-48b4e8b2d72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0de3b9e7-3b80-480f-b15d-0f7e1b736255" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0de3b9e7-3b80-480f-b15d-0f7e1b736255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a9e03ba8-4694-4d57-a0bf-a0a87446e5c4" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_a9e03ba8-4694-4d57-a0bf-a0a87446e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ba4d11e0-f2f2-4633-9d95-32e73b234912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ba4d11e0-f2f2-4633-9d95-32e73b234912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f2427843-206c-45fa-b39a-f61260bc19d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fde8aca1-8fa2-4b46-9d28-75d074611b2e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f2427843-206c-45fa-b39a-f61260bc19d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e7ace3d4-9afb-461b-9050-75ccb95eed05" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_e7ace3d4-9afb-461b-9050-75ccb95eed05" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_02193bbf-c4c6-4bf4-a582-bb12ca1fca02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_6d3e762f-4bad-40d5-934e-f49adb187912" xlink:href="mgnx-20210630.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c9c81-8dd8-45d0-8e20-81c37cd1dbbd" xlink:to="loc_mgnx_JanssenBiotechIncMember_6d3e762f-4bad-40d5-934e-f49adb187912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a3f2efff-00b4-4ff4-b721-be7ca9f2940c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_b092eb9a-816a-4191-8a86-ad1482fb168c" xlink:href="mgnx-20210630.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d2f0403-9418-4e6c-a7ee-5048dd78bbbe" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_b092eb9a-816a-4191-8a86-ad1482fb168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_be9ea227-7b9a-4ef3-95bf-b2054dd308a4" xlink:to="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b8217b47-93a7-4e2f-a52f-45272224d5a5" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b8217b47-93a7-4e2f-a52f-45272224d5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_e0cdcf61-c648-4aba-85de-4ec1d10d580d" xlink:href="mgnx-20210630.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_86f97d47-70e4-4f8b-9269-944951b1121a" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_e0cdcf61-c648-4aba-85de-4ec1d10d580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3607540c-b56c-46f2-86e3-7388563a35e2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c43c5b87-31a0-4b6f-8607-a0453fe687aa" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c43c5b87-31a0-4b6f-8607-a0453fe687aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_15146f00-8d25-45b7-b241-6654b65c0e85" xlink:href="mgnx-20210630.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_15146f00-8d25-45b7-b241-6654b65c0e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_911b5c25-514b-4a59-bb9e-de581658cecb" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_911b5c25-514b-4a59-bb9e-de581658cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ebf2682b-335d-4438-b75a-8d8bcbc0385e" xlink:href="mgnx-20210630.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ebf2682b-335d-4438-b75a-8d8bcbc0385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_131b6813-f33a-45a5-8013-2d41c6f1069c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_us-gaap_Revenues_131b6813-f33a-45a5-8013-2d41c6f1069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_731b7589-a0f8-4d76-b753-de1cd05af4df" xlink:href="mgnx-20210630.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bd76b9c-6360-459d-912f-169bcfab6463" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_731b7589-a0f8-4d76-b753-de1cd05af4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_86d2afda-999e-4392-b9b5-460aa2051d7e" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_86d2afda-999e-4392-b9b5-460aa2051d7e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b9da15f2-06ac-4b40-86ef-d43266e4653a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_8af26637-03f2-4715-a86a-def3136cf195" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa57f975-3f3a-4f9a-9a2d-34c005ced043" xlink:to="loc_mgnx_IMabBiopharmaMember_8af26637-03f2-4715-a86a-def3136cf195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a99ecd13-6dd3-40db-80e8-fa7f414e1bb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_f28f005c-d49e-4390-9fbd-626b8b980322" xlink:href="mgnx-20210630.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86f55d5a-3ca0-4fc6-bca6-8bd41faf6ea9" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_f28f005c-d49e-4390-9fbd-626b8b980322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3095e9d8-405a-4ebf-b9e3-51e1cbe184a3" xlink:to="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b3dd03c-2083-4a23-ac8e-45efbc4a20c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_718d107c-90d9-4f6e-b8ad-c04a2800ef48" xlink:to="loc_srt_MaximumMember_7b3dd03c-2083-4a23-ac8e-45efbc4a20c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f868a8e4-8299-42ca-9c59-f984d8121982" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ebf029b0-3b70-4cf7-aee9-e327b8b03e4d" xlink:href="mgnx-20210630.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ebf029b0-3b70-4cf7-aee9-e327b8b03e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cd72f838-173b-4b83-889c-7c94f85313c7" xlink:href="mgnx-20210630.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_cd72f838-173b-4b83-889c-7c94f85313c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_bccd6917-78bd-4b59-ab29-2051c9f09c63" xlink:href="mgnx-20210630.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_bccd6917-78bd-4b59-ab29-2051c9f09c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_f905ca80-97d6-4a94-9cf9-20397ccfb1c8" xlink:href="mgnx-20210630.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_f905ca80-97d6-4a94-9cf9-20397ccfb1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b8de4b3-1771-4848-88b7-55a464fa713c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_Revenues_9b8de4b3-1771-4848-88b7-55a464fa713c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7336b08e-1e5e-4d04-889a-e5ad61579aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7336b08e-1e5e-4d04-889a-e5ad61579aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0fb660c7-df17-429d-b677-0d62ac9e2cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0fb660c7-df17-429d-b677-0d62ac9e2cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0e4a57bd-112b-4b2e-8d3f-9094139fb65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd77334a-6135-4cfe-8f1d-0c976cba8d6e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0e4a57bd-112b-4b2e-8d3f-9094139fb65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_6d0a2ef1-a32d-4cf9-aed6-297627375e87" xlink:href="mgnx-20210630.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_6d0a2ef1-a32d-4cf9-aed6-297627375e87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90baae65-2100-4275-b640-873d49965228" xlink:to="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_84393c78-486d-44b4-a32b-fd14d3952756" xlink:href="mgnx-20210630.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7bc3022a-ec5b-46b7-9991-d8b1a2f1cf99" xlink:to="loc_mgnx_RevenuesFromGrantsMember_84393c78-486d-44b4-a32b-fd14d3952756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_669c91aa-5237-4b92-a98d-bb0cf5d5cfa2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3702e441-7691-4fea-bb6c-6f4a9c6d46c8" xlink:href="mgnx-20210630.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e62525e7-018c-46a2-a39b-61d31d9af42c" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_3702e441-7691-4fea-bb6c-6f4a9c6d46c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b2d77b1a-3679-4834-96b7-1c68c5accf9c" xlink:to="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8102c271-cd35-4e88-8796-0e5316c0070d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_427059a7-84e5-4fe8-ac52-9a854c011f06" xlink:to="loc_srt_MaximumMember_8102c271-cd35-4e88-8796-0e5316c0070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f0ce887e-9ddc-4774-b3f3-d764f68561fd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_e5e1efee-f31b-4676-abf6-c464afb7c761" xlink:href="mgnx-20210630.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_e5e1efee-f31b-4676-abf6-c464afb7c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_67e3649e-5743-4ec7-a688-a3740a4f6586" xlink:href="mgnx-20210630.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_FundedValueOfBasePeriod_67e3649e-5743-4ec7-a688-a3740a4f6586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_f63eb9b9-87db-4a2c-97eb-2183a8f3b221" xlink:href="mgnx-20210630.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_f63eb9b9-87db-4a2c-97eb-2183a8f3b221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_2fe59faa-d621-4114-90ae-373639f35d68" xlink:href="mgnx-20210630.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_2fe59faa-d621-4114-90ae-373639f35d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_e09cf2e3-3d0b-48d6-bea4-c71067e0b28f" xlink:href="mgnx-20210630.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_e09cf2e3-3d0b-48d6-bea4-c71067e0b28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0feb12d0-08c7-42fc-b6c9-369efe961798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e7fcd1f-e306-402e-ab46-4266765461bb" xlink:to="loc_us-gaap_Revenues_0feb12d0-08c7-42fc-b6c9-369efe961798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4be18ea8-1218-4a60-96fd-9e19b326e9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a87fc0a4-e394-4b2a-a7a9-238cae61e10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4be18ea8-1218-4a60-96fd-9e19b326e9cb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a87fc0a4-e394-4b2a-a7a9-238cae61e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f0eab5-acfd-4bdf-af74-cb10aa4c2d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_19d2ae8d-6f1c-499d-8f86-636a2e758719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f0eab5-acfd-4bdf-af74-cb10aa4c2d77" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_19d2ae8d-6f1c-499d-8f86-636a2e758719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36ad23fc-1ce0-40a1-8e75-dc3b15aa8a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f0eab5-acfd-4bdf-af74-cb10aa4c2d77" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36ad23fc-1ce0-40a1-8e75-dc3b15aa8a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_64d699e0-98d0-4930-8415-9a20232d235f" xlink:href="mgnx-20210630.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f0eab5-acfd-4bdf-af74-cb10aa4c2d77" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_64d699e0-98d0-4930-8415-9a20232d235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_124a5bd3-8880-44eb-ba0f-bf30b8a84c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f0eab5-acfd-4bdf-af74-cb10aa4c2d77" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_124a5bd3-8880-44eb-ba0f-bf30b8a84c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5157bfd4-eefb-4198-ba4b-a60cccba79f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5157bfd4-eefb-4198-ba4b-a60cccba79f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:to="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_73bd4d97-c40b-4452-8efb-9fbedafe0be1" xlink:to="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_533052d9-f9f7-45e1-86bb-5a32cda19af3" xlink:href="mgnx-20210630.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_533052d9-f9f7-45e1-86bb-5a32cda19af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_f8fdcf36-e421-4abc-92f9-c73c6fd8c7ca" xlink:href="mgnx-20210630.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_f8fdcf36-e421-4abc-92f9-c73c6fd8c7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_61002a07-4e08-473d-a03a-861ba9171d3d" xlink:href="mgnx-20210630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be4c24f3-f082-41c6-9882-a8effaefaefb" xlink:to="loc_mgnx_StockIncentivePlan2013Member_61002a07-4e08-473d-a03a-861ba9171d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb4a8e38-0565-4f01-9671-86082ce60fe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9bfe5a7a-5b58-4f20-95f3-260a6c94e9a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9bfe5a7a-5b58-4f20-95f3-260a6c94e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_53eddb75-0006-4192-95bd-d3cf01afd9f2" xlink:href="mgnx-20210630.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_53eddb75-0006-4192-95bd-d3cf01afd9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5f0fef0a-632d-485a-b807-08cf9b2fc656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5f0fef0a-632d-485a-b807-08cf9b2fc656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cad628c6-ac75-4c24-891a-9b7ef5293eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cad628c6-ac75-4c24-891a-9b7ef5293eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_3ac9497f-d567-4be1-8000-6a0eda5bf481" xlink:href="mgnx-20210630.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_3ac9497f-d567-4be1-8000-6a0eda5bf481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6889b9fa-0378-4d73-8aff-68e88933b410" xlink:href="mgnx-20210630.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6889b9fa-0378-4d73-8aff-68e88933b410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acbfe63b-1a02-4294-af51-14976f287ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acbfe63b-1a02-4294-af51-14976f287ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d51b7bce-60ff-4ed0-ba36-7eb99ddc39fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5f38b718-0329-4a07-ab11-b87822b840b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d51b7bce-60ff-4ed0-ba36-7eb99ddc39fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5157bfd4-eefb-4198-ba4b-a60cccba79f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e89ef44d-5a6b-4ae3-bd3e-aaadf991ad9a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_182a1e81-56cb-4b9c-b148-65e28501d9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_182a1e81-56cb-4b9c-b148-65e28501d9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_495039eb-5da2-4dd4-ad69-26e4a3084432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eb95c2d-9176-4745-ae4f-4947f3369e56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_495039eb-5da2-4dd4-ad69-26e4a3084432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_265c03a5-673a-4995-a42f-79b96b242529" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe3ee574-1968-4af8-9893-29142018e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a9c07f0e-e977-49ca-8878-8f1ed44d20c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe3ee574-1968-4af8-9893-29142018e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_310ba20b-930c-4ac1-8c86-2c236770e847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_310ba20b-930c-4ac1-8c86-2c236770e847" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:to="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cce88f00-e299-4684-8f95-0df7fd7806f0" xlink:to="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6adf50c9-cca5-44ea-826b-1c50a838e919" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:to="loc_srt_MinimumMember_6adf50c9-cca5-44ea-826b-1c50a838e919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1181661-3591-4f72-964e-0475f08d01b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c97b47f1-31de-43dd-99b0-a5313351dbfe" xlink:to="loc_srt_MaximumMember_d1181661-3591-4f72-964e-0475f08d01b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ee96bec-9cdf-4bce-a5fa-e36522ed7c73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75ad6e5a-5848-4017-9eb7-2dd640f9bcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75ad6e5a-5848-4017-9eb7-2dd640f9bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45ace583-b71a-4fd8-9f92-37d58e3d555b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45ace583-b71a-4fd8-9f92-37d58e3d555b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6505fda5-bed3-4377-88a3-0ae4a88299fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6505fda5-bed3-4377-88a3-0ae4a88299fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95d78e90-bcd9-4c36-b4e4-5d67deef7de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebfef55-f6e6-4855-a3a5-d7910b029e7f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95d78e90-bcd9-4c36-b4e4-5d67deef7de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4e7dec6e-60bc-4876-8024-8beae276bd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4e7dec6e-60bc-4876-8024-8beae276bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b18b63b-7412-4a79-babe-718ec047cd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b18b63b-7412-4a79-babe-718ec047cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_af6644d2-338e-4a46-8ac7-35115b606f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_af6644d2-338e-4a46-8ac7-35115b606f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6fb1765c-a9de-444e-b8b9-f12e34f59b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6fb1765c-a9de-444e-b8b9-f12e34f59b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dcccddbf-8c69-4ffb-9c71-07d1233fa999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dcccddbf-8c69-4ffb-9c71-07d1233fa999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c45b8e1-dfc3-480b-882a-715e4a59c70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c45b8e1-dfc3-480b-882a-715e4a59c70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b2afb9ad-d31d-456e-a0d3-f2df8f3cd1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7715fa2b-29e3-46e2-933c-1d6b10d21208" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b2afb9ad-d31d-456e-a0d3-f2df8f3cd1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bcd05f84-f40d-414f-90ca-061c26ea8302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bcd05f84-f40d-414f-90ca-061c26ea8302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c0ba16e-7e94-414c-b647-2f5e60258ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c0ba16e-7e94-414c-b647-2f5e60258ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90d27a5a-d8b5-4fba-b1d1-ad04e72a5dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90d27a5a-d8b5-4fba-b1d1-ad04e72a5dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37f159d8-6ed8-4ef6-ae7f-75b2f9bbaa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37f159d8-6ed8-4ef6-ae7f-75b2f9bbaa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d2f13c0-79de-4cdf-9a32-2c7ac37241d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d2f13c0-79de-4cdf-9a32-2c7ac37241d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f569cc90-91ff-4c49-b633-606f29f7ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f569cc90-91ff-4c49-b633-606f29f7ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dc97c0c-055f-469c-90d8-798d31989770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_605e3b37-f331-499d-b143-dfd25c1254f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dc97c0c-055f-469c-90d8-798d31989770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5c5fa301-684b-4780-9d56-7bf6cede8122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5c5fa301-684b-4780-9d56-7bf6cede8122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6ff0faad-52bb-45f4-922a-04283221c7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6ff0faad-52bb-45f4-922a-04283221c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5c001e59-5c68-4440-a110-b5dbec3f1e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5c001e59-5c68-4440-a110-b5dbec3f1e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c2f17b7-d79e-4043-9a7a-eaa45118ac23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c2f17b7-d79e-4043-9a7a-eaa45118ac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0760d9fd-116e-45c8-b846-4341812e43cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0760d9fd-116e-45c8-b846-4341812e43cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f0778aa3-3b36-4ee8-8e0b-43f57b041343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19e54986-3d93-45a0-ba36-5be0ce764f8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f0778aa3-3b36-4ee8-8e0b-43f57b041343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_07e7af64-e2b2-4f67-a91e-6dbbf63580ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_07e7af64-e2b2-4f67-a91e-6dbbf63580ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_78d50a99-5ded-48ae-ad7f-79bbde673da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_78d50a99-5ded-48ae-ad7f-79bbde673da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_87455130-7b74-4bce-b52c-733d17c3f419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_87455130-7b74-4bce-b52c-733d17c3f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c4f10314-5293-431e-ad33-f67c5e42d95d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c4f10314-5293-431e-ad33-f67c5e42d95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1717b7f2-4140-4c61-b8f8-0b35730031b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1717b7f2-4140-4c61-b8f8-0b35730031b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7823aed6-851f-45f8-bbdb-12e1e620cf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4b68d8f-8f2e-4050-acd3-d3d5953868c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7823aed6-851f-45f8-bbdb-12e1e620cf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20210630.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aed5955f-7dfc-4a1f-a89d-701ba5a9af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aed5955f-7dfc-4a1f-a89d-701ba5a9af49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:to="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1f311251-0a3f-4c36-994c-46fd10d89df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_554b22a5-5326-4a47-bf80-d68753c4c5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d34e122-d1b2-417f-a095-64a5ab73cd4b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_554b22a5-5326-4a47-bf80-d68753c4c5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:to="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_255acb9f-366f-4388-af6c-800b76b9b059" xlink:to="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_d0d4a754-c0ee-4808-824b-d057bb4974e9" xlink:href="mgnx-20210630.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b219cf78-8e3c-40a1-837d-daa82f6d0f99" xlink:to="loc_mgnx_StockIncentivePlan2013Member_d0d4a754-c0ee-4808-824b-d057bb4974e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc116f20-443c-4634-ad13-e3aa9de84854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb6398fa-ff00-4752-ba55-915c4be4c86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb6398fa-ff00-4752-ba55-915c4be4c86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_26ec94a3-b60a-4921-9a69-d857280e21c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_26ec94a3-b60a-4921-9a69-d857280e21c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7a357af1-c281-4fd5-9088-1c7962c42ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_7a357af1-c281-4fd5-9088-1c7962c42ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a688071c-dd08-4164-8023-2c05531ccf19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a688071c-dd08-4164-8023-2c05531ccf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b2fb23d-60f4-4a1d-89f5-facbf28b2e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4faf5424-ddb4-4dd9-8e19-2b6749f7794c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b2fb23d-60f4-4a1d-89f5-facbf28b2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_28654b80-36e2-4b38-affa-10fc5debef65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_28654b80-36e2-4b38-affa-10fc5debef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ef3f83d-fed5-4acb-8999-30fba7ceed29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ef3f83d-fed5-4acb-8999-30fba7ceed29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e00f37fc-1f3c-4bf4-bb2b-f690dae425f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e00f37fc-1f3c-4bf4-bb2b-f690dae425f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_292f74a5-cfcc-44c7-bd65-056fe79e7a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_292f74a5-cfcc-44c7-bd65-056fe79e7a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4bfcb7e-3830-4c0b-97bd-24b117b1d0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_44f6615c-ccf8-40e7-a49c-fbbb72650d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4bfcb7e-3830-4c0b-97bd-24b117b1d0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e19e1cd8-ba4d-4d61-a62e-06f495167774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e19e1cd8-ba4d-4d61-a62e-06f495167774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_95f7c07c-e5b2-4ab7-8f16-ccfa4b833069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_95f7c07c-e5b2-4ab7-8f16-ccfa4b833069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43377e6e-87ae-4c40-ae2f-42d51ef28425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c1a2d08-326e-4d96-8fdd-6e2150d6d535" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43377e6e-87ae-4c40-ae2f-42d51ef28425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_502f230c-21dc-47f2-af2c-f57b3050b5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7c57c800-657b-4921-9634-22b2d10f9260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_502f230c-21dc-47f2-af2c-f57b3050b5ea" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7c57c800-657b-4921-9634-22b2d10f9260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>mgnx-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20210630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20210630.xsd" xlink:type="simple"/>
    <context id="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i659b6753df8146d889434af7dfe25a17_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i99237d698c8c4afdbcef6350116b30ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia19bd22873f74ac0a9a206605b8cae68_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38f40f3786724fa1ad473ad09803006a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie0ff57e352254b318162eb9cc8c0797b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id0e9beb576154228ae3170843841bbf5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i76efd339d1ef4e28bcc5cdc42f49e9c8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i853dd351791c4152a984c61563c37d8f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e75e38251ca4a8caee14deab3bdd4f4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2b7bb08c48834c529595375229b7976a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e184d60537c4ef9839e6bb7da1ac27c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4c15e8ab11cd498393b7b69806d30fdf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i92cbfaf654bd427b8436cccb669008fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib201915352974536beb53d888f523fcf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c79f10044b14566889926dcb759d15b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i917763bbee93419ba52b562b02f1fc9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42019741bffb4bdebf0d0fc10733e31b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i258e113cac8545e29fa1c772231215cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie1dff43be20849fbbfa77443c32bea18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifbb93b0844574006b7a2e1722733077a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec2275ddaf7445d095b40fcc07d6df36_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6590518bff442f3b740132dadc9e104_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i161452ab42544aa7affbd585c14a6058_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i73079c43b74e40a19f380f476c7c8be4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7609a910c2984ce3b597382be696e095_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e70b8e9e28148aba70905165a33b688_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ed833c461084728bd70aaae36add592_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i93b668fed7b4433eb92e9256b8769b2c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iacf8ef72a04e4570ae9b32da2e3d487f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9c8177b0cd284c57877080228c9c1f65_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib24f781a3ab9414a96ce5ecf52017885_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id22b7b809f714fb1b47a02dbddde5636_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d06b08b99bb4bd48b3d044997ecee6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafe0486181da473b833e2f3577c97501_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i452ce6d02a3f4d0f8e59b4e1791096e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47458184ab624f7d9b70f6018c42192e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b3319bcc35e44daaa195857f42cdf9e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9328ec3a1cbb404aae355d158e8503d4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7c305587a633404589fa54ed876d5095_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i97169e2cb62e4625b4cc2b1e15526583_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7df5ab9d1dac462495733adf3296e40f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5477f3f6684f41afb7accd08c9b72160_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic127167e37e4421ca46cfaf5d2d8ed2b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71ca468ec7594cdda6eb47e595f7e56f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i41f8ccea1a3b42fa835d31417ecc4765_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae3d02417b124f71a20bb4eb62366e59_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i707cfef686b74380a90156b94f5ed6cb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib9349f9216d947e6995521fe00f225b1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3d373902fd2d4b8b9a7bd6404765e98e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i70478a7071c64ed8bc2a95031316c799_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b6997c210694fe3a545294cd574e330_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6fb28ceedb1540108416cb8bca024ee4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib51ff6fe1df945d6b5eadae49de900c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i83b573ab28a7443fb6e2a68919628472_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i40d06e9e2b764360be3789ec5ab6a466_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1b2e9df501b44b06a59a0ece2160ed78_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie3d2f52795c84d73812fd8848443f816_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i73dcce00de9e4cd2b1e37144f3a6efb4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id543c07e6c994f5e81a39df1116c9a43_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5eb0c9e3480346519ecf6c1f0c46c8d4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if44450b3df944c238f4634852f259160_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8321253ab6944229be7fba40e19eaef4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic17fd2407aa14c1885237d1cc1a99fee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9774f5bea6ae4560a38cc67f40b9694a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b77778502a64bc1ad848b961aa391bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7b11553fdaa4460bac14c9901e981643_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id3589e18fbb24f8fb2e18deeb6b2ff7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59efcafb8dc24c15928c3bf8b28d0df2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e5f4c9915d34ba697c4c5e8998d9344_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec1db23c95b04160ac16470c83f6bda2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie12e9d4d981b4c19ba9b2c60dd287996_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e33921e4885474fb00cc964f9793e92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife1b38058b7d418fb1b1f00846e9a5a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3868bf3d920462993a7d358e34b30d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc01255ced4f4b16a80a1fce94c5ffe7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba0e04aa3d8740cb98428d2ac4def939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd632afb09594801ad294cc7d9a4a993_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c8e49b4de5f49a99c026fef5d247a0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i52b46015190047069180f72c9a65f3be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec4534615a7743539c120849d9bac73f_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63752c4319324224891b621130d37dd7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1fb5607c3098402584a482d05ebd33a4_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i9a811db172dc46c389a4e8977a0b88f8_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9f80fe9e7bec4828b5adff9615c79488_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d4183f898a0423387191ba8e659530d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idc63dbbc38b240d1af689f955b93c987_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if8dec3cac0d747668fbb6d511275eb4c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7ed1c4f887fe4a6ab8129e8f4d557b41_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i18c024e23c894d508ae4b2d764a1da84_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9def7feacecb40599d50a6c2b00e945b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc58eaa1973040f49a6096c0ae8ec4e8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iec2554e54b31431db356c26b68680c0d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id94ec4f166294424905e9b5dfce87d38_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44ea624c784446d2945c9719b9e70291_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0b9ef71b5922414e9101d383252c8b6c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i497d64ec91f141f692c999a205a6507b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a034427f78f478893b443a6a23c1cd9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7dd946ed05704d57ad5030149625825b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i858f318333da414da051fa53d0aed818_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7bbaab8beada4a8e8fd4d70b878b36f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4f6d5d295fa4f4ab2ad7678c47b90a0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id4e465ebe0e74740a272ba2347ea429d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f0836069df741f4b40628f7e6d2e4cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70c80046e2754387bbfb3a68414afafb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i718f9275d3084eed957a877fcabb3eed_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i624b7721e711450790fb78703bdfac0e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id74f1cf826ca407fb2869bea2077efc9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1fa68fb09ce643209722e4c7061f1dc6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iddbdc4dc3248428491ce2f845de0d6f6_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i174499c398454c42876e617baa38de83_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i77288252481a45bb8d2a69bd1cc3b2df_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c57174988914ce89f16563fb7997562_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec8b966b3515458980b5cd1380246198_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60c54b835f12476ebcd59fb59d9aee2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea4736835e9e45ac8018479c040ee6e8_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfc33644441d49b491f669f6cee3cf52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib4ee5d7224384f51ae4351da2491f793_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia1829ff483154e78a6241246422a7a16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08846d12a1824787806650566090f18b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1a3cd8312cf4cf6b4d17e604f6ff948_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a108cdbe85846dcb5a3e8fb692e07e0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f8bc10e870f423c915193a8d2f50a02_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05ac94940d774c9cb563d01ff4332791_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i600a2baf71cc48788b482d5d843710e7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i13e521811ec142cbab4561d2d0e7f510_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i4e56a7a7446f43fe9e4dab1edaa5b3f0_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idf108d05a1a844ecbaf4f2cf4c8dd881_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85050d9a6f47489bab0765376deae7a9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i909de857ac8e40dc9bbdd2e2b24cd20d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i878570654cf7443295140f93cce32043_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc441b45390e4e3fbbfbe489832ffed0_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i0b3e59b96ba24ec9bcac6649b8b2df22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa6f92aaf8b145f0b3bd386357f824af_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0031895b9ddb486c9acfd64f0d661e1e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icda53c5d5b224a6bad5e09031f6b7b9b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a7422fa11414ef6a298de5f4f194412_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i38e4b9564f0e4552a41d250e30a98c66_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b3aad52d4204392803f61f058015d65_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifbbd69658d2544488a8943aea2078bc1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if53482425e144ebf87797a8800447626_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7d8751554712487b9de2c28ecbbfccf0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fd60f01b1334bea880a5f387322b593_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i801e96d91e944a44bdd5ee5ed3764993_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia217df68ded645e8b6c9001175c243cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1541411d98604ec694fc7cf490e3c299_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV8yLTEtMS0xLTA_b90c1014-f070-4114-aef9-ec8120f810d6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV80LTEtMS0xLTA_bb7546ee-24c9-4d85-a832-7f73abf49484">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGFibGU6MWQ4NTkxYTM4ZTE3NDc3OGJkMDJhYTJkNTk5ODg3ZmUvdGFibGVyYW5nZToxZDg1OTFhMzhlMTc0Nzc4YmQwMmFhMmQ1OTk4ODdmZV81LTEtMS0xLTA_8b917687-9806-49be-b233-941e471c561d">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGV4dHJlZ2lvbjphOTRhMzQzN2UzYTg0ZGU2YmU1YmMwZGMyN2E3N2QyMF8xMzA_fca966ea-99e4-4272-be96-668d81936d71">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180L2ZyYWc6YTk0YTM0MzdlM2E4NGRlNmJlNWJjMGRjMjdhNzdkMjAvdGV4dHJlZ2lvbjphOTRhMzQzN2UzYTg0ZGU2YmU1YmMwZGMyN2E3N2QyMF8xMzI_f6b305f4-31d2-41b3-82f8-f400d1d53585">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY184Mg_90beba8c-d575-4cde-a2a2-e472fd866f78">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NWMxNDdmZWE2Y2Q2NGMwMWIzYjM2YzE1ODMzMTE2NGYvdGFibGVyYW5nZTo1YzE0N2ZlYTZjZDY0YzAxYjNiMzZjMTU4MzMxMTY0Zl8wLTAtMS0xLTA_fad9a915-4ceb-4bd9-9104-f5f3b70c420a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xMTg_42d86a73-cb8b-43d9-83bc-d1ca481d8fb6">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6MTE4ZGNjMWJmMjc4NGM0YmJkMjlhNGZkMmQ5Njc0ZjEvdGFibGVyYW5nZToxMThkY2MxYmYyNzg0YzRiYmQyOWE0ZmQyZDk2NzRmMV8wLTAtMS0xLTA_20d4dbf9-6703-4f64-bde4-4afcf112c23c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yMTA_c7f6a98d-5574-4d48-a18c-78f4c52381a7">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yMTM_85cb9c39-2f93-406a-8d18-6c88af1d193f">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8wLTAtMS0xLTA_27416d61-d41a-4b1e-9fee-d88c5ea5aec0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8wLTEtMS0xLTA_e0b037f4-0898-44fa-9391-92c5eda0c647">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl81_92328cdb-2a77-4607-b953-82cdd587b94a">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl84_5d9ade07-75e4-41d0-9af6-15e111ac598a">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2YwYjIxNjQ3NDQ0ZDViOWJmNTJjZGZiNmFkNTJlNl8xMg_e575a9cd-9997-428e-b41f-d272843e1a58">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2I5ZDU5MmY1MzYxNDcyMzg5ZDVhYjU4NDk4NWVlN2EvdGFibGVyYW5nZTpjYjlkNTkyZjUzNjE0NzIzODlkNWFiNTg0OTg1ZWU3YV8zLTEtMS0xLTA_801f725d-957d-4356-ae82-9201f49c593a">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yNzM_2186cd3f-142d-4842-969b-78a2405056f2">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18yNzY_85a52d6f-d5c0-4148-ba74-cb063e6a7511">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTAtMS0xLTA_ab27f35e-c279-46c9-92ca-95f4252f8f17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTEtMS0xLTA_28238626-2d69-49a9-a7ea-b1aca67690a6">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6NGJkMmI3NzgxMWM2NDFjMWJhYWEzNTM4ODU0NzcwN2YvdGFibGVyYW5nZTo0YmQyYjc3ODExYzY0MWMxYmFhYTM1Mzg4NTQ3NzA3Zl8xLTItMS0xLTA_d6509f8a-4ffe-4e59-8eab-c41a8453364d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIy_ccf81983-b433-4e08-b059-fe25e4ed3953">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIw_c518c64b-716c-4eb3-8d95-2455d2d9f9c1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV8wLTAtMS0xLTA_5755db92-e896-4c4f-ac7f-006181fc53b4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV8yLTMtMS0xLTA_fbb697f8-4f91-4299-9bb0-6afedc51d6cc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGFibGU6Y2YxMDc0MTAyNTYzNGViYjkxYTFhODE1ODZiNTkzZGEvdGFibGVyYW5nZTpjZjEwNzQxMDI1NjM0ZWJiOTFhMWE4MTU4NmI1OTNkYV80LTEtMS0xLTA_29b00073-3e21-420f-9fff-662905a6457d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xOTIx_b7900040-3492-4e19-9210-455d6c8358ac">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i659b6753df8146d889434af7dfe25a17_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xL2ZyYWc6NWY3MGMxZDAzNDYzNDUzM2FjNmVkYzQwMDU4M2UxZmMvdGV4dHJlZ2lvbjo1ZjcwYzFkMDM0NjM0NTMzYWM2ZWRjNDAwNTgzZTFmY18xODMz_d5ea189e-5bc1-47b1-9378-348199dab0b3"
      unitRef="shares">61107288</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNC0xLTEtMS0w_efb8371b-330c-4b61-946f-36cf13ae46f6"
      unitRef="usd">188970000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNC0zLTEtMS0w_37e2a447-8335-4867-902d-fe512be91c02"
      unitRef="usd">181131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNS0xLTEtMS0w_990835f0-f945-4770-a8ef-2c19fdbe329c"
      unitRef="usd">108346000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNS0zLTEtMS0w_f9dd2bf9-8841-4cfc-9720-f9924845f156"
      unitRef="usd">91400000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNi0xLTEtMS0w_9afcfd85-6808-41f8-91f8-3a630a3d9252"
      unitRef="usd">45248000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNi0zLTEtMS0w_49cff3cc-06f3-42f4-b96e-f21aaf0fe67b"
      unitRef="usd">23081000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNy0xLTEtMS0w_682193d3-9e26-4929-99af-efd79abaddd7"
      unitRef="usd">6476000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfNy0zLTEtMS0w_8ef901b4-cbc3-49e2-ae30-306df8a6c551"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfOC0xLTEtMS0w_b2efe85c-f253-415c-8722-3f5de87bd062"
      unitRef="usd">17956000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfOC0zLTEtMS0w_9d1dfa89-62e6-48f7-835d-6a96009d5743"
      unitRef="usd">16982000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTAtMS0xLTEtMA_26eb8ea8-c8a7-4f7e-9ff6-1cfc86fcb3ee"
      unitRef="usd">366996000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTAtMy0xLTEtMA_4653feb0-b12d-42c3-ba8b-028bcf69d00c"
      unitRef="usd">312594000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTEtMS0xLTEtMA_93f2f5c6-2416-4e6d-8151-de0375dec203"
      unitRef="usd">39395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTEtMy0xLTEtMA_21d7207b-f689-4049-9b7d-d58cb6818f39"
      unitRef="usd">42225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTMtMS0xLTEtMA_d002e928-a7d7-4132-a477-24d3397b096b"
      unitRef="usd">19520000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTMtMy0xLTEtMA_72293abd-537d-4d78-9d59-164fa20b6cb6"
      unitRef="usd">23924000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTQtMS0xLTEtMA_b769e9f4-16df-4f07-8244-41b7ecef8689"
      unitRef="usd">425911000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTQtMy0xLTEtMA_a0d56f80-8d2c-49c2-ae8d-ad198040eef2"
      unitRef="usd">378743000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTgtMS0xLTEtMA_9be817e4-5cd1-4cd0-b517-810a6771c53d"
      unitRef="usd">9818000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTgtMy0xLTEtMA_d8e8e8b9-ec5f-4b25-8de3-c66f6dab3a3a"
      unitRef="usd">8031000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTktMS0xLTEtMA_b8fbbd42-2937-43dd-9a79-acb7381c42ff"
      unitRef="usd">39174000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMTktMy0xLTEtMA_605f6c48-24bc-4994-83f0-10c3f7a0760b"
      unitRef="usd">34198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjAtMS0xLTEtMA_cd765ef9-98df-435a-a161-36bbda564bfb"
      unitRef="usd">16565000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjAtMy0xLTEtMA_9905a982-6009-43e5-917d-eef29ea31c3d"
      unitRef="usd">4456000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjEtMS0xLTEtMA_2c7f26e7-357a-4890-96fa-7b8546fdd08b"
      unitRef="usd">4367000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjEtMy0xLTEtMA_54c0f662-367a-4a79-9d5b-1f3bfec88c88"
      unitRef="usd">3988000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjMtMS0xLTEtMA_f6ebbcd7-122c-4c3c-94a7-82959841ce62"
      unitRef="usd">69924000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjMtMy0xLTEtMA_12c7df5e-6f63-41e6-8afa-3c108499f9b7"
      unitRef="usd">50673000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjQtMS0xLTEtMA_46087f49-3aaa-4334-9775-c79317ec0b71"
      unitRef="usd">13476000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjQtMy0xLTEtMA_7b28d27a-371a-4434-8814-d314da2f999a"
      unitRef="usd">6926000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjUtMS0xLTEtMA_cc37e24e-3224-4536-a27c-77638ea8320b"
      unitRef="usd">23208000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjUtMy0xLTEtMA_0dcbe22a-4051-46a2-b89b-c9a2fb84cf8d"
      unitRef="usd">25260000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjYtMS0xLTEtMA_2e52204d-bcd3-4f7d-baed-5401e728052b"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjYtMy0xLTEtMA_9bd25927-f102-474e-b0ac-f5caa0da0d08"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjctMS0xLTEtMA_7665df7d-efaf-4f4e-813a-4af75e338f62"
      unitRef="usd">106866000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjctMy0xLTEtMA_10938a96-5482-4efb-9d86-1519906091f0"
      unitRef="usd">82859000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzE4_27c69d79-27bf-400d-a38c-6294064a03fc"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzE4_35cd2d32-e30a-4d5d-9ade-b89cadb2ef09"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzM0_464e1198-75df-4ec7-973c-785e77788cc0"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzM0_9b19166a-ccdf-4cb2-a5c8-edd10c9ab295"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzU2_d5108268-ca23-4fdb-8583-13f8b482d82f"
      unitRef="shares">60133447</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjYwOGI2Mzk3YWEyNzRhNzU4ZjdlZWMyMDRhODNhYTRhXzYz_3df84c34-8a3d-4eb0-ba46-b5c295e7b8b1"
      unitRef="shares">56244771</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMS0xLTEtMA_83494fe9-4141-479c-86fb-aa0444860cef"
      unitRef="usd">601000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMjktMy0xLTEtMA_f991961a-0b71-4c1f-a333-5b0b4725b235"
      unitRef="usd">562000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzAtMS0xLTEtMA_b99b0100-9e1f-442b-83c3-d98ccce6bd3c"
      unitRef="usd">1181471000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzAtMy0xLTEtMA_056b8372-dbb9-4fb8-893f-6feae7605e84"
      unitRef="usd">1067150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzEtMS0xLTEtMA_f0c7a06f-c4f7-40df-8b2d-815d726e0344"
      unitRef="usd">1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzEtMy0xLTEtMA_c6db48e6-6540-43bd-8cc9-105fa1233025"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzItMS0xLTEtMA_86ba6082-b6e4-492b-9e19-c13141e9e8e8"
      unitRef="usd">-863028000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzItMy0xLTEtMA_fa18d8d6-83d5-4a7e-856a-77d8d5f17664"
      unitRef="usd">-771821000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzMtMS0xLTEtMA_4a17a2d3-c15d-444d-8004-af12cd1e7c9a"
      unitRef="usd">319045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzMtMy0xLTEtMA_2584ddc2-eaab-4a46-b18d-67ed3da02987"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzQtMS0xLTEtMA_fc4a47f9-4d35-400e-bd4c-03237d59e99a"
      unitRef="usd">425911000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18xOS9mcmFnOmIwMjllYjFjYjg5NzRhNjJiYTkxOGRjZTQ4Y2JkYTc2L3RhYmxlOmZkNzM5NGEzYjNkMDQ4ZTBhNGM1OGI3ZWU5NzdjMjk3L3RhYmxlcmFuZ2U6ZmQ3Mzk0YTNiM2QwNDhlMGE0YzU4YjdlZTk3N2MyOTdfMzQtMy0xLTEtMA_d42a2e4d-0f35-484b-88dd-900bd2443ba8"
      unitRef="usd">378743000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ia19bd22873f74ac0a9a206605b8cae68_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy0xLTEtMS0w_fed02b53-081c-49c0-9859-2747002d3efc"
      unitRef="usd">27168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38f40f3786724fa1ad473ad09803006a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy0zLTEtMS0w_f2dcaea8-4a1f-4f5d-b430-1f703ae585c7"
      unitRef="usd">15636000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0ff57e352254b318162eb9cc8c0797b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy01LTEtMS0w_a0a95179-912b-4c0e-b070-b7cff99d9939"
      unitRef="usd">42352000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0e9beb576154228ae3170843841bbf5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMy03LTEtMS0w_98074dc5-f19e-4fb2-8d2c-36f502d0aeb5"
      unitRef="usd">28603000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76efd339d1ef4e28bcc5cdc42f49e9c8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC0xLTEtMS0w_8fa827df-6ad4-4de7-99d4-6881d112c9bb"
      unitRef="usd">3203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i853dd351791c4152a984c61563c37d8f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC0zLTEtMS0w_1fa01183-b338-4ee9-bf04-01fcc7ea3daa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e75e38251ca4a8caee14deab3bdd4f4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC01LTEtMS0w_6c0a272a-44b6-46aa-adda-ed64e7bf3183"
      unitRef="usd">4090000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b7bb08c48834c529595375229b7976a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNC03LTEtMS0w_7b70d452-38cd-4477-9568-e3483ab87aa0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e184d60537c4ef9839e6bb7da1ac27c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS0xLTEtMS0w_21e61f97-9319-4d5a-a08d-88094d8a011c"
      unitRef="usd">386000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c15e8ab11cd498393b7b69806d30fdf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS0zLTEtMS0w_d0dd7c73-e95a-493a-a4e5-399d9cccd610"
      unitRef="usd">4621000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92cbfaf654bd427b8436cccb669008fc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS01LTEtMS0w_fe8ff75d-d7d5-42c9-a044-864ec1d51367"
      unitRef="usd">1196000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib201915352974536beb53d888f523fcf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNS03LTEtMS0w_0f62f37a-a059-495d-9d4f-02685da8f571"
      unitRef="usd">5336000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi0xLTEtMS0w_e00b144d-8430-4de9-8a8a-eadc68070edb"
      unitRef="usd">30757000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi0zLTEtMS0w_ef7436d1-009a-42f5-9d12-86134f6a0ae1"
      unitRef="usd">20257000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi01LTEtMS0w_2fb695ba-7310-47f5-8b0f-39fb7757037a"
      unitRef="usd">47638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfNi03LTEtMS0w_62a2577c-dc08-4698-9e9f-ababe61f6000"
      unitRef="usd">33939000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC0xLTEtMS0w_e13859aa-747e-4ffa-9bf6-ed4cef21a1e6"
      unitRef="usd">22000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC0zLTEtMS0w_7aa3a343-179b-44f9-8086-d1417c9e71f8"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC01LTEtMS0w_4c8e1254-1fed-43c4-94a5-26601285e1cc"
      unitRef="usd">39000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOC03LTEtMS0w_84b7a245-f89c-42ef-b6e9-277ac7bc7fd8"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS0xLTEtMS0w_ac17b913-1401-4e4e-b8fb-ed48e081bae3"
      unitRef="usd">55780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS0zLTEtMS0w_a2ab7eac-1f77-4c78-98cd-06a8b3c397fd"
      unitRef="usd">57351000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS01LTEtMS0w_8a45bb4e-a8e7-4982-bbac-713f1f28cfd4"
      unitRef="usd">108901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfOS03LTEtMS0w_8257e7c4-50c5-407b-91bf-e32143d97d54"
      unitRef="usd">106245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtMS0xLTEtMA_23dd7115-4c29-4fc9-aece-b1182dd8f11a"
      unitRef="usd">15234000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtMy0xLTEtMA_94aac6ed-b952-48bd-aafd-1336c7507f89"
      unitRef="usd">10216000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtNS0xLTEtMA_983c9f19-3117-4814-9115-73c54209f11e"
      unitRef="usd">30270000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTAtNy0xLTEtMA_5d560c04-6a6f-4af5-8472-f4fca5ce73a0"
      unitRef="usd">20449000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtMS0xLTEtMA_ffb9f854-0d39-42b0-88c6-ecbb53856f32"
      unitRef="usd">71036000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtMy0xLTEtMA_6de89dd3-9cda-4258-b4f5-b036171bb22b"
      unitRef="usd">67567000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtNS0xLTEtMA_867d9e9b-9cb0-41d2-88d5-b5fada71821c"
      unitRef="usd">139210000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTEtNy0xLTEtMA_37715cf8-d2fd-417d-8440-6f284071f3c0"
      unitRef="usd">126694000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItMS0xLTEtMA_e3a2bacb-41bd-4075-85a3-a7720fea4586"
      unitRef="usd">-40279000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItMy0xLTEtMA_8dc508ee-c6af-4cb4-9268-9cbed092f6ce"
      unitRef="usd">-47310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItNS0xLTEtMA_61a81b82-7857-4c80-abce-7a5e678c644e"
      unitRef="usd">-91572000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTItNy0xLTEtMA_0b5dc9c2-1d2e-4c22-98c5-0534fdfa6da8"
      unitRef="usd">-92755000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtMS0xLTEtMA_53bced5e-8967-4a71-9d14-d68e92d1368a"
      unitRef="usd">344000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtMy0xLTEtMA_2ddee466-9320-4ff2-9194-2f4449cb4e4e"
      unitRef="usd">425000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtNS0xLTEtMA_0aeb3709-6d71-4a08-9d36-65f27ecc07ae"
      unitRef="usd">365000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTMtNy0xLTEtMA_966b4c56-d375-4a2f-baf6-2b172e40925d"
      unitRef="usd">1146000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtMS0xLTEtMA_c187e9c3-7e16-4028-9e2e-8c0c48e4ca5b"
      unitRef="usd">-39935000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtMy0xLTEtMA_dde62575-bb05-41da-b854-0f5ee277eb0d"
      unitRef="usd">-46885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtNS0xLTEtMA_3bc508a1-52d8-404c-acf8-24d306ea5847"
      unitRef="usd">-91207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTQtNy0xLTEtMA_5cdb5007-30a8-4986-b31b-b39e684c52a4"
      unitRef="usd">-91609000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtMS0xLTEtMA_ca875108-e2da-49a1-b178-eb142f8a2520"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtMy0xLTEtMA_e0983e7c-0137-43a5-a2c6-3c33226bd9ff"
      unitRef="usd">-55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtNS0xLTEtMA_dd258d7f-85aa-486a-9be0-1876ada7c9a7"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTYtNy0xLTEtMA_3555df93-0d63-4036-a4c4-a1f484effb0c"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctMS0xLTEtMA_c3d68706-fd6a-4a2d-9b9f-f012770bf77d"
      unitRef="usd">-39945000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctMy0xLTEtMA_a8bb6282-eba1-4aec-be83-ff2753c44c13"
      unitRef="usd">-46940000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctNS0xLTEtMA_3b542390-19b2-4282-994f-a4298a796370"
      unitRef="usd">-91199000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTctNy0xLTEtMA_6fa16779-b6fe-4e7b-9d11-643cf9a07e54"
      unitRef="usd">-91608000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMS0xLTEtMA_66564df2-229a-4788-aacb-fe0c8985ca8d"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMS0xLTEtMA_91f69e45-ab60-46ce-8f3a-21903db76f56"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMy0xLTEtMA_88453eef-7532-4608-adc4-94ad2d67e68f"
      unitRef="usdPerShare">-0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktMy0xLTEtMA_aa4a09c3-3ecc-4a6f-9e13-a9e69dd6b92d"
      unitRef="usdPerShare">-0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNS0xLTEtMA_2397a2f5-361c-4899-b2b4-b8278f316234"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNS0xLTEtMA_a9326181-8dfd-4ba0-bd33-c1fdb1c3d933"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNy0xLTEtMA_13cab94b-1510-43cf-b8d8-a40ce84e9e52"
      unitRef="usdPerShare">-1.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMTktNy0xLTEtMA_2a8ba2fc-d86c-4156-8bb2-156e9a496ce8"
      unitRef="usdPerShare">-1.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMS0xLTEtMA_259c99d7-d503-4d79-b0e9-613abe2f8189"
      unitRef="shares">60068315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMS0xLTEtMA_bf6cb0bc-80b3-4e96-b08b-f80fccfe5ea1"
      unitRef="shares">60068315</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMy0xLTEtMA_9c75ceb0-dc5f-44eb-a3e2-aaf184168fba"
      unitRef="shares">50018462</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtMy0xLTEtMA_eb246f10-725b-4914-90b0-3978d47722fe"
      unitRef="shares">50018462</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNS0xLTEtMA_6e60d352-8e8c-40fe-a663-f519abb259e0"
      unitRef="shares">58643496</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNS0xLTEtMA_d7aba41a-d8f4-4581-ab09-94ca42ba853e"
      unitRef="shares">58643496</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNy0xLTEtMA_1869a4ce-f0c3-4218-8cd4-d8ef42436612"
      unitRef="shares">49515562</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yMi9mcmFnOjBmMTNiMTc2ZTBiNjRkODRiMTk3ZjM1ZDk4MGVhZDAzL3RhYmxlOmVhMmNlY2FiZjAxMjQ4NDBhZWU3ZjE4MGU4OGZmOGU4L3RhYmxlcmFuZ2U6ZWEyY2VjYWJmMDEyNDg0MGFlZTdmMTgwZTg4ZmY4ZThfMjAtNy0xLTEtMA_83dc6cfa-cc9f-4788-bf91-f8d3e03a4a66"
      unitRef="shares">49515562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xLTEtMS0w_67df5104-82d2-4f58-8e51-1476714e140c"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc961ba6e09d4e54a09e82c04d1b2125_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0zLTEtMS0w_98220733-7539-408f-83ab-d7d57ba226a4"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c79f10044b14566889926dcb759d15b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi05LTEtMS0w_06391073-3610-468a-95a4-9d98a6c594fc"
      unitRef="usd">1067150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i917763bbee93419ba52b562b02f1fc9f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xMS0xLTEtMA_9929ed16-11d6-4c76-ac9f-f23463a7e605"
      unitRef="usd">-771821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42019741bffb4bdebf0d0fc10733e31b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xMy0xLTEtMA_bf95cff3-fd19-4f16-8553-00f0dadafb0c"
      unitRef="usd">-7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMi0xNS0xLTEtMA_44156634-100e-4181-9292-59ea355a1b77"
      unitRef="usd">295884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMy05LTEtMS0w_6ea46499-c507-481f-a731-1f3a1fed934c"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMy0xNS0xLTEtMA_350a0a79-c45e-4e4c-9775-b891412b98c2"
      unitRef="usd">5243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0xLTEtMS0w_862dd877-9856-4cf9-9dbb-eb350f3661da"
      unitRef="shares">3622186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0zLTEtMS0w_4e435e10-27a8-4c1c-a7b9-989c4fb21a6f"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC05LTEtMS0w_75618388-d520-4e20-b0e5-a81e11e04cf3"
      unitRef="usd">98164000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNC0xNS0xLTEtMA_abf8074e-370f-4996-a906-d91c28278f41"
      unitRef="usd">98200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0xLTEtMS0w_8b2fbf14-18e5-4067-b96c-b9f8d6bea353"
      unitRef="shares">144249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ic6a0b20d66264260bbac7ce276bb703b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0zLTEtMS0w_40a488cc-e969-4e69-b85d-9c0d327ef94b"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ib0f13aebb3f342b68beabfedae59563e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS05LTEtMS0w_5ef843be-9913-4f5c-9226-6e0c51f93acf"
      unitRef="usd">2456000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNS0xNS0xLTEtMA_b09f2b50-34ce-4480-97e6-b48f2a24272f"
      unitRef="usd">2458000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie1dff43be20849fbbfa77443c32bea18_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNi0xMy0xLTEtMA_2f8ded12-73e8-4c94-923b-023c2b59caf6"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNi0xNS0xLTEtMA_6c6b44e3-4f6b-4457-9682-f0ba1fe1b98c"
      unitRef="usd">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ifbb93b0844574006b7a2e1722733077a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNy0xMS0xLTEtMA_760bb2f3-73fc-4ccd-ab15-458fff51a994"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i258e113cac8545e29fa1c772231215cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfNy0xNS0xLTEtMA_6f22f9e6-550e-482c-93c6-9d74fb4f8ae0"
      unitRef="usd">-51272000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iec2275ddaf7445d095b40fcc07d6df36_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xLTEtMS0w_d987f761-3ed2-4058-ab02-51315b0e6eca"
      unitRef="shares">60011206</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec2275ddaf7445d095b40fcc07d6df36_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0zLTEtMS0w_9fa8c1c7-56f9-4e36-8c09-af60f43c3470"
      unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6590518bff442f3b740132dadc9e104_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC05LTEtMS0w_60881dc2-be1b-4165-a83b-f388add96393"
      unitRef="usd">1173013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i161452ab42544aa7affbd585c14a6058_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xMS0xLTEtMA_296198a4-3b0d-404d-858d-446a792d2fe7"
      unitRef="usd">-823093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73079c43b74e40a19f380f476c7c8be4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xMy0xLTEtMA_a29841ac-bc0c-4f67-be67-aec0443df2eb"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7609a910c2984ce3b597382be696e095_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOC0xNS0xLTEtMA_245d9e38-d875-48b0-8c56-0b0468d91c06"
      unitRef="usd">350531000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOS05LTEtMS0w_bfa55f1c-29f1-4469-ba06-b69f6cf2202e"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfOS0xNS0xLTEtMA_289b5957-ea8a-4b85-9f20-01fd10016dcb"
      unitRef="usd">6113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMS0xLTEtMA_2e11ba37-6e54-4684-8447-b5f59fcfb92c"
      unitRef="shares">122241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia118ec8be9d7457e95622eb0a67dd1f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMy0xLTEtMA_841ff142-67a8-4ba4-8e30-3b0fbd9c75b3"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia40c79f5ac4b467ea316eedd4e9c1c89_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtOS0xLTEtMA_977bb1a7-e96d-4abe-bf4c-3d8400a8b49f"
      unitRef="usd">2345000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTAtMTUtMS0xLTA_4fecf0c3-e36f-4830-a1e9-f69e41246aef"
      unitRef="usd">2346000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4e70b8e9e28148aba70905165a33b688_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTEtMTMtMS0xLTA_e7750fe1-dd7f-4a2d-bdcb-6cc93b080180"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTEtMTUtMS0xLTA_36d26c7b-313e-4801-9fb1-9f2f7a9b16c5"
      unitRef="usd">-10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="i7ed833c461084728bd70aaae36add592_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTItMTEtMS0xLTA_e6060651-3875-46af-b769-959458be2d10"
      unitRef="usd">-39935000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTItMTUtMS0xLTA_43cc7100-d4be-4256-86ca-8d5b2396fd8d"
      unitRef="usd">-39935000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i93b668fed7b4433eb92e9256b8769b2c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMS0xLTEtMA_de5326ee-1ba3-4fad-a76d-be4779a62ead"
      unitRef="shares">60133447</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93b668fed7b4433eb92e9256b8769b2c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMy0xLTEtMA_59c3851a-0ae0-42af-8cce-eec1fb575ff6"
      unitRef="usd">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iacf8ef72a04e4570ae9b32da2e3d487f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtOS0xLTEtMA_d76480ce-83be-426f-b73c-d2a54fb3589d"
      unitRef="usd">1181471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c8177b0cd284c57877080228c9c1f65_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTEtMS0xLTA_799fedeb-0c98-4e95-b3d9-f7b035a93742"
      unitRef="usd">-863028000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib24f781a3ab9414a96ce5ecf52017885_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTMtMS0xLTA_7ec21b91-a6df-4e5e-b147-c59c440e7cd6"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOjMyY2QyMmVlMTcwZjQ4ZmViNDY2MzM2ZWY3ZmJkN2VkL3RhYmxlcmFuZ2U6MzJjZDIyZWUxNzBmNDhmZWI0NjYzMzZlZjdmYmQ3ZWRfMTMtMTUtMS0xLTA_8e31e612-6050-421b-ad71-caff8f4e1a0f"
      unitRef="usd">319045000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id22b7b809f714fb1b47a02dbddde5636_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xLTEtMS0w_e3a0a257-0c2d-4c6a-8b41-c7b4e617397e"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id22b7b809f714fb1b47a02dbddde5636_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0zLTEtMS0w_6358329a-c3ed-4010-b3a5-f5748569a77a"
      unitRef="usd">490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d06b08b99bb4bd48b3d044997ecee6f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi05LTEtMS0w_af15d3a7-321c-4a58-bbf1-62c92990c014"
      unitRef="usd">872204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafe0486181da473b833e2f3577c97501_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xMS0xLTEtMA_50a0cb9d-ff10-495d-b98d-486f04a08889"
      unitRef="usd">-642082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i452ce6d02a3f4d0f8e59b4e1791096e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xMy0xLTEtMA_699df73c-5c0f-4332-bea9-9a0c4c136b38"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47458184ab624f7d9b70f6018c42192e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMi0xNS0xLTEtMA_e614ca3c-29e0-4be2-bc76-a940ca24afc0"
      unitRef="usd">230628000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMy05LTEtMS0w_1b86d583-1c58-4bfb-89c5-a29e946ccea5"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMy0xNS0xLTEtMA_8b9f5403-461d-4b22-85bf-8b63fd6d31d8"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0xLTEtMS0w_91bd0964-5dcb-465a-a3f2-8a1be73cf38a"
      unitRef="shares">172387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="iad4a771d01d14e14823674d0ac27e240_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0zLTEtMS0w_3427871f-f3b8-4bc0-9cb0-c0b59fe8209a"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i7f204f20aa07428e8205ab58d95d2a0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC05LTEtMS0w_5580fde8-8bd6-469e-9ecb-35a7a755af5f"
      unitRef="usd">160000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNC0xNS0xLTEtMA_b3f385e4-2c2f-4b82-8425-34931a0d5def"
      unitRef="usd">162000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9b3319bcc35e44daaa195857f42cdf9e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNS0xMy0xLTEtMA_d008737b-cc89-4468-8924-b5e03f1ec11d"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNS0xNS0xLTEtMA_42853536-8cd2-471b-8f38-47acf19a6ad4"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i9328ec3a1cbb404aae355d158e8503d4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNi0xMS0xLTEtMA_75c0b998-2f70-4a11-a1f7-84176fd2c011"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNi0xNS0xLTEtMA_731a241b-561c-4dd6-8d53-369137839aa3"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7c305587a633404589fa54ed876d5095_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xLTEtMS0w_08055792-57ff-4efe-a272-30a3081e1723"
      unitRef="shares">49131150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c305587a633404589fa54ed876d5095_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0zLTEtMS0w_da4a8fd4-330f-4688-8522-50ff3ac99f52"
      unitRef="usd">492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97169e2cb62e4625b4cc2b1e15526583_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy05LTEtMS0w_9060daa9-aed8-4e50-ab1d-a174e732de46"
      unitRef="usd">876815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7df5ab9d1dac462495733adf3296e40f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xMS0xLTEtMA_b5e6b658-7576-444b-ac2b-7460717aa122"
      unitRef="usd">-686806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5477f3f6684f41afb7accd08c9b72160_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xMy0xLTEtMA_f7b3ced4-ef7e-45e2-8c79-20b21add0ea2"
      unitRef="usd">72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic127167e37e4421ca46cfaf5d2d8ed2b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfNy0xNS0xLTEtMA_25bb634c-70a9-4fec-89bc-f726acccc4af"
      unitRef="usd">190573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOC05LTEtMS0w_bec649ca-f70c-4e57-953b-38b2efe9c0f6"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOC0xNS0xLTEtMA_3c6df5d3-2846-46c1-a11d-0bd1b5d3b110"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0xLTEtMS0w_15c5fce1-8d63-42ce-ade6-ae8cec97824e"
      unitRef="shares">4060482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0zLTEtMS0w_b96b16c1-810c-4aea-af0e-286f6507788c"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS05LTEtMS0w_d812136b-f5f0-4e29-a006-229cccbcb030"
      unitRef="usd">96472000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfOS0xNS0xLTEtMA_f51cc2a6-2408-412d-92a9-ca9df7494b67"
      unitRef="usd">96512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4b444aca195c4179b007ae68d43c408c_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMS0xLTEtMA_1cee33ca-9fbd-4966-9973-3ca2043f61f8"
      unitRef="shares">173371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i71ca468ec7594cdda6eb47e595f7e56f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMy0xLTEtMA_cf182718-4dfe-43e9-83f3-dd918f5f8d61"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ieda2e5d2ae4441769383936cd80193ff_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtOS0xLTEtMA_5a313de3-dca2-4fa1-bed1-7876e81f6cbc"
      unitRef="usd">2501000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTAtMTUtMS0xLTA_0c19c43c-df91-4258-8aab-9a5e7e51d219"
      unitRef="usd">2503000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i41f8ccea1a3b42fa835d31417ecc4765_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTEtMTMtMS0xLTA_51707647-a6b7-418b-8aa1-df7609fbc08c"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTEtMTUtMS0xLTA_bc7a6fc6-c31a-45c6-bac5-f6d2165a5902"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="iae3d02417b124f71a20bb4eb62366e59_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTItMTEtMS0xLTA_cffccf4c-d7c0-47b3-9eec-4f9f01eaebab"
      unitRef="usd">-46885000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTItMTUtMS0xLTA_c3cd3865-f580-4730-827d-481a787e184f"
      unitRef="usd">-46885000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i707cfef686b74380a90156b94f5ed6cb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMS0xLTEtMA_899431d7-d71c-4164-85b8-2a63375cc0dc"
      unitRef="shares">53365003</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i707cfef686b74380a90156b94f5ed6cb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMy0xLTEtMA_f788e8e9-8858-4eb1-b666-15d2f8dcdbbf"
      unitRef="usd">534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9349f9216d947e6995521fe00f225b1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtOS0xLTEtMA_df86e0ca-0a98-42dc-bdb8-b5cfed56baca"
      unitRef="usd">980924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d373902fd2d4b8b9a7bd6404765e98e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTEtMS0xLTA_cc84a419-872a-423f-a793-7a32a6c45868"
      unitRef="usd">-733691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70478a7071c64ed8bc2a95031316c799_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTMtMS0xLTA_e29316cc-1938-43a8-8cdd-2d96cee8ac5a"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b6997c210694fe3a545294cd574e330_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yNS9mcmFnOjM1MmExNjc1NTAwYTQzNjRiNjViZGEwNWIyMGE1ZjZlL3RhYmxlOmJkZjQ3OGM3Mzg3OTQxYzNhNGFjMGFmMjNmZjE0MTkyL3RhYmxlcmFuZ2U6YmRmNDc4YzczODc5NDFjM2E0YWMwYWYyM2ZmMTQxOTJfMTMtMTUtMS0xLTA_de2bd85b-0040-4294-8441-52541fc7dd68"
      unitRef="usd">247784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMy0xLTEtMS0w_7aba6030-3d39-4744-bce5-6aa52ee16d38"
      unitRef="usd">-91207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMy0zLTEtMS0w_c543969c-ef16-4e52-9a34-4c5c0f810cc6"
      unitRef="usd">-91609000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNS0xLTEtMS0w_3ca625b3-cbd0-443a-b2f0-277f2de24eb9"
      unitRef="usd">5510000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNS0zLTEtMS0w_e5208785-9316-40b5-b8a9-3086cbdf35ef"
      unitRef="usd">6105000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNi0xLTEtMS0w_d1144b2c-ca8e-4a70-af8f-d2a46a9cbe52"
      unitRef="usd">-808000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNi0zLTEtMS0w_0770b1b3-ec21-4cf7-8428-dd60716bde8b"
      unitRef="usd">401000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNy0xLTEtMS0w_4df84b59-2fa2-4d0f-a229-f92f9a3b9a00"
      unitRef="usd">11356000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfNy0zLTEtMS0w_27ac0fa7-5a85-4c61-9c72-f5ead6f8ec3b"
      unitRef="usd">9587000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfOS0xLTEtMS0w_14d7752b-e9ed-4604-839a-61cffd849243"
      unitRef="usd">22166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfOS0zLTEtMS0w_8230e9a4-6750-496c-a043-b28b84b0cd08"
      unitRef="usd">6461000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTAtMS0xLTEtMA_9adf7b0f-6b90-4f25-8af0-d4d370efab5e"
      unitRef="usd">6476000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTAtMy0xLTEtMA_24befbf6-2fa1-4f98-a45a-fe74ad30b42d"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTEtMS0xLTEtMA_c124f038-2db2-48ab-89bd-954c7a5a5225"
      unitRef="usd">974000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTEtMy0xLTEtMA_24ade18c-34e9-4f48-8609-17a1e62838b8"
      unitRef="usd">-3093000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTItMS0xLTEtMA_5bc1457c-0323-49c0-8612-bf54937e72c8"
      unitRef="usd">-4404000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTItMy0xLTEtMA_a98db3cd-7dce-4f6f-b471-b37be9c588b9"
      unitRef="usd">-995000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTMtMS0xLTEtMA_a203e4ee-e448-40bc-8e1b-fa7e2aabfe6d"
      unitRef="usd">1668000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTMtMy0xLTEtMA_460dfaee-56fd-46ec-a4f4-088ec821217a"
      unitRef="usd">-1476000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTQtMS0xLTEtMA_c6e46e19-0f57-43c9-80a6-dad1d9f19824"
      unitRef="usd">5365000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTQtMy0xLTEtMA_4d8e8c37-8ca3-48e3-ad23-ae9b7f7fd1ff"
      unitRef="usd">3337000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTUtMS0xLTEtMA_37ba8c04-f39b-49da-824f-d0002ae779f1"
      unitRef="usd">-1673000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTUtMy0xLTEtMA_bc2e614c-bb09-4dee-b054-6731a13638c2"
      unitRef="usd">-1534000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTYtMS0xLTEtMA_8fa0c78e-f036-42b4-a59f-97ce4360048b"
      unitRef="usd">18659000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTYtMy0xLTEtMA_9516fb3f-c274-4971-8ab2-e911bcebe257"
      unitRef="usd">-3767000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTctMS0xLTEtMA_4ea7c9a7-3d27-4360-89ca-efecb6908a2f"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTctMy0xLTEtMA_c4974030-58da-4fcf-b8f5-511af58905fe"
      unitRef="usd">1443000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTgtMS0xLTEtMA_5ebf9b88-ba1d-4f9e-aa1c-a3f91109bece"
      unitRef="usd">-74726000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMTgtMy0xLTEtMA_49e033cf-3ab3-4b0a-9509-3b43cf3befbd"
      unitRef="usd">-80688000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjAtMS0xLTEtMA_02ce8442-45dd-40bb-ad1b-3040ce4e9946"
      unitRef="usd">117546000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjAtMy0xLTEtMA_e6783658-1170-4a38-85a1-bf6af483ed10"
      unitRef="usd">72199000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjEtMS0xLTEtMA_ccaac107-17e2-4806-920c-8e4d11e96018"
      unitRef="usd">99800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjEtMy0xLTEtMA_1eb8bf9b-6e4e-4b80-b4a3-7f65c00ec6e0"
      unitRef="usd">125617000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjItMS0xLTEtMA_fdc36279-c8bf-405f-ae0c-096bc14e2bf0"
      unitRef="usd">2693000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjItMy0xLTEtMA_ec0f895c-9c56-4e07-b81e-fd25c55d08fa"
      unitRef="usd">1847000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjMtMS0xLTEtMA_4f914723-a0e2-4d0a-97ce-f29376e10c03"
      unitRef="usd">-20439000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjMtMy0xLTEtMA_b97f4f9a-7f1c-4c42-962d-9aba8892a753"
      unitRef="usd">51571000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjUtMS0xLTEtMA_7d706e2c-2c92-4ad0-9b5f-ecff078cb114"
      unitRef="usd">98200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjUtMy0xLTEtMA_a2c24b40-ee64-4f2f-8803-9ac1fe696aea"
      unitRef="usd">96512000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjYtMS0xLTEtMA_b5b145f5-65e9-4126-8be1-9e11f737cf3c"
      unitRef="usd">4910000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjYtMy0xLTEtMA_cec004be-63bd-476f-a32c-bc1a2244a49d"
      unitRef="usd">2665000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:RetirementOfTreasuryStock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMS0xLTEtMTg4NA_24bc5a94-eefd-403e-9a55-c5123a1f5de0"
      unitRef="usd">106000</mgnx:RetirementOfTreasuryStock>
    <mgnx:RetirementOfTreasuryStock
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMy0xLTEtMTg4OA_e7594163-3acb-4a50-af07-5b3f63a07ac1"
      unitRef="usd">0</mgnx:RetirementOfTreasuryStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMS0xLTEtMA_7a1343b1-ebb9-467d-ae67-511199bf8428"
      unitRef="usd">103004000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjctMy0xLTEtMA_3b6d5017-2ee5-4253-b3db-94cc84c90426"
      unitRef="usd">99177000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjgtMS0xLTEtMA_6403467e-3f25-46cf-8656-b3b285f70ce9"
      unitRef="usd">7839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjgtMy0xLTEtMA_afb1b3e9-eb76-4a43-a5a6-ad367582b795"
      unitRef="usd">70060000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjktMS0xLTEtMA_c5cdf419-0805-459d-93a3-eb4cd03a9a57"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47458184ab624f7d9b70f6018c42192e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMjktMy0xLTEtMA_d15509e8-5a13-4439-b119-a7badefa9c7e"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzAtMS0xLTEtMA_739fb4df-9b7d-4935-8db7-cb56f1c6d026"
      unitRef="usd">188970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9b6997c210694fe3a545294cd574e330_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzAtMy0xLTEtMA_802065ac-4bf0-45f8-acc3-cee0b2960fed"
      unitRef="usd">196532000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzMtMS0xLTEtMA_93af195a-26f0-4ca5-8064-4be308441d2f"
      unitRef="usd">118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18yOC9mcmFnOjM1NGEzNThmYjMxMTQ3NmJiZGQ2ZWQ4MjJmZWU5NjMzL3RhYmxlOjliNjEwZTgxYzkzMjRmZWZiMThiN2MwMDAyYjgzN2IzL3RhYmxlcmFuZ2U6OWI2MTBlODFjOTMyNGZlZmIxOGI3YzAwMDJiODM3YjNfMzMtMy0xLTEtMA_bcd6f06b-6c09-40d9-8e3f-a934e441a770"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNC9mcmFnOjA4YjBiYTc1ODMwYzQxZTk4NmM0ZDQ5YjlkNzgwYTFmL3RleHRyZWdpb246MDhiMGJhNzU4MzBjNDFlOTg2YzRkNDliOWQ3ODBhMWZfNTEzOQ_22a32144-b2fc-4438-85bd-30db0bca9579">Nature of Operations&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with our commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNC9mcmFnOjA4YjBiYTc1ODMwYzQxZTk4NmM0ZDQ5YjlkNzgwYTFmL3RleHRyZWdpb246MDhiMGJhNzU4MzBjNDFlOTg2YzRkNDliOWQ3ODBhMWZfNTE0Mw_29278ea7-40c7-4361-9be2-04fb73b91b69">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg5MA_68106058-c963-4851-9357-9dbaa2073c72">Summary of Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources the manufacturing of MARGENZA.  Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, the Company began capitalizing MARGENZA inventory costs.  The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, the Company&#x2019;s inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4Nw_8227fa1a-9257-4401-823d-b361c92e7a5d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources the manufacturing of MARGENZA.  Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, the Company began capitalizing MARGENZA inventory costs.  The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, the Company&#x2019;s inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <dei:DocumentPeriodEndDate
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfMzg0ODI5MDcwNjQzNw_42d86a73-cb8b-43d9-83bc-d1ca481d8fb6">2021-06-30</dei:DocumentPeriodEndDate>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4OA_4d9c1dc6-da9c-455d-b6bb-78f97663d7a1">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg5MQ_c3e2d3de-4188-4528-bd80-99c78a05fa44">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y18zNy9mcmFnOmVkZDRmYzZmMmQxZTRkNjVhNTNiNzg5MGIzYzVmZjk5L3RleHRyZWdpb246ZWRkNGZjNmYyZDFlNGQ2NWE1M2I3ODkwYjNjNWZmOTlfODg4OQ_abd1dafb-3f59-40bd-97f8-5cfff470fb1a">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2Nw_9223c22c-a6d8-459f-a891-8d9a2f94739b">Fair Value of Financial Instruments&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at June&#160;30, 2021 includes approximately $34.9 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2OA_3b545e55-e242-4d91-889d-8d7a7828f11d">&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMzE2NQ_8b2d5752-c505-4724-8d45-1be53291568d">&lt;div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at June&#160;30, 2021 includes approximately $34.9 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6fb28ceedb1540108416cb8bca024ee4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC0xLTEtMS0w_a291c283-adea-4716-80c8-03f17ec50db0"
      unitRef="usd">16606000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib51ff6fe1df945d6b5eadae49de900c2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC0zLTEtMS0w_a65cc32f-b47a-4936-a13d-bd3cc4f3a0ac"
      unitRef="usd">16606000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i83b573ab28a7443fb6e2a68919628472_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNC01LTEtMS0w_20f071af-4c67-4ed0-9e6e-b1d39101d71a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40d06e9e2b764360be3789ec5ab6a466_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS0xLTEtMS0w_90966ee7-616d-4fe3-b264-c5b1a6791cbe"
      unitRef="usd">79249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b2e9df501b44b06a59a0ece2160ed78_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS0zLTEtMS0w_974f18be-b09e-4e77-862f-8f3d23992aa1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3d2f52795c84d73812fd8848443f816_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNS01LTEtMS0w_ae758fe3-eace-4133-b2b0-50818556b025"
      unitRef="usd">79249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73dcce00de9e4cd2b1e37144f3a6efb4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi0xLTEtMS0w_fc4e1a19-a313-4bce-a9cc-6a516635741f"
      unitRef="usd">4537000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id543c07e6c994f5e81a39df1116c9a43_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi0zLTEtMS0w_5e27e12e-b2a3-49b3-8124-ea90bafdaa32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5eb0c9e3480346519ecf6c1f0c46c8d4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNi01LTEtMS0w_65bd8721-016d-47cd-8b01-dd30e81eb389"
      unitRef="usd">4537000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if44450b3df944c238f4634852f259160_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy0xLTEtMS0w_2295c68e-026c-4bb7-bfd9-71da48efe8b4"
      unitRef="usd">42809000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8321253ab6944229be7fba40e19eaef4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy0zLTEtMS0w_eadfa205-0ba1-4f07-9bef-2f6083a71ee0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic17fd2407aa14c1885237d1cc1a99fee_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfNy01LTEtMS0w_4abb2e1a-d854-4c20-a09c-99d3998aa210"
      unitRef="usd">42809000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9774f5bea6ae4560a38cc67f40b9694a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS0xLTEtMS0w_05c12200-057b-427e-b6a0-670b862db797"
      unitRef="usd">143201000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b77778502a64bc1ad848b961aa391bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS0zLTEtMS0w_7800f812-cd11-41e8-80a0-d61a41b01f56"
      unitRef="usd">16606000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7b11553fdaa4460bac14c9901e981643_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjY3YTk5Y2I4NjZhZTRkMDhiNDg2ZDk3YTdlMzVlMTBhL3RhYmxlcmFuZ2U6NjdhOTljYjg2NmFlNGQwOGI0ODZkOTdhN2UzNWUxMGFfOS01LTEtMS0w_0a8a7472-1c36-4b8a-9af0-87dc8c700948"
      unitRef="usd">126595000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id3589e18fbb24f8fb2e18deeb6b2ff7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC0xLTEtMS0w_0c8cacfa-5f88-40ce-89a7-e4a8c9910362"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i59efcafb8dc24c15928c3bf8b28d0df2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC0zLTEtMS0w_c859ce7f-02a2-445f-808c-9ca1df46ac1a"
      unitRef="usd">49004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e5f4c9915d34ba697c4c5e8998d9344_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNC01LTEtMS0w_eb9a6e1e-e978-43f5-82b0-edc0c7028dd2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec1db23c95b04160ac16470c83f6bda2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS0xLTEtMS0w_61eaa00d-7aab-4aba-8207-aa941b9480d6"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie12e9d4d981b4c19ba9b2c60dd287996_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS0zLTEtMS0w_734a2b36-43d1-4cbe-be52-c912f90e2372"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e33921e4885474fb00cc964f9793e92_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNS01LTEtMS0w_613223ce-b0e9-43a9-9f97-1b28c231783d"
      unitRef="usd">60623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife1b38058b7d418fb1b1f00846e9a5a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy0xLTEtMS0w_e4c98579-cc01-4800-88de-734963f25ec2"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3868bf3d920462993a7d358e34b30d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy0zLTEtMS0w_47656041-b521-4c5d-bd59-ab7188830fa6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc01255ced4f4b16a80a1fce94c5ffe7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfNy01LTEtMS0w_169386cf-2cec-45d4-9e71-6da4909e56d1"
      unitRef="usd">33776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iba0e04aa3d8740cb98428d2ac4def939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS0xLTEtMS0w_4fa6e61f-798d-4cc6-bcba-a77239c2e990"
      unitRef="usd">143403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd632afb09594801ad294cc7d9a4a993_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS0zLTEtMS0w_0b935186-3be9-4871-a479-23f6cae79777"
      unitRef="usd">49004000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c8e49b4de5f49a99c026fef5d247a0d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RhYmxlOjJjMjBmZDkyZjVjZTRjYjQ4ZjUyMzgxMzBkZWE0NWY1L3RhYmxlcmFuZ2U6MmMyMGZkOTJmNWNlNGNiNDhmNTIzODEzMGRlYTQ1ZjVfOS01LTEtMS0w_ea8ff338-4326-4916-8e11-e6bffc529d17"
      unitRef="usd">94399000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9774f5bea6ae4560a38cc67f40b9694a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMjUwNQ_ce7ad6e5-f9ea-4481-bd9b-d5889bf8731b"
      unitRef="usd">34900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iba0e04aa3d8740cb98428d2ac4def939_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180MC9mcmFnOjkwZTZmYWVkMjFjMjQ5MjFhNzViNjViNzUwMjZiZjhjL3RleHRyZWdpb246OTBlNmZhZWQyMWMyNDkyMWE3NWI2NWI3NTAyNmJmOGNfMjY1MA_637188b2-bf89-4f40-9388-831b60a2a653"
      unitRef="usd">52000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfMTAxMA_568ba40f-0ece-419b-b5fc-453d2b4bb3fa">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;All available-for-sale marketable debt securities held as of June&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfMTAxMQ_88083000-8e1a-4ce4-bffe-0c2988a4f492">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi0xLTEtMS0w_9c55ad73-3c81-4939-91b4-cdffcb634c65"
      unitRef="usd">79244000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi0zLTEtMS0w_94e592bc-41cf-4830-a580-be0f1af2de81"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi01LTEtMS0w_bb3e8a58-28de-492f-b116-6659c2a4142e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6bac3aad3b04aab8cf86d0dc16117ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMi03LTEtMS0w_0f1116fd-fea2-49ef-b9a1-ddb71213c77d"
      unitRef="usd">79249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy0xLTEtMS0w_969a6207-d4c8-4e6e-aa86-00c5769f6832"
      unitRef="usd">4537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy0zLTEtMS0w_52b47157-fb06-46a7-aa80-0cebbef0329b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy01LTEtMS0w_f5ea98e7-15d5-4929-83bb-274c93eedbec"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i450a42d65a474d28a3b9cfdf107e5fcb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfMy03LTEtMS0w_d5873bfd-12a6-4b18-9050-a3c6b3194088"
      unitRef="usd">4537000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i52b46015190047069180f72c9a65f3be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC0xLTEtMS0w_d597174c-20bb-47ea-9e45-3f06b814bbb7"
      unitRef="usd">24564000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i52b46015190047069180f72c9a65f3be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC0zLTEtMS0w_b1c65b39-2841-4ef9-9d9c-8c9018153336"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i52b46015190047069180f72c9a65f3be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC01LTEtMS0w_ba1d11ef-9704-4e5a-b23b-4c5abf25b273"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52b46015190047069180f72c9a65f3be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNC03LTEtMS0w_73f5fef4-34ee-482f-ab0f-00fda6309aad"
      unitRef="usd">24560000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS0xLTEtMS0w_884ed37c-04a8-44e8-991e-173cd812fc95"
      unitRef="usd">108345000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS0zLTEtMS0w_915bb142-08d6-4192-8c41-68baf5339d1a"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS01LTEtMS0w_765bea8b-b97d-4140-b539-b83d4799c6bc"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOmQ1ZWU5ODIwYmJmNDRhYTViODk2NGY4ZTQ1ZGVlMzUzL3RhYmxlcmFuZ2U6ZDVlZTk4MjBiYmY0NGFhNWI4OTY0ZjhlNDVkZWUzNTNfNS03LTEtMS0w_8f884f17-ddb2-4ec1-8452-8a14592237f8"
      unitRef="usd">108346000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi0xLTEtMS0w_85d21c87-6811-4433-bbac-5163af4811a4"
      unitRef="usd">60630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi0zLTEtMS0w_9eba1c56-6f77-468d-ad81-96a8fbc5ef7c"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi01LTEtMS0w_1f9ef834-22f0-40bf-9ecb-09c86b0adda3"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f37ea86fbe3464281a3b689c34fa6ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfMi03LTEtMS0w_3a518eb1-c495-4a73-9af8-91dde70e360b"
      unitRef="usd">60624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC0xLTEtMS0w_5571383c-cd42-4186-9699-ac28e851eb0e"
      unitRef="usd">30777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC0zLTEtMS0w_7823c6da-a0fb-48c1-b4f9-ce0899dfe9e3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC01LTEtMS0w_5a2e8a4c-a085-4552-8617-d17bbc1a1611"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d64957ade7c4a6fa0ee4e15da9e81f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNC03LTEtMS0w_8ae81d9b-3226-49ae-a4a2-e49f40fbecbe"
      unitRef="usd">30776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS0xLTEtMS0w_e2425498-d648-4e77-93f4-0df5a86029c7"
      unitRef="usd">91407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS0zLTEtMS0w_47a88a97-d344-4987-a35c-5cad74670756"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS01LTEtMS0w_64d565c5-a923-47b1-8bb8-abccdba1da57"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RhYmxlOjZlYTc3ZDYzZmEyMTQxYmJiMDkwNGU4YzcyM2I4YTUzL3RhYmxlcmFuZ2U6NmVhNzdkNjNmYTIxNDFiYmIwOTA0ZThjNzIzYjhhNTNfNS03LTEtMS0w_0c017eac-8d43-4d23-bf4c-75490d1fd1c2"
      unitRef="usd">91400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfNjc4_9497e606-0069-4a1f-8248-adeb2b9307de"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180My9mcmFnOjIxY2U2MGZhMjQ5MzQ5MDM4NzQ3ZmJiYTJmYjRiYmRmL3RleHRyZWdpb246MjFjZTYwZmEyNDkzNDkwMzg3NDdmYmJhMmZiNGJiZGZfNjc4_e417056e-bbb4-41ec-87c3-b39ba19a098f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RleHRyZWdpb246Nzg4YWM0YjNjMmUzNDAwYWFmMDFmMDcyZDc0NjA1ZDVfNDc2_ca76aeef-df0a-4a93-ba46-f9ffba6338d5">Inventory&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RleHRyZWdpb246Nzg4YWM0YjNjMmUzNDAwYWFmMDFmMDcyZDc0NjA1ZDVfNDc3_e7e04cbf-4ab0-4d18-8650-a31e4249c88f">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMC0xLTEtMS0w_058aadba-8241-4ddf-b575-16259b76f01b"
      unitRef="usd">607000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMS0xLTEtMS0w_7b9bf8f0-1852-4a00-88c5-449999693acf"
      unitRef="usd">5869000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180Ni9mcmFnOjc4OGFjNGIzYzJlMzQwMGFhZjAxZjA3MmQ3NDYwNWQ1L3RhYmxlOjk2YWVlMjIzM2M2MjQ5NTliYjQzYTE2NzU0NDQ5NWYyL3RhYmxlcmFuZ2U6OTZhZWUyMjMzYzYyNDk1OWJiNDNhMTY3NTQ0NDk1ZjJfMi0xLTEtMS0w_46391407-7746-4a00-8f44-98c327e6d9df"
      unitRef="usd">6476000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNzY5_2a57a12c-3d3b-4f5c-9c14-f026a1d099f9">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the three months ended June 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="iec4534615a7743539c120849d9bac73f_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMjAw_90a9efa1-53fc-4b6e-984c-1617c0206b7b"
      unitRef="usd">100000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNTc2_692a974f-8402-4303-9b51-27add28e538b"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i63752c4319324224891b621130d37dd7_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNjQz_c68d1a9c-4e72-4d28-9391-ed14b173a3d3"
      unitRef="usdPerShare">27.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id23c622f1dd645acaca3a084dcc7713d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfNjkw_4178fc80-028f-4336-b04e-d8191a95a968"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="iec4534615a7743539c120849d9bac73f_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMTA5OTUxMTYyOTI0Mg_46f76411-bbad-4d6e-97f1-7a7974bac04a"
      unitRef="usd">100000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="i1fb5607c3098402584a482d05ebd33a4_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y180OS9mcmFnOmU0NTcxYTBkNGFhODQ1ZTNiMjY3MGM0NDUxY2U2ZjkxL3RleHRyZWdpb246ZTQ1NzFhMGQ0YWE4NDVlM2IyNjcwYzQ0NTFjZTZmOTFfMTA5OTUxMTYyOTIyNg_7a067889-c412-4e80-aaab-0613d81d9c55"
      unitRef="usd">300000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI3MjI_0e5d6249-b3c5-4ac7-8856-4cbaad7cb79f">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.  In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. The PDUFA target action date for retifanlimab was July 25, 2021. On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its BLA for retifanlimab.  Incyte&#x2019;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluated the Incyte License Agreement under ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From 2018 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for deve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lopment milestones totaling $70.0 million related to &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.  Therefore the associated consideration was added to the estimated transaction price.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the three and six months ended June 30, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;it became &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;probable that a significant reversal of cumulative revenue would not occur for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; $5.0 million and $15.0 million in milestones related to development progress of retifanlimab, respectively, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. No revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2020.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $0.7 million and $1.5 million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $0.8 million and $7.4 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  six months ended June 30, 2021, the Company recognized revenue of $2.8&#160;million and $5.9&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $3.6&#160;million during the six months ended June 30, 2020 under the 2018 Zai Lab Agreement.  There was no revenue deferred under this agreement as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021 or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $0.5 million and $0.3 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $1.6 million and $1.3 million, respectively, related to the Zai Lab Clinical Supply Agreements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab will pay the Company an upfront payment of $25.0&#160;million, which was received in July 2021. Additionally, as part of the consideration for the rights granted to Zai Lab &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab agreed to pay the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the estimated $5.0 million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services  performance obligation will be recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2021, the Company recognized revenue of $14.4 million under the 2021 Zai Lab Agreement.  The upfront payment of $25.0 million and the purchase price premium under the Stock Purchase Agreement of $10.4 million were recorded in Accounts receivable as of June 30, 2021 as the Company has an unconditional right to the payments under the 2021 Zai Lab Agreement and the Stock Purchase Agreement.  As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021, there was $21.0 million in deferred revenue under the agreements, $13.2 million of which is current and $7.8 million of which is non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years. During the three and six months ended June 30, 2021, the Company recognized revenue of $0.6&#160;million and $0.9&#160;million, respectively, for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $1.7 million and $1.4 million, respectively, under the I-Mab Agreement.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $2.3 million and $2.5 million, respectively, under the I-Mab Agreement.  At June&#160;30, 2021, $9.0 million of revenue was deferred under this agreement, $3.4 million of which was current and $5.6 million of which was non-current.   At December&#160;31, 2020, $11.4 million of revenue was deferred under this agreement, $4.5 million of which was current and $6.9 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;The NIAID Contract includes a base period of up to $7.5 million to support development of MGD014 through Investigational New Drug application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $0.4 million and $4.6 million, respectively.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $1.2 million and $5.3 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i9a811db172dc46c389a4e8977a0b88f8_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjg5_514ddb46-a1b0-4ab6-ad9a-a134568c552a"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI1MA_145f8df4-5664-4b3f-9deb-1318ae206280"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTMwNA_08462610-aa3e-4c5f-bb67-ba9f8b45d297"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQyMw_8f04a492-3502-4c68-ba6b-7d72eb9ceda3"
      unitRef="usd">70000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i6d4183f898a0423387191ba8e659530d_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTU5OA_7e31e45f-cff9-4f9b-a096-6884de2a2b4d"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="idc63dbbc38b240d1af689f955b93c987_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTYwNA_18754aea-a40f-4314-b499-e38d8fd67413"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjE0Ng_50f9fac0-5288-4ce8-a210-07cd85be2c8d"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i9f80fe9e7bec4828b5adff9615c79488_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjkzMw_957634a0-c1ae-4be3-a241-b7b77355ef82"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="icc80225f5c5a4306a9531352081e6f65_D20180101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDUxMg_8f04a492-3502-4c68-ba6b-7d72eb9ceda3"
      unitRef="usd">70000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="if8dec3cac0d747668fbb6d511275eb4c_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDc4OA_4199fd66-4e30-4dfb-949a-b7c0b2b8a24b"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i7ed1c4f887fe4a6ab8129e8f4d557b41_D20170101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDkxMw_5cc5ab08-bfc0-483b-8ad5-8b939f3336e1"
      unitRef="usd">4000000.0</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i18c024e23c894d508ae4b2d764a1da84_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyOTk1MA_0771bb88-3117-4a75-ad98-73ebd6fa46f4"
      unitRef="usd">5000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i9def7feacecb40599d50a6c2b00e945b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNTcyMg_fe3b6d5c-ade8-4a64-8197-c455d59b2782"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="icc58eaa1973040f49a6096c0ae8ec4e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNTM0OA_df10cece-2790-41fb-8a21-32e506b30f23"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec2554e54b31431db356c26b68680c0d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNTM0OA_f9c25227-de23-4493-ac80-9128c34ace18"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id94ec4f166294424905e9b5dfce87d38_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjQ3NA_10c958a5-ab2c-47d8-bea0-a2949790fc61"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44ea624c784446d2945c9719b9e70291_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNjQ4MQ_3c48e161-145a-40ef-b450-1be8e72e098c"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b9ef71b5922414e9101d383252c8b6c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI4Mg_bccb9cb0-91cd-4bbe-b4dd-05c2d441af27"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i497d64ec91f141f692c999a205a6507b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI4Ng_a4bbc62e-0d35-42c4-b352-61e6573459fc"
      unitRef="usd">7400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a034427f78f478893b443a6a23c1cd9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzM1NQ_73f16751-63f6-4e21-96c5-7649bb74dc17"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dd946ed05704d57ad5030149625825b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjI5Mw_7084dec6-b01d-44ea-a6d0-8f8cae1c8647"
      unitRef="usd">5900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODY1NA_4a1f2d6b-cbce-41f4-95ed-b123383665cf"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODY1OA_4429d9fe-c2fc-4725-b602-2b6582c233fd"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODcwNw_c2efa122-f941-4ebd-b726-a05e5ea172d6"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i858f318333da414da051fa53d0aed818_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODg1Mw_76cc3c25-6546-4a72-bc40-e303f05d32d2"
      unitRef="usd">140000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:Revenues
      contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODg5OA_06b079e4-671d-4b8f-acbf-dc6dcb4a491d"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODkxMQ_a27fc0b4-6757-4f65-aa2a-46bd1b26542b"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesTaxWithholding
      contextRef="i38dde1119b90463aa2f42d688bdc6540_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfODk2MA_1f57fa2d-5104-4f1b-90dd-c2afafafdda5"
      unitRef="usd">400000</mgnx:RevenuesTaxWithholding>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i7bbaab8beada4a8e8fd4d70b878b36f9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfOTExNw_95abfbe8-cbd2-44c0-80fb-427d66755b19"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ia4f6d5d295fa4f4ab2ad7678c47b90a0_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfOTI0MA_76167091-3687-476c-8d2b-37f9b241a5bb"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA1NDA_4429d9fe-c2fc-4725-b602-2b6582c233fd"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="id4e465ebe0e74740a272ba2347ea429d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY5MTgxOA_af8d8d17-9f45-43bd-bd0f-8e90e0710fa4"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4f0836069df741f4b40628f7e6d2e4cf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI2NTk_8f5619c3-b9ba-420e-8f4f-c4260d1c7d04"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i70c80046e2754387bbfb3a68414afafb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTI2NTk_dd36a190-76dd-423c-849d-4ed2170222d8"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i718f9275d3084eed957a877fcabb3eed_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjUxOA_88ea5fce-753d-4e0f-af1b-5701f66dfee6"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i624b7721e711450790fb78703bdfac0e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjUyNg_ffdf265f-b322-4642-b1ec-d2aa2cec9490"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id74f1cf826ca407fb2869bea2077efc9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjYwMQ_2cd8761d-ba03-49c2-9918-f90efb5ad153"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fa68fb09ce643209722e4c7061f1dc6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjYwNQ_093044d6-b599-4eb7-9b4f-5958c3cda24c"
      unitRef="usd">1300000</us-gaap:Revenues>
    <mgnx:OptInFee
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzI3Mg_4726a58d-c838-42d4-ad47-cbdeffe03320"
      unitRef="usd">85000000.0</mgnx:OptInFee>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzI5Mg_245fb328-42fa-4724-98dd-f58f791d69b8"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTgyOQ_9bcad282-3665-4eee-a4ef-4988c1bdca6b"
      unitRef="usd">30000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4ODAwNg_555216f5-7f85-46fc-bf1a-ce33b4b51ff5"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTg5Mg_e633e453-4cf2-4a3b-84a5-928c5caa5eda"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDc1NTkyNQ_c681adf4-ece1-4f11-940b-b46dcd14a79c"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzMxMg_b737c98f-584f-4c68-9f56-30e134c4e1ef"
      unitRef="usd">800000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzMzMw_cf67daf3-3919-4983-8f15-a7f614ab46d9"
      unitRef="usd">600000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQzOA_4fef8785-c958-41eb-b0d4-b5eb180e1ef9"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ1NQ_cfa54518-51f6-43c1-9aff-da4675744aa4"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ3Mg_f7e3f32e-6097-43fd-8493-85140015a13d"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzQ4OA_aa185b4c-6397-4eac-bfe1-46428c769e0b"
      unitRef="usd">5000000.0</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iddbdc4dc3248428491ce2f845de0d6f6_I20210615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUwNQ_34b20825-5bf2-437e-977a-17c957abd8fe"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i77288252481a45bb8d2a69bd1cc3b2df_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUyMg_67700b62-91bd-43d8-ac8d-e9d85364c5d9"
      unitRef="usd">14400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUyMg_f0fe827a-2e62-40fc-a567-cc8d597f8bd9"
      unitRef="usd">14400000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i648f99985e1c4a64bd51c74cfba57ee4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzUzOQ_60651bbd-7c0f-49c9-b497-d4080eaab55c"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i174499c398454c42876e617baa38de83_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU1Ng_d1442c32-2987-49b2-a671-875d6444ccd9"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8c57174988914ce89f16563fb7997562_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU3Mg_7223eafa-f899-4c82-8228-e1d3bcc6fac9"
      unitRef="usd">21000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8c57174988914ce89f16563fb7997562_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzU4OQ_cf587f33-58ea-44a9-8303-f9d113cfa66b"
      unitRef="usd">13200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8c57174988914ce89f16563fb7997562_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTA5OTUxMTY4MzYwNQ_4a12d99f-73ef-4c67-b14c-c3e23811dc57"
      unitRef="usd">7800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQxNzA_e0406597-99ec-4365-acf1-b9cb64eabd8a"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="i60c54b835f12476ebcd59fb59d9aee2b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQyOTk_7080cd8a-adba-4bc4-8d2f-88afb3aacab1"
      unitRef="usd">312000000.0</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTQzNjQ_8a044d3d-f5d5-4c2c-a2ea-01fcb58872da"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i60c54b835f12476ebcd59fb59d9aee2b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTU0NDM_fde69e85-1839-4462-b61f-60f425e9138b"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="iea4736835e9e45ac8018479c040ee6e8_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTcwNTg_759a6ec5-51db-4a3f-bc50-3d878bd1ff29"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="iec8b966b3515458980b5cd1380246198_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTcxOTI_dcfecf66-5b26-48b6-9125-47b263c8ea58"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="ibfc33644441d49b491f669f6cee3cf52_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfNDM5ODA0NjU3NTE3NA_26448271-cca6-4da3-ae3f-e378a3a43b00"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4ee5d7224384f51ae4351da2491f793_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjQ1Mw_205e6dbb-bb59-4a5d-ad16-d6cc3e23c9b1"
      unitRef="usd">900000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgxNTE_05681fc6-11b5-4ebc-94e6-7854757cf878"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ia1829ff483154e78a6241246422a7a16_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgyNjA_6f5c5c52-7a14-44b2-9141-0636b8dd52f3"
      unitRef="usd">135000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i08846d12a1824787806650566090f18b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTgzODk_6adb7e60-9cdc-47dd-b029-e61dab1f0606"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTkxOTA_05681fc6-11b5-4ebc-94e6-7854757cf878"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="i6e6292f95f964b25a721399e72758c1b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMTk2MDU_69d676d1-b8be-4cd7-b03e-523ff705e17e"
      unitRef="usd">1000000.0</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <us-gaap:Revenues
      contextRef="ic1a3cd8312cf4cf6b4d17e604f6ff948_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjgyNg_11b335b3-af48-41a9-8b5b-a89b75b0b7ec"
      unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a108cdbe85846dcb5a3e8fb692e07e0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg0Mg_1a4a57e0-114c-4833-ae14-50bbec763f61"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f8bc10e870f423c915193a8d2f50a02_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg1Nw_625affbe-10b1-4e40-a999-b73605330c02"
      unitRef="usd">2300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05ac94940d774c9cb563d01ff4332791_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNjg3Mg_d4ec40df-a70b-46bf-8dae-54cb6f9d3ab5"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEwOTU_671bf42d-cf9b-463f-b85b-a74732cb2b13"
      unitRef="usd">9000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjExNDQ_d84a0687-d1c6-40eb-91b7-e0b58ad8c830"
      unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i600a2baf71cc48788b482d5d843710e7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjExNzI_a6410593-9a86-4941-9fe0-390b3174a5a5"
      unitRef="usd">5600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyMTA_a838f044-fee4-44d3-83bf-441c818c11c4"
      unitRef="usd">11400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyNTk_2ffbba1e-09fa-456c-ad9b-c4b9900517f0"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i13e521811ec142cbab4561d2d0e7f510_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjEyODc_798ac71a-aafa-4863-8a50-15d20bd9b884"
      unitRef="usd">6900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjE1MjM_a55924de-25f2-4ad5-8838-086e90597ce6"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIwODc_3c3a9764-202d-407c-a3c6-f73967f9226b"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIyMTA_4106cce8-7e74-413f-8cf4-1d8169a45cfb"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjIzNTg_ec7746bb-0af2-4d2b-bf75-9a32074559a4"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i4e56a7a7446f43fe9e4dab1edaa5b3f0_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI1MDg_3ea4bd65-f115-49c0-9fd9-091c70a3d3f7"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="idf108d05a1a844ecbaf4f2cf4c8dd881_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI2OTI_011498c4-ad1d-4686-bd25-7e6f04bab9e3"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85050d9a6f47489bab0765376deae7a9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMjI2OTk_f3c70ed6-4132-4254-9e04-d8a0de04eaa2"
      unitRef="usd">4600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i909de857ac8e40dc9bbdd2e2b24cd20d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzEzOQ_b25fc4e0-100c-4f7f-a1db-308bee87738d"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i878570654cf7443295140f93cce32043_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181Mi9mcmFnOjJlZjM1ODk0NThjYjQ1NGVhYmZkOTMwMjM1MTdiMzc4L3RleHRyZWdpb246MmVmMzU4OTQ1OGNiNDU0ZWFiZmQ5MzAyMzUxN2IzNzhfMzg0ODI5MDcyNzE1NA_fdf7a9f0-8115-423c-85d2-12f762fc8446"
      unitRef="usd">5300000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Nw_8f194eda-9a9c-4296-8c35-1020d0d3975b">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2021, 12,305 shares of common stock were purchased under the 2016 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of 203,138 shares of common stock outstanding at a weighted average exercise price of $2.98 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2021, there were options to purchase an aggregate of 8,407,760 shares of common stock outstanding at a weighted average exercise price of $21.92 per share under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 108.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,610,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,957,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,194,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2021 and 2020 was $15.11 and $8.30, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $1.8 million and $2.6 million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $4.6 million and $2.4 million, respectively.  The total fair value of shares vested in the six months ended June&#160;30, 2021 and 2020 was approximately $8.1 million and $7.4 million, respectively. As of June&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $40.9 million, which the Company expects to recognize over a weighted-average period of approximately 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, there was $0.8 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.3 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="icc441b45390e4e3fbbfbe489832ffed0_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDI3_a68aa9b2-cb98-41d2-a89d-e54bdf37c2cd"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNjI2_ea7e621d-d608-48a0-94fb-c63012fed5da"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="id140fe30ce934074ab123f76e2b28c22_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfODcz_478b11f0-1813-4071-8f5d-a4af6c2aabaf"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i0b3e59b96ba24ec9bcac6649b8b2df22_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMTAwMw_d9c82e5b-f229-4710-86f1-60c9f7f308d1"
      unitRef="shares">12305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMTkyNQ_4a54d5ef-8be8-4ee0-abac-6d0fd99c761c"
      unitRef="shares">203138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic8eaf7c8c28245488c04a8e51118a2a3_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjAwMw_47fb7138-8cab-415e-9f47-ad213aa998cc"
      unitRef="usdPerShare">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjQxNQ_7eaa4a29-a749-4078-b76d-e81daedaf61a"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i0031895b9ddb486c9acfd64f0d661e1e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjQzMA_529d534a-c98f-4fd2-8242-145d37039744"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMjc4Mg_8a6363bc-85c0-4775-aa70-c25d4096a0e5"
      unitRef="shares">13856781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzM1OA_0d99606b-8d00-44ad-a07d-4d033d29a6b3"
      unitRef="shares">8407760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaa6f92aaf8b145f0b3bd386357f824af_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzQzNg_30abb13d-e4e8-4ab0-ad31-88dd52f06b65"
      unitRef="usdPerShare">21.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0NA_cbe5c669-1bfe-4e61-9984-8dbb09fb4430">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icda53c5d5b224a6bad5e09031f6b7b9b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi0xLTEtMS0w_2ae0a14f-88cb-4dcc-8ff1-f40267777c78"
      unitRef="usd">3058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a7422fa11414ef6a298de5f4f194412_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi0zLTEtMS0w_21be2f55-9927-4575-9d71-f93e28e8c8be"
      unitRef="usd">2589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38e4b9564f0e4552a41d250e30a98c66_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi01LTEtMS0w_1d80e66c-f948-4e76-a621-2da41c332945"
      unitRef="usd">5785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b3aad52d4204392803f61f058015d65_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMi03LTEtMS0w_29afd018-ca29-443e-b875-f874d52f7b2e"
      unitRef="usd">5023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifbbd69658d2544488a8943aea2078bc1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy0xLTEtMS0w_0ab41700-121a-4f70-91cb-ffdf58e03eef"
      unitRef="usd">3012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if53482425e144ebf87797a8800447626_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy0zLTEtMS0w_50c08340-8528-4c73-8fa2-801aa26a4d83"
      unitRef="usd">2506000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d8751554712487b9de2c28ecbbfccf0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy01LTEtMS0w_2a4c2a22-141a-446b-a827-93c391f25ab7"
      unitRef="usd">5571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fd60f01b1334bea880a5f387322b593_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfMy03LTEtMS0w_6f8a5563-783e-4390-bf8d-23e49521da1b"
      unitRef="usd">4564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC0xLTEtMS0w_de423ed4-aa50-48c4-9d27-536a6d0d2f02"
      unitRef="usd">6070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f8ca2da58504be88b6257363949ec19_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC0zLTEtMS0w_023a64d2-d7e5-49f4-a035-40a8ba337d20"
      unitRef="usd">5095000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC01LTEtMS0w_ffd9e1bc-e91c-46f9-833b-20d096065aa9"
      unitRef="usd">11356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmJlNzNhZjhkZjA2MDRmZWM4ODkxN2ZkYmEwMDM1NjkwL3RhYmxlcmFuZ2U6YmU3M2FmOGRmMDYwNGZlYzg4OTE3ZmRiYTAwMzU2OTBfNC03LTEtMS0w_f6e2e9d9-8791-492d-9442-081b09e8cf9f"
      unitRef="usd">9587000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0OQ_087d518a-ea97-4baf-808f-5881c69a3435">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2% -86.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 108.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMi0xLTEtMS0w_05b69344-d099-465c-b7cd-4ebc13a4adb2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMi0zLTEtMS0w_e7600cf2-378a-4e15-8652-de2c69fb074d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0xLTEtMS0wL3RleHRyZWdpb246MGI3NDE0ODYwOGY1NDYzZDg4ZTc5ZDkwNjcwOWJlNTJfNA_5223ae19-9ca0-4776-b384-60a5232b5854"
      unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0xLTEtMS0wL3RleHRyZWdpb246MGI3NDE0ODYwOGY1NDYzZDg4ZTc5ZDkwNjcwOWJlNTJfOA_f43be911-a560-4cba-af70-4d041b107c1c"
      unitRef="number">0.867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0zLTEtMS0wL3RleHRyZWdpb246NTE4NTQ5NmE3ZTBlNGQ4YWE0OTUwYTU5M2JiNTc2OGFfNA_263ed3f2-c7a3-4149-b256-b57d7f98896f"
      unitRef="number">0.673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfMy0zLTEtMS0wL3RleHRyZWdpb246NTE4NTQ5NmE3ZTBlNGQ4YWE0OTUwYTU5M2JiNTc2OGFfOQ_efda3646-a582-4c7f-b226-3ff5d4fa0803"
      unitRef="number">1.088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i46d07a58eddd4c77b006020315ba1ec3_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0xLTEtMS0wL3RleHRyZWdpb246OTI1MmI0M2EzNGU5NGZmZmEzNGZhMWVkNDc0N2Q0ZTJfNA_c986606c-62d6-429e-9ed0-2a9f7ca81095"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9e4cceceabb14077b334cb7a251c5d60_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0xLTEtMS0wL3RleHRyZWdpb246OTI1MmI0M2EzNGU5NGZmZmEzNGZhMWVkNDc0N2Q0ZTJfOQ_fe821811-0d61-4ccf-8a79-9b523f781c6f"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1af5de3cab7a4630bd58ae077adfd1e7_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0zLTEtMS0wL3RleHRyZWdpb246YjRlNzRlYzBiZjgzNGVlNWE3NjM1Nzc0YmE2NzNiZDZfNA_f4ed76ae-78e1-4ec5-b952-7ae285761ec0"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic4aeeb5113bb48c8bebddef8b27788a3_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNC0zLTEtMS0wL3RleHRyZWdpb246YjRlNzRlYzBiZjgzNGVlNWE3NjM1Nzc0YmE2NzNiZDZfOQ_aea767e9-cc58-414a-8676-cba1e35ed510"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNS0xLTEtMS0w_346d91fe-1f3c-46f7-ad7e-a798645bb8f7">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmVmY2NmMWVjYjlkMDQ5Mjc5M2NiMzQ3OTBiNWVjZTMzL3RhYmxlcmFuZ2U6ZWZjY2YxZWNiOWQwNDkyNzkzY2IzNDc5MGI1ZWNlMzNfNS0zLTEtMS0w_ef03166e-c5cd-4303-adb8-6138a1759b34">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM1MQ_a5257f0e-7e0e-4a2e-a9ec-46e04f4f3307">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;&#160;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,258,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,610,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,957,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,194,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS0xLTEtMS0w_7d83f83f-c499-4427-ac6a-15cb28b871c9"
      unitRef="shares">7258353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i99237d698c8c4afdbcef6350116b30ce_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS0zLTEtMS0w_5a0f6b00-5292-4eaa-a089-2ac3be8b1d0c"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i801e96d91e944a44bdd5ee5ed3764993_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMS01LTEtMS0w_1e19492e-4146-41a9-83ef-c3e0d93d95dc">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMi0xLTEtMS0w_168e115a-5f79-44ae-8a15-6cc1a8658710"
      unitRef="shares">1790246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMi0zLTEtMS0w_389b08a9-5e16-4e57-a478-1fb9283f18b4"
      unitRef="usdPerShare">20.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMy0xLTEtMS0w_a4782a1a-e89b-4bb5-8f32-204826d16488"
      unitRef="shares">250175</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfMy0zLTEtMS0w_0137e945-6016-451b-944a-4314f4617942"
      unitRef="usdPerShare">18.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNC0xLTEtMS0w_ae6ca31f-4f38-46b7-a5dc-82dd23e1fe4e"
      unitRef="shares">187526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNC0zLTEtMS0w_a2ec16b5-f203-4546-8e83-ceccfba4162c"
      unitRef="usdPerShare">16.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS0xLTEtMS0w_5b79bcd9-2280-462e-b86d-19b6f772ce67"
      unitRef="shares">8610898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS0zLTEtMS0w_eb18587e-9feb-43bb-b0b4-fc7ec9ee11fa"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS01LTEtMS0w_7a3cd65d-07a8-4b3a-90be-19a8a517ce50">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNS03LTEtMS0w_66ece1dd-e5ee-49dd-96c2-a5cd457253e2"
      unitRef="usd">53928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy0xLTEtMS0w_34c917f3-b5e3-4a8b-a659-d36023acee80"
      unitRef="shares">4957615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy0zLTEtMS0w_1e793352-cee3-46ae-a086-00834161c5c2"
      unitRef="usdPerShare">22.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy01LTEtMS0w_2b984c12-e4be-4c17-b9ef-ce7fed77c074">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfNy03LTEtMS0w_8ecfe9d1-3f22-4127-98b8-3a9631192c3b"
      unitRef="usd">25634000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC0xLTEtMS0w_1531a7bd-dbbf-445a-aa82-c83635bab1d0"
      unitRef="shares">8194010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC0zLTEtMS0w_cab02188-ff20-4625-a294-787fe1fc94ef"
      unitRef="usdPerShare">21.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC01LTEtMS0w_2c8bbc88-c6c4-47f6-98aa-f582624e52cb">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOmQ5ODliZWI1MDM3ODQwNTc4MTJhYThmZTYyNDNmNzNhL3RhYmxlcmFuZ2U6ZDk4OWJlYjUwMzc4NDA1NzgxMmFhOGZlNjI0M2Y3M2FfOC03LTEtMS0w_6b37240b-d308-428e-a1b8-c7c674dd904e"
      unitRef="usd">50662000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzk3NQ_65e1c13e-6d34-4ab0-a089-5dbaf23608be"
      unitRef="usdPerShare">15.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfMzk4Mg_5145cf39-bdc4-482d-a11f-775715ad8fcf"
      unitRef="usdPerShare">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDEwMg_dfcfa30f-79be-4f33-bac1-d882e122ca0a"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDEwOQ_4d68d9a2-0d2a-4083-b623-05d61e2bd70a"
      unitRef="usd">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDIyOQ_45712c5e-98a0-44ae-8010-df6ac9351b8b"
      unitRef="usd">4600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDIzNg_405593f0-f7ef-4090-8d38-b562b466b214"
      unitRef="usd">2400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDM0NA_95392587-7d76-442a-bb74-76d182270db8"
      unitRef="usd">8100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDM1MQ_8b21d43c-bb2d-47d5-a702-8cb5d4db9e9e"
      unitRef="usd">7400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDUxMw_ec93fc5c-9f8e-4732-a4c5-0675ead90185"
      unitRef="usd">40900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNDYwNA_be6693a9-258a-4096-bd06-11014ce9ed19">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Ng_685ac825-d7a8-4da1-aa8f-49f43073bcb3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the six months ended June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia217df68ded645e8b6c9001175c243cc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMS0xLTEtMS0w_377af55b-bc02-408e-a9a1-c3df164556da"
      unitRef="shares">209250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia217df68ded645e8b6c9001175c243cc_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMS0zLTEtMS0w_6633191c-4be6-49d1-8cf4-788e9d343501"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMi0xLTEtMS0w_128e621b-0f5c-484f-9468-1563935b95ae"
      unitRef="shares">10500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMi0zLTEtMS0w_2bece42c-22cb-46ac-9a9e-ae3905676ffe"
      unitRef="usdPerShare">29.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMy0xLTEtMS0w_67d183d2-f57d-482a-a29e-c9441dc9517b"
      unitRef="shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfMy0zLTEtMS0w_3e861b47-64fc-4788-9d0e-42a3bbe49784"
      unitRef="usdPerShare">23.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNC0xLTEtMS0w_9c8ec305-0ebc-43aa-8fcb-11ad73022e28"
      unitRef="shares">17400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNC0zLTEtMS0w_df5ca32a-0717-4210-922f-0277bd1cc1fd"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNS0xLTEtMS0w_8472aad0-2725-4542-973d-0ea257c74f91"
      unitRef="shares">194850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RhYmxlOjJmNmUxZmIyOGMyYTRmYzE5NTE2MzI5NzgxZjEyNzM0L3RhYmxlcmFuZ2U6MmY2ZTFmYjI4YzJhNGZjMTk1MTYzMjk3ODFmMTI3MzRfNS0zLTEtMS0w_c97bcb85-1547-4a67-8513-a2a16dfaed23"
      unitRef="usdPerShare">16.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i1541411d98604ec694fc7cf490e3c299_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTE3Ng_c5ee9173-fa57-4e9e-a900-5db74a7db001"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i161ed7f79f4341a5b8367dd91c0b5a83_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181NS9mcmFnOjMxNzBkNTdlZTRmYzQyYzFiNmQ3ZjE5NGI5ZGFhZjViL3RleHRyZWdpb246MzE3MGQ1N2VlNGZjNDJjMWI2ZDdmMTk0YjlkYWFmNWJfNTM0Mg_7cfa8f59-a990-4531-a6ca-771a291652b2">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ifc2a3977b004411e985a36662f6b0659_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjU1N2Q1ZDQ3M2U5OTRmZDBiNTRhYTFmNTk2YjJmZDljL3NlYzo1NTdkNWQ0NzNlOTk0ZmQwYjU0YWExZjU5NmIyZmQ5Y181OC9mcmFnOmZjZmYyYmQ0Mjg2ZDQ1N2ViYTI4Y2VjNjg0YTVjZThiL3RleHRyZWdpb246ZmNmZjJiZDQyODZkNDU3ZWJhMjhjZWM2ODRhNWNlOGJfMTE3MQ_bca6538c-1649-4c53-8ba6-396f0d822ce5">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial.   On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534127651624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,107,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534127987432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 188,970<span></span>
</td>
<td class="nump">$ 181,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">108,346<span></span>
</td>
<td class="nump">91,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">45,248<span></span>
</td>
<td class="nump">23,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,956<span></span>
</td>
<td class="nump">16,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">366,996<span></span>
</td>
<td class="nump">312,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">39,395<span></span>
</td>
<td class="nump">42,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">19,520<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">425,911<span></span>
</td>
<td class="nump">378,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,818<span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">39,174<span></span>
</td>
<td class="nump">34,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,565<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,367<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,924<span></span>
</td>
<td class="nump">50,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">13,476<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">23,208<span></span>
</td>
<td class="nump">25,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">106,866<span></span>
</td>
<td class="nump">82,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 60,133,447 and 56,244,771 shares outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,181,471<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(863,028)<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">319,045<span></span>
</td>
<td class="nump">295,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 425,911<span></span>
</td>
<td class="nump">$ 378,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534048937416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">60,133,447<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534056295352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 20,257<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 33,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,780<span></span>
</td>
<td class="nump">57,351<span></span>
</td>
<td class="nump">108,901<span></span>
</td>
<td class="nump">106,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">15,234<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
<td class="nump">30,270<span></span>
</td>
<td class="nump">20,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">71,036<span></span>
</td>
<td class="nump">67,567<span></span>
</td>
<td class="nump">139,210<span></span>
</td>
<td class="nump">126,694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,279)<span></span>
</td>
<td class="num">(47,310)<span></span>
</td>
<td class="num">(91,572)<span></span>
</td>
<td class="num">(92,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,935)<span></span>
</td>
<td class="num">(46,885)<span></span>
</td>
<td class="num">(91,207)<span></span>
</td>
<td class="num">(91,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (39,945)<span></span>
</td>
<td class="num">$ (46,940)<span></span>
</td>
<td class="num">$ (91,199)<span></span>
</td>
<td class="num">$ (91,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">60,068,315<span></span>
</td>
<td class="nump">50,018,462<span></span>
</td>
<td class="nump">58,643,496<span></span>
</td>
<td class="nump">49,515,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">60,068,315<span></span>
</td>
<td class="nump">50,018,462<span></span>
</td>
<td class="nump">58,643,496<span></span>
</td>
<td class="nump">49,515,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative and other agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 27,168<span></span>
</td>
<td class="nump">$ 15,636<span></span>
</td>
<td class="nump">$ 42,352<span></span>
</td>
<td class="nump">$ 28,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">$ 4,621<span></span>
</td>
<td class="nump">$ 1,196<span></span>
</td>
<td class="nump">$ 5,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534128192552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 872,204<span></span>
</td>
<td class="num">$ (642,082)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(91,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,365,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">247,784<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">980,924<span></span>
</td>
<td class="num">(733,691)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">96,512<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">96,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,365,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">247,784<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">980,924<span></span>
</td>
<td class="num">(733,691)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">98,200<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,458<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="nump">1,790,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,133,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">319,045<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">1,181,471<span></span>
</td>
<td class="num">(863,028)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,011,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">350,531<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,173,013<span></span>
</td>
<td class="num">(823,093)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,133,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 319,045<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">$ 1,181,471<span></span>
</td>
<td class="num">$ (863,028)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534055543784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,207)<span></span>
</td>
<td class="num">$ (91,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">5,510<span></span>
</td>
<td class="nump">6,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">808<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,356<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(22,166)<span></span>
</td>
<td class="num">(6,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(974)<span></span>
</td>
<td class="nump">3,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">4,404<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="num">(1,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">3,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(1,673)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">18,659<span></span>
</td>
<td class="num">(3,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other non current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(74,726)<span></span>
</td>
<td class="num">(80,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(117,546)<span></span>
</td>
<td class="num">(72,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">99,800<span></span>
</td>
<td class="nump">125,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(2,693)<span></span>
</td>
<td class="num">(1,847)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(20,439)<span></span>
</td>
<td class="nump">51,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">98,200<span></span>
</td>
<td class="nump">96,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">4,910<span></span>
</td>
<td class="nump">2,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">103,004<span></span>
</td>
<td class="nump">99,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">7,839<span></span>
</td>
<td class="nump">70,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">188,970<span></span>
</td>
<td class="nump">196,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property, equipment and software included in accounts payable or accruals</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RetirementOfTreasuryStock', window );">Retirement Of Treasury Stock</a></td>
<td class="num">$ (106)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RetirementOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retirement Of Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RetirementOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054586312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the business</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. In December 2020, the U.S. Food and Drug Administration (FDA) approved MARGENZA (margetuximab-cmkb) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  The Company launched MARGENZA in collaboration with our commercialization partner, Eversana Life Science Services, LLC (Eversana), in March 2021. In addition, the Company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary, antibody-based technology platforms. The Company believes its product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current cash, cash equivalents and marketable securities is sufficient to fund its operating plans for a minimum of twelve months from the date that this Quarterly Report was filed. The Company plans to meet its near-term operating requirements primarily through cash and marketable securities on hand, and a combination of product sales and current and future strategic collaborations and alliances and marketing, distribution or licensing arrangements.  In the longer term, the Company plans to meet its operating requirements by generating revenue from product sales to the extent its other product candidates receive marketing approval and can be commercialized, or by potential future equity or debt issuances. There can be no assurances that new sources of capital will be available to the Company on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all rights to a product or technology at less than its full potential value. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, and/or downsize its organization.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, the Company will continue to evaluate the nature and extent of the impact of the pandemic on its business and financial position.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050375000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company adopted the following significant accounting policies in addition to those previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources the manufacturing of MARGENZA.  Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, the Company began capitalizing MARGENZA inventory costs.  The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company&#8217;s inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050334664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span></div><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2021 includes approximately $34.9 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented, and the Company has no Level 3 securities in its portfolio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050356760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>All available-for-sale marketable debt securities held as of June&#160;30, 2021 and December&#160;31, 2020 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of June&#160;30, 2021 and December&#160;31, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for any periods presented. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054554072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050375000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' EquityIn November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the three months ended March 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million.  During the three months ended June 30, 2021, the Company did not sell any shares of common stock related to the ATM Offering.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054507032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.  In January 2021, Incyte announced that the FDA had accepted for Priority Review its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. The PDUFA target action date for retifanlimab was July 25, 2021. On July 23, 2021, Incyte announced that the FDA had issued a Complete Response Letter (CRL) regarding its BLA for retifanlimab.  Incyte&#8217;s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $70.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated the Incyte License Agreement under ASC 606 and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2018 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, it became probable that a significant reversal of cumulative revenue would not occur for deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lopment milestones totaling $70.0 million related to </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Therefore the associated consideration was added to the estimated transaction price.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized ratably as services were performed over a period spanning 2017 and 2018.  During the three and six months ended June 30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it became </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">probable that a significant reversal of cumulative revenue would not occur for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $5.0 million and $15.0 million in milestones related to development progress of retifanlimab, respectively, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue. No revenue was recognized under the Incyte License Agreement during the three and six months ended June 30, 2020.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $0.7 million and $1.5 million, respectively, for services performed under the Incyte Clinical Supply Agreement. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $0.8 million and $7.4 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incyte Commercial Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price will be recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services.  During the three and  six months ended June 30, 2021, the Company recognized revenue of $2.8&#160;million and $5.9&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly known as MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation was also recognized on a straight-line basis as the Company performed research and development activities under the agreement due to the short-term nature of the recognition period. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation was recognized upon certain regulatory achievements during 2020.  The Company recognized revenue of $3.6&#160;million during the six months ended June 30, 2020 under the 2018 Zai Lab Agreement.  There was no revenue deferred under this agreement as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $0.5 million and $0.3 million, respectively, related to the Zai Lab Clinical Supply Agreements. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $1.6 million and $1.3 million, respectively, related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories. Under the Lead Program, Zai Lab received an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. If Zai Lab elects such option, Zai Lab is to pay the Company $85.0&#160;million plus any research costs incurred by both parties as of the option election date. Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program includes joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab will pay the Company an upfront payment of $25.0&#160;million, which was received in July 2021. Additionally, as part of the consideration for the rights granted to Zai Lab </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab agreed to pay the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock, par value $0.01, at a fixed price of $31.30 (Offering) which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. The Offering closed in July 2021. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the Programs, the Company could receive up to approximately $800.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of low double digit teens on annual net sales of certain specified products and of mid-single digits to low double digit teens on annual net sales of other specified products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the estimated $5.0 million expected to be reimbursed by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes the market is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services  performance obligation will be recognized over time as the research and development activities are performed. The Company will utilize a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company recognized revenue of $14.4 million under the 2021 Zai Lab Agreement.  The upfront payment of $25.0 million and the purchase price premium under the Stock Purchase Agreement of $10.4 million were recorded in Accounts receivable as of June 30, 2021 as the Company has an unconditional right to the payments under the 2021 Zai Lab Agreement and the Stock Purchase Agreement.  As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021, there was $21.0 million in deferred revenue under the agreements, $13.2 million of which is current and $7.8 million of which is non-current.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen) to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration is fully constrained until the Company begins its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in December 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years. During the three and six months ended June 30, 2021, the Company recognized revenue of $0.6&#160;million and $0.9&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $1.7 million and $1.4 million, respectively, under the I-Mab Agreement.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $2.3 million and $2.5 million, respectively, under the I-Mab Agreement.  At June&#160;30, 2021, $9.0 million of revenue was deferred under this agreement, $3.4 million of which was current and $5.6 million of which was non-current.   At December&#160;31, 2020, $11.4 million of revenue was deferred under this agreement, $4.5 million of which was current and $6.9 million of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div>The NIAID Contract includes a base period of up to $7.5 million to support development of MGD014 through Investigational New Drug application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  During the three months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $0.4 million and $4.6 million, respectively.  During the six months ended June 30, 2021 and 2020, the Company recognized revenue under the NIAID Contract of $1.2 million and $5.3 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050478056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the six months ended June&#160;30, 2021, 12,305 shares of common stock were purchased under the 2016 ESPP.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of June&#160;30, 2021, under the 2003 Plan, there were options to purchase an aggregate of 203,138 shares of common stock outstanding at a weighted average exercise price of $2.98 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the six months ended June&#160;30, 2021, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 13,856,781.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of June&#160;30, 2021, there were options to purchase an aggregate of 8,407,760 shares of common stock outstanding at a weighted average exercise price of $21.92 per share under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -86.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 108.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,526)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,610,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,957,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,194,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the six months ended June&#160;30, 2021 and 2020 was $15.11 and $8.30, respectively. The total intrinsic value of options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $1.8 million and $2.6 million, respectively.  The total cash received for options exercised during the six months ended June&#160;30, 2021 and 2020 was approximately $4.6 million and $2.4 million, respectively.  The total fair value of shares vested in the six months ended June&#160;30, 2021 and 2020 was approximately $8.1 million and $7.4 million, respectively. As of June&#160;30, 2021, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $40.9 million, which the Company expects to recognize over a weighted-average period of approximately 2.7 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $0.8 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of approximately 1.3 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054650968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020.  Plaintiff filed an Opposition brief on January 29, 2021, to which the Company filed a timely reply. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534048410632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources the manufacturing of MARGENZA.  Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to regulatory approval, the Company began capitalizing MARGENZA inventory costs.  The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of sales in the statement of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company&#8217;s inventory balance consisted primarily of raw materials purchased and work in progress manufactured after the FDA approval of MARGENZA.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Product Revenue, Reserves for Variable Consideration, Customer Discounts and Services Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the three and six months ended June 30, 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which we believe to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA in December 2020. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The updated guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. The adoption of this standard as of January 1, 2021 had no impact on the Company's consolidated financial statements and related disclosures.</span></div>The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054728648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at June&#160;30, 2021 includes approximately $34.9 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2020 includes approximately $52.0 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050437672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,249&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,630&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,624&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054599368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534054645464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2% -86.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 108.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>&#160;(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,526)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,610,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2021:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,957,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,194,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the six months ended June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534048988600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 108,346<span></span>
</td>
<td class="nump">$ 91,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">34,900<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,201<span></span>
</td>
<td class="nump">143,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">126,595<span></span>
</td>
<td class="nump">94,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">16,606<span></span>
</td>
<td class="nump">49,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">79,249<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">79,249<span></span>
</td>
<td class="nump">60,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">42,809<span></span>
</td>
<td class="nump">33,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 42,809<span></span>
</td>
<td class="nump">$ 33,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534055580824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 108,345,000<span></span>
</td>
<td class="nump">$ 91,407,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">108,346,000<span></span>
</td>
<td class="nump">91,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">79,244,000<span></span>
</td>
<td class="nump">60,630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">79,249,000<span></span>
</td>
<td class="nump">60,624,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,564,000<span></span>
</td>
<td class="nump">30,777,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 24,560,000<span></span>
</td>
<td class="nump">$ 30,776,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534050391352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">5,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Total inventory</a></td>
<td class="nump">$ 6,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534055324840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - At the Market Offering - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Maximum amount available for issuance, increase</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534128368424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">42 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 30,757,000<span></span>
</td>
<td class="nump">$ 20,257,000<span></span>
</td>
<td class="nump">$ 47,638,000<span></span>
</td>
<td class="nump">$ 33,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534148926760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 20,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 33,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 16,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">13,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesTaxWithholding', window );">Revenues, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptInFee', window );">Opt-in fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptInFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt-in Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptInFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PremiumReceivedOnStockPurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534056275816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 20,257<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 33,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Collaboration and License Agreement | Revenue From Performance of the Research and Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534056119912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 30,757<span></span>
</td>
<td class="nump">$ 20,257<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 33,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">16,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">13,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534055524664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,757,000<span></span>
</td>
<td class="nump">$ 20,257,000<span></span>
</td>
<td class="nump">$ 47,638,000<span></span>
</td>
<td class="nump">$ 33,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period amount</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options under agreement</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534056549032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,610,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,610,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,070<span></span>
</td>
<td class="nump">$ 5,095<span></span>
</td>
<td class="nump">$ 11,356<span></span>
</td>
<td class="nump">$ 9,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction discount</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,856,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,856,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,058<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">$ 5,785<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,012<span></span>
</td>
<td class="nump">$ 2,506<span></span>
</td>
<td class="nump">$ 5,571<span></span>
</td>
<td class="nump">$ 4,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534127953720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.20%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.70%<span></span>
</td>
<td class="nump">108.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534056250056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">7,258,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">1,790,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(250,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(187,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">8,610,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">4,957,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">8,194,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">20.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">18.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</a></td>
<td class="nump">16.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">21.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">22.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 53,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">25,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 50,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140534055543528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">209,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(17,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">194,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">29.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">23.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">15.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;5O\1>2:<@4,5P8:](:&0S:MIIEH4;G;>B.TN?MN6)CNC-(&F/V5$/IQ8AM
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M4,UJT[IPRW0M5N!F;G"[\A@&P%)FWK[FS/-^N:YQBI?,S<O#>^X8VK7,A*5
M"&."; NM8,G<L'3WW"%KQLQ$$>6(4PU9$V:24NAQ9 HHP[)P0)CJ:P, ," 4
MA53?79!&BYOV?O=T%ZK/3WB869NZ$QZF.,K<''U:PL. GBZ4\ !R9L+#3/#"
M"0\@""<\H*#%4PKD3'S_A(<I/+,GU[(]X!HSX"=5/T2$V2* HBEST]09.,W.
M\3"48<>V$ J7S(W+PPM ."":U!,R9%!YG&#+N"(?/ZHT/<":,3=Y1G&(F%;
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M9-0JD@-%[,\D*K&(68RG@;@9:J##H!9*X3VE"K$"3&1<-SM!-08*(U6PB\=
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MO5V(&QR.QMGS,=67T_Y6K-$8K/,$)BB3!7@"R#=^N"EFH#[\<GUY=/(G#([
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MEL[>41R2D3H^"/K/O9"V-K2/>AT2J>0XPP^LSYHN*."T6ML0TR/K%OD3@H?
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M7IJ6<D%?(2*6[,B3RZ0Q&U4OA:QX"9/XZY!"&A)+JLG(LMP$QW(RF.&T2 F
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MGZ+"P.G&?_Y)M7.Z\H\%X9AD> )^7V@DH1NP@?Y[X.6?4$L#!!0    ( &&
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M;QI:G\#QPAC:&;Y _TK.?P%02P,$%     @ 88#]4A8.F>8,!   0PD  !D
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M;:7;+4)'R/P^3'N4RPXE>09E!C>Z=J6%ZSK#[-@_I(B&L))]6)?)BX _MW4
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M(XLV -+(BF)43Z1])) 5D\!WX;,.(-YW[KMVEY+**.N4;C;K>8+$'XZ+ SY
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M  9-UVC*"!;,3!81RFHMD8. EEK";Q@6YIZIC&>E-?+G'46_@_0RT, #*XV
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MQ**B 7X3:@-<;>%P2@_0*Q3&_=Q9@,64%=7RJQN.C[!Q9;6"53[)UR"@'+Z
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M';(_RGQ-7QZ?Y24@0W\NI0!D\0&X/\_!.S0_< +W*?JG_P]02P,$%     @
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M^"R<^*%[]@Q>Q1R$>>/.M/G.D:OKQH!5[&"SY$L=NJ+_1[7@(^TC\P5ZB&=
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M^%"]-3G'I2O*O=7TE9.=75XQKN$3$S6"6L,5ETSFG FXEL;JFK)O#;Q_8)E
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M&@VGXP'H9HHW@E65GYR9LC2'_7)+/SZHG0)]7RLZ.:W@"+I?J>6_4$L#!!0
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M;"]W;W)K<VAE971S+W-H965T,C N>&ULK5?;;N,V$/V5@;$!-H LZV+=@L1
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M+NBG FHVH/6Y4G8W80?['Q^3OP!02P,$%     @ 88#]4M\C-&P*!0  :!P
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M]W-ANF1_8E\V92\7A_\!4$L#!!0    ( && _5(M-9E1W ,  ,$0   9
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M.B,'K=B:[C+UE1\^L"JADF#",UG^18>C;4P<E.RDXGD%!@9Y6AQ_Z8^J$"T
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M;/FX873%A#: [VO.U<- WV+K_UK,?@-02P,$%     @ 88#]4K(^S/D1 @
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M3%6DJM%3&486KAEOI*'6[I8I36M4]@*=;Z4T+X9UT,S_^2]02P,$%     @
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MZON"6"MY5TNVE^R;5]P:=["YK/-X!@'G"]1J X@W?2"#;=RU0=S6OMHK(@<
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M[GQ7+Y(GQ87@ Y>21\7CDE%8Z;D!_#[GH)WE2]Y!=?-^^B]02P,$%     @
M88#]4I[A:!OT P  O X  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
MO5=M;]LV$/XKA- !";!&HN37P#;@5RQ%NQG)NGT8]H&6SK90B=1(RFZ _O@=
M*5EV8EDS.C3Y$$O4/7</GSL>R<%>R"]J"Z#)US3A:NALM<[N75>%6TB9NA,9
M</RR%C)E&E_EQE69!!994)JXON=UW)3%W!D-[-A2C@8BUTG,82F)RM.4R><)
M)&(_=*AS&'B,-UMM!MS1(&,;> +].5M*?',K+U&< E>QX$3">NB,Z?V"=@W
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MK=SR\OU/K8S7:_]7?X6G#*CV1<M.&);6AS]H[XU*BZ-6OK_PZ (/-$GDL64
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MSCV\'R0]/4KU4>\!#/F4BT+/O+TQY3O?UYL]Y$Q?R1(*G-E*E3.#0[7S=:F
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M25QH&@PHG'0*)X,*?Y$&Q972H%_,&#DP43D3,SGMG-%0B&CP<NH$@Q+NE=P
M9)ILE<P)>ZV0W;9N^Y)I,!Z2W#LHZ45[$5E;R;>*V3;Z3/ZK9^G+[DJ_UO9*
M7_97^O\W6.K8#[^,9'NZ.NP2A^&-PY"&#L.UPS".7$GT>Q<?>W-^S]2.8Z4(
MV"(RN$JQ>51S&6T&1I;U7>A)&KQ9U:][O,"#L@8XOY78%>W 7J^ZOP3S?P!0
M2P,$%     @ 88#]4K2U!B_#!0  VAD  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S N>&ULS5EM;]LV$/XKA+$!+=#8(F5)=N 82.PDZ[!B0;*N'X9]8"3:
M%B*)'DG9R7[]CI*B-\N4T19="J26J+OCW3W'>TAIMN?B26X84^@YCA)Y,=@H
MM3T?C:2_83&50[YE"3Q9<1%3!;=B/9);P6B0*<71B%B6.XIIF SFLVSL3LQG
M/%51F+ [@60:QU2\7+&([R\&>/ Z<!^N-TH/C.:S+5VS!Z8^;^\$W(U**T$8
MLT2&/$&"K2X&E_C\UK:T0B;Q9\CVLG:-="B/G#_IFX_!Q<#2'K&(^4J;H/"S
M8PL61=H2^/%/8710SJD5Z]>OUF^RX"&81RK9@D=?PD!M+@:3 0K8BJ:1NN?[
M7U@1D*/M^3R2V?]H7\A: ^2G4O&X4 8/XC#)?^ESD8B: MCI5B"% CE5P2X4
M[+;"^(C"N% 8GSJ#4R@XI\[@%@KNJ0I>H>!E8.79S:!94D7G,\'W2&AIL*8O
M,GPS;4 D3'0I/B@!3T/04_,'Q?VGLRL ,T +'D.%2YK5R!DZ^NCZ65\S]&[)
M% TC^1Z$/S\LT;N?WJ.?T C)#15,HC!!GY-0R0\P"-=_;'@J:1+(V4B!XWKZ
MD5\X>94[28XXB=$GGJB-1-=)P((._859W^[3OS;KNP;]$22\S#IYS?H5,1K\
M1%^0C3\@8F&O*QRS]J]I,D2VI=4)[E!?GJYN=27CVV:_^;;9;\WJ2^8/B]2U
MU1M(V&7]VYD]^UC]ZUH]>SPL\DLA:+)FT'45>GQ!=;D[^I(-7^ZI"-!?OX%)
M]%&Q6/YM<&A<.C3.'!H?<>CWK9Y>(J -J6"YA,D:O8/EDR^J]UW5DAMT,H.:
M>G;SB8NMR70R&^WJN)XH=WLHYQ%G8CMV*=>(S"DC<XR1?<EH@05G=,<$T!QB
MSTSX(322K0A]AO@*2=UR$#^2@H!'$142;9G(T]&9C=P)K^8]P<-Q.Q<G2=WV
M237RX)9Y<(TE=QUO(_["&'I@8J<#/U:#']!E%'$_KT?(SCWS^3H)_]4ER$3(
MM;14\M0*]$K_/"-.>=_/W?'K2X+E?;\KZ;E%MY8HU_*L9C:7AT*.-75:P!P*
M86P[;E/JYE!JZDR\;EPF9=P38]S0C%U4@9.5XETJ_ UD MU%-#'D=EK.,7T;
M[09;U0; ,L-=F\IO5%^2QH^PU/2ZS!F=IFK#15: YI9T5<S9Z#66_M<-$:YM
M5[#16TB&@#8 N\T@S3>S02A]GB:JTPVS,6P-+>MG4Q9)Y1<Q^_5:*&4O@US&
MX%[>TJ!E^1I#&%<;AE8T%+"+$T]PUMC1*.U:4U<],TZ</N<K#L2VT=2BX6H1
M21_&UX71.L:8V)9S!.** +&9 >$491?+[V.BLP9GE;[UARL2PLX;68$5'V#W
M>U-^8;&>>V+9V&[37+]<T^>*(["9)'X0F1=>-!AX>+"QZ9-JQECQ 3830E<-
MZBV[;4*]8@+\1JB 5%1 ?CP5+,@A%4#].:XWP2T83Y%L1E;1!NFA#:XTB#1"
M-$E2^ D37S#=KTOG$?S!A@P"6G&!5JE*!3R5,J50 +U!XD/7IRYL*-JE>H)@
M,\2*@4@/ WUKB%2^TI1>SP!U?<EF!CH/BV:OQCTD12J2(F:2^HHN20X9:C*V
M/,^UVJCT"S:]KLB,F,GL!_7)PHO6265*VG'VB36CK$B5F(]V]U!7%+8-4'H!
M6K(=B_A6-RH3\!4]DK=Y7B(5&9+O?V(BAT<8V#NUVL6RD&KPMS.9MF'M.%EY
MD];)ZJ;#EF.1(X=Z4K$D,;/D+4N@LJ,,^LL@#I-0*D$U89IR6]$D,=/D_X6^
M7;&FW<.:7X%^8;*)/FXMUV6'%'&LUEGXND/*<;P6N=YT2(T==]Q"?U1[DQPS
ML<X^$DB4';#REVKE:/DAXC)[_=X:7^#S)>X8O\;G-_EGALI\_M7C$Q7K$!I@
MQ%8PE37TH%!%_B$AOU%\F[W'?N1*\3B[W# :,*$%X/F* P,6-WJ"\G/._#]0
M2P,$%     @ 88#]4O=$% ;_ @  '0L  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&ULS59=;]HP%/TK5J1)FS3R"8%6@ 2TTSJM&FJU[6':@TDNQ"*V
M,]L4^/>S'0AT"X%I?>A+8M_X')]S?9/<_IJ+I<P %-K0G,F!DRE57'N>3#*@
M6+J\ *:?S+F@6.FI6'BR$(!3"Z*Y%_I^[%%,F#/LV]A4#/M\I7+"8"J07%&*
MQ78,.5\/G,#9!Q[((E,FX W[!5[ (ZBOQ53HF5>QI(0"DX0S)& ^<$;!]22(
M#,"N^$9@+8_&R%B9<;XTD[MTX/A&$>20*$.!]>T))I#GADGK^+4C=:H]#?!X
MO&?_8,UK,S,L8<+S[R15V<#I.2B%.5[EZH&O/\+.4,?P)3R7]HK6Y=KNE8.2
ME52<[L!: 26LO./-+A%'@*![ A#N .&E@&@'L)GS2F76U@U6>-@7?(V$6:W9
MS,#FQJ*U&\+,,3XJH9\2C5/#1\6396NL$Y&B":>Z.B2V^6VA+X4=3 5)"%N@
MD=1';4,2O;T!A4DNW_4]I448*B_9;3@N-PQ/;!BC>\Y4)M$M2R%]CO>T^,I!
MN'<P#AL)/ZV8BR+_/0K],*C1,[D<[C?(B:J$1I8O.I70# MHS?Y.Z$@(S!:@
M7P&%9EMTO&Z*MS8\6F.1HA^?-26Z4T#ESP9![4I0VPIJGQ!TNRGT*Z-W2<D3
M28&E:$L@3^M.KIG(=WW_35V"_QGVS$>G\M&YS(<"0>O4-\-CM 4L)(H0M?57
M9^1_&)YYBBM/<2/E/6&$KF@#4[=BZKZ.LNM5@GJ7'=<3S[62G*AMW:$UD_1B
M-ZRON69<W'6CQJ*[JEQ<-1(]$+ELS04 (DS7'4B%!%90YZ29R'?C>B/G8)U&
M'X%_^,[[S:6&-V=*+3CZ9P2OH]B"\" I?(ER.\.BZZU;?TQG@('?<WO-)W7X
M@0312]7<&:; ;9]P<PYWPHMWU&A0$ O;?TF4\!53Y1^[BE8]WLAV-G_$QZ;W
MLPW,@:9L'.^Q6!#=8N0PUY2^V]4?95'V8N5$\<*V,S.N='-DAYGN7T&8!?KY
MG'.UGY@-JHYX^!M02P,$%     @ 88#]4D*V7/S3!0  N!@  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULK5E;C]HX%/XK%NK#5!H@=NX5@\2EW>U*
M54>=3ONPV@=##%A-8M8V,+._?NTD)#!)G*#=/I3$\?'YSL7G._9,3HS_$CM"
M)'A)XE0\#'92[C^,QV*](PD6([8GJ?JR83S!4KWR[5CL.<%1)I3$8V19WCC!
M-!U,)]G8(Y].V$'&-"6/'(A#DF#^.B<Q.ST,X. \\(UN=U(/C*>3/=Z2)R*?
M]X]<O8W+52*:D%10E@).-@^#&?RPM#.!;,8/2D[BXAEH4U:,_=(OGZ.'@:41
MD9BLI5X"JY\C69 XUBLI''\7BPY*G5KP\OF\^J?,>&7,"@NR8/%/&LG=PR 8
M@(AL\"&6W]CI=U(8Y.KUUBP6V?_@5,RU!F!]$)(EA;!"D- T_\4OA2,N!)#7
M(H * ?1& #HM G8A8+_5X+8(.(6 DWDF-R7SPQ)+/)UP=@)<SU:KZ8?,F9FT
M,I^F.NY/DJNO5,G)Z9-DZU_#N?)<!!8L4>DD<!:0(<@^@:_[['6FXT/E*[A;
M$HEI+-ZK&<]/2W#W[CUX!\9 [# G M 4/*=4BGLUJ)Z_[]A!X#02D[%4:+7.
M\;I -L^1H19D'OC"4KD3X&,:D:A!?FF6A\BPP%BYJ?05.OMJCHPK_G%(1\"V
M[@&R$&P M.@O;C798Q9?DK42ATWB5];89>3M;#V[+?)9P P+.>5"3K:08USH
M'GP]2"%5K&FZO0=SLJ5IJA[!',<X71-PI](A3Y+W3<F0ZW S';I8':<^<@/;
MM2?C8P,XMP3G]@+W&\>I5#G>@<*MH8!^:"'':T;AE2B\7B@^OA"^IJ(;AU?#
M,42N!7VW&8=?XO![X5 E<T.H]@?C@+SL*>^&Y-<AP<!W48MK@A)2<'OV?,Q^
M^Z9.4$,6>- *PJ!$EN^O^CQCBH6E!>$MP<6KN!-Q6$/BA*[OP9;P0JNJYE8O
M+#^(T-%5_M3A51RK7B0#1S7<A:W0<.5.&#H6M%K 75 --%:<GQD)DV@(9D?"
M55=1[@?PR.F:&&H11)429/1 EY)>=2IB<8RY 'O"<U<U>RI'XE]X"L&1$[3X
MJ2K,T/Z/)EQ6LYY8<Y7A)59KY*,6K%7MA^;BWXWUNN;U1.O4T,)@9+=MCXH,
MH)D-NM&V5L:>P-TZ<&]DM]1(6/$'-!/(C5G=4#][XO?J:7*5TD7GY=V4^14]
M03,_]<ZFLLCV-,NOFX5&85M8*NZ"9O+JQMM5B'OB#YK\[;;YNV(N&';W@,-5
MO?N?<55AMD0=\"18O8++>8_X-1N>G3"/[HOS@:*<6111_8ACL*1B'3-QT >"
M/V<K(;DZWOUEZL K@D-F@JM[_!O1QUN=[@O5[FM-!P7A.^')U:9H<FN'+A^\
M$A6;QE;=+.GEDB $27X$@0&(\*NIVT85C2+X/[K@8L,TNL"LRRT,\<^&>)UV
M5$R-;F5JDQV&C=1HEUGW.4#0.AN&G$[+*@)'9@*?;;><;+$DX+,R@Z:"KL$/
M'!_,9;K1C%R1=['Q73M$+1L?5;2-S+1M0-B5,/6#&G(]VVE!5%$S,E.S =&M
MH7?K/K,\KZ75014'HYX<C(MTW>HN;!AIS!M,.3AJN(!M ,MK8C[AIOX!U8D5
MNB,(K_EWT3!-M4?6Y3_88F[%Q<C,Q548:G:1<TO7:()?<S\,+.NM!?59R+-:
MCABH(F1D)N0%%CO R9K0H_+[1O5P_3#7CX:.5\=<GX6<5LP5"2/S^?'35>X4
M]VC'+.<;L=8/CP&L8PUK_O5;L=H5_=IF8GM.E7/9-J7_*/>N+SL&O3-3U?=P
M$N-B@Z8L'>9V )%=,[)SKY 2J6T]S]WD3;?J%X":3A,UV'AA6("[-,JQPE:K
M*D:US2S7QZKL>S:F=C!EC:'I4(,*T@G*K@"U<L[XXDHW(7R;78T+!>Z0ROS&
MLAPMK]]GV:7SF_$Y_+#(+]&K9?([_2^8J[.O #'9J"7585"E%,^OR?,7R?;9
MQ?&*2<F2['%'<$2XGJ"^;QB3YQ>MH/QCQ?1?4$L#!!0    ( && _5(#Z"'E
MO0,  (L-   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;+5746_B.!#^
M*U:T#ZVT)7$"!%: !.WNW9Y4J2K7W6<W&<"J8W.V*>WI?OS93DA208P6W;V
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M  T8$D7=.7AP'@6;<RK8_CXR^PU02P,$%     @ 88#]4I>*NQS     $P(
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MP?G QF+Q(&FV/UG=GPK?_@102P,$%     @ 88#]4N ]"5=H 0  2A0  !H
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MT_\DZX?6R[_^]=:N22U5<_!GW?_-V1=02P$"% ,4    " !A@/U2!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( && _5+O6,:Q[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( && _5*97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M88#]4O' @I@[!0  9Q4  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( && _5)8Q I<@ 4   \5   8
M          " @7X-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !A@/U2M+X(JF8"  #[!0  &               @($T$P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 88#]4@(&GY+Y!0  -!D
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M965T."YX;6Q02P$"% ,4    " !A@/U231"";4('   ;%   &
M    @(&X0P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M88#]4C<JR(+H @  B@8  !D              ("!,$L  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !A@/U2%/\C4V<"   Q!0  &0
M            @(%/3@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( && _5(6#IGF# 0  $,)   9              " @>U0  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 88#]4MH62,/#&P
MEGX  !D              ("!,%4  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !A@/U2\>>S< @+  !6'@  &0              @($J
M<0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( && _5)2
MCJ,"*@0    )   9              " @6E\  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ 88#]4A-'UC"9$0  I#0  !D
M     ("!RH   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( && _5+?(S1L"@4  &@<   9              "
M@9^A  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 88#]
M4BTUF5'< P  P1   !D              ("!X*8  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !A@/U2LC[,^1$"  "J!   &0
M        @('SJ@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( && _5)O\/LH  ,   L(   9              " @3NM  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 88#]4G%F+)87!0  DA@
M !D              ("!<K   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !A@/U2;Z+RI)P&  "%'P  &0              @(' M0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( && _5*>X6@;
M] ,  +P.   9              " @9.\  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ 88#]4@>9505:!   .1$  !D
M ("!OL   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !A
M@/U2%.[Z.F0#   >#   &0              @(%/Q0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( && _5*TM08OPP4  -H9   9
M          " @>K(  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ 88#]4O=$% ;_ @  '0L  !D              ("!Y,X  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !A@/U20K9<_-,%  "X
M&   &0              @($:T@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( && _5(#Z"'EO0,  (L-   9              " @238
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 88#]4OR9
MD L/ P  +!$   T              ( !&-P  'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    " !A@/U2EXJ[',     3 @  "P              @ %2WP  7W)E
M;',O+G)E;'-02P$"% ,4    " !A@/U2-6!NDTP#  "9%@  #P
M    @ $[X   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 88#]4N ]"5=H
M 0  2A0  !H              ( !M.,  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 88#]4AR:"5V, 0  YQ0  !,
M ( !5.4  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "D *0 6"P  $><
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/Inventory</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails</Role>
      <ShortName>Collaboration and Other Agreements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20210630.htm">mgnx-20210630.htm</File>
    <File>exhibit101collabliczairdct.htm</File>
    <File>exhibit102stckprchsagrmntz.htm</File>
    <File>exhibit31-1q22021.htm</File>
    <File>exhibit31-2q22021.htm</File>
    <File>exhibit32-1q22021.htm</File>
    <File>exhibit32-2q22021.htm</File>
    <File>mgnx-20210630.xsd</File>
    <File>mgnx-20210630_cal.xml</File>
    <File>mgnx-20210630_def.xml</File>
    <File>mgnx-20210630_lab.xml</File>
    <File>mgnx-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20210630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 322,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 31,
   "keyStandard": 241,
   "memberCustom": 25,
   "memberStandard": 17,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Inventory",
     "role": "http://macrogenics.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i45f3ba1a36e8467a8987bcdedd6cd618_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Inventory (Tables)",
     "role": "http://macrogenics.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i9774f5bea6ae4560a38cc67f40b9694a_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Inventory (Details)",
     "role": "http://macrogenics.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "iec4534615a7743539c120849d9bac73f_D20201101-20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CommonStockMaximumAmountAvailableForIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "iec4534615a7743539c120849d9bac73f_D20201101-20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CommonStockMaximumAmountAvailableForIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i9a811db172dc46c389a4e8977a0b88f8_D20170101-20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i9f9ab2c6e8234a7ca18db7b6c27bcf5f_D20180101-20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Collaboration and Other Agreements - Janssen (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
     "shortName": "Collaboration and Other Agreements - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "iec8b966b3515458980b5cd1380246198_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i6e6292f95f964b25a721399e72758c1b_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i25d0f8c97f73495bb36c5fdeb7ac4732_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i28b8746cb99b4d45ac83d7279e1b0e4d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "i99237d698c8c4afdbcef6350116b30ce_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia217df68ded645e8b6c9001175c243cc_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ia66dc7c41bb54d5a9fcb75ea89251c60_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "id22b7b809f714fb1b47a02dbddde5636_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ibf902aadd742411c9c207c7b280dfe95_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://macrogenics.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210630.htm",
      "contextRef": "ifc2a3977b004411e985a36662f6b0659_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Additional development funding options under agreement"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Maximum amount available for issuance, increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "FundedValueOfBasePeriod",
        "terseLabel": "Base period amount"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Supply Agreement",
        "label": "Incyte MGA012 Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteMGA012SupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech Inc",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration and License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OptInFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt-in Fee",
        "label": "Opt-in Fee",
        "terseLabel": "Opt-in fee"
       }
      }
     },
     "localname": "OptInFee",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PremiumReceivedOnStockPurchase",
        "label": "PremiumReceivedOnStockPurchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RetirementOfTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retirement Of Treasury Stock",
        "label": "Retirement Of Treasury Stock",
        "negatedTerseLabel": "Retirement Of Treasury Stock"
       }
      }
     },
     "localname": "RetirementOfTreasuryStock",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue from collaborative and other agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance of the Research and Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized",
        "verboseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Net Of Tax Withholding",
        "label": "Revenues, Net Of Tax Withholding",
        "terseLabel": "Revenues, net of tax withholding"
       }
      }
     },
     "localname": "RevenuesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Tax Withholding",
        "label": "Revenues, Tax Withholding",
        "terseLabel": "Revenues, tax withholding"
       }
      }
     },
     "localname": "RevenuesTaxWithholding",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]",
        "terseLabel": "Stock Option and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20210630",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r191",
      "r192",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r306",
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r191",
      "r192",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r306",
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r125",
      "r178",
      "r180",
      "r307",
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r125",
      "r178",
      "r180",
      "r307",
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r182",
      "r191",
      "r192",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r306",
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r182",
      "r191",
      "r192",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r306",
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r12",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r194",
      "r196",
      "r231",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r196",
      "r221",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r114",
      "r117",
      "r123",
      "r141",
      "r244",
      "r249",
      "r267",
      "r309",
      "r318"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r37",
      "r81",
      "r141",
      "r244",
      "r249",
      "r267"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r133",
      "r148"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r131",
      "r134",
      "r148",
      "r311"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r197",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property, equipment and software included in accounts payable or accruals"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r71",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r268"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 60,133,447 and 56,244,771 shares outstanding at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r53",
      "r313",
      "r324"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r176",
      "r177",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r176",
      "r177",
      "r179"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r176",
      "r177",
      "r179"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r183",
      "r190",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r57",
      "r307"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Product Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r135",
      "r148",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r113"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r54",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r97",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r314",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r54",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r314",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r107",
      "r142",
      "r167",
      "r174",
      "r225",
      "r226",
      "r227",
      "r238",
      "r239",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r255",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r256",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r258",
      "r259",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r183",
      "r184",
      "r189",
      "r190",
      "r256",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r183",
      "r184",
      "r189",
      "r190",
      "r256",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r76",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r153",
      "r154",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r35"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r36",
      "r76",
      "r106",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryWorkInProcessAndRawMaterials",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryWorkInProcessAndRawMaterials",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://macrogenics.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r308",
      "r317",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r81",
      "r118",
      "r141",
      "r245",
      "r249",
      "r250",
      "r267"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r81",
      "r141",
      "r267",
      "r310",
      "r320"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r81",
      "r141",
      "r245",
      "r249",
      "r250",
      "r267"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r48",
      "r52",
      "r70",
      "r81",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r100",
      "r114",
      "r116",
      "r119",
      "r122",
      "r124",
      "r141",
      "r267",
      "r312",
      "r323"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r114",
      "r116",
      "r119",
      "r122",
      "r124"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r83",
      "r110",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r39",
      "r40",
      "r42"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r60",
      "r62",
      "r132"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r197",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r60",
      "r61",
      "r132"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r48",
      "r65",
      "r81",
      "r87",
      "r95",
      "r96",
      "r114",
      "r116",
      "r119",
      "r122",
      "r124",
      "r141",
      "r243",
      "r246",
      "r247",
      "r252",
      "r253",
      "r267",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r158",
      "r321"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r235",
      "r337"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r174",
      "r228",
      "r319",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r142",
      "r225",
      "r226",
      "r227",
      "r238",
      "r239",
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Product Revenue, Reserves for Variable Consideration, Customer Discounts and Services Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r51",
      "r81",
      "r111",
      "r112",
      "r115",
      "r120",
      "r121",
      "r125",
      "r126",
      "r127",
      "r141",
      "r267",
      "r315"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sales of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r196",
      "r220",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r196",
      "r220",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r18",
      "r19",
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r197",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r30",
      "r79",
      "r108",
      "r109",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Awards granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)",
        "verboseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r202",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r195",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r216",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r107",
      "r142",
      "r167",
      "r174",
      "r225",
      "r226",
      "r227",
      "r238",
      "r239",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r107",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r193",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r167",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r167",
      "r174",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r167",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r81",
      "r130",
      "r141",
      "r267"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r141",
      "r142",
      "r174",
      "r225",
      "r226",
      "r227",
      "r238",
      "r239",
      "r241",
      "r242",
      "r251",
      "r267",
      "r269",
      "r270",
      "r274",
      "r331",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r183",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r183",
      "r190",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r97",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r338": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r339": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r341": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r342": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r343": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001125345-21-000099-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000099-xbrl.zip
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M)EM&7?O-?J[M3@*ERBNL]>I\[! 4,$PT]U.A]E$EF=/\I'P./X=1W)S%U'<
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M;,FJ.[/G$@P5$X85I<F>Z\"=PS)AK S;:M!DR&Q3&?45GF&$T@.'=#F75_A
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MYDQ !=K@;6NG#QY'=^H1=)93?:<.?7P WXHT37,O&*QZ+VAV>(<EW^EX:H&
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MX-$D#5497(RP@)E=N]5N2OIMN?%$^?W[E-TQNDK+6MN3_G)IFQ3Z?J#8)O1
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MB@SR8S@K%U&)2KQ>-:L5D#88"%8DTJ+8OMT1C3F?<B:VD2C<A^TG# 95&70
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M0F&2L$_'@:U2YTQ1#,PXUX9?'._X=W'BB6.CQ52,9W VE@'\5QA&G08H^TX
MG\$A/'>3#/-9-H7.07C8)I02RH<8J0%C;VK@U]D K_7+U&FH,AS'R[0E?5WQ
M]:PX)\@J2VD3"V"4L5+0GU-<DE>WCQ8=-DDU.:MU):G-5XT!2QS)?2*$H"4C
M^S--Y>]M/I5_L"VI_%J[IE=P^KK Z9_#XH?0H^SR_(M\%_;D=3S8Z="*S?N;
M$!0P^,YNDRSTRT:=3\ZFH\84&A(J[K1BNO;F\;4Y4SX2-+4P$.)JLC-*Q.7P
MC\^GIW.#!:&8^3&@[V.,#JM$F+46J);MQV3B*(6X>A$,TQ#"W_V:"Z_75AG)
M$52W53OU825L'J0Y1*#*.;=A9N/Z0/J<D""2&==\("DX+&2%E31(J9+ R0IA
M'QGXLH\=I_T9,Y93  CA&I7A53\P;:4;62T5_QRFLQ)R&93%2B$Y-RV2P4R2
M[^")VIA$LY8:&[LC?.\.[I_B-U;_R*H\ZCB(CLO-)M7I"YR]T%U+I> O80F\
M$QS&LP)3E5F";"*$/D>(QXGPAS>9%G\[4F/'T):8FKKX0)('$DM.QB&81(CA
M\:#LVNQJ/LQLN[O,D S0LDJFPA]2K%'NR5:VQT@;QBWIZPTQ;1T?KX=],+Y5
M8Y*O4/3M@*+7%@YUP54XBH6_ LB#;LV<>B1+J&6AHI/RUDH&N9)/87!#S9*B
M8G8C7&M\)2BM'8#K-C])-+]T,!P.P1S2%;CS'@2W,.8S$.Z?^#$0*,$0N.FY
M&<UID5Q:!@FDV-J7F#B(8*PT;\L,[%SS7*(#;,<H<6 )MT<FIYILB0F<&YCD
M8]Z"TY[X&OFA9#*QGB'1Q=3F4BQ^%Q@ 6]E@OTQUF+5<Q@9>W&WB,;1P76FS
M7[U):QS@U/SMOXL8ZW0Q4\P8FY:R8.;P3J.[N!"B?GXG\=)-8K PU\S1Q,79
MW+D/$<)F5LJ3^;9J6EJ_IYXM<U/PD,THI7C4_W[^A#X;H0G/+KY^O@HHZ=@#
M9'=PGMV ;NF1@8AQ-*%@Z%:L'2N:Q!%=6SU^UC9A4_&8#!4D%(NX0PEF_?!'
MEM^G<70C&\15YP/4J40JF;G7!*J)AK%8/0<-G(D^C3%B"R>)L:QS\OSS-)&8
M(?%=G(X(=EGDLYM;DYON= 0P"W3>@#MP-F#3.RX5^:"X?;7CO:9'DE$2(_8]
M#_4X5Y2[:#2Y#6:A/W:AA);7[4)%_=-]X*L6NQ@I^"3(Y?EHQ((G%)HP%221
M&6UA;CL3EB;2";<T\64B[AG0)*"+P.(QX%2CI!#*Z>++!PE=XIU GR^-^^WU
MK3&P@0N@?E*>(:1+9LA0!B;G9(HW<YQHBD6SC*=$#H.)(N/F$MYB[$HSN22&
MS$VR- >G^^2DRLGA;9C=H#/?RIY"GD5'[Q]C:C_B%&JU(VZ<X@-"GMU'8JQW
M@X^S @2@KSA*D8C#%B1C0(#"&6,>#PJ5[)5V14;6-U275(1B>:-&BT:M/^2R
M5)YPJ>6'B]<@ O4UUAB)S2^Q%1H$QR=.8S;#& G9VE2P%P$=%#$]$&?,2#ZR
MF%EV<67PA><LC'@)K!]D,7(L"_H]0JO0HIO)W@:, )_3;^I'-7S[XC*(^YO/
M(+[;E@QBO1C8NR"FATW%+N.A4+6>M0Q[99OW-'+Z&^6RNK6&+T:*-CZQ(U(-
M-4#B_(&H08S4%Q:V%TM\A/P3.B8JPOLP1=L9(>ITS8[)V(DU=F4L=)LB/A:G
M2'P7XG&GO.*>K MWG^X[7L $X<5]P ;BA"<C7#T8$ZPJYZ3#Z"XIT?PQ>@6P
MKXTQ4JAX+&(F++B-,Q.V249DF6-'R]%#+:(!)G$XE>1TE21P/BL(7Q_=2;I'
MM++"(DTH6PC1C"039H&2A$N6)?$Z"E-0*@@ZMA( HCO-,LWOBUZ/2W)W06(X
M[XH6Y2 &,<3W <;87$^:HX62JBNKO#>:@_A\2N8RG-X,,^E+>(@A>8L8KE:5
MJ%8-K.%MXF,Z"7ML@U)_;6KVV&JU[H,Q:ZU+4\Z7F7[+HC36()*4M5=Q$V8J
M-BGNDP!1+SA'2@<1&0G:=///H&4(5^K9,B?@_@E&W:(8IS[>EJKH[5IUT?NM
MT$7^*"/9SL@_9?0\BG0VI%QJCS>52[ULYZ+&Y+1A-3)W?)=?_UAK1JX]HGT-
MGNVJY*@'1UWJ'*]:)!VV:9'4S58_7=@)IUIV'G99=CZW)XR[#<SJ1>8[@Z>J
M+U_IM=# &_9(CU&CI'5H,O=8*LE]247TJ!)VYY->#O6Z>TL>>Z.V)/7Z68?4
MZU\_?SZ_/+LX_73Q_Y]>7WS]\GBN;]]XUH^WAF?]R9OY;0$GT"L%^^,Y@?[0
M90S/E1)H93I%H1W:=R6L)ZO%D?Y8++$K+*,S%1'ES:4A%_^,AS.R!3$&C4,;
M:E!"&LZRX6W?-/^06I=3*Z$V#\"6:C">J*"M^JH[)O8R&0]F11E7FB7U^L+2
MA!I%.5RH-LHIJ#_(\Q_P<1G*]H.JCDI:3Y6N3)C5%X.63<O[!AG-4&BJ7 Q0
MK.L$<*#FE"ES;1Q'R$'XSUE<*"X\?@CBGS#(+1\S$C/'7,N:T*X1*S,W%J=Z
M)Y(#6BVR7T(T(#>Q=.M'<^UBBN>W&ZZ[DMP@@Q*2BMF)?YR=21(]FW!/)RK@
M$O($,J9+KAGE8-O.A6JJ_,JCA__2\"0'F\>3G&PMGF09)J:.[![%@"[;SXU"
MVDL/F@H= U;0Z4O&O)@)5.R\-F$'4,AX.I!&GGN2/5J/:?YU31<":5]5E:3A
M::1(DB$C5)L'Y=[N3Q^JVP(K^I59\_%6]-<7P*SY.#-Z";[-5<UI.NN7Y&#<
M4/^R=]YO^U?JOJW*"EZ,'@G[=O)L'&')5G\N2DJU3<$=E4G&_*@9]:[+"=R)
MN?N\2"-AV<6N>@!5&*(9NL_R-PY]\$VZN&S7*$Y1HZ&-]&EW@VN"FC?<AE%D
M)C;=(,W@Z@%XSCC\R^D &XX)%3'JSL@#-$#$-8-8/&4$$V2@N"3/>G,QFU@>
MJ8=UY8;X;PQBPMUXL(4Q>M"(^++(W(C4J\E P[703/!8#:Y+*0:SZ":>EO.U
M<D73-B9CH9[9G3!.:O;@SJ\]F;REM?O'U9GJ!83+.YV[H S[! >]" 9AF92<
MZ_H1JP8]=O$I/4;*(O/#4.$4\:/5L^U-!Z&+6Z5N43OGJ:S3U\"XUWI'JSIT
MJ>"!Y YTBX(A=A6J0*-K0?.221ES:B_AM+C""W/AD.N*,C@'50\R&%J-\I./
M\](VB:STKF;"'T*U_0/V07ZCVNY?BQ 3T 0A^29CEN*;STS(_:S**A91!FUQ
M*;(W]JZLL_#/W&W5KM<OMQ9/ +=V=ONTE3>J]H6Q.@TV<O(CGL- 7^#I:/#0
M2&:( 6L/,4]PHYL'?4IX41]247+!%0_3AXH1DZG(SEIHZN['MJ<BNR0T5@57
M+-BA,]^7]9$OANODP]H$L/^H/,7NVD5F3XE%6*KW69.4]0$T%4^4W\I]BW%E
M76\.-4/8MXTZ+N'*ME]K8<GACTU&1;#&6K1%=LB:C7 C^DLD5:BJ"2W$Y$Q@
M/E,8R,)X .))2?W)@L?S.E3<S7/>QGP2U.V@<Q-&</BR>9DOF'[AP)@W@7HL
MVR?JI&AS"VP)?XP)?\M[/(J=F>0)"/[>8"BMYI(ZSJY&;[+:<2YLW+S!7WF2
M0<V@LCJT^RB#&-6(!1'$*E?<J6+E;2T%/^^FZU#B+M6\*+/(@2M;^<J!UG,*
MSLA5<\#$RA_2.D9B0J*E]7>+'.0+JXSTI^!=5B.9/5 O*X0EW6JN<]I:LN/Z
M=1%&,:"HF+Z-Z*ZA'2='VF")H0K:T?Z+::'$H&8CL?-F!10X%YH7N;%G)HJU
M3NT96;V=2/7GJ'ZZJ ,QY0@4E"KDEF:8XVL(,;N3?TR5R878Y(_QD"= / KU
MV 44.,"#A680:N,'&6;B9C&QWT^,J(YLLS:7NEV^0)L&N)J4D52!(5,O!7!T
MN'' T=[^U@*.6)G[@"[:.Q(O;87N80NWB=VW-YVJYL-CVSP?>@7-0B"DA"LI
MNC"V$* /00N*24E2+.;U9B9$F.MY[N?]3*E9;G,.<%Y T<;EL$@&L<*;NC4=
M+YB$Q')?9G)]'Z'F@OFBU)32?8PL!6A?T*RGX3 V6YG#])/BSV_RDGN?RXDA
M_CGG[!# ]:ZG@WGSUV^K9BR +M9$*CS5QD4RU9@[*R#09V-;307$'>Y"(FMU
MH&NMGE+BD'Y#ZQ.6\QM;V,6 .IU6B2L9L]SD)BD3RC5'9NR#R^$BP\8B"P8+
M?K&L#J+#L-=52U9:/7O>AM@D8D'BL&R*1-/O(!N[)'ZR$!->3KGAA:SH)*DV
MQ]?^IO>0FE2JIU$@6D:(]I])GM+#!A5?\N!# K3>8@$W6"/6=/Z>;('+Z4VP
M3F;^#/P% TV&^5V<A1EK!HP4LX\GMAZ=[EDNG+$X09T3)4!<EJ*N%;/,?_7Y
M!(MEJ4U?U]&(SZC;5#\H8]!=!:&M2R@4=A]F9MW,71*BZK@ #M\LGL+OQP"*
MRHL(F&>!W0H<U-NDB.C-A%Z*H@*;:Q7Z9^+>TUQ,O?J259+!*:5<\:7)M5_#
MT)V'H2]&DJ%]CI$$88L(=-84+=,Z+W]=!+S)R'W/0FZQ![:"#U!OE9.3IL,.
M4A'@MH4_'?A#17/2KV(/,99C,ND3O%#AH;39)BW3I-0$ZCUD) <4*"*; //G
MVY*=TKMXL6+]2A2,TX00M^*PUEX/.!.;4]UE<!^;FPE3FC(,F*"%)ZLA^V9O
M.G&0C"=I_A"+8P$LZUDZA70&K/6-X3*5^:P8RH@Z=<Q&>+!?2_I-&#]YIRDF
MM07%I FO!WOP$9(6N1/E=!H:KE^?7W7*TP$];]&G.?)/4@<\O!$CK^?]:" ;
M13HFSRS@'3QP3;!!ABID9)ID,Q6/59#3.2@,;)<BU(?VPN$ND/690:&L0=(>
MW@AGI9PVCJYGM'4?<^FR4+UCHW*L)8!U,!.>:CADW.R<R=(=L%RS=>]JU2!G
M0RZZ8J2Q#C9 $0)U*".Z'1+0\E62[ [@X#?8-T?<"0,'<GE@'$HI-)W"8O)@
M/L2/QS@I-#BA'_I(U)I%E90>P:!KH^8\*@@NRZ4X$F8T7OA S7G%]5PP/J9Z
MK4P@!!SZC>2P*S]*DO\[ED/5L]>&,J(M:%8* *%8:3&*51E371RL<&,Q]#<X
M=''3%&C)U!93X:D%;[$;?,FG<+]R:L2I  )WDR-8>BG&,QP8G#\LK.)Y=W7\
M=/M(4]><:2T*LEXYTYX'9]H*A85S*< 4A\"TD0_,I(7 LI4F:@C7@Y9CAF@B
M)%L'$T2KT37 &M81+)7/#^QUJ,1$YU&R+14';;I1R]CG2TOC'FT^C7NTM6E<
MWYC-]G8/_#E.-+.9)()\3C4SBXV/%K'$%T*EUD)89#6X%VU(:I629C]C.$/@
M8."DOAD)HS!^BW['="P0P:D=9P,F*FC_4'!%L?Y(NA5-%<1]Y6GGQ4[9JQ04
MBT]Z'+W#[ $/ 4(6>;.%I [C6OM/]<X;#=-OZ;YZ*G*55ON*"AM-M..93#OU
MA5 R=D0&982@_A$6!53\=PV#A**O?#8-TF2<3*6-?4/Z@7O_: #B@5!F9 Y3
M&JUOQ[ZII2P%OG.Q989Q4?8YH987]-XR.$I_57]N[32,EXK_%L;TW?$6Y+ J
MQQ?$%M3;L@QVIOE-C#8QZA(QWG[@28X#YN[2?A]/HJOA5/D*%4) 7$XCI@@F
M/"HYC*2_)A"W)#,.' P.\3."X^[4=S"!N*#8SW2J01X\*;&A.'TA'$(9Q27I
M"1]D5!J\[7&>Q739C7B<^T;\3?5.XF-F(Q,W@K#P31"G)<JD\/IGP'&2ZVP.
M/.PWH72+#!__%1004*>(8Q@SZ139'8G?D5SSUR$J-PS0;J1$H"L!W*<9D4D(
MX7BC1N1ZD- U53TDP;>FB8PAN@>943"?X#)"[!7"+M&,3@E-Q(!P"(@=\0D"
MH0DQ%UXD+"%'*<3H8@RAAKA(/4E6 B._F-XBO@^+R)ITT,FU05.+M&&/PRGF
M]??Y+(4>R?4?4?8).LW+8QZW)F:P*8!TR[L--Q>E+("X!E$'%&;G9]PFPN:&
MAO?X X2[$#]MR'("WW$=!0%B$"&;%V;1P=RG&[#;,(E8:\117VJ-2"J43&9&
MF*0?[G6?8 ?N+!XE4&2QNE; V<?,+671&"(T-]LP#J?"<3&J2##YP44>-6=&
M9ZT.K?VJA0'O,T\8V(U)@#\FMBX7GXJKC4M?BTZW!NVS\+3N-R+5RESXHR#Y
MM-MCDF!D6\JY)SSM1WU0J[WH/FBI$W6>6D5#I\)[>7.6%\6,<+;@@W?2M' ;
MY,L? 3,J\U1NEC1PL[A5(S.X]$%E[0W( ":LL60>2 !DGZ>0X9:HKNF<,BA!
M!I ,A^0G(O2%DQ="7L+2N/5P3(\#.%7Y5(G=%(02JI1'LP+N9/8B-?*W.!E#
M.+72.+I1;7"R40(A* M*U)G3TR+-NG=XV)V0[WDCXD>[1TK$;T/)6A@3KTR"
M>-D0^<PPY^J*TS4+.,(?L()503'A,948!6K:"(TS6:T,DH@5D2V=:T?S7"C
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M.P:G.JV4R=($4IQ6H2(K&_/]-;N2BG6(42-BWJX5@&DJ]!,MU8]:2WR_ !F
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M.7'6/P3S)81B9/J6]"VIU.9[AX#_",N*RJAPVFN=(Z.S:"8JCWGNP S29DD
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M-5)*]-,6*4#\W/;F#O>Z95;>WUT0FG)*XSC\^89;(NSN'QW^QR\0(V-22OK
M6874[N;S1?VP(NHKKH('$]ZUJ[5W2"B!*Z.3=1:II,+5\#:.9MPP>"5.ZY6L
M"F.;<:*SSDV^*!_JV&?'G;*]>V0GOSN4" 7VIDW#$#:>6/&]MW938P:[VPNN
M3O,/897!U*U)GOQ\J9<3'HFUL#W,89J7L6)H715L\Z+0-A[:S)J,?R?))'_W
M]!:6EO'0BXW='EK3F6H%'PZ'Q8P@F2@;;(OCQNB+74/=8!7&I)Z#M4'2CO[@
M%?(B&R&(1B@_DSI]/SGRJTU]0M<YI@.OCM,C(QX=G/\<BF/R)O:@6< I<>:S
M9Y6#,*)W-G@(J%,H0HWS&G;!)<KZ:,!;B+WU_2J0M?7BAH,P^R%V'>1E"C'H
M40P(L2 9C^,H$1,!SIC"F0$[?TF%@/@S2,8 =(LW[/<L@4C(U53\3FR!N!12
MB+$1\3V$=F"7#S@+;PR;VD,GV5V>#./2!H9PD"\O[L,B<KQRG^Y&S<'-G\S*
M&"LCY*(BN[YP-2< /"AO25' S3:\TGC'OR=3L26'+=;^#QC[U52LW33X1SXK
MLC#M-$X>*E2P.GD'LU)<5I;2S$@!+*,^C,('^8M)$0]C5.UC\9Q;Q$L;:U^*
MUQOBFIB)PK'X?0BR:PC-;G >*C )PT+"'S'&[2:Y,(6IK4 \0=F,LQ*AX>8>
M@K0CBG_+30,Q9WDN#3  B.GG(A]CHPH=W*.7:!MN>%J[HVM=?^B?KK\.?\8=
M%Z)8(#B(IH'%<YNG$08&[\(4K(XH0L1\(;,EX4\P*HKXG[.D('#<@$REVSBE
M*'*$N&#Q'0JI$GQ'0*YR/)#XGQJ%!N%]*0.1T, $L,;0GV4*SRNG82:[K8"A
M=B-WU%"\>@'U+F*\<9)1B@9A?6/8JASP8^PRWMYX;_Y;=HK!2/DX3&AC6HF=
MO@I"$FH88O(-$R$QA>)6D%4P0?\,N"OR20%G7' #U7D9]U4)9\(2%=O[84?H
MHYX*YLJS3B@W,RXI.2QI](0YMBY044U8<_$EU[;R2XJ1*2Q#4O718>WC?"1D
M9E0M/<&JCY:@YN>)07OW=N,8M*.]K<6@^=<3SI>S8/^8NI\SUL3[X/7;W;VU
M60TM0(@O)$&]3&E07,9A,13V*Q?ZD8&HB_WD 6;6^Q'L^!3*;A*P:W<[M>)K
MYC,<KH3$-D[!@G:$.)T0/A'L)+V \G(K3P!:.71(AFHNL-<<G='B2$ZF:.=D
MF$P?Q&)XHZ#@G+I).<,GOQ@/)OC /1#WR3B[B$<E'*+8ZTR#Z57*/ !J!/QY
MDHDC?4SCNXFSN CGC,1^"N8NC4F @UQ5ZG_.TW@X@TPJAN5E?+W)O: HU3 L
M8Q>LL:RC_&<ET.A%^7"&AHJRHVC9Q'^ *  ^G!0PU^"54+& 7%<5",!:Q=$H
M&298N4!I6(#("U'@//8((/LXS)L\CX(2+TW$3X3HB.D *@3 <PHM A^"97F?
M%S_$Z+*8!U7.TBFAYZ?"C^)9F0I)2WE.,&-,JSJ:%>02RA%B!""%B88[R$2Q
M(:M@E4V(&H$>AZ8J>&3"U!46"[S\]PE[J(8)!B9T7$X9DT01A*I#*+?(#Q75
MH_FSZNWHOG@S$'\.9-0VVC"$0(0+)X)" OELM$VO9@.RH(?B)="-'>;C2?H@
M0:Y&/0?0< D]V?+P.'C:^.(+B76W.CXHU@W.P<<D$UL; '$^6!W!'T*F<N"Y
M3<84E -A%CLJOLGA+[OLDL7-Q-S]B.,)R6<\C5FY#V>%>88TJ9BE@!VFFV=@
M6,0W[,JY=.MN<#J=L^LM7U*_TH+=;ORJON]>"OC*P[)M4Y">Q28S7VA-FXUC
M'BMM,G,X;3>;!G&J32>&X'JU!9M._*HM"]!30GB[#JMZ6*G]":31#YX?1XUQ
MICD4(:7K3)(Q35<99V9];"QS;?<0;H,?-U0@F07!$ ,LK4;:!DZC'L938Z,]
M06EL\1RQ6V'W8#A799DQ)3WE[(J8.)76HLPS^3%G0M]@>N[+[NEN/YBDL[(=
M(8--G- /;O-[,8]%GUF-:KP4M'5A!/'/81Q'3+'X,QG/QL)ZOX%@*I%_J]>!
MJW>#:[O\&.^C+J%[PVJ@ZJRM!<Y(_!,<S9(CT6R^,S63^ UDD0@54"+05CAH
M0AD9H5>PQ2F)-3(%9%.'^S:D:SPL_\02L. 2E[5;M:)\2<?I)G/5.^"J[[_M
MM)SHLN*2=EMC):9C[Y>>9!]0%D(8W:'Z%'L\&9)- ]L=*5$=A4$R5J+07G_&
M8='DMD_0I8;4/VRK28Q[*Q@"1A71/IC_'\IL#F9UDV(,RX@*B*@%L-@4;)*;
M3+PO]&GGK%>)5 :D9JM3S8$(C6$?#N/)U(P76+@%T*C$(R>4V01"2'T3RX2Y
M= JM91"N2G6*79B5%"*P32?*G0]B<PR:ADY<?@?+2.DU5.B4MBL*J':1%B ^
M?A + 4>>+,5_963*$:M1BXI5SM-(1@4?[&4+8IK(>>MM46U(^C5^5YQR.D"J
M2TCK'R4E(17X][55RH$_39SG7(8FBW(((R"G ]]1S8WD!";(V) M;(QC"L'*
MY(O"H\7-P F!\-.7G!?<##BJ")>F)\KK8VR:WQ#U(9XJ, >0$H9_HZV/7\E"
M"HCOXKY!8E#QXR*?W: [@H=?,HJU<:+6#"-Q2/'$U4GYJ!'S5N/AL+V""UZP
MZAI!_A,W(AS+>KX:@W"0#J[-CLD91:>Y<2=W)E5>!\)4NU\4IXG8&Z4+'.)Z
M"Q61K92KE3E*!,%&,'L?FHA#1+5$1&/"V"..!9(\CV((C=\*OX;TBW,"M?PP
MC5WM;1CI"+?'_2KM+'ZD^7)DM8FGK437=1]'#A)ITLV W4$6&(QO-Z^M2_@K
M[F2;:7EZW.\6T'F\]\^>.\NS$:D ,6W=&B<N3!FT(JJEB%CJ;:6@2T3CNT0,
MR W*;W 6A_8LL/V3O8%,@<M[U%DC5^GG,T=Y[&T>Y7&XM2@/AVK:V]USJJ:.
MU% U"U8]SQ"O.44CB>D<M=5<VR?*4M%Q%[!Z%+6;@H;I:$PEZ]97I&!B )3O
M%;<9TTZFA+B,:Y@Z@.RQ$:.W3# =L\$V#'23X<M#]SI[!?KQ"/7#Y#-G&QG0
M22O?_.N7CQ<?SK]<7YQ^NKC^L\LH 07ZOG4X%]]__71Q=GI]\?7+)DTW[U!P
M>QY1]PBKC+E[\HR]9L#-?U6LB4]-O?2*3ELA _HA'B59HL! E\*5*A(BB.Z^
MALFT]X,+XT"549IH84D3)W"F8G!6448\RIE*[EPU/_F L:+""%/$JM\,'O7S
M@A9]LU"*T'%4N62<_ /IG0[CY,X._.FLQ2"V7\_U"^XL8=8UBO'-YOQ"IFH9
MWH2^^V2*Y!F*]XZ@]V@=R5 /Q=)DH (3(7;81 Q3/:1O<M4 \U.+D! "[W#"
M';3;]0YRC1(A&V>8ME35#ZNTVL@YQB#C[[>0[,E,VE?QFZIM)EY&^EI,:YM5
M#<MJ2X#^0J]-/Y+Y?QP%>#NG/85S(SGFW#=L:PHZMWX&K+H.RU8J0Q2XSMW*
MH'&":V:M.=FAY80&.[_VL.(CR680+G[(80? ;RJ17!(:C!+E09I#H'3>T!4L
M=?Y(PXJ8M!NY66M<;;?D)C.6M1W.;WL<M5/EZ;8&@(NB9G%OV(&$:V0$HRX3
MT3K=9KFT<8'"N! GE)OZ;&U-T-ID,COOB.1-Q;OL .K2=#\RR/TT'2FDON'8
MP]S4M*1+)KP!0<PXJ@_*&;6\8<3Q7>L*7FP=B2!N/&M4?%MEG J#EW.#E8YN
MF6N*:/@E<O[(G.R[YY(Y0'6)M1PC*5BA# %.BD8YYHVD7&7B@"V$SA[- ):"
MP9)1.$NGLO#7O$--A-8N*2LV<#O9!GWED?3(#FXNZ2EG \+13-,'P\95:'A;
MA=5ZH]W?YIBB3L-[(5)PBQS, B12)/B5LLCFVW R-5S1;LWTB&LD_MSF1H%W
MWDC9_NY1HY1%5%_3[ H9P(X4R08:K2SZI2R*WL")^,1=*E_+,M96EG&6CP<<
M"^@Z4)(!9Z4:#0CT* ZAV0B>U]JJ*YTNAE"&(_C4($Z*?PH_IZR["Q5/(1@+
MUST%R!#G9U1C,#T  ,5HRA2(!%2+H*B$+I4V!*&#< _!6X+M !0=,1'6N:T%
M$[-@SH2P>N-T1!Q,A7#>D@FQ24.5&GN"3S&\)R;W:&'MOA:"5,.@NI+N@]XO
MW>[K+Q7&C)HK'^#N#'A_!HX=VG?N%K"A%,QM483!C*5.\R5XT3=JEV^#1^>-
ML22#"!9+B>*&,4I?0Z'LALQ!+JP3(D_AEEO41QQ/%/'A38B75.K [\*4*D^Q
M/#L8BF$!L:NLVJ6?BO7^(<16UC?WA4TT97H7'7]@)"IB+5D1BZ6%F%H3.+4^
M3.9AH4IR[@FB>W.^%/S+_N;Q+\=;BW_9ZB"E/PI&1HR8BJUZWH"A6=J[U<QQ
M(6P]02;A49)"=3ZP--T0(3UDG&:I. +A#Z6S;!9ZR;#4P"Y1ZZ6MSC?603ME
MK]^ 2@^%=3?EPQ%4BKB?^!=U'L0S&2@/PZ%,$,H2?+C("$$8=!1F-VCQ7/B1
M\PEYF/6#$56DBN<0OV%,9/ETW3]G"6F</MCA-U!F!9.5ITFD$I9E(E8^+*QA
M[D 83L)NX<$XA]4"SZ30!55B7H3!#)9!(JG]#3(.TNK5'W,I%9C>E<13R-P.
M%)C!LE1U6V.<-#?F0<1CH*H'XY[06X:JN0@BQH]NP9O!<4@XKQ(=0K 3JP3Z
MFJJ>,Y?ZN#QEHB^\!+.)^;AZDAG4@<1*2,(_R,7P(%C0-F,'H3/8!0F6EJAU
MA:,1K#@0/)5P=C7]L+L92P2^*SAFCL  PM538[HMVP!*<9JZ-P<[<,!#!<9M
MCET@HAD[7XEXN%"L0A>)R:3>H#"P+*1-RR4 PC(O06R3W7BWS[L@+\2, V <
M4/<P8"A71$A>)A3U=,8"9-<^ A&(MC#(JACW]<QP<I6K%5LGGHT"+OPA;$(<
M [ 3"R<Y!*F&7&T\+.)IOP'QU[3L5-,Y 28/5Q;4S&J:#[8?VI:C3SQ@9]!K
MGT)?\\LX4[I8ONYZ5SU$>KMU)V[G9&[)9D7C-!E98\<AEC7'R>"OE6)M9.TM
M!0G!;%WDX@:TF)D]4Z1O8[M62,/,YSS22^K1C@,4D4\!"HHWZK $5KS@]A#G
MQS^$6 _9=CB-Q &<E-,"71:P,L#BZI8Y[$)K1W-CBY'_98P\M$<^H9&C7;%2
MG$+GF_XR&E:#3C*VBZ-4P@R?],V-S15'XCR93%.YSVO/M4$9M"5I)(,8;1Q(
MBTYMHX89/VN[7%PS@:JP6<89JR$,(08J:C%ANK+=>)BYJ1<#I2R,68O%L$H#
M#1Y\>XZ7K$VQ)UP62K+;H%,MC2]C(G?2\)YL\!FDE7&"*US/1/'LBB"8T$"*
M)-!AP?>IFTE]@RF:WQO!3)%]-&%)D$53T/0JQ@CZL"*S4I:Y:KL*BTA#H?<5
MLUD\&F'M*:CX> B#J2.?ZF.H8*$2(%^;I1'+XQ264Y86S]MV:?)#66MH:FE9
M?+DD1[%/1P?%MK\:]@7R$%QK'&NWIX-B1;"0M84%NZWC; 'I*G\8AT6:8!13
MT2G$B5DF[PI(2%4F)#=K @,006$#S$[E<UOL9J:<G* Y1X3,?8<[Y@K2<TD1
MX)O%#1C#6PQODSL"+2+*K\_Y+:<7$S:\.Z< 34,[@M1"_A @0T&1"^LX&"4I
ML6U*A3A7@S5B$FDDA6X@@8==(28''#_0UZ4"J:D$N:FC!N'PQYO9A(ZB"+UJ
M4_'#[XQ1U_@LB=5;O!V3ARM^2QX9.B1\']!Y,N57FPDTSLU%E@5C3"[ +C@O
M-I>N\<' CO\2QV4%%%RO!+5*YM=+!;P@*>-=78Q/;=9.9%\8S!@O40ES\-I(
MN-,4L%XOT$:7Q$#;;0Y8-@HV0Q88OQ0:,<OOTSBZJ?D.ZG"R K@$<C#RR))>
MEZIJ53A7ADW1?[PIPK$S&\C<-BI0SDK=H/D=YN,Q^2YHU>>*M >OFTI6%OT#
M]3Y697V8EKEFTJ'(RG@VM3C!8'S*9A='8Q)):E^V9N4A // GT )D#YJZ$:2
M8M@(G!G:GN#Z_[@Z8\4N?A#BG)K'$IS07-(OWFZB):HTDP#P$F?006F0LY6C
MYAI&P(S0;[Y"@$E^TR=O@Q80*F.X@&=4@?A,%)#!.")?6M+S8.-)SW=OMS;I
MN<2)T='I8$<%3'M>=4V/QY,T?P!JEWNIUG+B PW-;6?N.B08YR120]L^,U+,
M6&+G;NQ)LBAB_G&&:<ED5ZVL\@G&6F0EG3G&G"#+LRG,!!$*BL_"U(SMA! '
M@$99#517I6[J2B5 UNWQ(Z#A9]YW-[A(D<OVD;H_RPU7A,\/:M^M#P^#A(B/
M'3=/OP1F ]\0-0,(OJ6A76KH.L*<Y8?SBP-6K1/N,(]?]0KX!#'.%778:(BQ
M.(F(@+II><PF".)CEQP;_0MTS:M:(:S@5*EBY^_E^AGVB90#<[$"+%%P,/B"
M'[J2:+5Y.3DXLZE]LT#I)@^/%_S*Z)QG_6JRW];/6ZTV8>_ +[_.(^#W_H'L
M/:O,NV^F>4<].[2*+=LMU$KL!TVPI??; %OR!K4D89'72N-6HV1(9JFPWEB!
MS5U.(",USB/L74+K+TF?[8/7/'3-GB.4@P#8B.EMJ$_ED6T4\A;Q.+^3)_6B
M$%SE=2BS_VN/:(HH4!J:''G"C@D?E)NHAU^U*LRWJ62Q,&M@O8UZ6WR$Z4EM
MKKJX!05(YQO GQV@*CV=4B-%18+ZQHCO=4O8PH X&KDD9WV]4<ARMX/RXC'Q
M@D S.@$C.3ZSZLI^ 1+K^:;Q/!%?P%P!"4"B;.=&0H2O(7U@!!IB%<Y0TR29
MQK,%;TI!8X@^1ZX8L.(*/!27I?G])K$<KP6RZRV0Q=R7G>AR,& @-8RXH!Q)
ME.G((*Q7R$4A2N.)21B#WL&<?092Q7!$=#/B2)/BM=\A3R]O>Y2-\%W>_*N4
M17$SLJ0:9U'&,6(GC67O.]6I2FB5"9S[P#H>Z=8T"$@;"<<F7D RLK]FJ5FQ
ML'\+"J[]D:*CW7>M+(4V-O$<?3)79<5(4 XJTKPA*C!J*F)"H4:KV,F;[*?J
M7\KTP->4:2*I&+X3+N +Z)0G[U;XRB:X2@ZU@(3:90RQZJ[K9Z]UB(XUB- Z
MLYCC\43"@..4=&J.X@F QYW_O$T&0O6<0S.B?$8%.521& ]G31T,3HT8(CV7
M@"*2 :4R!,JY41JC,@2J"JK'U %+1'%U1$/9X4)5CUF'QS*P55V!5%#H9\PR
M QL)YN!MG&)5/#I2<32_OU.6SWNJMCL5Z"@!;'#CC,!) 9!&>FVH#$,$;1H;
MW#%E#?,.(WDVJ8$]J!X9 _1H"A@P9\8*2 NQWXIP,I/XCED,=$<JJ+DJ\V%"
M\6C9Y=CHTR(Y3CA0O]^C7!#--]S+6-,P^/73J<1'I<28F$,W05C.G2;!T'U/
MH+8/^2EX-9V<E]Q&;.>@%R S:6CZ/79-L1&X/^PAY(!J_((T%/OTEFMSJ-I.
MSDM56O EP(1(\EF);!9J^T!:!+!C"BD=FOEU]+1LT_8 ^NK*%G)48@8 "RA_
MA,44NPS&J7*"8N:Y*U V!7[0OAL_I\#G;J2X2C22;20SC58-VH+LH96BE!L0
M7ET9^T(SOC00P>%J( +_X !;IO:P8?@HQ/);HK8A/585?#A9(>/?AVY,6,^!
ML$Z(R/4EW"?%P#WK#FJS0Q!_HWQT9-5LFJ0RK8KF-&( /0IHX/[2=LK1YN$V
M!]L,M^EH(QF-[65(>CQ+;T(C8OX]P_875U,\F:^TO06_/?\YO VAX B*Y]EC
MYT-44H>D\5V(+Y8/?P BC:X7%UE<(\@K\M0T2&]W3[SWX/Q);ZLZPR]Y\!47
MEYUOL?836''+">_&H?MB(<'(*IIQ>[ L!'YWS#\"P8Q,K,+'6"^7W^0NIP0H
M!BPT&219,D9]#"7?=WS?UE&#FTDPC[ Q 5)39U./?Y*GH[!@8%):!&+&$)]\
MU_@?]_"0/NQ4^@L^!4"$'R)+OB7GLX7Y$X(^O56B'#-[2?' ?0#Z2%^0R$@I
MJWJ0 _*KE,-@^^W(HI^*4SEZJ+E5%&]EMTKY6#:$V=5H< KMLXDA!![/[%#:
M+T/4M>;QDVG5AA'6BZ]D@7(Y4U5.SI^4LN6L _"I'3#SAVT\+WANR+VEZ[=H
M-&^!JJ'-ZG##6HI=<4<!# !1:^MBDF,+;BOSC76TTNX&$%N8/I1$JZ48.#:R
MTCNRLRI7%&"=-4%BU5UJ<2*:3>M[]29""\=(/]8/_N]__MO!^U].@W)8)!/9
MNPNK6'L-$F8&!BL2Y9A5)#J!:$9H#[&GS@  $*KD!YEG"":K3\2Z<7Z+DF3>
M(?_\H6!0R+_SGTDYE4W@U;&_P=JN5^[#1R^>!/D)LU8S:/AGQNJNTYA74')&
M/8<<O3RM MBPKA(U08-N]*/./4=2_D!LN)8ZY^VZ=,[AB0'FD&I'[+;#3I%"
MWHBNL,4)GC>7F]:CDM*]P\/N%N[4&ZS$WM'N\2'IG'J-364[2_Q>M<Q)M^E6
M:V^2X=A: JL6&]2$I%21G*P2^2/K#=TL>57*54K8]17UM48.YY,D,]%K-LPQ
MC6^P*]4L*^.T3]RPXPDG%U<*K0:^!;4PS=R0LD'B&6.RX/G4O")@DD/4WG=Y
M@BX,T.Z,A=!1%BA&NL!*=-I)K>+<^1MM&= BLM:I,OC5'V7PCC$IY^;V!O<"
M*YM7V-%,5!%.A0^6Q0_ _T$]D<.,*YC#Z"XID2*12Z\UPRC2AA;XW0*V4X-@
M5/.NRJTPHEA!GEK,HOPT? V*+T3&#;7?"/$XYFZTU$:?7%*C+5 ";)&PO828
MX<30363NIL_DH_HAQ,P:*UI2XWT@FPF):K"=E%(-A0*XR3CPIXE!'9W])!6A
M0XFK:QRLA.K2>4P?<\@]Y</F$'S*>:<[S>M[Q^@)R9<K6T'RF0"/@$ H(07T
MNCX]0:#GVN7,0^VB&1,>HUM,I\+DXJV2%Q1<(MI?EG,9@]]IGDPUJ$/6;D;!
M9R&>PUD:R_.8@1O]U[VYPMY\IJGF=YM/-;_;EE3S2=56.VP1&NH:=NP/4=/^
M/KG'EQVVL3__=GE^=?[E&CO97P6G7SX\$1^?>SA_=#@5IY>7IU^N+\ZO6A9.
MK\_>:-, [>"HRX"JV#5[WNR;$]8?E[&9:"'7XX^P*."P))BGP??0;<C5))XH
MY+!IQ/<T8O3$@4V#R)5"1?)@=X?O,RKR+LZH)05<OH&F2,\!W/)4Y0DMS&29
MID^(^7@&;1^+FQ HQ2A#B:QAXE/ENVH:M 51*BDG?\V*I(P25:298'FO3*]*
M]_B66Z1 _U(J NX+'_4>#=I(=BPBOF? !&,3CBK.I&\VPS"#><K?ORG0AL?D
M)MK6I6U ,K*1@X\'FV[+O*7R^U3@K%;R2QG(BG.1<(05DNX)Q9BQ%"0AOR,&
M]V(8,_U"K7@<))0<&!DD5@4M?<EL1;Z0D-91DJ:20[K:@ 7C/"2/$L90(174
MI2I1CAER<(.$;%*;C7YPE^0I:E?H+UV@KT?==+BA!5('4.]HS235T&S'H "O
M4ID37\4 .@DGXA'FJ0 <[="3I2^&5\CQX&,D@$ J GR(2Q-TLHW\9_I\*K36
M$L< 5IVH=E3,K 3JDTM=2E,;_TOK>?B=S@$H=2U3"Q0CG6"_&KN)";2R&W",
M8& W(&FR-%SQV7E[M+(!:U5"LMQ'CF,):6V=\'T.XOI4N),EM#Y9+0@LN@^+
M6)8S4 0(JOD2PIYF(' /&J,E-:)LBD3"AY$UZJE$:G"(W/]8P,WZ<WH++0.X
M'1.:1HGL;E'K+/7D"L__[C%/U0)@&<-7=SKC++"4H KM;Z5;VE21/F#:%ME(
MZ /J^,Q.E-V]3Q+B:50UEY+A<0T9H$HB&&ZX1#(8R0!^0BV/3$.!Y3M-W@C[
MIIA-E+&-GPV*9  Z,I4W+<R;ZA="JP1?RJ0+O!#3,H9T,O5B0D@@6P=&4>)"
M%\'$X]!#N!YI1LYS"%QC8,WG]/2U[ZMGVA=^Y,U.VQ?3>LS*^HR$LM34<<)E
M2Z8, #!IJ]E?@^M,F^";$!PXS/O6IRI/PCUN&[[]/UE^_^;W_+[&&ZZNN)95
M$KP!I%-*+'?:?Y0!$<.-I.9!4TI/<.,9NEJ9^$M(;VN,0@MWTG]AO?%&6$W+
M A8?=!^N(F!\;)5(BQM)XO$826'[E1Z9#V:[3WE# +]DU=LA(L9Y-S*>&4E
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M;X$W:QU25]0H=6NK?Z212V!AZ4^!/)"@D%3*&E=+>:5W:::0(43E+RH1\#I
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M"\.?53\)3@%+;'T&K&U5& G+\J55*G^P-W6_T4[+R=0&=#=/[Y3;;[;8J4G
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M-'3X].D!VPG+*3.D\0E-A8A"44=E8!QC HT,?<,W*>IO($9UP'J]X(?XL=%
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MECR 7 0#VQK.F\I*%CMOM)>':7X18]N-\<ABCXVU=)&*&#"[9NE0DVY\H6+
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M]EJ+=ZU@KM$)D7..%NPR[:(7(_49@-K&;'$%\6P]9GFPL/5^Y.E\9#4:0W?
M61VQ1(GHF:^#J+>*G9TA11-2QM\U5MI3*L5H!\J_IE'IN5&\W,)EL4QUSC?J
M%XK$X',M^J]<.&,!"CHQ9.K& I]-0@UMJYK3[JN:2DB,Q. E3@%NOT/[LS7\
MJI+'-6OG&-F+.Z'*&>9QZ:?, #7+*E>/2OU5O#:/FN(!%.]NK!K,3>QD0%E*
MU8;EH%"/<8XL'X\L'SOE1W&VW;-<RG)A"9G0+-;ZF@:U%VAAJ;HLX/PK[!?N
M7A+OK#LB1R7Q.&.,=-Q(^"0-#^P]!:T[F$.[*0X,U<(A6=RMNEK18,:UJQ*.
M#?$U+,]Y_0+!L#W[Z?4A\L$IU8R^B*X'^Z>M$K;?&<(^Z^^?D;0JH\+,$"$9
MD32GV!.=.%Y60!_L41^ MM=[VBP^[@]0O>[(:C8J4@D*24V'H7%X?E&X-\*2
M>"2]0)!;YQ,"6V(")+DT!#!X9@P:S J/5=3H2^X9*%)DU:@4<K&IO&QX[-AG
M(U'#1^D-&-1FI_#:NZV\!3XS;_9=<% :;O8\OR6ULA :WMB\,WF<Z_1HZEBV
M035'ZQS;'98][N]3_G0^!'C!F]: !01,IEWKQ%%]Y3)^8S5I+<19&)"3.(?]
M@21&K7"6H*67!6+MM-0 X:E]2NH.*8%Y1]+?X@@E6?SH/RYUCN]-)#QVYAP/
M^L?5<WP1,Q?UXWO+R1ZN/R=[MK4YV>58M26N!#I7DSFKWI0UC2CSMWE^TV(9
M65 X+<-SB_?-H5IJ0]9&*V?QMXT5L:WMV"+,W0SXSJ5B^Z 2(2N,/-4HS$"-
M2(JER*!3B12ZQ0^JP%YZRFWANDHII0'O47H"=X47E\&O-<;&*,3"*2#+6O<!
ML6W5&#%,IY??JI!GZ9%E/@I<A0=,-8S#1-X8 Y#R/3TQIF9EV^J&5+B(\\=L
M1[R#C["]&K9SI_#_B>5'RM](J]_MMJ:IM\#?[HZF/NZ?D/&>^V^Q2+,X+/5>
MJ/0> Y<++AC6G&3@-./G.EWY*WBL(T03U_1I$1E2&N'=00V#$Y"H1%W$LW2H
M,#@&QV"2H\#B<@NY18*!;67A)*S*Z]%A<=L;V3GC/9FJC]UQ.92IFC/ B&K*
M@8QDC*A2Y2YJB(4NK*,MN,%0:6]US1SJ,C/TYA3R!"3F##\4(5!2H"H7I;I)
M+,-L/#]F]']C4GD1K V[1&6]\R5L%FIEYPNC10A9.(7+K4S$8<Y,S5LINB>$
M=QH[@.\KBSR?@/KV/)S8; *[1W+#70^VP$\0IP(^MNPN5N2HS85?E9:J=T#A
ME.!4:KA1Z3(3X2*LNT>YLA6WGTT5UWOT$XZTH20"H20+"TI29Z<D=G9MNTO&
MEF6+J60%H2BQS@,)TL70"!5]8%=E@!7F88CIS] Z20Q_LZ#>YX=RGB><NB.=
M#H_[QZ2?E>*SB9>EU%:9MBW]H%1K6?I</1\,?-!INA/)ZKJ4?8JH;&I>[!*-
M2GI$:QMT)Y964O1NA]%L$O-[(&<PB-T 6//F]@K^^^'3!?SW]NI"SFGQXFP"
M;('B \LO<0M($"B.2XGC7.4NP5.*V\"%X!I]DK"F.(0NO-T\,"ZW?R?9+>]C
MU>/B@BGLMZ?N*C=U3:&N5\9?*(">1#(U B+E.+<@.[[Y(94]P6$BJL\3/"Z)
MN#871  >FQZO430ZI&=C?C@N]X5):<5G7!IP/J'MHE@*!V9+&R%?\Y)?$T2B
M)T!^?*O]"9+NN))%X :[1.;M7'G<VAG4M^5B+9,RU+2076.JR14O1J,>&?LI
MATWI6CYSJXUV+PD:)AN6\2\_9NE<Z*\S!W"F-*)$M<<)O7;UWC]"E_-$;H=D
M[D'_B$Q"#COGR8F\FE:5 JITA2WL<=@_+"<A$'R<K+,18B?%DCE<::+IN^HV
MF&F&&;I<:NG1JZ:IH:=4Y1H_7[303-$"X6U%YOM[9^A.>2+5XE!$1OZ&P_<*
MB587R[X=1DV6FH+-S%GT)$?YN2G(R% \:VR&.57%<L83WO\A"KR$IH9* $#$
M\HBJ0GM9XEKA,(C.UPIUL,'U9EU%."NH$2HV,D@"QSEF]NJ<-Y[W.5I[WF<P
M>"=YGVYIF\X(!55G970/G.VX.#ZOYU0^LWWX:/_0E_/W*O?XOFMR=<]ZT6/A
M&C.'8@DQ*9!>62JB'-2/-&3@0Q;#@:-+7,"KX$JOBB]-<9Q\,FRAH%*GS5JJ
M(-D.NNX.8:MJI!>5'@R?K3G9-:5D7Y&1M;72+5=*X13*:C#HHIFMF,<C3BW^
MM-*-03&*BAMBS[2J!*HM+SP_@5K.F9;OVYF<Z9R4:1<SIDTFJ[4O8;HC8E25
MFD7[R5F\K+\J;%('\'(&U(@R=.- 0>>==Z-&W3EUH^5B.3>JN8M4[R%Q#\7+
M6CU6\7Q+XRKV?5.*C_ =I3#5/MQ\OVV=Q=O;(,TZ0]7*#[ ?+#4@)$OT'-:2
M&F4I#-V]\YU#])7*;]N<A"4HNA)QI7S \ZXY$'"I-'_Q,<5<?V4)9.Z\-'6_
M1!+>Z.*H-J_FZ\ U+I-TKWO7CF7>9=Z\;DO6G3OO.0I"T#+5'KMR&./V^PP)
MFT.D4=R&XWB\#9*P.Z)0>8YE45C2@R4Y=K%;OJ J&2R>@QP154H8JPFKECPR
MR;$/9< _$F6EYY=_?/8325M+9A[E8K,LOH8^+-UA#F&7<VH-!FKL#8[;;-O>
M^5=G:/% VIJ5@UC;N)/N=U][G3F=EV=45FB*%SY[;PF2X_4G2(ZV-D&R#(.W
MQ,R%(>+EZ7@R"]TH$(I<!O0I9(\(!E%5X,ZBEFO[2'IFOX?$F"I$:Q8(X77G
MN\^[+YY%E\2SCM24Y'$5N\N4SA3'D"/\% P*#P7./R_9<6IBO 4:<VYRP#9[
M6+8FT&-W)<&;4<)B<LP^G:<FL[&3["I@RS);F/@!#0E[OREA;]WPC?-MPNVQ
MSNIJ=A:'/V![VI9,+X7ML9WZZM%WEGO*$L'>QDK1^!6CYI6A]'CR_$*?\N#0
M##!O\/0'QZV&>N'QI1T[E+'>56&U+!.=:FG[7X8F\Q+]9J71'Q4=/_!E?E0'
M=3%W7W$P2U.2OCSXL2=3+#N+FOE+45E57V9KOAH^RS(5=#9+<)E%'[-Y]5 C
M1UGW 2'T/CT=P? 1(/EE'C,7.E3"W\-G=IC@=G#7,;)HX?L\S&5Y&,:W->!I
M-%.-E:"11@^4K>(YM7!V.NGBXQ!J:@2J(CT4;!B5S:('E:T;#&U36L>\-542
M[LVI)%P&G^R]L7QW$ Y^-'C_:/!NM\'[_71W=U\P=4<N*>25[>DR).MXJ=["
M-YI].EE_]NET:[-/=<*A0:UIZ\*A.W[*]C6#_IAR^E:;0)>-.+.;"4XNXWD8
MM>ZE"^?G@(ONIDWY#4[ZY]R@YN_:JB)>E1(&P^O!A^60T<8^;=&3M99YV3S+
MI'(=O)T;B^*G&^:?!LC$/TK_WW9"^7PU">4*5\W/**](^"\FW[;'3L$JNY),
M/I<IC7OJ]LMGV[:Q,3AHV.SU-S1%L261C V3Y&,LJO;C.@909@VC^'#AJTQ@
M)<Z"-QZ/UR=*B"8],9(H"O]!#AY>!93I.@^Q&/__?_KS8I]@\*?NK'OP__UO
M]Z]M$E'/&1S"_Q^3"A^<%MK)?QSV:M>-$U1&$@6@[7,_[1]BKR2!#^"_1_+?
M(&L/]_"_9WK22\6.+>6Y4=%FX<SU/7JO'Q2S0O$ RJ]M2@&:&!"QR'_@*0\.
M^D?PWZ/^H(?V#__WB/Y[UEN])]J6Y8&6'<E%>,5]$HV]HGN%#J#XCMF.1-A@
MO<'&PUGA]P_@I& Y.L'F*</Q"%7O]?<'?PB77.T-2K+WA/X\+5YT0-E,W#:^
M5ZJGCAOI.L,0@!^KTI/!/MU0WVL5KU*T,\B&-2V+>$E+NYA+T%B!\/'4_8;3
MP$,7PS;^= @^+,-/(G+@* I'E'+F5U:#?"6N29*/94*[9C2*,PP!+QB95#22
M^LX%"+UE7BT?1NMRV2'1.*]N"+2=3XLVTT36GDWR<BF;.W?QM:MK.LOV)?[P
M40/OM^U:U.Y,K3TXX'K17]>RH/,&ZP'/^_[R^M.GB]OKSU_O5SN9<D&-LE7@
M-TATM>Q]GO8'G:$?Y7U^Q'GGSJ_N[R*+1;LNZ*W,6)L-X4/A/(C <T DHSJ2
M<BHRK@LC@J;Q4,*1?"?QYHFQFP5Y[SI>%&.[.36E5%S4L>L'! \;PR\#%\?O
M8<<)HM!2*0'6N&A16R-:"PJ']%?UKHE#@XM5^!(L85ADXHSC:,K?)/ NSY&$
M[='0MT+/75 %-:0(A"J&RA/[8CH$UHEPTON3&_=PGB!I!OC#V7EZ$%P2X,HM
M0R0>UF6@7791BR>HW4:RI1I4 VK%D?_H!S2P,))?)&GL?\-G!-'H6Y2EAJ8D
M9$+'\Y,TBX>8((>KQJ!ZX;]!%'D\@5Z:&7)M/^,(]HC_AG]HS&FU;9R('ZD:
M"CR,2?0HXA#WW:7!-8PV++&2"^2AFGK;X[L.\9AJ9N9PCRXH01HVP+2T*7'Y
M^1\W8$R>@_D#%#_U1S(K@%4<DX@80U][K7&XKM"(P!YM(#$_Q+R81^%'I[ -
MSO6C8CX#PCRQF3_L.I:1O1'P7*T7[4BTCPRL:+BQ2(0@YBD7T-0LFG>EQ%K:
M^ )=4B$NE7$;TYM-Y9N-_'B439.4J!^?ED0@--S$7-XL1H(>N0%;ZK+R&\3
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M;I ^%_PN?"VP-/RQ#[>297/P?RCA^L[]<F] )77X&FJ[M;/IB0"L")D<L;_
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M_3O\9]?Y!%8G6&3+&1ME]CYH"7*6N/LNBJ;.P>'^H ?__<N?CTY_^MAS;I*
ML./(5?V"D"S.\6#?^3L-RI-X@W>1"Y;H+4T<^"WR\X!X5RTN>EU]=B]ML&AY
M_<W,K]6&$C=II9UT13C0;C<WTA:UY;QALZUR9!83!FP#0\:]!Z.M^,:;KR$Q
MNTH+?RDUMDAU+9*#%COUX R5>TNO?#@ *Q7+W>[36(BTYQP![WX,HBAV+MWI
M,/:]"=JI%\[^P>#HH*&#6GGEEJR4Y0WIM4PQJ!HOYZV=-_?F4NA=-DUQ4 Q#
M8BID3TT@3P]@X4C,:C^1";\):,LP+_P89W'H)P]YI8]9L68$)HOY/0QBHHK@
M5*!LP*#GZ*!FJ?ENB$"5_&RJ=Y&QO17G_E[4([H%V<"3[@7>C>*=&[/B[#=5
M<?;)?6H_*D^!8Y7&5ACDR8,_,PF56X&$%<67RJ!FA+4HZY9OP@):B>K(D(",
MP&@)5O49]0W4857*#<8ZB<B5<OQC3B_B8U3Z[?<L]A//YQRZGFA:PD_73W;&
M?L A=M5NPF_)K9%],)<)Q\\U4:FQI %+*1E[(G\=^8ZRCI7+:,JU*DW@!?0^
M\R(X(R%+#)*4\ :LM0/%?;A/9;4G4L=_1?&WGO/U_D>7ED54= >.0(N*:P+@
MR&F"\8@OX)\>%:*VCW*6DZO,S">2:VGA1->8X.;BGR+1VR:'JCD44S?%F"&7
MV99[$C7.H+5/3*<)68Z)[S-2\5P&$&#N3.- \QT*BP2NE65R4<SI=5G,UE/K
MG;BQ]_+E&JC7EB7W*/V99)AW%)XHE1=54NWE)UU_]Q-&C+^Z*!^/["%VD7:$
M;!&7B(MRW<XT\BBY"%\BMB=*&UW*YY/(H3MY&;>$C#*)]RY;QC&7&0O<;>PD
MQ]@"+7D8I0_ZS/%):<1KZT 1O[EA':C?=Z;"#24P,:9ZT37YE;'++S$MC6+2
MY[(9HU1:8IF;K"5T*S:W9Y?FKJ#I.3)N"*=+_;^D*[&5.(B2ZJ@$L^^R3&TV
MZ]4(#IBK!S,@?YA-\6V^@.1L"PS9L^YIIU^$2R*S?2TT<F=L5RFY3 5W08[9
M)26<@C9PP3"-=5VR(4\1,@\OFL+UC'O ,P9"GVK$T&Q-$I^K?P,"(I>E)S'O
MA?WI!?BP#A1,;0.]=VA.J:+W&]B9F:#M08F68FT<^$0M5W22^R*M'"Q.1+*2
M5?7E\18YF#[53N5O,\K?)N^OY!I,V5*"CI^I:=*GJ%346(H',XN%@GS&GO,[
MIGL<]"(EAH\[P<:6O"O!7"NB$.5KU?.R<F@:!3Q'U?GHX&C(N=S\D* WV%OE
MI[KQ#'_QS0_9 $)IH6[#I>\]QPQQ5PO7"_T"+VE\V+SGM0W,WD$@Z7^Z6/#7
MOFI[HG6@+59HWY&DS-$%PW^0?1L:+*M"@$9_GVP/82@O9>T5*#SG[-RR<]62
MY!)DT*.X$*J$-+^7#S'0P8;/9B26UZ8PM2BRHSI30E?)#!U[>5F#VQLM%#E_
M6:%(]TH^%LNR\VV09=V#);S,IAE3N7.'/.RW7?9]&RD8JEB,12S;I:W=)MAO
M%WH*J0<'J@19XF,C,=KJ)%2TLA[E[ZE&RTE 7M73JR*T#9YMRAO'?02I12%C
M%F^!^U2OR=^FG#FOUAFOO"#M9'L+TJRF5_>E55=$U<%!_RPWN]  N,NX*?:2
MLQUDGK<KM:[S?M0'-X'_YW!N-)M%<9J%TC%!VS\+Y)2I492!)Q#4-0O'XM$7
M3SW'BX&T52@A%),H]>OP]9P+2OC Q8$$0XGE1HV,C9*(0#008.A/,I]STG49
MICRC9"+DZ%65P!MYG,ZF/9D&@-;M,E-W0/X4,UWB+ @1HR/>@2!=)1>A<PA(
MF4^1[D@=&<ONL8I'T-VB8ZZ\$6QE]R<(0"^C=]QB+].]T80="CD6.0]/8 >L
MRL<D[E08"8YUPK)OJ8?>'50-1=H?LYB14)(DBPF3M3.Z@6G-S)(1I<D60G*Z
M"9U:6K3%=)IQ)2;B&(A6OFM.HARE\R(N!S!OAG1=^)&K!DJ#[*?T9C%EB% 7
MG)KECF2-38!(:SI/"AHJ&AE/-E9"T] D0^= NE&L:JI,]QXO,V![%6*/53F6
M;7'4K&Z,MP8F)S&ADUS!<[F#G3HZ98>RBO0-!>5H$1HB%JJ. EL]P:0O5H7)
M$JXBTD@L':>&*:MW,@.N.V +N<[KC+G(-4-/&!0C L4H.YR<X5;*1F?$E\>K
MT/)%0'NVZQ!6*L, F (-0+[E.\T"$'I!S_AWX1?\19;/59R(8M^T40(E*['X
MBKQ&X0EL3)6ACV*5GT: ZT3A0@A>4D(39FC@-G924S](%._VG7\^B)!>J<3,
MY'8GC%\39M,AF_L>^'0:ER'?(0W9)F6A_$%^CY$;P-)AE_ &I6R@%1&XDM1#
MR%V\'?^!E0\R>!!&!";!\+H@ D4RBGU$"R;8=*H6"[ BFO=^%,T$HW:E.O1?
M$6*T:>I[ K312&!S4#=D)!B.),DQ@8D:Y,'T2A\G&ATX](I?R78<_,Z2LA^J
ML85Y]G_V$.. 3GD3E?*@]W:YJ83NUG?NU!Z:T,4RZZD>&<6E+_*%4MN_>0=\
M.)\V5N/59D\US>0I,,H(>4:TF J!/'@Q-V9X^Z\AUK%S;5SB7/$W??A8HX+,
MXU6R3V,3SD-RIHAC/XUB0OTH;@<EJIB41Q@\(@7)\Y]Z.8"UPF0"'<$TD:J*
M(LM9F?( _C_<HUE*2..Z/$Q#>3&"R%268O)MTV@YK?72[RS&\UFE,^#X6,Z?
M;:>OY8Z@9CR61!APDEPJT1H<7*0S#-SP6WV#RQN-^@W6'_4[?UM1O[PLOA,F
MF@D_1*ET.32G.G''=,E9^OLQNR=S*OQJYW^\5D@,N.2E)"A,OWO3U8*J#>KK
MO?/ITV5=SV\!BN0F'#4,)QRLJ-]F0SMDI[4/S]QCVI[A/6]H)YFF"?W7N7?A
M0>F#ZUQE=0?9;D&H?4W=WF"GL,,C4&W.WR/@A,FB+=XJ(K\% ZO3I["EM-W-
MW<Q/6U&TB("BFU NJ_T.4>X7A(3O-.E>7G_N'GG4D^R;V- Z3V9P]+8\F8.U
M>S*'!ROP9,A]6*$GLT1EW+I/?(4[?;R"G3X\V(3/V*AUVGS$ZOABOY%PN_Q\
M^_'FZOKVR\W%IW5&?4P(PM>Y.&?]T]/JKLI/C5T=$?)8*][B/*&L)KU_6%L+
M?\VNG5D ..2GW=BU/_W5; /0X/9?8M<3\'K?DO72YZ*!VIO66P<'".1Q=7'W
M!33VZ=%/SI<[8E3^ZPU)\[,.1@#?I-X\&G1PIZUZ\_RM2OVK3>O*+9#Z1>RI
MW^)H#!MU_X"INL\S,Y/_.OG]NE+#UN+W?M)1[[)"TFWLCS-">)1$5C.%;CC"
M)O-9X(8X.Z)' "E92'6LLRA >'A9'X1SU;PL%DDY\^V'&MI&E4E=B4<11+,I
MMWXFBC@)\9*I]2]_/CS[R?D4)0E_U].E%#+Y(E$PS7ZIR@PC.1WMOUU?8V;J
MV9LRR[*051KF&P8OKLMM@3/JT!LD^>T-^C4GU&PO#M>-<_/&R_NM<J-<G96[
MO'9A<B<2X<8T%<6KG&;+U9WW$N>%RE) ' -+NY/8G3TX Y8!^N\#7:'2<9&]
M-VAS2Z6@6UJX]0J()%P5D[ HAG_-)R&LF,FHWXMK;<C69;2B99=1U\]A/M-Z
M+S69;2?9-2MQ9[$8P2;QH)W+7R][COH3-)&^94]6K4YG;LA(+>XDA#?S1^95
MW!?W7=Z:1]N/ C>FL4M8#=1TE\KX3"Y<,)T)TJ3W:>91E>]O- I6I%CTBU_3
M4#3XQ]#G82=\96_AT)$5ZZBR0<>0ABV5TAXL8HD!(L7NN+LM<20\ON0TG)*T
M7B23#92$* [1^AJG-#,'?0EGYWC_?^QB'4D9A:+F,C)ZCL]_D$85RG5GV!II
M'%=)8Y\ >TM#&Q"7#@YWM;YM@X;PSA_=J$M'QUQ=1 -;5^M"2ZY"N[UYC2WA
MA:>PJE3 ZWJ5NX!%OKZ]L0#1'S5H,]T[/)' "F^Z&:\!+9]RS\U+CNME<&;E
M6.]&CV>AQ.=B\M;LN-7*FOT7,%1CZ/!.Z^VC=DTNBS5N,;E>75_]-LYJ2VVL
ME96 -S[%%K%(&IZBUZ53;,1Q]F#RF\ %:"@E19>DY,LY;V71A%:![AORV;@[
M?';>WW^Q ;FJ9.\V'-FD.T?V&M'86,%MN3HCT?C0)='X\C-K[ 9LG9_F=\=/
M.^J?'E4.R&G,'BU,&,.)C&_7TV_8-OY[?3=X1XYHG8IURWS))G(3SG1QA_\6
M57L>;4NUIRU&O46QY[7&RFHR*1VQ=<@^#;ICGY[;5.D/^[0JZ*;=L4\/7W-F
M[ZD.(.P.G_T(D37DLZ@[?+:"1,*22NZ<:FLWK]H7%0P?].OJME=<,;Q X;>:
M;F[F)W>HB/A4[D/+NKW+\<*NI:!?%99?%9=MW2EN1]7?>I&MFOE&'3Y$9L76
M<M,-6?$-13M.MSG:L60KT<NML\6.T$&'F>I-E0J\E[3SCU*!K@7#WU>IP,MR
MF%O@FW6HK/TUOMG:^V^[Q%/MM7FMM%CQ93RU=6?&1GQKGIC-B'^YO;&ZD47=
M/[*N^UV;G_IN-S=:,@=;:V*I6(,'!V_8)S[>?UL^\?RNPB6"A"\;2[@%)N&F
M)C(U-@GG@BN+5.9A&#0<TS""$S%PFU8Q/S9NN7:Z8J"KENO75\,E]1POBQ7,
M4TU.T/DBXFFO>*\B$@F-RD.0# 8C$7]D-#=FA\90EC X&#5A*EPYI=7$1U"(
M"FY,P[1H)$>8(LHTSOS9M6$G,"H(SJ9X\I?]K=JE&CXL(X!4-A.A3)P=.=)I
M,\11R>P2;2Y(YFZ>7M&BH,E6NQNOB>ATO=@/?VKK_*DWU6/Y(NB1+3#[CKMF
M]JW9W7U1"VR7!6-G3:RVBVVZ?VC;5Z>QUJ-I20*>=$<"5B-*]7RS?2&EPVT.
M*74L4M2:O7#:'6[I0CMQEU/Q/THZMP#CI%E,P# 55M,:MAD%W#YH6W=:@[<N
M_?@J$+ 5BMCC+AOR?&BME16N-BSU,HME"UWFMU17N%[PK^X?8WNEAI5CM)8:
MUJ-Q;)\'=[*-'ERS.I9EIA&N2DPV</5:9J[V\*.:]:!NMM5[&W+M[:%'M=[[
MU1Q,IM-:[;A5C*D7 V.\%P;[O>,GL\28E UG6TX'+850.@?;MM\_J1J*2PPQ
M:5H_L":DK;8/LCLG"3KNY-!^DLVGFJRU67T+^+)+YWG4/WYQMUACOV#+0M0-
M?85O'?<5-M^GV>F"NFT'8-N^Z,GY-D9/.MM2L7T<Q^JN-?B\JK)[#7S>ZDI8
MNPS%\J;0\]8*-MIE^X09KS4\O:[6CG=:6#+GS=X&YZUPY$27SXSY[(^WP6?O
MJD,O[@Z?+8G7LG5NP,G!MK@!9V^@1("H.^D.=9_UCP8;;4':5BV2=D>+O 89
M_GV W3";9=UALU<% %=7'-YE-N,S>WPC9_8^^(Q%XU-W1./1*]39^S@R9K/O
M;X/-5H<UT&W12/FLY[>1SWI)U&\U*8"-9Y+_M>LLV*%W$SASW5VG/9'3;A]Q
M-\Y! I8,=QVGK9-8IKMJ^^(HQ]L21SDOR]+!6?_TH$K0\E/CL0BX).*UBU/;
MT)MYZ&MJ',[U:AVJXAB'2MH)]N?,NFMGW=DU!)022>+<B4"XR:IG I6WX]PB
M%<\JIM6RVW$1^VY0MPEGBS;A$*>'(JC8)W=( &,F2MDUKL2Y"=/(^1!'KN?<
MIT!=8N*/G,LH"-RA)#;$#+L2CR*(9G2/RV@Z17@V>*%_(=B:&,$S_9$;.!]\
M!!GSQW"'BS#UAY&'J&I^Z'P.\14GSYLMW:+N_?H,M^HQ'9PMHY'F'LA"/71X
M*#'%!H-ED=::/9CN\Q]^"H<S6KB4$DL/^H?D4RB"F<0ND(CGC*+IT ^9%J*Q
M$P.)1"$<]T7BNR&1Q"2(AO ![7%".'G9#,EF'&6Q<WEUN.=$^+]'IWM#8$3/
M&>:$,HT",<H"D2R!R# G[-W*H1YUYU KWHHZ5)/S9W'TZ'O FO+ X*34F>/9
M^?#1U<7=E[_\>7!Z1*6SSI>[FZOK6_7)- M2?\_19S@#PP1^.$WH6M<!<>LA
MXJ!PX]$#/@TH:>JDP*TB19!&,$I\STFS:12_XM@'5#+_@Y<;\;+ER$V*(&A+
M$:<N"&L?F#X IDPS8&GXW0P^?W;(^B0,2F)D^D4B L*4Q(.4QUM_GBMJ=GB-
M@_NZ\R:+XOZ7B]N??[FXZ3GW%[?.Q[N+V\N;^\O/1/AWGR___H^;3Y^N>\ZO
M5SWG;UDHG,%)SSG8/Q@X.S]_^ORAD8UV\,K.J8W2_^WU/^__>7-WC<X^<8*6
M))_\J8\$LW-[<7]U\7^H$\;Y[T\7'[@@_Y>_7_\G?W9^<G9&^*= >6'T2#X.
MZAQI9  ;@!\!*B.:/;CQU!V)+"5K RZ9N>%SKV+8%)[XZ\^W_XEWK[\!D/(H
M0ZT$ZLUC.P>%%-YU9)@Z^)FQP&D41J, ]>">R[;.LU1NZ8.(W1D]A!D+L5E3
M<(/2*4*V@@8=N2$P&RX\C#+X)W*5YSXSD"Q>S2M#X^G!?20 6!'#53[::K!/
MXOLHR!+>)M-0PR6#K!!A(AC+EA[HAX]1\(C+-Y2R/YUF8;072<,L5\,=J3C<
M*!%_@2T?^W&2EO93::Y1]"CBI*+8U)[QN?FPE?$,?PK'9I"C!#4FC:HU)1T5
M&%5>@N81J\W0 :_.3X"HB(I(G,I;(R+R#'T9(@+6OS-XL*E(^PZ^1H@[.1&A
MD*^ =T=JBD))>TA>M!2+#0;4ECA#(9 /$C@,%O?@H0,K@ZD_>DZC;[AY,3M4
M3O(<>G$T%<[3@P^_GH+V0 W"W ,6 BL&_%GP#-S@N"-@'3]]YJ4FX,X2C]FV
MG%"0:=]AV]5>1(B&S$LC731\-C>Z[WR$IPVC-#^9I$?B"%P4 =R2&/RL]"#L
MYL_(FO"<RP<P<D%LN\!Z+%3^'L%7%?$R_VZ(_!RA"'#@GK&?1C&P,2\-MYXH
M2"VOIX6EOB=0042(UL"L\!]X_NB!]A-V1GAB[..A:(<+.$ D*9PM[@WL)FP7
M"Q!MH[LQ&/$3)0A0?"AC_7B?0**/]W'/$7:90*^[T!'< 8F@?>8@B9QHB%2=
MY&*WI_90"EL0\\ &!2*!G9:ZI =\$69CH/TL%A6M B?W!(<".Y#R@>6"6-,,
M"6S)&$#12!):=TD^"=/8'V:IJ#'>8#52)H R\8DZYWMEKG;?WU*0\FQK@Y1+
M5#)NW/TYV/_IGT#80-P@?IY!Q0DV@TA:@]X"DD<)AD0LOOL)>8!,)E&8//@S
M!JB7'-=S"&P?& ^.Q'M&K1IDY+<HB58CN-G2 EY2PE':C9IO))*[D[B@,N]'
M0(8@WX%9)V"M]Z_Z/>>W!_X?T+,^>I,<['KPQ=BY_@X\26;?YS&P!SP3-&E!
M]<B-P+= )>K"]L<1SB.(W=$W%.]1[%'PQ)WY7O#,RP*%[LN9!5)8* O1,#1G
M$J!_A/OHD74![T[OC'H4;(-0/#DS-TZ!P6D_1>@.08 X&8FAWR.0"?!$-"U0
MG_;4L^C]/!'XJ&1G48IC!FC>P1!T"GC4>Z/ 39*B.9N2K**HZ@R6!S_1]DT6
M3D%'3X5'FBD4PDOZ<L_?H4DIZ<%4"=JX A6,E*O.C,X!=;BTSM!$0++(G0 _
MI"^DS>YHHWWLB\ K$;8+V@:,1N<JTQ3],:)T00^(QO5CT @)#LR80]F2%S55
M2_8V.)O9FG@ZT5'C@B6G&#D 8HN!$1.VS/1+Y63C_Y&)W*@>@?DU] .?!W)@
M;)'L(JV01R,DOF+X0MT+]1V86V N@LH3HX<0MPGO4URQP5QZ*\%P!\,\\"/T
M K6-!'K17Y**5U>5\6I@YA60\5<D''9@!<;W)(EJY[)GMXQ! J,L0<,$9:FT
M[<E(4@<)=_JWXV.T8 .B%A;T[#J [0O7AL@ASTHB_MN!OEBY2^*/#)P)]&]!
M8.GK#O?U=< W%BI!\PN^!+L9)#.PX;\=#OKP(^ +:0([-Z&VR(HOB(X8G(4_
M#,CBEN\K_>I_&_2/P(;2C]8BU13N/51D&2B_"&BT: P:UKQ\[SQ\4# !88%C
MI1:DZ<E!@T(L(!9%0],KOLI3E 4>V[?J->+HV0V([VB/PXSD.%":&[ 0DF>G
MQ_28'LZZ^S@VQ@CV3.+%,,I2M0'-HGB#1D9<%[A<\62S4!URP4N#=6:L;8@#
MFWRVD<($HR(RLH8F!*Q11J4I5D:LXH=C<&S\*)-YABR-2"4*M&U0-9&@5W:)
MMI+XXAB5(/')4Q0'7M]!I>9/38L&XPKH_8 "M5DS>,, (Q$]9^R"A32)HR?*
M9H@),ZL4CJ4W!YKX)M*^\YGL7Y RL#H*^0EW2C9! AH8HWN&"2>'-BE+0&FC
MFEV5&DY[>"YL+>9S9_Y,X&'CPDS[+C^YGEP=/EW)$]RMJLU)^T7!2!(9P\P/
M4J:"O0<X$,&O0ZN6EJ\79Q-M=+*LHX-FPQ\-^5J53\.W@)*&@9^HZ(?Y+H::
MIZ<8IC&MH)".Y)U_]!,2RPG[)2.,6KE--_BYIU\$KNX946+3N:\+&I/HUN8%
M$!&X JA4@53)!89[P9G <V##'S*XG_,@0 X_,*&"J]DT*+.R)CDSL]:.5,*,
M*H8_C, (<#^+"%1.)(WS2#D<$!NG=,ZI\_3TU/^7ZTMU"*JV#]=AM /.((B>
MT#-R^:H4" ;4&'Y/X3 0A2 )_^_/1!#K[E'HA$XSC((>6#ZC-Q3P.1V\K8!/
M#?CV1FV%DCF\QKR:\\*\&F<7+N4BE%9,J*RAI$;*@150*W LL%5L5=,O#&63
M@+]!/RUG6<HK5;[G<UX:H?QAUJ&S60!;14H/5"/L*)@?K+2-MW2\"%,J,K-3
MJL(QSN%_6A^H%'DJ0.4(M+0$J2\V0E*<KDF1*A2(O+MZSTQC NXP]2E,9=DO
M? 0E)SFWD)"O']2%!(K:N40TG!"+C#?1Q@U'PJ=1+$PEH$5^@C,[\]7_3WB,
M&"9X4E+&3W&K)ARH@YOVBR(/?VH2-3P[ZG&*S*A\(9L$7LL3:#$EJ$LP(IEP
M8M;\8KR$1%T7CF#+BD7Y$W!L3V[L[7V*,&\X<>Y3( NRE1MY4 UDXMFKYZ&O
M)'WLHYQ %T)E1C$C0SFC1+^R-%K&&>6!D E'*;,%4C(\7C$L#6IE":>#XCHZ
MTB,>PAL%6%\A.<%X"E E;+D**^>WHYO38_#&"^0Q_S0O[+35ZQF2>H79OU,:
M'MCVB>;I+P[.4L;,V&1YO+A58*2#:YADF+-(5, 4'$L=EE4?P2U'/CBGHOS-
M$#02'$?YXQ$&:,H?@E<$&JIZ#R:G\J=PTF($KFKY\TGD!N7/,'$85IXW=9_+
M'R$153X#_85!L=ZB4.F"X\=(W%+](:N+U&L'N?QNF&&M?(9GHSXS* 18,G!C
M5:R!O-UW[I$TBK0#AYABLG8LY6,@Y:-Q%7*Y#/OCC&GR(\=RNK7_B(KY'L,&
M[#-_@O^9L&5P)ZB\Y&)$!M'@_/RXK\6PY3&HU<(H-3^"GX$\PZ@><CZZMG!%
MS/KO08!!E;E4%RQ(";I)DL5H=M$/I7 #^X+4-'Q<>?HK N)'FR:-TD:Q<1=5
MXZ"F,.< !NS*=";_UH$AM)GXWQ5]H:(>23;\78[I]D,@*4&A*%F9B6?=<V(_
M^<9/&3U@:0?%I49^/,JFL%XZ"2H: M9U/'\\!KI$B1%S[$=&BR.IH\1T%JA2
M&HXSUY%*'VDJX[!-%L".++R_'V+P3-Z<!*2ZNV.C1/0E^-ZX1X]@AF.@SY]B
MZ 0C<DB)49R8F8)AEA+U!K+4,(U>2EWG&Z:LG<%NA8J4.X"&=$9IKG&&6UHL
M%Z&4F#+.8] ;829R;P4<BSAZ-,)Y','=.9C[N#'X%4 X= >L&#$H>9@E&(I5
M*9U4%BEYLB@&.)ZS^U0.3$J0:[R(5'<.JX]5Y(/NFC(OV/ 1>_J#<C:<_;"2
M]P'W/]J502!47IRP!_THA:4'%@O)8*!/3R@*1XY[1'HR\S 94*R4I;G]9%Y
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M.S@>[!T/3@\Z1YD#C"NB;4ID6:K3Z[AN_-]8\ G_\Y!.@[_^/U!+ P04
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M'VY!>B8M3XT3N=J]OM-5Z3WJ[*GQ']<$'>)4 )M)$HPSSC]Y1]-<48KV"Q9
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M,+ -0Y;[(IY52<E@B40N4]QON&;#2KN1JV2[*; @PJ!N2%>@IH]3$?$NB/H
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M;^\RMX\G#H:@Z[>\5T$?L@FND1C4?X@"T+2I1)[&0?J)XWX%W#V5V 6I]WL
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M)Z-$+0B[^ D]/-*(:3!3YH<HI\ PO.\*>R3+!\-LOJ#DK^1UBQ@&&^2<$"[
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MS\S]WB!LJ/7S.=>5.$]][QG=I\\]S<%(CY$O29W@W#5W6NH-\:M<R=X7O=Y
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MAD'I-'3,<&-D5SG5.0EB$DP. ':+'!\:?19UTJJ=3U6KS,) YA_S9X_YL[K
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MDRHARBBB74#R0BV)MS\\ T7%]:ACW!I4W-&X4%)7>ZQRM+B]8[(5-HTS'V3
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M6;JJ9. *3M;-?A<.E> J%+3V]2V;(64.6CD6RCJ3#U./\<')G%X+S(-6(V<
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MQ=8DU%EX",&#;0#GAC* ^@OK ]D@)#!.!,412#W40#_F[WQ%\0RE0[),T!Y
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M=>&ZGUIL?0\.>^W04'QF4H'S7EQB:"9$9 ;)CI,8%V(4IT)@Z?#AG<=85S?
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M20P8Y$-A8GF)&VW5S>5\DRUR/XF52X8%2#?+D_29_::.(1.FAONDD8*99'4
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M)M6I)UTLI:WQ]7C\L0!9V;TL=?C0X TL;M8ZE"M>H]U 9_ML(83&S5 84B.
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M<3\'  !8(P  %0   &5X:&EB:70S,2TQ<3(R,#(Q+FAT;>U:77,;MQ5][Z]
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M$87,\<@)6^H@@DUV.P85Y>2]=$LV*>4M1=2LV_1XIN ,NC0Q3Z /-LBU0UZ
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MA(=[!\*;.Q%[YFN U4*%:<3FN<9MC.*UD(XB7A!_/3(4\R !I".C_83-V:P
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M&'U+ICZ=^,"^^1D3\MD@W_>MW-'>@?RA6[EXYJF6*Z.YYBNFSTVDKJF+$?<
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M<QAX=,_;2*U[I?=9A,V5R"K]6.1OKH;K9W-+K>_+HS\!4$L#!!0    ( &&
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MU5P7$PH&P7V-6U>HC=2Z>X5W(FQFE*CLMLB?W+K6[^8"6%]%Q[\!4$L#!!0
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M@9:&/O,#5IZ$C@X34(@R4 G@DZ1B5L)%$\'!]BIX8I^/CK.:@9#60E-  2:
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M=UJ#<9X"9@U%6E7RV2>RJ'_#OY>;88Y-OQ;S%KC\IM6",]*&QQ0)^,\P3W$
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M0=&Q!SP<E%0=25?EMSR3-$T&FT:K(R6EQL&.^Z6H7&X:+2)5A'I"0GT%)\Z
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MRQXCG9'*L*1"&D7AZMKX]19KRFY4U9XFYSQHCAY3I<$:=WK4ZX)'D8TFQ[D
M'OJW)ORNF@PPHAG-]49*$>T_8)J_^ZH/F?]GO\>CZ1>+/_-(O[MKT6R._/8B
MU7=B>]]C)O"K=_XA(CSU/:8DB$6!(3G7!$W];<K-H? A13$^FU;9T/<F:1_S
MYJ@V7Y5A[W[U__FI5YQ\M5ZZZUR]VQ_Y^<M.M_.J9\KJ%,-./MA+!6:&?;]2
M1'!A],4/.5%622:<U=HRS[AQBGI)I [8HL#\IYV$J9"@:"4%K/*V:?7_7,E
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MH@#'*74;6U(UA5RX($?1_.>H^8\9<"B:OZ#FST08M%3!1.- \\'<<Q(HV/P
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M'OO<S= +'A8\K,%;S]72!<#.*$Y<2HZ[$%W" 2>?N02+C'R'&]Y2J:> WM.
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MB0'S A192:^\=O$[1*(@0!T08)JW:*G1G%B/G,<^)T,I8 [PPT:/.6<AT>B
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M@^$%ZJ2/WWY<]63T5B\8S'WH#MU9'%4^68\B0S>>MS',2:E3#,IQSEATAD;
M+>DTL U'_;C.T.+';$H5]?N@U?[L(9D0!:,R1I2/RB">;$!6R8!<Y$H9*VFT
MH:JC3AAK<JZ6=.1O&;KSQ)L#3P8/M8/6_WD*Z<\A]5HAYG6N=S^X+(49ZP*F
MTX-*PGBF!;$(VXB!^8&#K8&FH1@]24XHD7)#:8D7/JI46Q1=W4AM0?N"]H^2
M\>Z3CDE1BWGD0@%2&)?+^=/( M<JW8[VI0AGO0W!S%FQH"37&)!?LRH$('.D
ME7D4J!4\.2:T"55%?TV:7#U?<U!@ML#L$T50C==$*8=]H)I[H;126&-*M3=
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M4'^IG'/X-[0^;?UO]6/D#KK>+UN7KN&=+DZ^:\:E\S%[^1L_>&8UA$N_<^1
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M 60'+V=RU0UQ 1O)D0C> 98)BRQ+@&66N*B83TS;C2VB:)/IA=N#E::D=0&
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MD]5,!$8X4=%[KJ2X ^6_K%]6.K ]')G?!3*_?TGF!5%82:Z0E4XA3K3+9)X
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M2!\DT7?HIU?@Z%'AZ.LE''G!F9'&HYB(1#P*BHQE''$O/$Z:8.]E!4<2FWK
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MZ&2]"4:.OG8&W=[%FFUVK0ZMF$BH%4M\?*X4T>/MV:90QH8$$DQ(.@,8E*A
MVB:, @],X9BL$['"(+4(H2B[7&L3E?H:>]U@^Z=%@Q]4@Z>=B"AW,;DD<W29
MY :_&EDN+$I1<1L8=IR&R\:Q-=JN7I]HQ9M>/+>M,$GI'46DNH/3V&OX8:\'
M2C .5948QD.2C1_AT5A,.S%%$$K8'4EKNQ,.LZBV*PD5H)H+J'9GJ8;/;>0Q
MTX@&1Q'7UB%M7$!&<*^LL()2L;%EU/5RN"5R45L=KOM9LJ+FCZ/FLWS$ADBT
M1XQ' WR$:Z0E-H@H2Z*DFFFG-[98$YME=9@MH8UY-+9:YHL0CK7PBI[D'/YU
ML*J$=3C9T2S@= ]PVIOE(,)YPH7R"#/*$#<> S@1BEP2W# 5%?4 3KS)\<)%
M^4O,H[[:O4PJ4E3X,51XRB^LT<$Q'Y */@*_D DYK@AR3+EHO- ZGQ8T9N&C
M1276L4AFQKF]6,.TC)79/IG(Z<U(3!/WYQ*G_I@F3!6PF@NL]F?YAJ6811XC
MBAS\((Z=1SH2!XM/16JM2U&&C2W2E'+ADT0E]%'C\&5-8A]%ZQ]0ZZ<4A4L<
MD@6M%S+E-*WHD>6)(ZQU]'D?AJC<77'!3=42_;@?/^D-XW?W8F9RA4M\I+;L
M)4NQP-5]X>K/*QLS,@)&$8-P$@IQY@W2V$H4;"#!)&(TY;G^"I-U\JE*4*1^
M09&BTD^JTC,,).BH/5-(>\L0UY$A&RC\B,:II%(@*>5-&,86/JY4PB3W4,L_
M\J)?F&FLA^_TJ%LQ[9/.EQO0J9)7P:;[8M-?LW2#*6>UQQPE9ASB)E@$!".A
M $N.VJ@44(XJ)J*N;Q"73)!GH=*/&@XI*OU *CVE&\[3* GWR#EL$ \Q(H=%
M/MC"B"5,,NUI5FG!:I+<M3X!CTF>4Z,7/\7.\'X;,FOA_SQM2.,E#"4/\I_6
MX/3EL \S%GL3=+HHV#07-KV;I1LZ6>R5CBAA)A&GCB,K3$)&^<B9!&'G&E!$
M-T'$-?*%2GACI4E'4?1'4O0I"3&"R.180IXJ#GZ%(DA;1U$TA#@?7:1"Y9B'
MDHMT7RGACGOGG,*$+VV3977]I*=C)'<_FE?)Z^5(5,5%NB\Z^5D:PJ-5WEB%
M6*!YDT5BI(VW".BY=])@;6E:VC&]$ORHKU(_[39+T>PE:?:4=WB@&CRW?1,Z
M6,233\CI)) @Q":A#18I5MD>_!D>>*DOYSBX2QNE1:(AM_8K744 J^V&S$Q3
MN-PE]TVO^ZD%8/G;Q5\@5L"SR\3Z2YD6+)L+RTZNG(^)+AFG-0(+%7(Q@8BL
M)1Y9EL"+PL9%#UBF>%/1)=0#N9L&K5 $96TAX:GZ1!9(>"!(F$DE,1$S!J2&
M6<<0=]@B([!!S''X*\O%1T)NA=&4^GH.>\T@X1DU#+];(_E6U45B"8WDQQ/Q
M8_'<JZKM79W'Y8_PV=/@-\.>/[4YT[F;2C^G&I>X>V,OJFXOQ]UM_W_#5B]N
M?[*MLRRK5]W>$5BOHTN)[40W*"9M'I/VX4K1.TP]T!1.$1<AY%-9#ME '&*8
M8Q]Y-(;+W)!!-04O9>^>J6X_9ARNZ/8#Z_:4KD:I-)-"(U!?C+AE&@%H$^22
MM(EK%@/!X,'2)C&+=#VOWS9@C2E(KPNS%<:4M \KNSIU!:HS7O/+I29KL8OP
MJ,QD++]7(+X,5MN=L#^2W<5ANAW)"HK-A6)7:^5Y:SW!"A$5<ZT\+)&A.!\>
MYR%+6V*B<Y&+IL:E)_8S5O-')2E%S1]'S:=DA42G<\ =2? Z$'<:(P>4!:DD
MA<<X>AES9S@JFI(\P[Y2-:8LLU&3\U[>.AQ<-!L1R/MYNRK8"P2FWTV#S[:W
M;BG5*Q- >3.6VYLSVQD FNU.I%<@:R[(NE)!+P7/)%4&>4 NQ+%(R$9@)MC(
M7%LO4I< LFA3WE#>LT1.GH52/VGDI"CUTI1Z)FCB<=)&>&2\D(A'<#R<)A&E
M0(47(F"=JH(UFC^OU.GZ$I#+[*7S\>YVPUTT?AJG,OT\W[[>';RHM4U<J%,N
MT]Y$J"5QX9Z@=J7V'D^&<)6+7N!8M=VVU9DOE*AA2D:"/<[-$G&3LT4BP7-I
MT H%5IX5)-24W10@>#@@F#F=;E0",+!()>(1]YPB(VE QCJKM:%6"0 "09I"
M76^T>+\@2\W2F.H;?KE;&E-J=6S'+R&-Z<Y99D_=X/NATYA6C0]?W4-L]?M#
M6! Q1^=\M]WNYO%T_<=FHP.\&?[830F^!]:+[_;7KJ]67>-S,_L+>V,!'J:7
ME?B.LO2*C9O+QETIJJ2"PC)2CZ@W0'9MP,@XD5#T*6&EO2.$;VP9W:1EP_ Y
M*_13;1@6A5Z*0L^TN:"><L<QBE'RW)@W(:TQ ]+J28K22!LM*+1L"D)KI-"/
M2DU#ZU,=V$A%/1K=\THWXY?8\ZU)9>G=HS=O&N>3S<1+@50#7Y.=A9JQD:H:
MW$1^67P54AU6PNOOCH47\L8"B.YR&[@@V5Q(=J4 DQ..@%D22(K<$)!0B;2+
M!)E(2%),^<1\[KEER,+,I&P;UE>Y'X.9%.5^'.6>*7X0/8"UBT@R%Q!7,B'+
MP UQGEA*.;?<A"H=H%:UXY]]N.38?HFY!U<KUWT\LX,8&H-N%1SIG]I>3K$>
M#,YBE<G4355:T^"B83_;7EBW8,F3-"&O<.IM'+1ZE0P.TW$NSS+L712W:7X\
MFBFS='S"#W('8N>%-1Q<I]Q^![,(7I,0R(.KQ"Q)(E19E;@FS7=*#*3>3./;
MLFE%>9>KO!=3Y3W<_C<J83B1##'K'>)68&035D@XEB2S6%E/ZE@G[1GMR<V1
MD337QMPB!52>?][!8V[%W))W\&HBS9)WL#@7V?Y76<(X<P1%YPP"2Q20C5+E
MPG#$&)<TISKS$-;$2VLW?F<%6J&XR!J#0@V2D0HH+)'C;/_+G P"$X5HC )Q
M*AAR+#ADN/>:>X,YE=7)3J*6U9KKP3'AV8=3*NYS:CLG,1>2K%A0WMVI?LG!
MDT^@#9W%\DS6&.0>D_EDA,O_WYU*[6WL#WHM/X@A7]CNA*M_F+GS#4Q%-UPO
MJNO/AED\NU]&:^2M'<3=E*(O9U+F \HKI2@EQPQ,7D0L40!*Z1/24DA 2T>U
M2 K[:#:V5%/?D+V]Y*3-YYC%_?QAY3&Y4X&5>L/*3%Y-<L2Q:, I4Q)QRQFR
MPDID Y-*:.J4$0 KN(GELA+EZL>_5BWV]/(VQM6P@X:+)ZU.)\>@\EG]2I?6
M[$3^'*!H#&4J2*.]]MRFX'Q,DH%#0J1C8%+_W<M82"@C3X.%!=KF@K:/5XH&
M"1\2SWW<-0;&)$Q AED&2,=]P,P:FQL@$4V:A"U\T*6DVM17R;GB0A/-K9.4
M)Q6,4SCEDE&>4V)HI>3$%"5?'26?\I= A, F:B0L88AS9I CH/-6.1MBLL:K
MW&V$RB97"R<&EY2;)7&4"'^_E9T\X$G<FZ;H25'L?Q[HY9\-=E/MM.+2.V,<
M#UQ8KUE05)E('(X\5 3M"6-@!;OGP>ZO5^I.*V82"#4A,,@!<<,$TL$IY)V0
MB7@9<([]$ZV;1CVX\UFGB%9!P(* 4Q?526.4SR!G>(K,"BZH 1=&*!X9PR,7
MM2#@ZB#@E+UJD)P$FX:X2QA<U*21]9XAX)G842-QB@$0,!]K8\LZUO8HM1@F
MHY@L>E;AV],6#H Q-$)WF$MJU[6VP9V&^(Q<AYO+71P-S\]'V?CVK%'Y$:_.
MNI\;>YT1H,'27Z1G3UTZ\ZQI_YT?%(]MM*I]GE&+2L!">-=!/KEQ497"[_;R
MWWI#,''WS/H8H=6MBO8<>=/\$_!LN-/23JA,F=)Y"U!I]\MY[(368-B+_;U.
MU<0]_#8<''0'[^+@C6V%0HKF(D57"M499A,QPB(J,RGR%MQ"G _]N\BP!CF&
MW!J<D.OM]1;*![N#8CQQ1+] 7(&XQS[=4X#OH8%OIC ?""QAZ9#TV"".@T$Z
MLH2L83P"[EFE\-+.^CP:^/V TH96__S,7N17B=_'R\>ZLPRX#/A9#/B7JG_8
MI+[.976@K?]UO5^VKA;?N=O%!S"#U1-?9-/2\M\WC+0*#<38Z'0'\!6#;K:#
M5?2J.L\_/GIGSV"0\(>J2O[FM?>8O,$,A'FX,_8>/]11O4_CUA&.;^,"GG/>
M[;<RQK^HBA>T/L5?/[?"X'1"%F8^-<9Q//V(=3!'P\'M'WG\J;A9M/R;<E S
M/_-H*S(AA HB<,5R3](4L!/<YA/L1CJ:@O'_,K(Q^=#I91#RW)Y$Y'K1?D0V
MP0N^L&>?[45_XY<K\]!N==#LI'\[7_=4GMHNO?WMEV\/7^\>[+T\:C;V#E[>
MKBQMVSN!R1FO+7/5:WC2=S@X/-X]:AP?-EX>'AP=_K&WLWV\N]-XM7>P??!R
M;_N/QM$Q_&%_]^#XJ/'3L&.'P%QC^/GZB]YQ<?&-.\W.^"\YH&LJ!^XIIH9L
M-L9>Q,&P#8_P2XB,7'4)#GLGMM/Z6@5D7UY",?S'=B>\ ?\@QV_S?QZF5Q-L
M/KJ$YIU6WY]U^^!'P-U'L)!:"1AD9[ ]"OD!Z7P#S_.MV#^&,?]V5I42>$J'
MXNO!I4.QS=]]^*WU[M@3(/*?WWW]\\O[XX_\H+V/X;O%NP]G'P^^GGS.WPG.
MP5G\[]N+]_^$<T>YW-\Y;>V__OWTX.M??/_K;Q\.=E[!]Y[0=U_??CS8.6L=
M_O,G.]SY[73_G_?IX'CWZ^&?_U*0$R6<(UB$/B<XY0:N+B"&@\/.6R.4&;F$
MK<XPANWLQZ6@N/(12Q OUP(;<!B8#,00[E/4<:,1P4L[SV#4&P)G.,A][:KJ
MP8?GL5<)K3_Q+\:KYQM4@VOCKZSN'DGFAU];$[V9DW/LP&3U6J-RAC!%@]/8
M<,,^W-;OSPN9K4Z Q?^"R4> A9M?9M_Z7O=U[+1\'U"_XS<;/^47>MEMPV N
M?FZT^CD"W^V==WL5K6IUJA>N.%5^^QU@(#E.O]DXGGXL?\HV7*M[?FI[;>OC
ML'('<RWJZG+J^JI5"TQ@B)_B6?>\*I&0D\.Z[78N0P:B^)K_UNITNI\JB@.7
M!RW7#1?(V?Q9&$4/EFQ^<A^>DKN,C*HXM;MAF$LZ5>,\'<(,-5KM]K 3&X!!
MY["28PYP5%<'P $&DRI//M=G[6W"),!+^=AVL=?($9)F=>M?FT>;C5?=;JB&
MN=,;GC2V U"$5G\P4I#&3Z]VMG]NV/-<_P%&LK_]%HSI^^W&3UGV<3#\TFI;
MAWS[H_NY.B79;3N P>JCGUN#TX8_C>WNZ*TN;AZAA1<;-,[A,U7>7/6I=AS8
M+ S \__NOJ5HQ/-@NC*_Z0_&;]7X?-IMG-I/>0Y\;.7Q#3YW\_9)NPN*?MYK
MY9T4F&"4'P(WG< :Z\"*L(/&6?4<\"7R$#Z?MOQIX[/M5R.<^7)P.O*IG,W&
ME75P9H<=>*^9V:C>_.S,NFYOYMV[P]X5T8\NG=O>H!-[S<;NI]B#16X;?[12
M;!R!%<C%S8]B[U/+1QCE'W^\;/PTN>GG9OZ2?=N#@69354DTQRWR,T?"G SO
MU.9U>MXZCUDQQKT,P]!7TQ8J1R(O__$J\G!3M8P'X]Y"@U.8GFI678QP/<L*
MWA5F$T0.JMK(J !K.&]8];KP9YBNWD7SVDJ._K0#ZGYRT0"_;9"C;_VKZN1@
M?* G_<FCOAUB-8;\8N?@"L'#\QC'\K8@))M/?Z3A62-6QZ.RVE7K*@]NLIK^
MTQAV0)QP=ZC>L5/5;X7Y:7<[EZNRVZOFMM]MQYS&F:?^II5<W3^KH T@W-]U
MO[Z+_:)&V/]'Z_^&+5A*%ZN']#,+J@H9JE]!N  HK?.S>-.BJH*YG4%>QC#V
MW@2I*S#ZW#H[ Y2H.LY5#9[&;.U2SVR^#(B0E3 #YNR'815V>["0*_49;^\V
M8(X <#)PG0-$332M/P"*/JX5_*WZ-:N_ E1EM._V+L;0"S>,X*P*"$P@!50Q
MSNW0/+W,ML=V= 8BQC;T.I!-82=E@84*++J7_&VDFN=7*C-7ECSWFP?DRW?/
M]HK(FCTN?#CI%@'JW@,Y JT<MYD8S*R@JZAN3WIQ1.R;8[O>&>3 ]$B4)SV;
M#=CE& [L>,WL=4"T@^&(6FR?G<4>O''^Q%XG(U>K.^PW=D:6IM_XZ6!O>V_G
MYTNQ+E= =+YXS=-PMPX :Z53(S7H@?!!0JWXN3^[/"[5W4ZZ5#?.)CC6F(20
MLK[,K!@P#6X8@+=4TP\*&WVF 16_ZK0&8WK2'Z;4JLSQQ80*?_N=G[N]CU6G
MD=&&T6@Y9 OH6^<CG!GY#95![39"SWYN#,_S$KH<;!_H@1_U&KY\2FMR_/>R
M.F>%,BXC"E"RX7CMP1/[PW,@KX,KMG,6CJ:5N38;O]DQ+;WI3=K=_J#B3YUQ
MI:_<@>=R:JXJY!6+/4;2ZD/-&\X_P,A!<S_&P>AM+UN'9QI].</5W&?-_D9*
M0!DZ(S8&IAX0LCUL5Z+X',] J""LP>F,IH41,0;@'9S"T_\< L6*>=F\C=4D
M5<RN=1;#50(R^I(L_!A',]D!;$?PT?;,4,8&H9KZ&3@:G/:ZPY/3:5V0FU\6
M9OT4KHX7R!56,4/,,ER-[<%X5JOU.:P<UHJ+ W?U5]%H=+\].VME,CP[X949
M"9G#M]QP]%4]T V?35'V2'J]?+)\%#MN9!Z9Y_"L"W^#]0\O?U7HUV?IEKEQ
M%PT@1--+,YAZ]3WA6?D+*N,X?F+%K6XPUV-B/WVQJ3T<G;KIP**\0K(CS#6\
M+@QF2AO'$SD!_MY8I<;=*T:TM!<G3^MT@2'VA[W1M%;+J@/0=EU?1X0!/C%5
MZO&K3>:NVYD9&RP:ZWT\'ZV1/-&9::;LC<#%3; ,_6Y>)Q>3\5X5=W-F(2PH
M=?C$Q271F1TO#/\D3_?P?$2'L_YE3I3AN9*;O112QLJI_:X\JGXU6YU*HD#,
MSV8D  (;@ANU=P5-,Q(,.Y-YJR*L@'-5R>+/5\<[(CZP[+(;,69N$TV!:^/Y
MFIKG_,>N&]A69Y:[7<+L[!@J&8*\\^@K6!O+%HC>6."C*<[H-YFSRB,/8&(N
M,G> Z1C-8M^#9L#ZJ!8@0&4[:WH<.9ECGW1,22:3>"N;A!N 3K2K%_F6-U98
M\DM>Q=W/G6Q91RHT$Z?\P8[0TS/ (Y@;,.P3=1FI?Z_5_]A(8+BZO7Z6-:SH
ML8&8D==_^I=AJ;$<#__>VT'$@,\'K]4&Y6CG+X)%DNPGT!T':M>"C_K!-X^Q
MKG66X2"O^1%L9<N?93%=,=DR@?)L-EZ#5HQP<I@C#WEEP4?'82-P"%L!OJ:J
MV)%U;:20E5 C$(%N>Q27'CVV/UN<^\8WN&&!3B*?E:)D99J$@CJCH&;U52,\
M'3.6\3N/_^MR<KHC]9S,X<C.7&XJ3O;3-J_%0?]_]MZT.8I<6QO]*Q7<\]X#
M$9:WI%1F2KWO2X0;-QSZM,L-F";P%X=&NTP-WC5@S*^_:RG'&CR!P65<3338
M53EH6//PZ =&V,$\Z4WVPT),_*+X^Q''Q>G>^1%7/)=>YT10"W\E&2/*>$ZH
M""9/C&(F4XMQ[@<9?HY$@-3:SJD\/-<6S4NLYXZLBZ*@SL>A9H-G#J[/YR_X
M'*U8W-G8G^EQ4S4^=O$\Q.@#QU!N(<@:2P,NU35;H?$*[SI#$^SIJYV=OY]%
M [L:5S.47M."4!C,*T=9Q3C00-#N=#:9%I\_Q0GVBECB:-B/+M00GX<Z%95V
MM$::&YY5ECM:>;7KM[ &M>>!Q?-#, HG$SV^*!V$H'MH/#9T4TN]V'D]J;XK
M[?^)7S%GN )\_O+YHVG]#C3U@:Q _T9W$AY<7>F_G'D;][!T&Z/)$WI8&=BY
M +4>+9,8@;X Q6(F8#M$>[=\=S&XFX9OHN?^*Q%Y13[3\F&SDO*74S>Z] [/
M3T9(V6#TP#-Q0<'5APU"@ZAU4^?]_W;^ O,BTC[<V?ZJ_!Q-[7XQU"IW4X\
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M%N'Q(]K*;[5!=6TY[>9,VOPA%]7>S&Q=48Q[K7DT;TZI+',^TQDS+(@@M<[
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M3(P-(Z\O(V<^211G7DB9BEP$0ZFU*A-!Y2KQ:J.5UY>;6R@R+.%@62&4K%?
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M!'T&+QJY2:=<(N^VXG[A5R]& YC"!<Q_@D\K]CZ9V_MAIP=KA/P3@"M&*W@
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M1.@\(4H'211SSN?4)QDUA1_&U^H(FVM"6^N7(WTH5SX&/..[A;QY%$!IJ<M
M0.0:A((5.@N:>B\\2YU67K*0;8)OZRWTYR!OTC1GB4PLL4YP(IC,P-]5BFC+
MI9<I\X:"/$CH5IZO/V+:!OWP'IAZ$\.Z=W9N8EBYY(G-G"::!D.$M(P8$12Q
MGDJE7/#*@__(-YS\P#CY5K V]\S*FU#0=[!R$PI*-?=2"PNL+,$=2[&P-\-B
M7Y8;8YG&4X= ,W]_7\2&BW\I?;R)J-PS"[<*]#7LE5.&))QG1"CMB1::$R]4
M$*"@O365<7U7]?D_(:#R2T#=W@XII9S@IKWJQR[-+R.]E>))[C(EK03I'9RQ
M/F1)2AG+3$+MICYIW:5X&RG%<\%3H20!E8QG/>4Y44D0A+J0:IE1KFS^Y+EB
M6X)^=XCD#KGIGA$*-[)T(TOO699N(E/W+D6;R)3(M91:@?^:" &VL,R)3E)+
M4JM=+K*<YFFVRIW="-"- -T(T.\*"-ZW!-T$!+]#@C8!P4RX-$MM2C3L)Q&Y
M840:(XDVUCH$P=9ICNW^WP]TO9&>&^GY2TO/]7;E-X'8NQ&=32"66LIRKRV1
M3H#H=" _31"6Y.#74\>"8Y:7+OQ=X8O?IPQ= <)13JH[&P#'V.)WI//><*;C
M+-LP'?%MO:'SP^EO21;E:C%Y["VM%V(1W..2NWXB;[.TY.WVS I626FPBF5Y
M[G(F;*:5R!"XT2L!7.VY>?)\I]_OZ(H3"3 OF0"S=09Z_,D7&"4+%6*=$]]W
M'3WIC$+GS]G0%W22T A/P#IZZ#H5:$'Y58E<T#G1+@H9I+"9[L,[IM4SX5E]
M/YETIB>P<J.A[UQX/=[N='!T\-WTQ'=>C :PK!?_/;GE<'M#&!.(NLHLZ_3!
M+NN<C2:]N$S?,I%S/_;QN0O/@N&TIL%X9P"S/9EL%[=WWL^/ :<]7#69Q1E\
M\Q"'(W@.\$DO ,\,I_'Z^,79& 3R&(BPXV:^,QUU+ SXN%BL'O9W^\FT@^6!
MDRWXW?9GR)OE(G?LV+L>//@,9N/@ GPJOJE\%%R/3<HPR?+"<6_R"2<Q&=D>
MFLF=\][T!&X'K0#C:DT4]]M:$!'PLO[%5N>'JZO7W9=S^@IXSZ+..H<Q3/QP
M46$M&/X+Z@M(=72NAQ9_?Q%GC@Y K;SHPU1>??\_;R\./[@SPT6V=_KR]/#@
MXSDJL.[NIZ_P__G>U^.DN^L&H,Q.]@:'O>ZK/WN'KPY#]]2*(R54[C.:$4HS
M181F@4@NP'8'$N=&)31W_B< N&WV^0?OLQ<LIVGFB3%&$,$\F!RY!6LC4>"A
M*4V5#$^>#T=+1L;2!QU=+6^4IJ4(*<7EV$<_&Z7,M1IA48B>:[P?I0L\ !\-
M=W;.0->.'$AP$'B(:^&V.P?-@\%T@1M1M*%,',;W3CQH)'CY!!7 9Q"3 [AO
M$F4@C+-77#X G[_3[WWR(&"C*L /X8=I>]@@!N%1QL.H_C/KC?W<X^<>;F(0
M(8X>[)^+4B'V8 I5N@N8! 2V :D+\OC\I&=/0%A?X,/AG:6:O=A>MGXZM[5J
M+K.%"F,CS5WJ1)YXI41PU*1" \NG*C,\.&6/1/;D<G0T- K53S"?EC!$.+I&
MZ7:E;DI;<5[N!,MUHO+<4"H$ _M)ICK)LHR'S- L54>[4>[ ']((H'FI\AIV
M=#@=C2]V>Q,+!#T;^P-X_N_]D?UTSS*CVZMDAA7[KUZ>=E^!0_'USS[(C/.]
M5R]/#D]WX)Z=9&_P!F3 QW-X+EN4&=VOQ^+CASWZ\;1[NC=X#S)CY_SCAY>#
MO5W\WUX<[EK:/=V!.?P3NKN6'UF=9]K[0%R@&G2# G&A14:""L'H+$FD2POI
M#^3JW0Z*[C1/I4SR/+4Y%UH*HTUJ8;69I3P1E#_I>!##9TB_XQEHEGK-EQV!
M-@6O-IVO?=?\V!*F+=C85'*:B-2"AT65TAG5B3>*:5[KN1]%8._LB7>SOM\/
M];1?S,9C^.D 1>,C)K;DR.>>"FL"T)FAX DS2606#TAG7G"AK 0%M4 \E\NH
M?\])1[:=WH?7%\762O^H5VU_J3 GE<*$U\T".E]C-.?AOKV=MZ_^Z![N@.6-
M>B^,4/GB=R4ZI0?M [H'S/7+WO 4/(;IR6@&DW"39[]=JD^6A/R#P;_,U;9(
MTSO'/F1R&\3$31_[LYO<;@$D]K"PPM"+[E0.] W@UG[H*F_Z%*^+6+_5YVB_
MPLW@R'TC://U$'>_6D;CUO/_9=(6=W4X1FU! 0'N5?2W-HF(;S2ARD0$O/O#
M/_V]T]=?]SC\.7V3=@_ZO8^G;[Y^//B#=[^^I]U=^.S#QXO%1,3^P>')X8?W
M%WNG>_"^CQ@;8/L?_NQU=[LG>P<?D^X!C!\^.SS],^RUVRUI*K5V1F/TAX'Y
MY0(Q8%\3EO%4F3P+E,4>^[OJM;P-N.7:8+(_AOKS#Z/Q)PPRGXU'UD^^K=O\
M49SO_!-.JJAE'&[*Z^'?Q99LA-QMA%R[8#HWR@09*&$RY>!H4DJDM"D10L%_
MF4JT#4^>IULR4[_X8<X/#IKD,9C2L?6G\=PWQR5OSECZM337SM!MK/5O561M
M9&*1)8H)FI,<]K%49$$(HJ1->.XSIQPHLFQ+W%G[YOI57M[Y<4"WJD0JYT50
M-LX'F*\I1FJ%69/%./6]U";Q2GHL)UBN3YC\/>Z-QAB\?KF[T]%GX#1\UOUV
MW!I=B?J$%*SPV(J!ZI@-A<OJR%',S_HO9WXX\<NE*%>&QHN"F3IS'+/($Z_'
M]B0^U/G/OC\ZPT1M]8+MSKN9F?C_S/"SA<%OS66 C3^&S;#ZK#?%NB!\<Q-9
MQTDLI;R;8?JY^/V*U.[EN=UY(KF;S*ZZ)K.;W%MF-_OAF=UWTY']=#+J@Y":
M_/&?66]ZT1U-_?JE>???E8IH $KCP'[Y>/#[)SQU;W\7WGG0[>V=PFA>[8%2
M>!]+1PY//WU9S+SAB7[=KR]/]EZ]P7>([BXH)_[ZHGMJSS]^A7$<8.G(X6#_
MX&7H?OV8'G&=YIIQ2Q*7&")":HD"MB>!\DPS!RP?U'(J5>I4F\R*W F0""KH
MC'FO'<LSE>IT,5/7WH#_[A1;<'7&]ZK#V?Y]5;)O_83H=4LUO[1*<TUE",9*
M*E0:I,I2S5CF4J6M2B7FS#O=T>=%D5J)K)C1 7G4 R'5T1TLM0&!>CSV/HK
MI^_B!SO5!\\*"0NKI8]+<8@E+EN=,!X-.E-8GRC9X-^MSN1$CXM2T!X(/CL:
M#$:XR+"UG1/]&85C? P\^AB!"XM7G\'>1E$X.\,G_=<M#%5O19J(C*4:[)PD
M38 L.95".05V2IZ$R/F4E9P//RQ8K.D-+-;!\?#+;R_B5"*1[NDOO<%LL#,
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MOA,K0V)W6US9=AZ_"A_XL>UA7KY8EE&87PS$_^AC09WKV7A%T7K=]W,[!;?
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M8 M5WGE[=Y^N9B#PAZK/&EC3E0\H7**)K]\6B0)KX>N]_74Q85<OWE;]T8]
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MTM2?^55VL[5CRR$M?\#U<^M?K7ZZ(3-8BV9HI_>V-*WY%D*&-;6 M1G;O#X
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M"ZGBO!!QKG*N=7BSKCHW*>U;*.C;':DW/D7G:/3*1GFQYO]!R^$EC.DD#;)
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MXS3(I!(ZB]'E+$7,(YT5(LE#':0ZL,EW?LF#[9+?XI('![#DG"&_9D H,O\
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M4A')(D EC%&9T4Q2*AG8/%<9/3_P?+EK\=B>+\\O8<PG(9@I@E--@KS@!-9
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MO"!KJ[^T?\ZMFMW@<1")3.F<JU0RT*UY&LN 2AE)FF94B$=7B'&R.>%$VX8
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M4B#=H"0YS\&8TU$>Q$F:% 7LZS#?H>D=U5#^/!KD.]W.=1+P ^-!7K-)Z_V
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M'-50*7OX:&*-#CPQ)H;NT4X4'"5C>Y#4/4B021$>,AS#\L.98,=:$KP).A9
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MV71H6X_,L&=&Q'$^YI?<+S0\/,*15[-A2TD:S>K6H+.H7'TVM@F^XFPR@8'
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M[9OUGHTGY_[JQ_:S)P913F";%'PTP,!R[S&89./>I]'X8H3.V_W#9P<O=X.
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MO56_C..$C!164EA)854JV*UL2;N0E=4@>.R'XC*\IZ*?//3O'<<GR_&]-_3
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MF3UHF;?+=KFBF!\'GC6%OT;AV/GE_P%02P,$%     @ 88#]4BIEW06^#
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M^50?M.%NO7/?Z#[VGII?FIU^^VOSH=O?9J#E -=36RV7:SIJ%Q49W9:QJ,J
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M&/?#<W@]CECC[$WZ?NO<#T=E"<VK27?D1W $6.Q<*HKT/U@*74T7[.=W_M-
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M[;@52*RKU^5>,__+FS)N'/F.6E!I/SLN/"DB%>/$J_+**959UN!#,"O*F=^
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M0^;,)E??EQ_!]_#[3_\'4$L#!!0    ( && _5+JLO'KSSH  ,"F @ 5
M;6=N>"TR,#(Q,#8S,%]D968N>&UL[7U9=UM)DM[[_ JY_.KHRGWI,ST^+"TU
MLJLD65)UVW[AR252@AL$- "HDN;7.Q)<Q WDO<!- %Q.]U%1)(6,Y<O,B,A8
M_O6_?SL:/_N*L_EH.OG;3_PO[*=G.$G3/)I\^MM/?WQ\!>ZG__YO__(O__I?
M /[W+^]_>_9BFHZ/<+)X]GR&88'YV9^CQ>=G_\@X_^>S,IL>/?O'=/;/T=<
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M+AW17&*;%,55!#TP8*PO[ :/A1?H>DZV^8@^]718?<+1UUJ2<!&QW-9^,Z6
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M$UQV@X?I@'H9,"!Z@9X?-5AX5E'5A:@>&3!]0'.=FNTFNPRCJ.M:'TC*6X-
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M"=YJF;DWZ"7KBHRNBSYBL#31R]"&UB4Z3SL'7"%/J!"4]QJ(5[KLE:U3$DT
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M/7D>OHP687P^Q,*RVM66KD1?I[:2QQI*)#=3\."TMI)WLB5ZP^%6JK;_@C"
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MR&*NS::E9^!+S&"$B2YZQZ3H5O6_QN+WM52KEXY7FJ,-%-1LUI=DM9EU;8_
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M/,J\2%?9O_W%_ZOW%R SOA)I=O=O?_GR^1TD?_EO__Y/__2O_P>$__/5QU_
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MD]O0R%RGL5Y5B>A:5QZMY'<C(!OT[2AH8$Q')J$6SD;<"LTZK5]+3X,[_QP
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M$$>!#QE"2IOSDD$BXP@BHG])?2X1<KO6/+D*<UM!S^4UG<B+UO^3&-EG-LE
MS]]#MO&!=8 XF[1TG&BF%QO)6?B]^FOQ?7BY+AZEP7Q:ETO2PX-UD_&G4O[Z
M\[7G!Y_6#P_+I^N[7%9R-A4W@I $,L0,^B)&>N'C$:1QY,&(ZT\MYA'W?*LJ
MEW;=S6VYJ@4&M<2@%AEL9';PWIP'VL+/-2A\(R\"IY$#O]<"6Q9ZMH30P1<V
M*)03N<5Z?HQNOC%K8$ZZR<ZW,IW'S%JC'>>9_5L7TN[SC]CS$\&%%T*?Q@(B
M3&-(I=#_B1(_Q(D*";.ZQG:NHWE3[:4<>R&[SIU7#THY @-<.O?G,>M=Y_N
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MY7I-(-KT"9B$28(IE)RKA H9*B6LLXL?Z61N&_U&3-#(:6XQ./#.,20MV&4
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MGKP;V+_UZ6X/7HS SOW"RUL;U)UP^U!UTK74%W&"HE!$/E2)Q!!1%$!"M<&
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MYD;LK>BFO)1[*LC+!L9N'SP9W"/3_Y':V)L!:+2IS/<Z+GZ[6^YH-&:A[![
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MI+3#'4W*12=U?4XBIQ_N7<=D=2\W9X6_F-$Q%T9, '!  LPQ#6 0)IXV(%$
M$\P3&'(5A8C&)&"A8U7D8WW-C0EJ4<'V=+L5ME>$]2F0[6AA(.A&)H?>J/4I
M47(.CX$KDQSM;NJ").?T/E"'Y.PK_;BCNE)FZ"B77[4ADS[*NJ]?5D7Q/ JG
M$X$C_O>Z*(TH[V5YJTRT&\.,84RYMC/\1!.-_BF)/ 1UKQ*A))8T=BHS.I1@
M<V.E3J#;G:9^\,-2*_2C<:VFV:.L97<,5QQL#.UX["5&9F32NWU]<P7.1"Y^
MJB(7?Z[&S*CZXQ6@JC3GSAO-J@WIH!&+0V,])*$.)MND[#LTHL^I>O#V>Q=Z
MK]+ 51O/.J_3[;HL2OV%IMG=0L981%+&D LOABCA,:0JC*!((DQ8A)D?<<>J
M[R>ZFQL'OVT*G=>)\BJ9-WG5.F([5X0_A?AI;AT>Q['WD!="V*=TO 4RE]>1
M/]7)U$7E+10^4&'>YJWQ2C__2O,[6:Z_I?>4-9$@2GI$XBB$R#?UD+PX@BP*
M*$P0%SZF6%%IE37@,C'F1D('BCYWA1Z^KO"!D3E-2M/A/3)9N540[JHR8IGG
M \,Q?(WGRX9EE@6>K2;)*,6=CX,Y1&7G ZW/KJSS<03ZU'0^T=J@CM#&><\]
M3YNW4D+J*V%J9>AE** ,,L^/B*_7)HJ'<(7.\UCDA%NOU_G(::@O<HC.[KSD
M NR&<HJ.=X!RNL,Y.$9/'ZC8O=2/3_1>W%R[^I"O'E,AQ:NG+X5)C-PDPLCN
MFK-<LW]O+P:&B8P]CCW(?:0-WBC2_,*C&"J.HU@*'WG*:F/=7X2Y,4]UH5!5
M%PK-D /5B@[H1G8W[NDQ+':$-"[8([.4%KZ^O-F*;_+(_V T &GV(]@H ;9:
MC'+#LS^(0]):#RDFY;K^*#TGP M:ZGU'IJJU]4%_?N:6SMNVXI:69)'@&%'F
M>Q 3Q2!"7@B9TEM_R96,5!@QCSD%+)[J;&Y,=ZX(6;\K-<>QMB.UH1 <F;ZV
MX%6";NJ</M2[OO<GD.MS!><L) /?R#G>W]07=,YJ?N"^SOEW^IY2?*;?;H0)
MV59I;;B]7]>ND%A*WT<$RL@4A)!>!"D2"$J2Z.TU\@-!B=L!Q9&>YD8BC6-=
M2PMVQ06UO*Z'$L< MCV/& "V:8XBW!'K<09Q!HV+CQ^.M3_QR<,9-?</'<Z]
MT..\X3KP?%)[DLXZDIIS!J6-#\FUQ1&B1'.&X)"()(1>Z#,4BC 2#CDIG+N?
M&Y$8^<'>(8.#']M] "R.$T:%=62BV4'4PE?=Y_# '72'0X-1P9_HL,!U$ 8Z
M(N@-W<FC ?=6ISL2Z*WQSE% _U9Z+!F?_UQ]_KI:%WKO\"G]5DJ9O;U_6*Z>
MI*R.PS\TM1"-(=M,GIC+2,1Q (4P*14#CT#J<P43A 2-$D$]W^J*1+_N9[AD
M1*"5N;E.U4I=;<L<B,Q]+"Q6CU$1'GGU<)9](.;JC=E)YG)O=3KFZJWQ#G/U
M;Z6?6VU;S>-6[5XKJS(=FE2TQ5[9QF)[EY0S['N!MGD5BSV(/!% &A(?2A:*
MF.& *^H4@'VA/'/CMFK0X*N]RJMN_KA+!\G.93<A]".3WID[O0/7&QH8OR%=
M@)>*-*F7<"#\GCL2AVJV]V'N-A)[H9",B4+&H2@E1"04D(4^AF',0VT/QDB8
M8!#[*@([K3MQWP0E LS1H+EFXGS,V@$L4)XG(AQJK&@"$54$,B$1#%48:^ \
MZ7&G"BW] 9M@L1@$L)A(&H0AC!A3$)E#,.9["O(H1#CTXI!(LGB4.5N-#EFW
MEWF#9K<^]@9BY-7.(- $"]57A,!U6>8I6Y=5#HIRI=? ?!"?Q$DD!CY'[W0P
M]1'YOFX'3K\//-0[?#"7>NEY(^M_WV2W#]*X*[*[U_0AU3R]B2?Q$I5@1<R4
M%N:VHQ_!A$0(ZF5%8B21DI@YQA):=CTWJGS]U1AS!4@SL&I%!K0H9),S:YE2
MEBZK^(._.8<8V@Z''6V, _+(G-(*#7YHQ?[18+V1'#2BCQ++XX[8P*&)MKU/
M':?HB,J!H$77%BZXWGU=S<;W6KEU;I:?1:2\F/E! *-01A")V(-)(&/HQY$0
MF%/?5]CYKO;S7N9&5'79VYJ9>MROW@/1CG,NAF9D>FF* 5<"7H&MB -?83Z&
MP.#WD?<ZFOYR\3%=#]X4/OIPS]@\/;CO]7!7:4D\$4L_T58)#F.]Q_62&%*B
M9SWQ.8H$TO\GW=)7=QJ?V^PVL@$C7*_D+CNPV4WLOF",/)^M<7 /FCN@\*!!
M<MWVIPV*.Z#97A#<H6?Z;C,>]41?Y4^'RM$3XDL:Z4D:1U3HI9E(2)&Y.BMD
M@ @)PD@Y5=@^U=G<YO!&5M=]P@D\;7<&PZ T^EZ@$1-LY1S)A6Z#R+"V_HG^
M)K;NSVN^;\];O',A6_RVRO^X,8F+N2R*A5"4)HI'D,0FMZ,,(I@@@F%$!/9C
M1 (1.5YF/-3-W!C""&=VOP^U>#UY8A=)1X;HC<]4W' %6I0:(:_J$HLC<,-!
M+$9AA=V>7H8/#FI[E D./WUIBO'/.35Y/#J)@S)1[2.:/]3;B2JW[,(WH?*4
M!E Q@;4!P86AB 0RG$0JDE&<4">*Z"7%W!AD+\E7(_+5YL))^;3S]W=_A^]O
MFBS2CKN*?L-FQT>C#\;(=#72.%R0PKL'CN/DYG81Y(62;O? ZG@V[3Z-]2WI
MJNVQFZ)82_%&]Y7=?9!YNA)_I\NU?"__K/ZB32L6<\J#6%-F0" RY)E0C*%,
M?.J'L1*1YW32;=7KW'C22$7U5V&*)_ ZR5=1)_G*9%4G=J64-,KHOQ:N#E6[
M<; DPJ'1'9GXZJC:6F!02PQJD:] );2YZ_AG_<" -IL33,,6X+7I>.)*O Y8
M[)?D=7FY'T^9^]R:!,V_S$KX2)<F$.H=3?.JF^TF<\$Q9YQ3 24F#"+N:1M/
MAA0FC# 54^X'V.K*DW//<^.K*O.!,1VX^4%N97=C)GOD[=AI%#Q'9J@-E-4/
M';&U$:8%KUFJXX$:CJ2<T1J2J.P[GY2LG#%Y3ECN#?0\:L[O:);^9Q71^7J5
M%:ME*MJK/A_T]]E>#;M536H*NMQD[2FV4ER;</N[K+I(FI77G*_6F3D7_Z#;
MX]HX[-3&"D48$!]#Y3,.4<P(9"PAD%.EXH +G 34Z11[8@7F1J'O:6G\R=JV
M:X(1- :.!^53?P*69_ S'MBQC_<[JE^!'>4KBN^J;T9^ \ VVUG1/6PP[W1
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MJU''YHYOE3A>J&@K=[N>8<]3PD[L'4\,?2$:>%6P %,S?BEU]*W^?Y!6DT[
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M0)0 8_0]C=(+B7[6C@J :];F*DUS0 NA-\"*Y(#A1( DA;1(XZ)0TBJB^M)
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M8MR!"PW:(W%<6=#AVG.O17M2/^J?_O,_FD_T/\:P_\__^']02P,$%     @
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M;[R]VJ!HB9]QOII^Q3HBZA1?+U:KDZ]A.JM/42\7RP]AAMN>J]7LY__O[+Q
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MALY<4"8)\,&3]10J>^:D*QH'P<^C9(W;>F(8*/6GAP:.K3>XOK8EC#26^$_
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M7&Y:*UWM.664Y)H;P( 6E-0!/-:I! $%6>V,T@]2X=*9PM9J78X9H!RHKP:
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M<FN!;^=_7FV74*PRQ1N(&2,H3!:"+0@\*2T5YNCR(,TPNI'7K"';!2^W#=D
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MD*"LUPS>P>ISQL-I+PIKP-3>VF^WN#R9S1:_4SQ;__V,B)NNZ[Z;1*R!0W%
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M;5F>+4Y/%_,- [^&/Z:G9Z<GIXNS^?IZRM"KU>JL9@M-M*F3=CU""<Z#0B7
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MO]LAH4^".F'2_["8'$VW3[//Q_\-4UIZN.8>-S__"!T]'F'HN&T\6#(RVU3
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M0"->0<?1%9%Y@=$'.AA- ,4]G9C!&0B9*R=*Y,9UR\38:=DGB\I],7&/AS&
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M6%L.RBE'QCI:T#HHHTJP9*W_D?L\&.H.TD<#.'I\I">)PT3F$#AJ!)69JIY
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M3Y\\Q@K"D^2VFX*)<TO_D]V)14HOK67RS7[9KE,0+!((=*8*7X1,9C+IG[R
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M.W(L6Q-C/8C1"D,Z:0=5:]F:Q4L;FZ'91!5ELE0&Z^A#,8\D==&3RP;)Q/1
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MG%?[FS\1-%9K.9 &MEULT00YB!@RU)224]:(TJ>X=3 ^+#3*7,SE:C=,+CG
MG)!]&^6MP>0%Z+8D&I-N"?<:08J:3:%$U8Z5(IR0^-7?V?;3G@$MP4E0_LW=
M][[./D=55\].4:5BV"G*B9VB$$"+FJ)K;?)J82=ZCS$YXYWEOREST!/4JW8)
M/FW;?YUQ)$35KF:0M16N)(Z34E()J@VB1$)EZL+20R=R8/6WV2NP!CU!O6IK
M\&2)YQ%^55#58320:V:N87:0BC4@C*WD KFH^^T>F9W\U=^GK\ .=(/SJHW
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M1OV/?_@/4$L! A0#%     @ 88#]4EZ, G<C3 $ T/8+ !X
M ( !     &5X:&EB:70Q,#%C;VQL86)L:6-Z86ER9&-T+FAT;5!+ 0(4 Q0
M   ( && _5*C^.7*^V0  !X5 P >              "  5], 0!E>&AI8FET
M,3 R<W1C:W!R8VAS86=R;6YT>BYH=&U02P$"% ,4    " !A@/U2\%2M<3\'
M  !8(P  %0              @ &6L0$ 97AH:6)I=#,Q+3%Q,C(P,C$N:'1M
M4$L! A0#%     @ 88#]4B\!&+@Y!P  6B,  !4              ( !"+D!
M &5X:&EB:70S,2TR<3(R,#(Q+FAT;5!+ 0(4 Q0    ( && _5(LS=S4\ ,
M (H/   5              "  73  0!E>&AI8FET,S(M,7$R,C R,2YH=&U0
M2P$"% ,4    " !A@/U2@[_\D-X#  #E#@  %0              @ &7Q $
M97AH:6)I=#,R+3)Q,C(P,C$N:'1M4$L! A0#%     @ 88#]4K3L'7AZ<@$
M7DP/ !$              ( !J,@! &UG;G@M,C R,3 V,S N:'1M4$L! A0#
M%     @ 88#]4BIEW06^#   57H  !$              ( !43L# &UG;G@M
M,C R,3 V,S N>'-D4$L! A0#%     @ 88#]4OMG767($0  EI\  !4
M         ( !/D@# &UG;G@M,C R,3 V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M && _5+JLO'KSSH  ,"F @ 5              "  3E: P!M9VYX+3(P,C$P
M-C,P7V1E9BYX;6Q02P$"% ,4    " !A@/U2W@30RCV3  #36P8 %0
M        @ $[E0, ;6=N>"TR,#(Q,#8S,%]L86(N>&UL4$L! A0#%     @
M88#]4J@+G*YA70  \VT$ !4              ( !JR@$ &UG;G@M,C R,3 V
@,S!?<')E+GAM;%!+!08     #  , "X#   _A@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
